{"c0713cd16ef0d30221483b314837bcf9e642a884": [["INTRODUCTIONThe most insidious primary vasculitis in childhood is Kawasaki syndrome (KS), an acute multi-systemic illness which predominantly affects children under 5 years of age (1) .", [["KS", "ANATOMY", 85, 87], ["vasculitis", "DISEASE", 39, 49], ["Kawasaki syndrome", "DISEASE", 66, 83], ["KS", "DISEASE", 85, 87], ["acute multi-systemic illness", "DISEASE", 93, 121], ["children", "ORGANISM", 150, 158], ["children", "SPECIES", 150, 158], ["insidious primary vasculitis", "PROBLEM", 21, 49], ["Kawasaki syndrome", "PROBLEM", 66, 83], ["an acute multi-systemic illness", "PROBLEM", 90, 121], ["insidious", "OBSERVATION_MODIFIER", 21, 30], ["primary", "OBSERVATION_MODIFIER", 31, 38], ["vasculitis", "OBSERVATION", 39, 49], ["Kawasaki syndrome", "OBSERVATION", 66, 83], ["acute", "OBSERVATION_MODIFIER", 93, 98], ["multi-systemic", "OBSERVATION_MODIFIER", 99, 113], ["illness", "OBSERVATION", 114, 121]]], ["Currently, this disorder of unknown etiology remains the main cause of acquired heart disease among children living in developed countries, where rheumatic fever has been surpassed (2, 3) .", [["heart", "ANATOMY", 80, 85], ["heart disease", "DISEASE", 80, 93], ["rheumatic fever", "DISEASE", 146, 161], ["heart", "ORGAN", 80, 85], ["children", "ORGANISM", 100, 108], ["children", "SPECIES", 100, 108], ["this disorder", "PROBLEM", 11, 24], ["acquired heart disease", "PROBLEM", 71, 93], ["rheumatic fever", "PROBLEM", 146, 161], ["heart", "ANATOMY", 80, 85], ["disease", "OBSERVATION", 86, 93]]], ["This condition was originally called \"mucocutaneous lymph node syndrome\" by Dr. Tomisaku Kawasaki, who was its discoverer, and was thought to be a benign children's disease; nowadays, the illness has been described worldwide in children of every ethnicity following the presence of fever persisting (at least) 5 days together with (at least) 4 of the 5 following signs: bilateral conjunctival injection, oropharyngeal inflammation, abnormalities of hands and feet, polymorphous exanthema, and non-purulent cervical lymphadenopathy, usually unilateral (4) .", [["mucocutaneous lymph node", "ANATOMY", 38, 62], ["conjunctival", "ANATOMY", 380, 392], ["oropharyngeal", "ANATOMY", 404, 417], ["hands", "ANATOMY", 449, 454], ["feet", "ANATOMY", 459, 463], ["cervical", "ANATOMY", 506, 514], ["mucocutaneous lymph node syndrome", "DISEASE", 38, 71], ["Kawasaki", "DISEASE", 89, 97], ["illness", "DISEASE", 188, 195], ["fever", "DISEASE", 282, 287], ["oropharyngeal inflammation", "DISEASE", 404, 430], ["abnormalities of hands and feet", "DISEASE", 432, 463], ["exanthema", "DISEASE", 478, 487], ["cervical lymphadenopathy", "DISEASE", 506, 530], ["lymph node", "MULTI-TISSUE_STRUCTURE", 52, 62], ["children", "ORGANISM", 154, 162], ["children", "ORGANISM", 228, 236], ["conjunctival", "MULTI-TISSUE_STRUCTURE", 380, 392], ["oropharyngeal", "ORGANISM_SUBDIVISION", 404, 417], ["hands", "ORGANISM_SUBDIVISION", 449, 454], ["cervical", "ORGAN", 506, 514], ["children", "SPECIES", 154, 162], ["children", "SPECIES", 228, 236], ["mucocutaneous lymph node syndrome", "PROBLEM", 38, 71], ["a benign children's disease", "PROBLEM", 145, 172], ["fever", "PROBLEM", 282, 287], ["bilateral conjunctival injection", "PROBLEM", 370, 402], ["oropharyngeal inflammation", "PROBLEM", 404, 430], ["abnormalities of hands and feet", "PROBLEM", 432, 463], ["polymorphous exanthema", "PROBLEM", 465, 487], ["non-purulent cervical lymphadenopathy", "PROBLEM", 493, 530], ["mucocutaneous", "OBSERVATION_MODIFIER", 38, 51], ["lymph node syndrome", "OBSERVATION", 52, 71], ["benign", "OBSERVATION_MODIFIER", 147, 153], ["fever", "OBSERVATION", 282, 287], ["bilateral", "ANATOMY_MODIFIER", 370, 379], ["conjunctival", "ANATOMY", 380, 392], ["oropharyngeal", "ANATOMY", 404, 417], ["inflammation", "OBSERVATION", 418, 430], ["hands", "ANATOMY", 449, 454], ["feet", "ANATOMY", 459, 463], ["polymorphous", "OBSERVATION_MODIFIER", 465, 477], ["exanthema", "OBSERVATION", 478, 487], ["non-purulent", "OBSERVATION_MODIFIER", 493, 505], ["cervical", "ANATOMY", 506, 514], ["lymphadenopathy", "OBSERVATION", 515, 530]]], ["Several years after the first description, fatalities occurred among children with KS younger than 2 years living in Japan, prompting clinicians to reconsider KS's long-term risks related to systemic and necrotizing effects on the vascular endothelium of small-and medium-sized arteries, which have been acknowledged in all guidelines related to the management of KS (5, 6) .", [["KS", "ANATOMY", 83, 85], ["KS", "ANATOMY", 159, 161], ["vascular endothelium", "ANATOMY", 231, 251], ["arteries", "ANATOMY", 278, 286], ["KS", "ANATOMY", 364, 366], ["KS", "DISEASE", 364, 366], ["children", "ORGANISM", 69, 77], ["vascular endothelium", "TISSUE", 231, 251], ["arteries", "MULTI-TISSUE_STRUCTURE", 278, 286], ["children", "SPECIES", 69, 77], ["systemic and necrotizing effects", "PROBLEM", 191, 223], ["KS", "TEST", 364, 366], ["necrotizing", "OBSERVATION", 204, 215], ["vascular endothelium", "ANATOMY", 231, 251], ["small", "OBSERVATION_MODIFIER", 255, 260], ["sized arteries", "ANATOMY", 272, 286]]], ["The most relevant sequelae of KS include variable degrees of damage within coronary arteries in combination with angina, myocardial infarction, ischemic cardiomyopathy, and sudden death; these complications should be preventable with a timely treatment of high-dose intravenous immunoglobulin (IVIG), which is the recommended therapeutic strategy in KS (7) .", [["KS", "ANATOMY", 30, 32], ["coronary arteries", "ANATOMY", 75, 92], ["myocardial", "ANATOMY", 121, 131], ["intravenous", "ANATOMY", 266, 277], ["KS", "ANATOMY", 350, 352], ["KS", "DISEASE", 30, 32], ["angina", "DISEASE", 113, 119], ["myocardial infarction", "DISEASE", 121, 142], ["ischemic cardiomyopathy", "DISEASE", 144, 167], ["sudden death", "DISEASE", 173, 185], ["coronary arteries", "MULTI-TISSUE_STRUCTURE", 75, 92], ["myocardial", "MULTI-TISSUE_STRUCTURE", 121, 131], ["intravenous immunoglobulin", "SIMPLE_CHEMICAL", 266, 292], ["IVIG", "SIMPLE_CHEMICAL", 294, 298], ["immunoglobulin", "PROTEIN", 278, 292], ["damage within coronary arteries", "PROBLEM", 61, 92], ["angina", "PROBLEM", 113, 119], ["myocardial infarction", "PROBLEM", 121, 142], ["ischemic cardiomyopathy", "PROBLEM", 144, 167], ["sudden death", "PROBLEM", 173, 185], ["these complications", "PROBLEM", 187, 206], ["high-dose intravenous immunoglobulin (IVIG", "TREATMENT", 256, 298], ["most relevant", "OBSERVATION_MODIFIER", 4, 17], ["sequelae", "OBSERVATION_MODIFIER", 18, 26], ["KS", "OBSERVATION", 30, 32], ["variable degrees", "OBSERVATION_MODIFIER", 41, 57], ["damage", "OBSERVATION", 61, 67], ["coronary arteries", "ANATOMY", 75, 92], ["angina", "OBSERVATION", 113, 119], ["myocardial", "ANATOMY", 121, 131], ["infarction", "OBSERVATION", 132, 142], ["ischemic", "OBSERVATION_MODIFIER", 144, 152], ["cardiomyopathy", "OBSERVATION", 153, 167]]], ["Higher acute phase reactants and younger age at onset of KS are nodal points in determining, respectively, a failure in the response to IVIG and an increased occurrence of coronary artery abnormalities (8) .", [["KS", "ANATOMY", 57, 59], ["nodal", "ANATOMY", 64, 69], ["coronary artery", "ANATOMY", 172, 187], ["KS", "DISEASE", 57, 59], ["coronary artery abnormalities", "DISEASE", 172, 201], ["IVIG", "SIMPLE_CHEMICAL", 136, 140], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 172, 187], ["Higher acute phase reactants", "PROBLEM", 0, 28], ["KS", "PROBLEM", 57, 59], ["a failure", "PROBLEM", 107, 116], ["IVIG", "TREATMENT", 136, 140], ["coronary artery abnormalities", "PROBLEM", 172, 201], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["phase", "OBSERVATION_MODIFIER", 13, 18], ["reactants", "OBSERVATION_MODIFIER", 19, 28], ["nodal points", "OBSERVATION", 64, 76], ["failure", "OBSERVATION", 109, 116], ["increased", "OBSERVATION_MODIFIER", 148, 157], ["coronary artery", "ANATOMY", 172, 187], ["abnormalities", "OBSERVATION", 188, 201]]], ["The prediction of IVIG resistance is also crucial in KS patients, as recognizing these high-risk children should consent to start an intensified treatment protocol combined with IVIG to prevent coronary injuries (9) .", [["KS", "ANATOMY", 53, 55], ["coronary", "ANATOMY", 194, 202], ["coronary injuries", "DISEASE", 194, 211], ["IVIG", "SIMPLE_CHEMICAL", 18, 22], ["patients", "ORGANISM", 56, 64], ["children", "ORGANISM", 97, 105], ["IVIG", "SIMPLE_CHEMICAL", 178, 182], ["coronary", "MULTI-TISSUE_STRUCTURE", 194, 202], ["patients", "SPECIES", 56, 64], ["children", "SPECIES", 97, 105], ["IVIG resistance", "TREATMENT", 18, 33], ["an intensified treatment protocol", "TREATMENT", 130, 163], ["IVIG", "TREATMENT", 178, 182], ["coronary injuries", "PROBLEM", 194, 211], ["IVIG resistance", "OBSERVATION", 18, 33], ["coronary", "ANATOMY", 194, 202], ["injuries", "OBSERVATION", 203, 211]]], ["KS incidence varies widely among different ethnic groups; for instance, in the United Kingdom it has stabilized and remains low at 2.8 per 100,000 population under the age of 20 years.", [["KS", "ANATOMY", 0, 2], ["KS", "DISEASE", 0, 2], ["widely", "OBSERVATION_MODIFIER", 20, 26], ["stabilized", "OBSERVATION_MODIFIER", 101, 111]]], ["However, general practitioners should be aware that the condition occurs throughout childhood and across the seasons, and-given the potential cardiovascular sequelae-KS should be considered in all children with persistent fever, even in older children and adolescents (10) .", [["cardiovascular", "ANATOMY", 142, 156], ["KS", "ANATOMY", 166, 168], ["cardiovascular sequelae", "DISEASE", 142, 165], ["fever", "DISEASE", 222, 227], ["cardiovascular", "ANATOMICAL_SYSTEM", 142, 156], ["children", "ORGANISM", 197, 205], ["children", "ORGANISM", 243, 251], ["children", "SPECIES", 197, 205], ["children", "SPECIES", 243, 251], ["adolescents", "SPECIES", 256, 267], ["the condition", "PROBLEM", 52, 65], ["the potential cardiovascular sequelae", "PROBLEM", 128, 165], ["persistent fever", "PROBLEM", 211, 227], ["persistent", "OBSERVATION_MODIFIER", 211, 221], ["fever", "OBSERVATION", 222, 227]]], ["KS is most prominently recognized in Japan, Korea, and Taiwan, reflecting increased genetic susceptibility among Asian populations.", [["KS", "ANATOMY", 0, 2], ["increased genetic susceptibility", "PROBLEM", 74, 106], ["most prominently", "OBSERVATION_MODIFIER", 6, 22], ["increased", "OBSERVATION_MODIFIER", 74, 83], ["genetic susceptibility", "OBSERVATION", 84, 106]]], ["A recent study reported an incidence of \u223c240 per 100,000 children under 4 years of age in Japan (11) .", [["children", "SPECIES", 57, 65], ["A recent study", "TEST", 0, 14]]], ["There is still much controversy about the etiology of KS, though epidemiologic and clinical data suggest that KS might originate from an abnormal response to undisclosed infectious diseases in genetically susceptible children (12) .", [["KS", "ANATOMY", 54, 56], ["KS", "ANATOMY", 110, 112], ["KS", "DISEASE", 54, 56], ["infectious diseases", "DISEASE", 170, 189], ["KS", "CANCER", 54, 56], ["children", "ORGANISM", 217, 225], ["children", "SPECIES", 217, 225], ["KS", "PROBLEM", 54, 56], ["clinical data", "TEST", 83, 96], ["KS", "PROBLEM", 110, 112], ["an abnormal response", "PROBLEM", 134, 154], ["undisclosed infectious diseases", "PROBLEM", 158, 189], ["KS", "OBSERVATION", 54, 56], ["abnormal", "OBSERVATION_MODIFIER", 137, 145], ["infectious", "OBSERVATION_MODIFIER", 170, 180]]], ["There is no agreement whether KS-related infectious agents are of viral, bacterial or fungal origin (13) , and the underlying immune mechanisms behind KS have not been completely highlighted, remaining only partially known.", [["KS", "ANATOMY", 30, 32], ["KS", "ANATOMY", 151, 153], ["KS", "CANCER", 151, 153], ["KS", "PROBLEM", 30, 32], ["infectious agents", "TREATMENT", 41, 58], ["viral, bacterial or fungal origin", "PROBLEM", 66, 99], ["the underlying immune mechanisms", "PROBLEM", 111, 143], ["no", "UNCERTAINTY", 9, 11], ["infectious", "OBSERVATION", 41, 51], ["bacterial", "OBSERVATION_MODIFIER", 73, 82], ["fungal origin", "OBSERVATION_MODIFIER", 86, 99]]], ["The absence of a proven unambiguous cause of KS has induced the scientific community to pay attention to other environmental hypothetical triggers, and in particular the composition of the resident intestinal flora as a potential contributor to KS has been evaluated by different research groups.INTRODUCTIONThe main aim of this review was to analyze the relationship between the microbial community, or the \"microbiota, \" and the overall impact of bacterial or viral infections in the potential development of KS.", [["KS", "ANATOMY", 45, 47], ["intestinal flora", "ANATOMY", 198, 214], ["KS", "ANATOMY", 245, 247], ["community", "ANATOMY", 390, 399], ["KS", "ANATOMY", 511, 513], ["KS", "DISEASE", 45, 47], ["infections", "DISEASE", 468, 478], ["KS", "DISEASE", 511, 513], ["intestinal flora", "MULTI-TISSUE_STRUCTURE", 198, 214], ["KS", "CANCER", 511, 513], ["bacterial or viral infections", "PROBLEM", 449, 478], ["intestinal", "ANATOMY", 198, 208], ["flora", "OBSERVATION", 209, 214], ["main", "OBSERVATION_MODIFIER", 312, 316], ["bacterial", "OBSERVATION_MODIFIER", 449, 458], ["viral", "OBSERVATION_MODIFIER", 462, 467], ["infections", "OBSERVATION", 468, 478], ["KS", "OBSERVATION", 511, 513]]], ["Scientific papers have been searched from the electronic databases of PubMed until January 2019; the retrieving words were \"Kawasaki disease, \" \"Kawasaki syndrome, \" \"microbiota, \" and \"microbiome\"; additional reports were identified and analyzed through the specific references cited in the retrieved papers.", [["Kawasaki disease", "DISEASE", 124, 140], ["Kawasaki syndrome", "DISEASE", 145, 162], ["Kawasaki disease", "PROBLEM", 124, 140], ["Kawasaki syndrome", "PROBLEM", 145, 162]]], ["Only papers published in English and those showing evidence-based data were included in our evaluation.EVOLUTION OF THE MICROBIOTA IN CHILDRENThe microbiota, a microbial community of trillions of microorganisms and at least 1,000 different bacterial species, some eukaryotic fungi and viruses, and which covers every surface of the human body, plays a contributory role in many infections, immune-mediated disorders, rheumatologic diseases, and disorders of the nervous system.", [["surface", "ANATOMY", 317, 324], ["body", "ANATOMY", 338, 342], ["nervous system", "ANATOMY", 462, 476], ["infections", "DISEASE", 378, 388], ["rheumatologic diseases", "DISEASE", 417, 439], ["disorders of the nervous system", "DISEASE", 445, 476], ["human", "ORGANISM", 332, 337], ["body", "ORGANISM_SUBDIVISION", 338, 342], ["nervous system", "ANATOMICAL_SYSTEM", 462, 476], ["human", "SPECIES", 332, 337], ["human", "SPECIES", 332, 337], ["our evaluation", "TEST", 88, 102], ["microorganisms", "PROBLEM", 196, 210], ["different bacterial species", "PROBLEM", 230, 257], ["some eukaryotic fungi", "PROBLEM", 259, 280], ["viruses", "PROBLEM", 285, 292], ["many infections", "PROBLEM", 373, 388], ["immune-mediated disorders", "PROBLEM", 390, 415], ["rheumatologic diseases", "PROBLEM", 417, 439], ["disorders of the nervous system", "PROBLEM", 445, 476], ["MICROBIOTA", "OBSERVATION_MODIFIER", 120, 130], ["bacterial species", "OBSERVATION", 240, 257], ["eukaryotic fungi", "OBSERVATION", 264, 280], ["viruses", "OBSERVATION", 285, 292], ["human body", "ANATOMY", 332, 342], ["infections", "OBSERVATION", 378, 388], ["nervous system", "ANATOMY", 462, 476]]], ["The microbiome, on the other hand, is the collection of the whole genome sequences of those microorganisms, consisting of more than 5,000,000 genes (14, 15) .", [["whole genome sequences", "DNA", 60, 82], ["5,000,000 genes", "DNA", 132, 147]]], ["In particular, the gut microbiota is strictly linked to the chronological age of each individual and modulates host physiology and metabolism through different mechanisms.EVOLUTION OF THE MICROBIOTA IN CHILDRENEach stage of human life is characterized by a specific intestinal microbial composition: the microbiota that initially colonizes the fetus' intestinal tube consists of aerobic organisms such as Enterococcus and Streptococcus, is then gradually replaced by anaerobes such as Bifidobacterium and Lactobacillus and finally reaches the adult composition dominated by Bacteroides and Firmicutes (16, 17) .", [["gut microbiota", "ANATOMY", 19, 33], ["intestinal", "ANATOMY", 266, 276], ["fetus", "ANATOMY", 344, 349], ["intestinal tube", "ANATOMY", 351, 366], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 19, 33], ["human", "ORGANISM", 224, 229], ["intestinal microbial", "MULTI-TISSUE_STRUCTURE", 266, 286], ["intestinal tube", "TISSUE", 351, 366], ["Bifidobacterium", "SIMPLE_CHEMICAL", 485, 500], ["Lactobacillus", "SIMPLE_CHEMICAL", 505, 518], ["Bacteroides", "SIMPLE_CHEMICAL", 574, 585], ["human", "SPECIES", 224, 229], ["human", "SPECIES", 224, 229], ["aerobic organisms", "PROBLEM", 379, 396], ["Enterococcus", "PROBLEM", 405, 417], ["Streptococcus", "PROBLEM", 422, 435], ["anaerobes", "PROBLEM", 467, 476], ["Bifidobacterium", "PROBLEM", 485, 500], ["Lactobacillus", "TREATMENT", 505, 518], ["Firmicutes", "TEST", 590, 600], ["host physiology", "OBSERVATION", 111, 126], ["MICROBIOTA", "OBSERVATION_MODIFIER", 188, 198], ["intestinal", "ANATOMY", 266, 276], ["intestinal tube", "OBSERVATION", 351, 366], ["aerobic organisms", "OBSERVATION", 379, 396], ["Enterococcus", "OBSERVATION", 405, 417], ["Streptococcus", "OBSERVATION", 422, 435], ["Bacteroides", "OBSERVATION_MODIFIER", 574, 585], ["Firmicutes", "OBSERVATION_MODIFIER", 590, 600]]], ["The fetal microbiota is prone to be conditioned by the type of delivery; the mother's vaginal flora is a relevant source of Lactobacillus, Prevotella, and Bifidobacterium.", [["fetal microbiota", "ANATOMY", 4, 20], ["vaginal flora", "ANATOMY", 86, 99], ["fetal microbiota", "MULTI-TISSUE_STRUCTURE", 4, 20], ["vaginal flora", "ORGANISM_SUBDIVISION", 86, 99], ["Lactobacillus", "SIMPLE_CHEMICAL", 124, 137], ["Prevotella", "SIMPLE_CHEMICAL", 139, 149], ["Bifidobacterium", "SIMPLE_CHEMICAL", 155, 170], ["delivery", "TREATMENT", 63, 71], ["the mother's vaginal flora", "PROBLEM", 73, 99], ["Lactobacillus", "PROBLEM", 124, 137], ["Prevotella", "PROBLEM", 139, 149], ["Bifidobacterium", "TREATMENT", 155, 170], ["fetal microbiota", "ANATOMY", 4, 20], ["vaginal", "ANATOMY", 86, 93]]], ["Conversely, a cesarean delivery delays contact with these species, producing a similar-to-skin flora, dominated by Staphylococci (18) .", [["skin", "ANATOMY", 90, 94], ["skin", "ORGAN", 90, 94], ["a cesarean delivery delays", "PROBLEM", 12, 38], ["these species", "PROBLEM", 52, 65], ["skin flora", "PROBLEM", 90, 100], ["Staphylococci", "PROBLEM", 115, 128], ["skin", "ANATOMY", 90, 94], ["flora", "OBSERVATION", 95, 100], ["Staphylococci", "OBSERVATION", 115, 128]]], ["The feeding regimens and food supplements also play a role in modifying the resident flora; a greater complexity is normally seen in infants fed with formula, rather than in breastfed babies who have an \"adult-like\" structured microbiota with a population rich with Bifidobacteria, Lactobacilli, and Bacteroides (18).", [["Bifidobacteria", "CHEMICAL", 266, 280], ["infants", "ORGANISM", 133, 140], ["babies", "ORGANISM", 184, 190], ["Bifidobacteria", "SIMPLE_CHEMICAL", 266, 280], ["Lactobacilli", "SIMPLE_CHEMICAL", 282, 294], ["infants", "SPECIES", 133, 140], ["The feeding regimens", "TREATMENT", 0, 20], ["food supplements", "TREATMENT", 25, 41], ["Bifidobacteria", "TREATMENT", 266, 280], ["Lactobacilli", "TREATMENT", 282, 294], ["Bacteroides", "TREATMENT", 300, 311]]], ["The infant gut microbiota is variable in composition over time and highly changeable during the first year of life, being influenced by specific bacteria to which a baby happens to be exposed, as shown by the resemblance of infants' stool microbial community with mothers' milk and vaginal samples (19) .", [["gut microbiota", "ANATOMY", 11, 25], ["milk", "ANATOMY", 273, 277], ["vaginal samples", "ANATOMY", 282, 297], ["infant", "ORGANISM", 4, 10], ["gut", "ORGANISM_SUBDIVISION", 11, 14], ["infants", "ORGANISM", 224, 231], ["milk", "ORGANISM_SUBSTANCE", 273, 277], ["vaginal samples", "MULTI-TISSUE_STRUCTURE", 282, 297], ["infant", "SPECIES", 4, 10], ["infants", "SPECIES", 224, 231], ["specific bacteria", "PROBLEM", 136, 153], ["microbiota", "OBSERVATION", 15, 25], ["variable", "OBSERVATION_MODIFIER", 29, 37]]], ["Thereafter, the infant's intestinal tract progresses toward an extremely dense colonization, ending with a mixture of microbes that is broadly very similar to an adult's intestine.", [["intestinal tract", "ANATOMY", 25, 41], ["intestine", "ANATOMY", 170, 179], ["infant", "ORGANISM", 16, 22], ["intestinal tract", "ORGANISM_SUBDIVISION", 25, 41], ["intestine", "ORGAN", 170, 179], ["infant", "SPECIES", 16, 22], ["the infant's intestinal tract", "PROBLEM", 12, 41], ["an extremely dense colonization", "PROBLEM", 60, 91], ["intestinal tract", "ANATOMY", 25, 41], ["extremely", "OBSERVATION_MODIFIER", 63, 72], ["dense", "OBSERVATION_MODIFIER", 73, 78], ["colonization", "OBSERVATION", 79, 91], ["microbes", "OBSERVATION", 118, 126], ["intestine", "ANATOMY", 170, 179]]], ["During adulthood, the gut microbiota becomes stable and this intestinal homeostasis remains in equilibrium with the host.", [["gut microbiota", "ANATOMY", 22, 36], ["intestinal", "ANATOMY", 61, 71], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 22, 36], ["intestinal", "ORGAN", 61, 71], ["this intestinal homeostasis", "PROBLEM", 56, 83], ["stable", "OBSERVATION_MODIFIER", 45, 51], ["intestinal", "ANATOMY", 61, 71], ["homeostasis", "OBSERVATION", 72, 83]]], ["Food habits influence the composition of the whole intestinal microbiota, as testified by the lower prevalence of Bacteroides in those suffering from malnutrition and by different microbiota changes occurring in children with diet-related diseases, such as allergies and obesity (19) .EVOLUTION OF THE MICROBIOTA IN CHILDRENArumugam et al. identified three distinct enterotypes, namely Bacteroides, Prevotella, and Ruminococcus, which reflect many individual alimentary profiles: Bacteroides correlates to a highfat or high-protein regimen, whereas Prevotella is associated with higher consumption of fibers and simple sugars (20) .", [["intestinal microbiota", "ANATOMY", 51, 72], ["fibers", "ANATOMY", 601, 607], ["Bacteroides", "CHEMICAL", 114, 125], ["malnutrition", "DISEASE", 150, 162], ["diet-related diseases", "DISEASE", 226, 247], ["allergies", "DISEASE", 257, 266], ["obesity", "DISEASE", 271, 278], ["sugars", "CHEMICAL", 619, 625], ["intestinal microbiota", "MULTI-TISSUE_STRUCTURE", 51, 72], ["children", "ORGANISM", 212, 220], ["Prevotella", "GENE_OR_GENE_PRODUCT", 399, 409], ["alimentary", "ORGANISM_SUBDIVISION", 459, 469], ["Prevotella", "SIMPLE_CHEMICAL", 549, 559], ["fibers", "CELLULAR_COMPONENT", 601, 607], ["children", "SPECIES", 212, 220], ["Bacteroides", "PROBLEM", 114, 125], ["malnutrition", "PROBLEM", 150, 162], ["related diseases", "PROBLEM", 231, 247], ["allergies", "PROBLEM", 257, 266], ["obesity", "PROBLEM", 271, 278], ["three distinct enterotypes", "PROBLEM", 351, 377], ["Bacteroides", "PROBLEM", 386, 397], ["Prevotella", "PROBLEM", 399, 409], ["Ruminococcus", "PROBLEM", 415, 427], ["Bacteroides", "PROBLEM", 480, 491], ["a highfat", "TEST", 506, 515], ["high-protein regimen", "TREATMENT", 519, 539], ["Prevotella", "PROBLEM", 549, 559], ["simple sugars", "TEST", 612, 625], ["intestinal microbiota", "ANATOMY", 51, 72], ["malnutrition", "OBSERVATION", 150, 162], ["different microbiota", "OBSERVATION_MODIFIER", 170, 190], ["MICROBIOTA", "OBSERVATION_MODIFIER", 302, 312], ["distinct", "OBSERVATION_MODIFIER", 357, 365], ["enterotypes", "OBSERVATION", 366, 377], ["Bacteroides", "OBSERVATION_MODIFIER", 386, 397], ["Bacteroides", "OBSERVATION", 480, 491]]], ["More recent data have consented to unify Bacteroides and Ruminococcus enterotypes due to the large similarity between the two (21) .", [["unify Bacteroides", "TREATMENT", 35, 52], ["Ruminococcus enterotypes", "PROBLEM", 57, 81], ["large", "OBSERVATION_MODIFIER", 93, 98]]], ["It is well-established that early events of birth, environmental factors during infancy, sex hormones, diet, body weight, and use of antibiotics can undoubtedly differentiate the composition of the microbiota (22, 23) .", [["body", "ANATOMY", 109, 113], ["body", "ORGANISM_SUBDIVISION", 109, 113], ["antibiotics", "TREATMENT", 133, 144]]], ["There are no ideal culture methods to give us a real overview of the complete intestinal flora, though molecular methods, e.g., DNA microarrays with comprehensive coverage of most bacterial taxa represented in the available database of small subunit ribosomal RNA gene sequences, should allow the characterization of most taxonomic groups of the intestinal bacteria (24, 25) .ROLE OF THE BACTERIAL FLORA IN CHILDHOOD DISEASESThe ancient symbiosis between the human gastrointestinal tract and its resident microbiota involves diverse reciprocal interactions between the microbiota itself and the host, with relevant consequences for human health and physiology.", [["intestinal flora", "ANATOMY", 78, 94], ["intestinal bacteria", "ANATOMY", 346, 365], ["gastrointestinal tract", "ANATOMY", 465, 487], ["intestinal flora", "PATHOLOGICAL_FORMATION", 78, 94], ["DNA", "CELLULAR_COMPONENT", 128, 131], ["intestinal", "ORGAN", 346, 356], ["human", "ORGANISM", 459, 464], ["gastrointestinal tract", "ORGAN", 465, 487], ["human", "ORGANISM", 632, 637], ["small subunit ribosomal RNA gene sequences", "DNA", 236, 278], ["human", "SPECIES", 459, 464], ["human", "SPECIES", 632, 637], ["human", "SPECIES", 459, 464], ["human", "SPECIES", 632, 637], ["ideal culture methods", "TEST", 13, 34], ["the complete intestinal flora", "PROBLEM", 65, 94], ["molecular methods", "TEST", 103, 120], ["DNA microarrays", "TEST", 128, 143], ["comprehensive coverage", "TREATMENT", 149, 171], ["most bacterial taxa", "PROBLEM", 175, 194], ["small subunit ribosomal RNA gene sequences", "PROBLEM", 236, 278], ["the characterization", "TEST", 293, 313], ["the intestinal bacteria", "PROBLEM", 342, 365], ["The ancient symbiosis between the human gastrointestinal tract", "PROBLEM", 425, 487], ["no", "UNCERTAINTY", 10, 12], ["intestinal", "ANATOMY", 78, 88], ["flora", "OBSERVATION", 89, 94], ["intestinal", "ANATOMY", 346, 356], ["BACTERIAL FLORA", "OBSERVATION", 388, 403], ["ancient", "OBSERVATION_MODIFIER", 429, 436], ["symbiosis", "OBSERVATION", 437, 446], ["gastrointestinal tract", "ANATOMY", 465, 487]]], ["The quality of the microbial flora has an impact on the maintenance of health and also on prevention of diseases.", [["the microbial flora", "PROBLEM", 15, 34], ["diseases", "PROBLEM", 104, 112], ["diseases", "OBSERVATION", 104, 112]]], ["Indeed, there are numerous roles carried out by the intestinal ecosystem, as the stimulation of angiogenesis, control of host fat storage and protection against other pathogens.", [["intestinal ecosystem", "ANATOMY", 52, 72], ["fat", "ANATOMY", 126, 129], ["intestinal", "ORGAN", 52, 62], ["fat", "TISSUE", 126, 129], ["angiogenesis", "PROBLEM", 96, 108], ["host fat storage", "TREATMENT", 121, 137], ["protection", "TREATMENT", 142, 152], ["other pathogens", "PROBLEM", 161, 176], ["numerous", "OBSERVATION_MODIFIER", 18, 26], ["intestinal", "ANATOMY", 52, 62]]], ["In particular, the microbiota influences the formation and progress of regulation of both innate and adaptive immunity in close interaction with the intestinal mucosal immune system.", [["intestinal mucosal", "ANATOMY", 149, 167], ["intestinal mucosal", "MULTI-TISSUE_STRUCTURE", 149, 167], ["intestinal mucosal", "ANATOMY", 149, 167]]], ["The intestinal mucosa may be considered as an immunological niche as it hosts a complex immune-functional organ comprised by T cell subpopulations, neutrophils, macrophage-dendritic cells, enterocytes (that possess tight intercellular junctions) and their related anti-and pro-inflammatory cytokines as well as several other mediators of inflammation or antimicrobial peptides, defensins, and secretory immunoglobulin A (IgA) (26) .", [["intestinal mucosa", "ANATOMY", 4, 21], ["organ", "ANATOMY", 106, 111], ["T cell", "ANATOMY", 125, 131], ["neutrophils", "ANATOMY", 148, 159], ["macrophage-dendritic cells", "ANATOMY", 161, 187], ["enterocytes", "ANATOMY", 189, 200], ["intercellular junctions", "ANATOMY", 221, 244], ["inflammation", "DISEASE", 338, 350], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 4, 21], ["organ", "ORGAN", 106, 111], ["T cell subpopulations", "CELL", 125, 146], ["neutrophils", "CELL", 148, 159], ["macrophage", "CELL", 161, 171], ["dendritic cells", "CELL", 172, 187], ["enterocytes", "CELL", 189, 200], ["intercellular junctions", "CELLULAR_COMPONENT", 221, 244], ["defensins", "GENE_OR_GENE_PRODUCT", 378, 387], ["secretory immunoglobulin A", "GENE_OR_GENE_PRODUCT", 393, 419], ["IgA", "GENE_OR_GENE_PRODUCT", 421, 424], ["T cell subpopulations", "CELL_TYPE", 125, 146], ["neutrophils", "CELL_TYPE", 148, 159], ["macrophage", "CELL_TYPE", 161, 171], ["dendritic cells", "CELL_TYPE", 172, 187], ["enterocytes", "CELL_TYPE", 189, 200], ["anti-and pro-inflammatory cytokines", "PROTEIN", 264, 299], ["defensins", "PROTEIN", 378, 387], ["secretory immunoglobulin A", "PROTEIN", 393, 419], ["IgA", "PROTEIN", 421, 424], ["an immunological niche", "PROBLEM", 43, 65], ["T cell subpopulations", "TEST", 125, 146], ["neutrophils", "TEST", 148, 159], ["dendritic cells", "PROBLEM", 172, 187], ["enterocytes", "PROBLEM", 189, 200], ["their related anti-and pro-inflammatory cytokines", "PROBLEM", 250, 299], ["inflammation", "PROBLEM", 338, 350], ["antimicrobial peptides", "PROBLEM", 354, 376], ["defensins", "PROBLEM", 378, 387], ["intestinal mucosa", "ANATOMY", 4, 21], ["may be considered", "UNCERTAINTY", 22, 39], ["cell subpopulations", "OBSERVATION", 127, 146], ["macrophage", "OBSERVATION_MODIFIER", 161, 171], ["dendritic cells", "OBSERVATION", 172, 187], ["enterocytes", "ANATOMY", 189, 200], ["tight", "OBSERVATION_MODIFIER", 215, 220], ["intercellular junctions", "OBSERVATION", 221, 244], ["pro-inflammatory cytokines", "OBSERVATION", 273, 299], ["inflammation", "OBSERVATION", 338, 350], ["antimicrobial peptides", "OBSERVATION", 354, 376]]], ["The intestinal microbiota may also have direct or indirect effects on the natural course of viral infections, interacting with viral particles and leading to differences in either pathogenicity or anti-viral immune response through recruitment and activation of several T cell subpopulations (18) .", [["intestinal microbiota", "ANATOMY", 4, 25], ["T cell", "ANATOMY", 270, 276], ["viral infections", "DISEASE", 92, 108], ["intestinal", "ORGAN", 4, 14], ["T cell", "CELL", 270, 276], ["T cell subpopulations", "CELL_TYPE", 270, 291], ["viral infections", "PROBLEM", 92, 108], ["viral particles", "PROBLEM", 127, 142], ["pathogenicity", "PROBLEM", 180, 193], ["anti-viral immune response", "PROBLEM", 197, 223], ["several T cell subpopulations", "TREATMENT", 262, 291], ["intestinal microbiota", "ANATOMY", 4, 25], ["viral infections", "OBSERVATION", 92, 108], ["anti-viral immune", "OBSERVATION", 197, 214]]], ["A large amount of data has also depicted the relevance of gut microbiota-immune system cross-talk in several diseases, and indeed an \"imbalance\" of the intestinal flora has been shown in patients with atopic diseases and various noninfectious diseases, including metabolic disorders, chronic inflammatory bowel disease (IBD), irritable bowel syndrome, pancreatic diseases, atherosclerosis, and rheumatoid arthritis (27, 28) .", [["gut", "ANATOMY", 58, 61], ["intestinal flora", "ANATOMY", 152, 168], ["bowel", "ANATOMY", 305, 310], ["bowel", "ANATOMY", 336, 341], ["pancreatic", "ANATOMY", 352, 362], ["atopic diseases", "DISEASE", 201, 216], ["noninfectious diseases", "DISEASE", 229, 251], ["metabolic disorders", "DISEASE", 263, 282], ["inflammatory bowel disease", "DISEASE", 292, 318], ["IBD", "DISEASE", 320, 323], ["irritable bowel syndrome", "DISEASE", 326, 350], ["pancreatic diseases", "DISEASE", 352, 371], ["atherosclerosis", "DISEASE", 373, 388], ["rheumatoid arthritis", "DISEASE", 394, 414], ["gut", "ORGANISM_SUBDIVISION", 58, 61], ["intestinal flora", "ORGAN", 152, 168], ["patients", "ORGANISM", 187, 195], ["bowel", "ORGAN", 305, 310], ["bowel", "ORGAN", 336, 341], ["pancreatic", "ORGAN", 352, 362], ["patients", "SPECIES", 187, 195], ["several diseases", "PROBLEM", 101, 117], ["an \"imbalance", "PROBLEM", 130, 143], ["the intestinal flora", "PROBLEM", 148, 168], ["atopic diseases", "PROBLEM", 201, 216], ["various noninfectious diseases", "PROBLEM", 221, 251], ["metabolic disorders", "PROBLEM", 263, 282], ["chronic inflammatory bowel disease", "PROBLEM", 284, 318], ["IBD)", "PROBLEM", 320, 324], ["irritable bowel syndrome", "PROBLEM", 326, 350], ["pancreatic diseases", "PROBLEM", 352, 371], ["atherosclerosis", "PROBLEM", 373, 388], ["rheumatoid arthritis", "PROBLEM", 394, 414], ["large", "OBSERVATION_MODIFIER", 2, 7], ["amount", "OBSERVATION_MODIFIER", 8, 14], ["several", "OBSERVATION_MODIFIER", 101, 108], ["diseases", "OBSERVATION", 109, 117], ["intestinal", "ANATOMY", 152, 162], ["flora", "OBSERVATION", 163, 168], ["noninfectious", "OBSERVATION_MODIFIER", 229, 242], ["metabolic disorders", "OBSERVATION", 263, 282], ["chronic", "OBSERVATION_MODIFIER", 284, 291], ["inflammatory", "OBSERVATION_MODIFIER", 292, 304], ["bowel", "ANATOMY", 305, 310], ["disease", "OBSERVATION", 311, 318], ["irritable bowel syndrome", "OBSERVATION", 326, 350], ["pancreatic", "ANATOMY", 352, 362], ["diseases", "OBSERVATION", 363, 371], ["atherosclerosis", "OBSERVATION", 373, 388], ["rheumatoid", "OBSERVATION_MODIFIER", 394, 404], ["arthritis", "OBSERVATION", 405, 414]]], ["Furthermore, the gut microbiota, interacting with pattern recognition receptors (PRRs), signaling receptors that can recognize molecular structures of pathogens and activate the cascade of innate immunity, plays a crucial role in maintaining the homeostasis of the innate immunity responses in the gut, and leaks in the intestinal mucosal barrier lead to the translocation of bacterial products into portal circulation which promotes systemic inflammation (29) .", [["gut microbiota", "ANATOMY", 17, 31], ["gut", "ANATOMY", 298, 301], ["intestinal mucosal", "ANATOMY", 320, 338], ["portal", "ANATOMY", 400, 406], ["inflammation", "DISEASE", 443, 455], ["gut", "ORGANISM_SUBDIVISION", 17, 20], ["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 50, 79], ["PRRs", "GENE_OR_GENE_PRODUCT", 81, 85], ["gut", "ORGANISM_SUBDIVISION", 298, 301], ["intestinal mucosal barrier", "TISSUE", 320, 346], ["portal circulation", "MULTI-TISSUE_STRUCTURE", 400, 418], ["pattern recognition receptors", "PROTEIN", 50, 79], ["PRRs", "PROTEIN", 81, 85], ["signaling receptors", "PROTEIN", 88, 107], ["signaling receptors", "PROBLEM", 88, 107], ["molecular structures of pathogens", "PROBLEM", 127, 160], ["leaks", "PROBLEM", 307, 312], ["the intestinal mucosal barrier", "TREATMENT", 316, 346], ["systemic inflammation", "PROBLEM", 434, 455], ["gut", "ANATOMY", 298, 301], ["leaks", "OBSERVATION", 307, 312], ["intestinal mucosal", "ANATOMY", 320, 338], ["bacterial products", "OBSERVATION", 376, 394], ["portal circulation", "ANATOMY", 400, 418], ["systemic", "OBSERVATION_MODIFIER", 434, 442], ["inflammation", "OBSERVATION", 443, 455]]], ["In addition, the microbiota can maintain a segregation between intestinal mucosa and bacteria via PRRs, though pathogens might usurp innate signals to their advantage (30) .ROLE OF THE BACTERIAL FLORA IN CHILDHOOD DISEASESSeveral immunologic, metabolic and nutritional processes are normally controlled by the intestinal microbiota, and changes in the local microbial communities have been linked to chronic low-grade inflammation (31) .", [["intestinal mucosa", "ANATOMY", 63, 80], ["intestinal", "ANATOMY", 310, 320], ["inflammation", "DISEASE", 418, 430], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 63, 80], ["PRRs", "GENE_OR_GENE_PRODUCT", 98, 102], ["intestinal microbiota", "MULTI-TISSUE_STRUCTURE", 310, 331], ["-grade", "PATHOLOGICAL_FORMATION", 411, 417], ["PRRs", "PROTEIN", 98, 102], ["a segregation between intestinal mucosa and bacteria via PRRs", "PROBLEM", 41, 102], ["pathogens", "PROBLEM", 111, 120], ["THE BACTERIAL FLORA", "PROBLEM", 181, 200], ["chronic low-grade inflammation", "PROBLEM", 400, 430], ["intestinal mucosa", "ANATOMY", 63, 80], ["BACTERIAL FLORA", "OBSERVATION", 185, 200], ["nutritional processes", "OBSERVATION", 257, 278], ["intestinal microbiota", "ANATOMY", 310, 331], ["chronic", "OBSERVATION_MODIFIER", 400, 407], ["low-grade", "OBSERVATION_MODIFIER", 408, 417], ["inflammation", "OBSERVATION", 418, 430]]], ["Alexander et al. demonstrated that the microbiota has specific effects on adaptive immunity, such as the induction of regulatory effector CD4+ cells and production of cytokines and antimicrobial factors, influencing the individual response to various environmental stimuli, as seen in IBD, Crohn's disease and ulcerative colitis (32) .", [["effector CD4+ cells", "ANATOMY", 129, 148], ["IBD", "DISEASE", 285, 288], ["Crohn's disease", "DISEASE", 290, 305], ["ulcerative colitis", "DISEASE", 310, 328], ["CD4", "GENE_OR_GENE_PRODUCT", 138, 141], ["ulcerative colitis", "PATHOLOGICAL_FORMATION", 310, 328], ["regulatory effector CD4+ cells", "CELL_TYPE", 118, 148], ["cytokines", "PROTEIN", 167, 176], ["antimicrobial factors", "PROTEIN", 181, 202], ["adaptive immunity", "TREATMENT", 74, 91], ["cytokines", "PROBLEM", 167, 176], ["antimicrobial factors", "PROBLEM", 181, 202], ["various environmental stimuli", "TREATMENT", 243, 272], ["IBD", "PROBLEM", 285, 288], ["Crohn's disease", "PROBLEM", 290, 305], ["ulcerative colitis", "PROBLEM", 310, 328], ["effector CD4", "OBSERVATION", 129, 141], ["environmental stimuli", "OBSERVATION", 251, 272], ["IBD", "ANATOMY", 285, 288], ["Crohn", "OBSERVATION", 290, 295], ["ulcerative", "OBSERVATION_MODIFIER", 310, 320], ["colitis", "OBSERVATION", 321, 328]]], ["In a recent work, Schwiertz et al. have shown microbiota changes characterized by decreased numbers of Faecalibacterium praunsitzii and increased numbers of Escherichia coli in IBD (33) .", [["IBD", "DISEASE", 177, 180], ["Faecalibacterium praunsitzii", "ORGANISM", 103, 131], ["Escherichia coli", "ORGANISM", 157, 173], ["Faecalibacterium praunsitzii", "SPECIES", 103, 131], ["Escherichia coli", "SPECIES", 157, 173], ["Faecalibacterium praunsitzii", "SPECIES", 103, 131], ["Escherichia coli", "SPECIES", 157, 173], ["Schwiertz et al", "TREATMENT", 18, 33], ["microbiota changes", "PROBLEM", 46, 64], ["Faecalibacterium praunsitzii", "PROBLEM", 103, 131], ["Escherichia coli in IBD", "PROBLEM", 157, 180], ["decreased", "OBSERVATION_MODIFIER", 82, 91], ["numbers", "OBSERVATION_MODIFIER", 92, 99], ["Faecalibacterium praunsitzii", "OBSERVATION", 103, 131], ["increased", "OBSERVATION_MODIFIER", 136, 145], ["numbers", "OBSERVATION_MODIFIER", 146, 153], ["Escherichia coli", "OBSERVATION", 157, 173]]], ["Additionally, in celiac disease De Palma et al. have described a difference in the microbiota composition with a reduction of Bifidobacterium, Clostridium histolyticum, Clostridium lituseburense, Faecalibacterium prausnitzii, and an abundance of Bacteroides and Prevotella strains (34) .", [["celiac disease", "DISEASE", 17, 31], ["Bifidobacterium", "CHEMICAL", 126, 141], ["Bifidobacterium", "SIMPLE_CHEMICAL", 126, 141], ["Clostridium histolyticum", "ORGANISM", 143, 167], ["Clostridium lituseburense", "ORGANISM", 169, 194], ["Faecalibacterium prausnitzii", "ORGANISM", 196, 224], ["Bacteroides", "GENE_OR_GENE_PRODUCT", 246, 257], ["Clostridium histolyticum", "SPECIES", 143, 167], ["Clostridium lituseburense", "SPECIES", 169, 194], ["Faecalibacterium prausnitzii", "SPECIES", 196, 224], ["Clostridium histolyticum", "SPECIES", 143, 167], ["Clostridium lituseburense", "SPECIES", 169, 194], ["Faecalibacterium prausnitzii", "SPECIES", 196, 224], ["celiac disease", "PROBLEM", 17, 31], ["a reduction of Bifidobacterium", "TREATMENT", 111, 141], ["Clostridium histolyticum", "PROBLEM", 143, 167], ["Clostridium lituseburense", "TREATMENT", 169, 194], ["Faecalibacterium prausnitzii", "TREATMENT", 196, 224], ["Bacteroides", "PROBLEM", 246, 257], ["Prevotella strains", "PROBLEM", 262, 280], ["celiac", "ANATOMY", 17, 23], ["disease", "OBSERVATION", 24, 31]]], ["A significantly higher biodiversity in coeliac children's duodenal mucosa was demonstrated by Schippa et al. who also highlighted that the possible pathophysiological role of such microbial differences needs further characterization (35) .", [["duodenal mucosa", "ANATOMY", 58, 73], ["children", "ORGANISM", 47, 55], ["duodenal mucosa", "MULTI-TISSUE_STRUCTURE", 58, 73], ["children", "SPECIES", 47, 55], ["A significantly higher biodiversity in coeliac children's duodenal mucosa", "PROBLEM", 0, 73], ["further characterization", "TEST", 208, 232], ["significantly", "OBSERVATION_MODIFIER", 2, 15], ["higher", "OBSERVATION_MODIFIER", 16, 22], ["biodiversity", "OBSERVATION_MODIFIER", 23, 35], ["coeliac", "ANATOMY", 39, 46], ["duodenal mucosa", "ANATOMY", 58, 73]]], ["In addition, many immune phenomena were shown to deteriorate under the effect of changes in the microbiota, as revealed by the correlation among intestinal bacterial overgrowth, increased permeability, and development of non-alcoholic steatohepatitis (36) .ROLE OF THE BACTERIAL FLORA IN CHILDHOOD DISEASESMuch interest has also been paid to the role of the microbiome in the development of \"sterile\" inflammation, and recent studies have proved that either depletion of the microbiota or changes in the diet and in the gut microbiome might lead to the improvement of inflammasome-mediated manifestations of autoinflammatory disorders, which are caused by dysregulation of specific components of innate immunity (37) .", [["intestinal", "ANATOMY", 145, 155], ["gut microbiome", "ANATOMY", 520, 534], ["bacterial overgrowth", "DISEASE", 156, 176], ["non-alcoholic steatohepatitis", "DISEASE", 221, 250], ["inflammation", "DISEASE", 401, 413], ["autoinflammatory disorders", "DISEASE", 608, 634], ["intestinal", "ORGAN", 145, 155], ["gut", "ORGANISM_SUBDIVISION", 520, 523], ["many immune phenomena", "PROBLEM", 13, 34], ["intestinal bacterial overgrowth", "PROBLEM", 145, 176], ["increased permeability", "PROBLEM", 178, 200], ["non-alcoholic steatohepatitis", "PROBLEM", 221, 250], ["THE BACTERIAL FLORA", "PROBLEM", 265, 284], ["\"sterile\" inflammation", "PROBLEM", 391, 413], ["recent studies", "TEST", 419, 433], ["the microbiota", "PROBLEM", 471, 485], ["inflammasome", "PROBLEM", 568, 580], ["autoinflammatory disorders", "PROBLEM", 608, 634], ["immune phenomena", "OBSERVATION", 18, 34], ["intestinal", "ANATOMY", 145, 155], ["bacterial overgrowth", "OBSERVATION", 156, 176], ["increased", "OBSERVATION_MODIFIER", 178, 187], ["permeability", "OBSERVATION_MODIFIER", 188, 200], ["non-alcoholic", "OBSERVATION_MODIFIER", 221, 234], ["steatohepatitis", "OBSERVATION", 235, 250], ["BACTERIAL", "OBSERVATION_MODIFIER", 269, 278], ["FLORA", "OBSERVATION", 279, 284], ["inflammation", "OBSERVATION", 401, 413], ["autoinflammatory", "OBSERVATION", 608, 624]]], ["These diseases can be subdivided into monogenic and multifactorial disorders, with the former being caused by mutations of genes involved in the regulation of the innate immune system and the latter by a combination of genetic background and environmental factors (38) (39) (40) .", [["monogenic and multifactorial disorders", "DISEASE", 38, 76], ["These diseases", "PROBLEM", 0, 14], ["multifactorial disorders", "PROBLEM", 52, 76], ["mutations of genes", "PROBLEM", 110, 128], ["multifactorial", "OBSERVATION_MODIFIER", 52, 66], ["disorders", "OBSERVATION", 67, 76]]], ["Given the evidence for the role of the intestinal microbiota in the inflammatory state of IBD, atopic diseases and numerous non-infectious diseases, it has been speculated that intestinal microbial agents might also play a trigger role in the development of other inflammatory disorders which do not have a clearly defined etiology, such as KS.UNSOLVED PROBLEMS ABOUT THE ETIOLOGY OF KAWASAKI SYNDROMEThe etiology of KS remains obscure, although clinical and epidemiological features suggest a primary infectious cause.", [["intestinal microbiota", "ANATOMY", 39, 60], ["intestinal", "ANATOMY", 177, 187], ["KS", "ANATOMY", 341, 343], ["KS", "ANATOMY", 417, 419], ["IBD", "DISEASE", 90, 93], ["atopic diseases", "DISEASE", 95, 110], ["non-infectious diseases", "DISEASE", 124, 147], ["KS", "DISEASE", 341, 343], ["KS", "DISEASE", 417, 419], ["intestinal microbiota", "MULTI-TISSUE_STRUCTURE", 39, 60], ["intestinal", "ORGAN", 177, 187], ["KS", "CANCER", 417, 419], ["IBD", "PROBLEM", 90, 93], ["atopic diseases", "PROBLEM", 95, 110], ["numerous non-infectious diseases", "PROBLEM", 115, 147], ["intestinal microbial agents", "TREATMENT", 177, 204], ["other inflammatory disorders", "PROBLEM", 258, 286], ["KAWASAKI SYNDROME", "PROBLEM", 384, 401], ["KS", "PROBLEM", 417, 419], ["a primary infectious cause", "PROBLEM", 492, 518], ["intestinal microbiota", "ANATOMY", 39, 60], ["inflammatory", "OBSERVATION_MODIFIER", 68, 80], ["IBD", "OBSERVATION", 90, 93], ["atopic diseases", "OBSERVATION", 95, 110], ["numerous", "OBSERVATION_MODIFIER", 115, 123], ["non-infectious", "OBSERVATION_MODIFIER", 124, 138], ["intestinal", "ANATOMY", 177, 187], ["inflammatory", "OBSERVATION", 264, 276], ["KAWASAKI SYNDROME", "OBSERVATION", 384, 401], ["KS", "OBSERVATION", 417, 419], ["primary", "OBSERVATION_MODIFIER", 494, 501], ["infectious", "OBSERVATION", 502, 512]]], ["Indeed, a self-limited and generally nonrecurring illness that manifests itself by fever, rash, mucositis, conjunctival injection, and cervical adenopathy fits well with an infection.", [["conjunctival", "ANATOMY", 107, 119], ["cervical adenopathy", "ANATOMY", 135, 154], ["illness", "DISEASE", 50, 57], ["fever", "DISEASE", 83, 88], ["rash", "DISEASE", 90, 94], ["mucositis", "DISEASE", 96, 105], ["cervical adenopathy fits", "DISEASE", 135, 159], ["infection", "DISEASE", 173, 182], ["conjunctival", "ORGAN", 107, 119], ["cervical", "ORGAN", 135, 143], ["fever", "PROBLEM", 83, 88], ["rash", "PROBLEM", 90, 94], ["mucositis", "PROBLEM", 96, 105], ["conjunctival injection", "PROBLEM", 107, 129], ["cervical adenopathy", "PROBLEM", 135, 154], ["an infection", "PROBLEM", 170, 182], ["mucositis", "OBSERVATION", 96, 105], ["conjunctival", "ANATOMY", 107, 119], ["cervical", "ANATOMY", 135, 143], ["adenopathy", "OBSERVATION", 144, 154], ["infection", "OBSERVATION", 173, 182]]], ["More precisely, clinical features of KS resemble some peculiar infectious diseases, such as streptococcal infections, staphylococcal toxic shock syndrome, and atypical measles (12, 13) .", [["KS", "ANATOMY", 37, 39], ["KS", "DISEASE", 37, 39], ["infectious diseases", "DISEASE", 63, 82], ["streptococcal infections", "DISEASE", 92, 116], ["staphylococcal toxic shock syndrome", "DISEASE", 118, 153], ["measles", "DISEASE", 168, 175], ["KS", "PROBLEM", 37, 39], ["some peculiar infectious diseases", "PROBLEM", 49, 82], ["streptococcal infections", "PROBLEM", 92, 116], ["staphylococcal toxic shock syndrome", "PROBLEM", 118, 153], ["atypical measles", "PROBLEM", 159, 175], ["peculiar", "OBSERVATION_MODIFIER", 54, 62], ["infectious", "OBSERVATION", 63, 73], ["streptococcal", "OBSERVATION_MODIFIER", 92, 105], ["infections", "OBSERVATION", 106, 116], ["staphylococcal", "OBSERVATION_MODIFIER", 118, 132], ["toxic", "OBSERVATION_MODIFIER", 133, 138], ["shock syndrome", "OBSERVATION", 139, 153], ["atypical", "OBSERVATION_MODIFIER", 159, 167], ["measles", "OBSERVATION", 168, 175]]], ["Additionally, age distribution, winter-spring seasonality, high rates of KS in siblings, and occurrence of community outbreaks are suggestive of a transmissible childhood disease, though many efforts with conventional bacterial and viral cultures and serological methods as well as animal inoculation studies have failed to identify a final unique infectious agent of KS (41) .", [["KS", "ANATOMY", 73, 75], ["KS", "ANATOMY", 368, 370], ["KS", "DISEASE", 368, 370], ["community outbreaks", "PROBLEM", 107, 126], ["a transmissible childhood disease", "PROBLEM", 145, 178], ["conventional bacterial and viral cultures", "TEST", 205, 246], ["serological methods", "TEST", 251, 270], ["animal inoculation studies", "TEST", 282, 308], ["community outbreaks", "OBSERVATION", 107, 126], ["suggestive of", "UNCERTAINTY", 131, 144], ["transmissible", "OBSERVATION_MODIFIER", 147, 160], ["childhood", "OBSERVATION", 161, 170]]], ["Reported non-infectious factors associated with KS include carpet shampoo, preexisting eczema, environmental pollution, and house dust mites (42) .", [["KS", "ANATOMY", 48, 50], ["KS", "DISEASE", 48, 50], ["eczema", "DISEASE", 87, 93], ["non-infectious factors", "PROBLEM", 9, 31], ["KS", "PROBLEM", 48, 50], ["carpet shampoo", "TREATMENT", 59, 73], ["preexisting eczema", "PROBLEM", 75, 93], ["non-infectious", "OBSERVATION", 9, 23], ["eczema", "OBSERVATION", 87, 93]]], ["The higher incidence of KS in Asian populations, presence of familial clustering, and elevated risk of recurrence vs. the risk of a first episode in KS-na\u00efve children are all strong evidence of a genetic contribution to KS susceptibility, probably in association with an infectious trigger (43, 44) .", [["KS", "ANATOMY", 24, 26], ["KS", "ANATOMY", 149, 151], ["KS", "ANATOMY", 220, 222], ["KS", "DISEASE", 24, 26], ["KS", "DISEASE", 220, 222], ["children", "ORGANISM", 158, 166], ["KS", "CANCER", 220, 222], ["children", "SPECIES", 158, 166], ["familial clustering", "PROBLEM", 61, 80], ["recurrence", "PROBLEM", 103, 113], ["KS susceptibility", "PROBLEM", 220, 237], ["an infectious trigger", "PROBLEM", 268, 289], ["higher", "OBSERVATION_MODIFIER", 4, 10], ["incidence", "OBSERVATION_MODIFIER", 11, 20], ["familial", "OBSERVATION_MODIFIER", 61, 69], ["infectious", "OBSERVATION", 271, 281]]], ["However, KS does not appear easily transmittable and does not respond to any antibiotics: these characteristics should contradict a primitively infectious pathogenesis of the illness.UNSOLVED PROBLEMS ABOUT THE ETIOLOGY OF KAWASAKI SYNDROMEThe most current theory about the pathogenesis of KS is that the disease results from an exaggerated immune response toward environmental stimuli occurring in a genetically susceptible child (13) .", [["KS", "ANATOMY", 9, 11], ["KS", "ANATOMY", 290, 292], ["illness", "DISEASE", 175, 182], ["KS", "DISEASE", 290, 292], ["KS", "CANCER", 290, 292], ["any antibiotics", "TREATMENT", 73, 88], ["the illness", "PROBLEM", 171, 182], ["KAWASAKI SYNDROME", "PROBLEM", 223, 240], ["the disease results", "PROBLEM", 301, 320], ["an exaggerated immune response", "PROBLEM", 326, 356], ["environmental stimuli", "TEST", 364, 385], ["infectious", "OBSERVATION_MODIFIER", 144, 154], ["KAWASAKI SYNDROME", "OBSERVATION", 223, 240], ["exaggerated", "OBSERVATION_MODIFIER", 329, 340], ["immune response", "OBSERVATION", 341, 356]]], ["The prominent role played by the immune system in KS is confirmed by the high number of studies revealing the activation of neutrophils and multiple immune cells with overproduction of pro-inflammatory cytokines, including tumor necrosis factor (TNF)-\u03b1 (45, 46) .", [["immune system", "ANATOMY", 33, 46], ["KS", "ANATOMY", 50, 52], ["neutrophils", "ANATOMY", 124, 135], ["immune cells", "ANATOMY", 149, 161], ["tumor necrosis", "DISEASE", 223, 237], ["neutrophils", "CELL", 124, 135], ["multiple immune cells", "CELL", 140, 161], ["tumor necrosis factor (TNF)-\u03b1", "GENE_OR_GENE_PRODUCT", 223, 252], ["neutrophils", "CELL_TYPE", 124, 135], ["immune cells", "CELL_TYPE", 149, 161], ["pro-inflammatory cytokines", "PROTEIN", 185, 211], ["tumor necrosis factor (TNF)-\u03b1", "PROTEIN", 223, 252], ["the activation of neutrophils", "PROBLEM", 106, 135], ["multiple immune cells", "PROBLEM", 140, 161], ["pro-inflammatory cytokines", "PROBLEM", 185, 211], ["tumor necrosis factor", "PROBLEM", 223, 244], ["TNF", "TEST", 246, 249], ["prominent", "OBSERVATION_MODIFIER", 4, 13], ["multiple", "OBSERVATION_MODIFIER", 140, 148], ["immune cells", "OBSERVATION", 149, 161], ["pro-inflammatory cytokines", "OBSERVATION", 185, 211], ["tumor", "OBSERVATION_MODIFIER", 223, 228], ["necrosis", "OBSERVATION_MODIFIER", 229, 237]]], ["Manlhiot et al. have very recently proposed a new pathogenetic model of KS in which the disease risk is determined by concurrent interacting processes: genetic susceptibility, habitual exposure to allergens, atmospheric biological particles, and infectious agents (47) .", [["KS", "ANATOMY", 72, 74], ["a new pathogenetic model of KS", "PROBLEM", 44, 74], ["the disease risk", "PROBLEM", 84, 100], ["genetic susceptibility", "PROBLEM", 152, 174], ["atmospheric biological particles", "TREATMENT", 208, 240], ["disease", "OBSERVATION", 88, 95]]], ["A study exploring the immune responses during the acute phase of KS showed increased levels of lipopolysaccharide (LPS) bound to the surfaces of circulating neutrophils via CD14 receptor and found markedly increased levels of the soluble CD14 in the plasma (48) .", [["KS", "ANATOMY", 65, 67], ["neutrophils", "ANATOMY", 157, 168], ["plasma", "ANATOMY", 250, 256], ["lipopolysaccharide", "CHEMICAL", 95, 113], ["LPS", "CHEMICAL", 115, 118], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 95, 113], ["LPS", "SIMPLE_CHEMICAL", 115, 118], ["neutrophils", "CELL", 157, 168], ["CD14 receptor", "GENE_OR_GENE_PRODUCT", 173, 186], ["CD14", "GENE_OR_GENE_PRODUCT", 238, 242], ["plasma", "ORGANISM_SUBSTANCE", 250, 256], ["circulating neutrophils", "CELL_TYPE", 145, 168], ["CD14 receptor", "PROTEIN", 173, 186], ["CD14", "PROTEIN", 238, 242], ["A study", "TEST", 0, 7], ["the acute phase of KS", "TEST", 46, 67], ["increased levels of lipopolysaccharide (LPS) bound", "PROBLEM", 75, 125], ["circulating neutrophils", "TEST", 145, 168], ["CD14 receptor", "TEST", 173, 186], ["markedly increased levels", "PROBLEM", 197, 222], ["the soluble CD14", "TEST", 226, 242], ["increased", "OBSERVATION_MODIFIER", 75, 84], ["markedly", "OBSERVATION_MODIFIER", 197, 205], ["increased", "OBSERVATION", 206, 215]]], ["Furthermore, Chen et al. (49) demonstrated that NLRP3 inflammasome activation is associated with the development of coronary arteritis in a mouse model of KS, and that infusion of visfatin, a major injurious adipokine, can activate NLRP3 inflammasome and increase interleukin (IL)-1 production, leading to enhanced endothelial dysfunction.", [["coronary", "ANATOMY", 116, 124], ["KS", "ANATOMY", 155, 157], ["endothelial", "ANATOMY", 315, 326], ["coronary arteritis", "DISEASE", 116, 134], ["KS", "DISEASE", 155, 157], ["endothelial dysfunction", "DISEASE", 315, 338], ["NLRP3", "GENE_OR_GENE_PRODUCT", 48, 53], ["coronary", "PATHOLOGICAL_FORMATION", 116, 124], ["mouse", "ORGANISM", 140, 145], ["visfatin", "GENE_OR_GENE_PRODUCT", 180, 188], ["NLRP3", "GENE_OR_GENE_PRODUCT", 232, 237], ["interleukin (IL)-1", "GENE_OR_GENE_PRODUCT", 264, 282], ["endothelial", "CELL", 315, 326], ["NLRP3", "PROTEIN", 48, 53], ["visfatin", "PROTEIN", 180, 188], ["NLRP3", "PROTEIN", 232, 237], ["interleukin (IL)-1", "PROTEIN", 264, 282], ["mouse", "SPECIES", 140, 145], ["mouse", "SPECIES", 140, 145], ["NLRP3 inflammasome activation", "PROBLEM", 48, 77], ["coronary arteritis", "PROBLEM", 116, 134], ["visfatin", "TREATMENT", 180, 188], ["a major injurious adipokine", "TREATMENT", 190, 217], ["NLRP3 inflammasome", "TREATMENT", 232, 250], ["increase interleukin (IL)", "TREATMENT", 255, 280], ["enhanced endothelial dysfunction", "PROBLEM", 306, 338], ["inflammasome", "OBSERVATION", 54, 66], ["coronary", "ANATOMY", 116, 124], ["arteritis", "OBSERVATION", 125, 134], ["enhanced endothelial dysfunction", "OBSERVATION", 306, 338]]], ["These novel molecular mechanisms of vasculitis mediated by inflammasome activation open more specifically the road to innate immunity pathways in the interpretation of KS (49, 50) .THE COMPLEX RELATIONSHIP OF KAWASAKI SYNDROME AND INFECTIONSUnchallengeable proof that an infection is the starting point of KS is not available.", [["KS", "ANATOMY", 168, 170], ["KS", "ANATOMY", 306, 308], ["vasculitis", "DISEASE", 36, 46], ["infection", "DISEASE", 271, 280], ["vasculitis", "PROBLEM", 36, 46], ["inflammasome activation", "PROBLEM", 59, 82], ["KS", "TEST", 168, 170], ["KAWASAKI SYNDROME", "PROBLEM", 209, 226], ["an infection", "PROBLEM", 268, 280], ["vasculitis", "OBSERVATION", 36, 46], ["inflammasome", "OBSERVATION", 59, 71], ["COMPLEX", "OBSERVATION_MODIFIER", 185, 192], ["KAWASAKI SYNDROME", "OBSERVATION", 209, 226], ["infection", "OBSERVATION", 271, 280]]], ["Different epidemiologic studies have supported this hypothesis, based on documented infections by various microorganisms in many cases of KS.", [["KS", "ANATOMY", 138, 140], ["infections", "DISEASE", 84, 94], ["KS", "DISEASE", 138, 140], ["Different epidemiologic studies", "TEST", 0, 31], ["this hypothesis", "PROBLEM", 47, 62], ["documented infections", "PROBLEM", 73, 94], ["various microorganisms", "PROBLEM", 98, 120], ["infections", "OBSERVATION", 84, 94]]], ["Further clues are the occurrence of KS in epidemics, higher incidence during spring and winter and early age at which the disease might be acquired, that is 6 months to 5 years (5).", [["KS", "ANATOMY", 36, 38], ["KS", "DISEASE", 36, 38], ["KS", "PROBLEM", 36, 38], ["the disease", "PROBLEM", 118, 129], ["disease", "OBSERVATION", 122, 129]]], ["Striking perturbations of many immune pathways occur during the acute phase of KS, which determines a multi-cytokine cascade in the vascular endothelium with focal disruption of small-and mediumsized vessels.", [["KS", "ANATOMY", 79, 81], ["vascular endothelium", "ANATOMY", 132, 152], ["mediumsized vessels", "ANATOMY", 188, 207], ["KS", "DISEASE", 79, 81], ["vascular endothelium", "TISSUE", 132, 152], ["mediumsized vessels", "MULTI-TISSUE_STRUCTURE", 188, 207], ["Striking perturbations", "PROBLEM", 0, 22], ["many immune pathways", "PROBLEM", 26, 46], ["a multi-cytokine cascade", "PROBLEM", 100, 124], ["focal disruption of small-and mediumsized vessels", "PROBLEM", 158, 207], ["multi-cytokine cascade", "OBSERVATION", 102, 124], ["vascular endothelium", "ANATOMY", 132, 152], ["focal", "OBSERVATION_MODIFIER", 158, 163], ["disruption", "OBSERVATION", 164, 174], ["small", "OBSERVATION_MODIFIER", 178, 183], ["mediumsized", "ANATOMY_MODIFIER", 188, 199], ["vessels", "ANATOMY", 200, 207]]], ["However, the exact key steps leading to coronary arteritis are still far from being clarified, though endothelial cell activation; prolonged start-up of neutrophils, CD68 + monocyte/macrophages and CD8 + lymphocytes; production of oxygen intermediates and lysosomal enzymes; and oligoclonal IgA response by plasma cells all appear to be involved (45, 46, (51) (52) (53) .THE COMPLEX RELATIONSHIP OF KAWASAKI SYNDROME AND INFECTIONSThe contribution of viruses to KS has been suggested by ultrastructural studies which found cytoplasmic inclusion bodies containing RNA of viral origin in the bronchial epithelia (54) as well as by studies revealing the detection of intracytoplasmic inclusion bodies containing viral proteins and nucleic acid aggregates (55, 56) .", [["coronary", "ANATOMY", 40, 48], ["endothelial cell", "ANATOMY", 102, 118], ["neutrophils", "ANATOMY", 153, 164], ["CD68 + monocyte", "ANATOMY", 166, 181], ["macrophages", "ANATOMY", 182, 193], ["CD8 + lymphocytes", "ANATOMY", 198, 215], ["lysosomal", "ANATOMY", 256, 265], ["plasma cells", "ANATOMY", 307, 319], ["KS", "ANATOMY", 462, 464], ["cytoplasmic", "ANATOMY", 523, 534], ["bronchial epithelia", "ANATOMY", 590, 609], ["coronary arteritis", "DISEASE", 40, 58], ["oxygen", "CHEMICAL", 231, 237], ["KS", "DISEASE", 462, 464], ["nucleic acid", "CHEMICAL", 728, 740], ["oxygen", "CHEMICAL", 231, 237], ["coronary", "MULTI-TISSUE_STRUCTURE", 40, 48], ["endothelial cell", "CELL", 102, 118], ["neutrophils", "CELL", 153, 164], ["CD68", "GENE_OR_GENE_PRODUCT", 166, 170], ["monocyte", "CELL", 173, 181], ["macrophages", "CELL", 182, 193], ["CD8", "GENE_OR_GENE_PRODUCT", 198, 201], ["oxygen", "SIMPLE_CHEMICAL", 231, 237], ["lysosomal enzymes", "GENE_OR_GENE_PRODUCT", 256, 273], ["IgA", "GENE_OR_GENE_PRODUCT", 291, 294], ["plasma cells", "CELL", 307, 319], ["KS", "CANCER", 462, 464], ["cytoplasmic", "ORGANISM_SUBSTANCE", 523, 534], ["bronchial epithelia", "TISSUE", 590, 609], ["neutrophils", "CELL_TYPE", 153, 164], ["CD68", "PROTEIN", 166, 170], ["macrophages", "CELL_TYPE", 182, 193], ["CD8 + lymphocytes", "CELL_TYPE", 198, 215], ["lysosomal enzymes", "PROTEIN", 256, 273], ["IgA", "PROTEIN", 291, 294], ["plasma cells", "CELL_TYPE", 307, 319], ["viral proteins", "PROTEIN", 709, 723], ["coronary arteritis", "PROBLEM", 40, 58], ["endothelial cell activation", "PROBLEM", 102, 129], ["neutrophils", "TEST", 153, 164], ["CD68", "TEST", 166, 170], ["monocyte", "TEST", 173, 181], ["macrophages", "TEST", 182, 193], ["CD8", "TEST", 198, 201], ["lymphocytes", "PROBLEM", 204, 215], ["oxygen intermediates", "TEST", 231, 251], ["lysosomal enzymes", "TEST", 256, 273], ["oligoclonal IgA response", "TEST", 279, 303], ["plasma cells", "TEST", 307, 319], ["KAWASAKI SYNDROME", "PROBLEM", 399, 416], ["viruses to KS", "PROBLEM", 451, 464], ["ultrastructural studies", "TEST", 487, 510], ["cytoplasmic inclusion bodies", "PROBLEM", 523, 551], ["intracytoplasmic inclusion bodies", "PROBLEM", 664, 697], ["viral proteins", "TEST", 709, 723], ["nucleic acid aggregates", "TEST", 728, 751], ["coronary", "ANATOMY", 40, 48], ["arteritis", "OBSERVATION", 49, 58], ["endothelial cell", "OBSERVATION", 102, 118], ["monocyte", "ANATOMY", 173, 181], ["macrophages", "ANATOMY", 182, 193], ["lymphocytes", "ANATOMY", 204, 215], ["COMPLEX", "OBSERVATION_MODIFIER", 375, 382], ["KAWASAKI SYNDROME", "OBSERVATION", 399, 416], ["viruses", "OBSERVATION", 451, 458], ["cytoplasmic", "OBSERVATION_MODIFIER", 523, 534], ["inclusion bodies", "OBSERVATION", 535, 551], ["RNA", "OBSERVATION_MODIFIER", 563, 566], ["viral origin", "OBSERVATION", 570, 582], ["bronchial epithelia", "ANATOMY", 590, 609], ["intracytoplasmic inclusion bodies", "OBSERVATION", 664, 697], ["viral proteins", "OBSERVATION", 709, 723]]], ["Recent investigations have supported the hypothesis that immune responses in KS are oligoclonal rather than polyclonal (as found typically in superantigen-driven responses), and that IgA plasma cells play a crucial role.", [["KS", "ANATOMY", 77, 79], ["plasma cells", "ANATOMY", 187, 199], ["KS", "CANCER", 77, 79], ["IgA", "GENE_OR_GENE_PRODUCT", 183, 186], ["plasma cells", "CELL", 187, 199], ["superantigen", "PROTEIN", 142, 154], ["IgA plasma cells", "CELL_TYPE", 183, 199], ["Recent investigations", "TEST", 0, 21], ["the hypothesis", "PROBLEM", 37, 51], ["immune responses in KS", "PROBLEM", 57, 79], ["oligoclonal", "PROBLEM", 84, 95], ["IgA plasma cells", "PROBLEM", 183, 199]]], ["Indeed, higher levels of IgA have been found in the vasculature of patients with previous KS, indicating an antigen-driven response against an etiologic agent which might have a respiratory or gastrointestinal portal of entry (57) .THE COMPLEX RELATIONSHIP OF KAWASAKI SYNDROME AND INFECTIONSAbout half of all KS patients might have one or more respiratory viruses detected by polymerase chain reaction, without any particular predominance, but a positive respiratory viral test or presence of respiratory symptoms at the time of presentation should not be used to exclude the diagnosis of KS (58) .", [["vasculature", "ANATOMY", 52, 63], ["KS", "ANATOMY", 90, 92], ["respiratory", "ANATOMY", 178, 189], ["gastrointestinal", "ANATOMY", 193, 209], ["KS", "ANATOMY", 310, 312], ["respiratory", "ANATOMY", 494, 505], ["KS", "ANATOMY", 590, 592], ["KS", "DISEASE", 90, 92], ["respiratory symptoms", "DISEASE", 494, 514], ["KS", "DISEASE", 590, 592], ["IgA", "GENE_OR_GENE_PRODUCT", 25, 28], ["vasculature", "ANATOMICAL_SYSTEM", 52, 63], ["patients", "ORGANISM", 67, 75], ["gastrointestinal portal", "MULTI-TISSUE_STRUCTURE", 193, 216], ["patients", "ORGANISM", 313, 321], ["IgA", "PROTEIN", 25, 28], ["patients", "SPECIES", 67, 75], ["patients", "SPECIES", 313, 321], ["higher levels of IgA", "PROBLEM", 8, 28], ["previous KS", "TEST", 81, 92], ["an antigen", "TEST", 105, 115], ["KAWASAKI SYNDROME", "PROBLEM", 260, 277], ["more respiratory viruses", "PROBLEM", 340, 364], ["polymerase chain reaction", "PROBLEM", 377, 402], ["a positive respiratory viral test", "PROBLEM", 445, 478], ["respiratory symptoms", "PROBLEM", 494, 514], ["KS", "TEST", 590, 592], ["higher", "OBSERVATION_MODIFIER", 8, 14], ["IgA", "OBSERVATION", 25, 28], ["vasculature", "ANATOMY", 52, 63], ["gastrointestinal portal", "ANATOMY", 193, 216], ["COMPLEX", "OBSERVATION_MODIFIER", 236, 243], ["KAWASAKI SYNDROME", "OBSERVATION", 260, 277], ["respiratory viruses", "OBSERVATION", 345, 364]]], ["Other studies have investigated a potential relationship of KS with coronaviruses, though without finding definite proof of cause and effect (59, 60) .", [["KS", "ANATOMY", 60, 62], ["Other studies", "TEST", 0, 13], ["coronaviruses", "PROBLEM", 68, 81]]], ["Many viruses have been suggested to be implicated in the pathogenesis of KS, such as adenovirus, parvovirus B19, rotavirus, H1N1 influenza virus, Epstein-Barr virus, herpesvirus 6, coxsackie B3 virus, parainfluenza virus type 3, measles virus, dengue virus, human immunodeficiency virus, and varicella-zoster virus, but no significant differences emerged from case-controlled studies (61) (62) (63) (64) (65) (66) (67) (68) (69) .", [["KS", "ANATOMY", 73, 75], ["KS", "DISEASE", 73, 75], ["parvovirus B19", "DISEASE", 97, 111], ["rotavirus", "DISEASE", 113, 122], ["H1N1 influenza virus", "DISEASE", 124, 144], ["parainfluenza virus", "DISEASE", 201, 220], ["measles virus", "DISEASE", 229, 242], ["dengue virus", "DISEASE", 244, 256], ["human immunodeficiency virus", "DISEASE", 258, 286], ["varicella-zoster virus", "DISEASE", 292, 314], ["KS", "CANCER", 73, 75], ["adenovirus", "ORGANISM", 85, 95], ["parvovirus B19", "ORGANISM", 97, 111], ["rotavirus, H1N1 influenza virus", "ORGANISM", 113, 144], ["Epstein-Barr virus", "ORGANISM", 146, 164], ["herpesvirus 6", "ORGANISM", 166, 179], ["coxsackie B3 virus", "ORGANISM", 181, 199], ["parainfluenza virus type 3", "ORGANISM", 201, 227], ["measles virus", "ORGANISM", 229, 242], ["dengue virus", "ORGANISM", 244, 256], ["human immunodeficiency virus", "ORGANISM", 258, 286], ["varicella-zoster virus", "ORGANISM", 292, 314], ["parvovirus B19", "SPECIES", 97, 111], ["H1N1 influenza virus", "SPECIES", 124, 144], ["Barr virus", "SPECIES", 154, 164], ["coxsackie B3 virus", "SPECIES", 181, 199], ["parainfluenza virus type", "SPECIES", 201, 225], ["measles virus", "SPECIES", 229, 242], ["dengue virus", "SPECIES", 244, 256], ["human", "SPECIES", 258, 263], ["immunodeficiency virus", "SPECIES", 264, 286], ["varicella-zoster virus", "SPECIES", 292, 314], ["parvovirus B19", "SPECIES", 97, 111], ["H1N1 influenza virus", "SPECIES", 124, 144], ["Epstein-Barr virus", "SPECIES", 146, 164], ["coxsackie B3 virus", "SPECIES", 181, 199], ["measles virus", "SPECIES", 229, 242], ["dengue virus", "SPECIES", 244, 256], ["human immunodeficiency virus", "SPECIES", 258, 286], ["varicella-zoster virus", "SPECIES", 292, 314], ["Many viruses", "PROBLEM", 0, 12], ["adenovirus", "PROBLEM", 85, 95], ["parvovirus B19", "PROBLEM", 97, 111], ["rotavirus", "PROBLEM", 113, 122], ["H1N1 influenza virus", "PROBLEM", 124, 144], ["Epstein", "TEST", 146, 153], ["Barr virus", "TEST", 154, 164], ["herpesvirus", "PROBLEM", 166, 177], ["coxsackie B3 virus", "PROBLEM", 181, 199], ["parainfluenza virus type", "PROBLEM", 201, 225], ["measles virus", "PROBLEM", 229, 242], ["dengue virus", "PROBLEM", 244, 256], ["human immunodeficiency virus", "PROBLEM", 258, 286], ["varicella-zoster virus", "PROBLEM", 292, 314], ["significant differences", "PROBLEM", 323, 346], ["viruses", "OBSERVATION", 5, 12], ["parainfluenza virus", "OBSERVATION", 201, 220], ["varicella", "ANATOMY", 292, 301], ["zoster virus", "OBSERVATION", 302, 314], ["no", "UNCERTAINTY", 320, 322]]], ["One of the most difficult infections that are harder to distinguish from KS is caused by adenovirus, due to its frequent incidental detection in KS patients and frequent laboratory finding of increased inflammatory markers (70) .", [["KS", "ANATOMY", 73, 75], ["KS", "ANATOMY", 145, 147], ["infections", "DISEASE", 26, 36], ["KS", "DISEASE", 73, 75], ["adenovirus", "ORGANISM", 89, 99], ["patients", "ORGANISM", 148, 156], ["inflammatory markers", "PROTEIN", 202, 222], ["patients", "SPECIES", 148, 156], ["adenovirus", "SPECIES", 89, 99], ["difficult infections", "PROBLEM", 16, 36], ["adenovirus", "PROBLEM", 89, 99], ["its frequent incidental detection in KS", "PROBLEM", 108, 147], ["increased inflammatory markers", "PROBLEM", 192, 222], ["most difficult", "OBSERVATION_MODIFIER", 11, 25], ["infections", "OBSERVATION", 26, 36], ["increased", "OBSERVATION_MODIFIER", 192, 201], ["inflammatory", "OBSERVATION_MODIFIER", 202, 214]]], ["In particular, adenovirus has been detected in 8.8 and 25% of cases with complete and incomplete KS, respectively, by Jaggi et al. (71) .", [["KS", "ANATOMY", 97, 99], ["adenovirus", "ORGANISM", 15, 25], ["adenovirus", "SPECIES", 15, 25], ["adenovirus", "PROBLEM", 15, 25], ["adenovirus", "OBSERVATION", 15, 25]]], ["There are reports that have emphasized the possible relationship of cytomegalovirus (in one child from Turkey) and human bocavirus 1 (in a French cohort of 32 patients) with KS through serologic tests and molecular techniques, but this link might be only casual and misleading (72, 73) .THE COMPLEX RELATIONSHIP OF KAWASAKI SYNDROME AND INFECTIONSRegarding the bacterial origin of KS, it is debated if the infectious agents might be conventional bacteria or bacteria with superantigen activity.", [["KS", "ANATOMY", 174, 176], ["KS", "ANATOMY", 381, 383], ["cytomegalovirus", "DISEASE", 68, 83], ["KS", "DISEASE", 381, 383], ["cytomegalovirus", "ORGANISM", 68, 83], ["human", "ORGANISM", 115, 120], ["bocavirus 1", "ORGANISM", 121, 132], ["patients", "ORGANISM", 159, 167], ["KS", "CANCER", 381, 383], ["superantigen", "PROTEIN", 472, 484], ["human", "SPECIES", 115, 120], ["patients", "SPECIES", 159, 167], ["human bocavirus 1", "SPECIES", 115, 132], ["cytomegalovirus", "PROBLEM", 68, 83], ["human bocavirus", "PROBLEM", 115, 130], ["KS through serologic tests", "TEST", 174, 200], ["molecular techniques", "TEST", 205, 225], ["KAWASAKI SYNDROME", "PROBLEM", 315, 332], ["the bacterial origin of KS", "PROBLEM", 357, 383], ["the infectious agents", "PROBLEM", 402, 423], ["conventional bacteria", "PROBLEM", 433, 454], ["bacteria", "PROBLEM", 458, 466], ["cytomegalovirus", "OBSERVATION", 68, 83], ["COMPLEX", "OBSERVATION_MODIFIER", 291, 298], ["KAWASAKI SYNDROME", "OBSERVATION", 315, 332], ["bacterial origin", "OBSERVATION_MODIFIER", 361, 377]]], ["Superantigens (SAgs) are the most powerful T cell mitogens ever discovered, with potent immunostimulatory actions that simultaneously activate the major histocompatibility complex class II molecules and T cell receptors, leading to massive activation of various immune cells.", [["T cell", "ANATOMY", 43, 49], ["T cell", "ANATOMY", 203, 209], ["immune cells", "ANATOMY", 262, 274], ["Superantigens", "GENE_OR_GENE_PRODUCT", 0, 13], ["SAgs", "GENE_OR_GENE_PRODUCT", 15, 19], ["T cell", "CELL", 43, 49], ["T cell receptors", "GENE_OR_GENE_PRODUCT", 203, 219], ["immune cells", "CELL", 262, 274], ["Superantigens", "PROTEIN", 0, 13], ["SAgs", "PROTEIN", 15, 19], ["T cell mitogens", "PROTEIN", 43, 58], ["major histocompatibility complex class II molecules", "PROTEIN", 147, 198], ["T cell receptors", "PROTEIN", 203, 219], ["immune cells", "CELL_TYPE", 262, 274], ["potent immunostimulatory actions", "TREATMENT", 81, 113], ["T cell receptors", "PROBLEM", 203, 219], ["massive activation of various immune cells", "PROBLEM", 232, 274], ["massive", "OBSERVATION_MODIFIER", 232, 239], ["various immune cells", "OBSERVATION", 254, 274]]], ["Matsubara et al. conducted a case-control study with a serological approach based on enzyme-linked immunosorbent assay and measured serum antibodies against staphylococcal enterotoxins, including TSST-1, and streptococcal pyrogenic exotoxin (SPE), such as SPE-A.", [["serum", "ANATOMY", 132, 137], ["serum", "ORGANISM_SUBSTANCE", 132, 137], ["TSST-1", "GENE_OR_GENE_PRODUCT", 196, 202], ["streptococcal pyrogenic exotoxin", "GENE_OR_GENE_PRODUCT", 208, 240], ["serum antibodies", "PROTEIN", 132, 148], ["staphylococcal enterotoxins", "PROTEIN", 157, 184], ["TSST", "PROTEIN", 196, 200], ["streptococcal pyrogenic exotoxin", "PROTEIN", 208, 240], ["a serological approach", "TEST", 53, 75], ["enzyme", "TEST", 85, 91], ["immunosorbent assay", "TEST", 99, 118], ["serum antibodies", "TEST", 132, 148], ["staphylococcal enterotoxins", "PROBLEM", 157, 184], ["TSST", "TEST", 196, 200], ["streptococcal pyrogenic exotoxin (SPE", "PROBLEM", 208, 245]]], ["They showed that KS patients had significant elevation of IgM antibodies against one or more of five SAgs throughout the first to the fourth disease week (76) .", [["KS", "ANATOMY", 17, 19], ["patients", "ORGANISM", 20, 28], ["IgM antibodies", "GENE_OR_GENE_PRODUCT", 58, 72], ["SAgs", "GENE_OR_GENE_PRODUCT", 101, 105], ["IgM antibodies", "PROTEIN", 58, 72], ["SAgs", "PROTEIN", 101, 105], ["patients", "SPECIES", 20, 28], ["significant elevation of IgM antibodies", "PROBLEM", 33, 72], ["five SAgs", "PROBLEM", 96, 105], ["significant", "OBSERVATION_MODIFIER", 33, 44], ["elevation", "OBSERVATION_MODIFIER", 45, 54], ["IgM antibodies", "OBSERVATION", 58, 72]]], ["In a further paper the same authors analyzed the studies regarding the role of SAgs produced by Staphylococcus aureus and Streptococcus pyogenes in the pathogenesis of KS, finding numerous SAgs implicated, which brought the total number of the known staphylococcal SAgs to over 20 and streptococcal SAgs to 12 (77) .THE COMPLEX RELATIONSHIP OF KAWASAKI SYNDROME AND INFECTIONSThe most recent work that analyzed the relationship between SAgs and KS examined different SAg derived from Streptococcus pyogenes in the stools of patients with KS.", [["KS", "ANATOMY", 168, 170], ["KS", "ANATOMY", 445, 447], ["stools", "ANATOMY", 514, 520], ["KS", "ANATOMY", 538, 540], ["SAgs", "CHEMICAL", 79, 83], ["KS", "DISEASE", 168, 170], ["Streptococcus pyogenes", "DISEASE", 484, 506], ["KS", "DISEASE", 538, 540], ["SAgs", "GENE_OR_GENE_PRODUCT", 79, 83], ["Staphylococcus aureus", "ORGANISM", 96, 117], ["Streptococcus pyogenes", "ORGANISM", 122, 144], ["SAgs", "CANCER", 189, 193], ["SAgs", "GENE_OR_GENE_PRODUCT", 265, 269], ["SAgs", "GENE_OR_GENE_PRODUCT", 436, 440], ["SAg", "GENE_OR_GENE_PRODUCT", 467, 470], ["Streptococcus pyogenes", "ORGANISM", 484, 506], ["stools", "ORGANISM_SUBDIVISION", 514, 520], ["patients", "ORGANISM", 524, 532], ["staphylococcal SAgs", "PROTEIN", 250, 269], ["SAg", "PROTEIN", 467, 470], ["Staphylococcus aureus", "SPECIES", 96, 117], ["Streptococcus pyogenes", "SPECIES", 122, 144], ["Streptococcus pyogenes", "SPECIES", 484, 506], ["patients", "SPECIES", 524, 532], ["Staphylococcus aureus", "SPECIES", 96, 117], ["Streptococcus pyogenes", "SPECIES", 122, 144], ["Streptococcus pyogenes", "SPECIES", 484, 506], ["the studies", "TEST", 45, 56], ["Staphylococcus aureus", "PROBLEM", 96, 117], ["Streptococcus pyogenes", "PROBLEM", 122, 144], ["the pathogenesis of KS", "PROBLEM", 148, 170], ["the known staphylococcal SAgs", "PROBLEM", 240, 269], ["streptococcal SAgs", "TEST", 285, 303], ["KAWASAKI SYNDROME", "PROBLEM", 344, 361], ["INFECTIONS", "PROBLEM", 366, 376], ["Streptococcus pyogenes", "PROBLEM", 484, 506], ["Staphylococcus aureus", "OBSERVATION", 96, 117], ["Streptococcus pyogenes", "OBSERVATION", 122, 144], ["staphylococcal SAgs", "OBSERVATION", 250, 269], ["COMPLEX", "OBSERVATION_MODIFIER", 320, 327], ["KAWASAKI SYNDROME", "OBSERVATION", 344, 361], ["INFECTIONS", "OBSERVATION", 366, 376], ["Streptococcus pyogenes", "OBSERVATION", 484, 506]]], ["Stool specimens were obtained from 36 patients with KS during the acute phase and 26 age-matched healthy children.", [["Stool specimens", "ANATOMY", 0, 15], ["KS", "ANATOMY", 52, 54], ["KS", "DISEASE", 52, 54], ["Stool specimens", "CANCER", 0, 15], ["patients", "ORGANISM", 38, 46], ["children", "ORGANISM", 105, 113], ["patients", "SPECIES", 38, 46], ["children", "SPECIES", 105, 113], ["Stool specimens", "TEST", 0, 15]]], ["The authors examined genes related to five Sags-SPE-A, SPE-C, SPE-G, SPE-J, and TSST-1using polymerase chain reaction; throat and stool cultures were assessed to evaluate the presence of Streptococcus pyogenes and Staphylococcus aureus in KS patients.", [["KS", "ANATOMY", 239, 241], ["Streptococcus pyogenes", "DISEASE", 187, 209], ["Staphylococcus aureus", "DISEASE", 214, 235], ["SPE-C", "SIMPLE_CHEMICAL", 55, 60], ["SPE-G", "SIMPLE_CHEMICAL", 62, 67], ["Streptococcus pyogenes", "ORGANISM", 187, 209], ["Staphylococcus aureus", "ORGANISM", 214, 235], ["patients", "ORGANISM", 242, 250], ["Sags-SPE-A, SPE-C, SPE-G, SPE-J", "DNA", 43, 74], ["TSST", "DNA", 80, 84], ["Streptococcus pyogenes", "SPECIES", 187, 209], ["Staphylococcus aureus", "SPECIES", 214, 235], ["patients", "SPECIES", 242, 250], ["Streptococcus pyogenes", "SPECIES", 187, 209], ["Staphylococcus aureus", "SPECIES", 214, 235], ["five Sags", "TEST", 38, 47], ["SPE", "TEST", 48, 51], ["SPE", "TEST", 55, 58], ["SPE", "TEST", 62, 65], ["SPE", "TEST", 69, 72], ["TSST", "TEST", 80, 84], ["polymerase chain reaction", "PROBLEM", 92, 117], ["throat and stool cultures", "TEST", 119, 144], ["Streptococcus pyogenes", "PROBLEM", 187, 209], ["Staphylococcus aureus", "PROBLEM", 214, 235], ["throat", "ANATOMY", 119, 125], ["Streptococcus pyogenes", "OBSERVATION", 187, 209], ["Staphylococcus aureus", "OBSERVATION", 214, 235]]], ["They reported that at least one of the SAg-related genes was detected more frequently in the stools of children with KS (78).", [["stools", "ANATOMY", 93, 99], ["KS", "ANATOMY", 117, 119], ["KS", "DISEASE", 117, 119], ["SAg", "GENE_OR_GENE_PRODUCT", 39, 42], ["stools", "ORGANISM_SUBDIVISION", 93, 99], ["children", "ORGANISM", 103, 111], ["SAg-related genes", "DNA", 39, 56], ["children", "SPECIES", 103, 111], ["KS", "TEST", 117, 119]]], ["Furthermore, among 358 patients with KS, 54 developed concurrent pneumonia and 12 of these (22.2%) had high titers of anti-Mycoplasma pneumoniae antibody (>1:640), suggesting a potential role of Mycoplasma pneumoniae in KS and the importance of anti-Mycoplasma treatment (79) .THE COMPLEX RELATIONSHIP OF KAWASAKI SYNDROME AND INFECTIONSAnother study has reported a possible role of fungal infections in the development of KS in Japan, San Diego, and the island of Hawaii through an active role of tropospheric wind patterns leaving from Central Asia, in which toxins of Candida species are aerosolized (80) .", [["KS", "ANATOMY", 37, 39], ["KS", "ANATOMY", 220, 222], ["KS", "ANATOMY", 423, 425], ["KS", "DISEASE", 37, 39], ["pneumonia", "DISEASE", 65, 74], ["Mycoplasma pneumoniae", "DISEASE", 195, 216], ["KS", "DISEASE", 220, 222], ["anti-Mycoplasma", "CHEMICAL", 245, 260], ["fungal infections", "DISEASE", 383, 400], ["KS", "DISEASE", 423, 425], ["patients", "ORGANISM", 23, 31], ["anti-Mycoplasma pneumoniae", "ORGANISM", 118, 144], ["Mycoplasma pneumoniae", "ORGANISM", 195, 216], ["KS", "CANCER", 220, 222], ["anti-Mycoplasma", "SIMPLE_CHEMICAL", 245, 260], ["Candida species", "ORGANISM", 571, 586], ["anti-Mycoplasma pneumoniae antibody", "PROTEIN", 118, 153], ["patients", "SPECIES", 23, 31], ["anti-Mycoplasma pneumoniae", "SPECIES", 118, 144], ["Mycoplasma pneumoniae", "SPECIES", 195, 216], ["anti-Mycoplasma pneumoniae", "SPECIES", 118, 144], ["Mycoplasma pneumoniae", "SPECIES", 195, 216], ["KS", "TEST", 37, 39], ["concurrent pneumonia", "PROBLEM", 54, 74], ["high titers of anti-Mycoplasma pneumoniae antibody", "PROBLEM", 103, 153], ["Mycoplasma pneumoniae in KS", "PROBLEM", 195, 222], ["anti-Mycoplasma treatment", "TREATMENT", 245, 270], ["KAWASAKI SYNDROME", "PROBLEM", 305, 322], ["INFECTIONSAnother study", "TEST", 327, 350], ["fungal infections", "PROBLEM", 383, 400], ["Candida species", "PROBLEM", 571, 586], ["pneumonia", "OBSERVATION", 65, 74], ["Mycoplasma pneumoniae", "OBSERVATION", 195, 216], ["COMPLEX", "OBSERVATION_MODIFIER", 281, 288], ["KAWASAKI SYNDROME", "OBSERVATION", 305, 322], ["possible", "UNCERTAINTY", 366, 374], ["fungal", "OBSERVATION_MODIFIER", 383, 389], ["infections", "OBSERVATION", 390, 400], ["KS", "OBSERVATION", 423, 425], ["active", "OBSERVATION_MODIFIER", 483, 489], ["tropospheric wind", "OBSERVATION", 498, 515], ["Candida species", "OBSERVATION", 571, 586]]], ["In addition, due to the observation that Candida albicans-derived substances, such as Candida albicans watersoluble fraction (CAWS), induce a coronary arteritis in mice similar to that observed in KS, Sato et al. evaluated the role of a free-\u03b2-glucan diet on CAWS-induced vasculitis and found that quality of diet might affect the progression of systemic vasculitis (81) .", [["coronary", "ANATOMY", 142, 150], ["KS", "ANATOMY", 197, 199], ["coronary arteritis", "DISEASE", 142, 160], ["-\u03b2-glucan", "CHEMICAL", 241, 250], ["CAWS", "CHEMICAL", 259, 263], ["vasculitis", "DISEASE", 272, 282], ["systemic vasculitis", "DISEASE", 346, 365], ["Candida albicans", "ORGANISM", 41, 57], ["Candida albicans", "ORGANISM", 86, 102], ["coronary", "PATHOLOGICAL_FORMATION", 142, 150], ["mice", "ORGANISM", 164, 168], ["-\u03b2-glucan", "SIMPLE_CHEMICAL", 241, 250], ["CAWS", "SIMPLE_CHEMICAL", 259, 263], ["Candida albicans", "SPECIES", 41, 57], ["Candida albicans", "SPECIES", 86, 102], ["mice", "SPECIES", 164, 168], ["Candida albicans", "SPECIES", 41, 57], ["Candida albicans", "SPECIES", 86, 102], ["mice", "SPECIES", 164, 168], ["Candida albicans", "PROBLEM", 41, 57], ["Candida albicans watersoluble fraction", "PROBLEM", 86, 124], ["a coronary arteritis", "PROBLEM", 140, 160], ["a free-\u03b2-glucan diet", "TREATMENT", 235, 255], ["CAWS", "TREATMENT", 259, 263], ["vasculitis", "PROBLEM", 272, 282], ["systemic vasculitis", "PROBLEM", 346, 365], ["coronary", "ANATOMY", 142, 150], ["arteritis", "OBSERVATION", 151, 160], ["vasculitis", "OBSERVATION", 272, 282], ["systemic", "OBSERVATION_MODIFIER", 346, 354], ["vasculitis", "OBSERVATION", 355, 365]]], ["CAWS should act as a pathogen-associated molecular pattern in mice and activate lectin pathway of complement by binding to mannose-binding lectin and inducing an acute inflammatory reaction in the vascular system (82, 83) .WHAT IS KNOWN ABOUT MICROBIOTA AND KAWASAKI SYNDROMEThere are three main reasons that led us to postulate a role of the microbiota in KS.", [["vascular system", "ANATOMY", 197, 212], ["KS", "ANATOMY", 357, 359], ["CAWS", "CHEMICAL", 0, 4], ["KS", "DISEASE", 357, 359], ["mannose", "CHEMICAL", 123, 130], ["CAWS", "SIMPLE_CHEMICAL", 0, 4], ["mice", "ORGANISM", 62, 66], ["lectin", "GENE_OR_GENE_PRODUCT", 80, 86], ["complement", "GENE_OR_GENE_PRODUCT", 98, 108], ["mannose-binding lectin", "GENE_OR_GENE_PRODUCT", 123, 145], ["vascular system", "MULTI-TISSUE_STRUCTURE", 197, 212], ["lectin", "PROTEIN", 80, 86], ["mannose-binding lectin", "PROTEIN", 123, 145], ["mice", "SPECIES", 62, 66], ["mice", "SPECIES", 62, 66], ["a pathogen", "PROBLEM", 19, 29], ["mannose-binding lectin", "TEST", 123, 145], ["an acute inflammatory reaction in the vascular system", "PROBLEM", 159, 212], ["acute", "OBSERVATION_MODIFIER", 162, 167], ["inflammatory", "OBSERVATION", 168, 180], ["vascular system", "ANATOMY", 197, 212]]], ["The first is the unsatisfactory microbiological data that limited the association between infections and KS and a lack of evidence of any clear relationship between one or more pathogens with this illness.", [["KS", "ANATOMY", 105, 107], ["infections", "DISEASE", 90, 100], ["KS", "DISEASE", 105, 107], ["infections", "PROBLEM", 90, 100], ["KS", "PROBLEM", 105, 107], ["this illness", "PROBLEM", 192, 204], ["infections", "OBSERVATION", 90, 100]]], ["Second, the most frequent bacteria or viruses associated with KS have a higher prevalence in the overall pediatric population, but only a limited number of children will develop the disease.", [["KS", "ANATOMY", 62, 64], ["children", "ORGANISM", 156, 164], ["children", "SPECIES", 156, 164], ["the most frequent bacteria", "PROBLEM", 8, 34], ["viruses", "PROBLEM", 38, 45], ["KS", "PROBLEM", 62, 64], ["the disease", "PROBLEM", 178, 189], ["most frequent", "OBSERVATION_MODIFIER", 12, 25], ["bacteria", "OBSERVATION", 26, 34], ["viruses", "OBSERVATION", 38, 45], ["disease", "OBSERVATION", 182, 189]]], ["Third, the association of genetic predisposition and environmental factors in the pathogenetic process of KS makes KS itself similar to other multifactorial diseases.WHAT IS KNOWN ABOUT MICROBIOTA AND KAWASAKI SYNDROMECurrently, the majority of data has found that the composition of the gut microbiota in KS patients differs from healthy subjects.", [["KS", "ANATOMY", 106, 108], ["KS", "ANATOMY", 115, 117], ["gut microbiota", "ANATOMY", 288, 302], ["KS", "ANATOMY", 306, 308], ["KS", "DISEASE", 106, 108], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 288, 302], ["KS", "ORGANISM", 306, 308], ["patients", "ORGANISM", 309, 317], ["patients", "SPECIES", 309, 317], ["genetic predisposition", "PROBLEM", 26, 48], ["environmental factors", "PROBLEM", 53, 74], ["other multifactorial diseases", "PROBLEM", 136, 165], ["multifactorial", "OBSERVATION_MODIFIER", 142, 156], ["diseases", "OBSERVATION", 157, 165]]], ["Lee et al. have postulated that the immune system should lose tolerance toward a part of the resident intestinal flora and that environmental factors, i.e., a Western lifestyle or improved public hygiene systems, could transform the commensal flora into a pathogen one, as observed in different gastrointestinal disorders (84) .WHAT IS KNOWN ABOUT MICROBIOTA AND KAWASAKI SYNDROMEA recent study about the resident flora and KS was focused on throat flora.", [["immune system", "ANATOMY", 36, 49], ["intestinal flora", "ANATOMY", 102, 118], ["commensal flora", "ANATOMY", 233, 248], ["gastrointestinal", "ANATOMY", 295, 311], ["KS", "ANATOMY", 424, 426], ["throat flora", "ANATOMY", 442, 454], ["gastrointestinal disorders", "DISEASE", 295, 321], ["intestinal flora", "PATHOLOGICAL_FORMATION", 102, 118], ["gastrointestinal", "ORGAN", 295, 311], ["throat", "ORGANISM_SUBDIVISION", 442, 448], ["flora", "PATHOLOGICAL_FORMATION", 449, 454], ["the immune system", "PROBLEM", 32, 49], ["different gastrointestinal disorders", "PROBLEM", 285, 321], ["recent study", "TEST", 382, 394], ["throat flora", "PROBLEM", 442, 454], ["intestinal", "ANATOMY", 102, 112], ["flora", "OBSERVATION", 113, 118], ["gastrointestinal", "ANATOMY", 295, 311]]], ["Horita et al. (85) assumed that throat flora could be a reservoir of microorganisms triggering KS and, following this hypothesis, they investigated throat microorganisms of KS patients for their content and individual SAg activity.", [["throat flora", "ANATOMY", 32, 44], ["KS", "ANATOMY", 95, 97], ["KS", "ANATOMY", 173, 175], ["KS", "ORGANISM", 173, 175], ["patients", "ORGANISM", 176, 184], ["SAg", "GENE_OR_GENE_PRODUCT", 218, 221], ["SAg", "PROTEIN", 218, 221], ["patients", "SPECIES", 176, 184], ["throat flora", "PROBLEM", 32, 44], ["microorganisms triggering KS", "PROBLEM", 69, 97], ["throat microorganisms of KS", "PROBLEM", 148, 175], ["throat", "ANATOMY", 32, 38]]], ["In particular, they collected throat swabs at the start of IVIG infusion in 21 KS patients and compared them with non-KS controls (displaying other febrile illnesses).", [["throat swabs", "ANATOMY", 30, 42], ["KS", "ANATOMY", 79, 81], ["febrile illnesses", "DISEASE", 148, 165], ["IVIG", "SIMPLE_CHEMICAL", 59, 63], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["throat swabs", "TEST", 30, 42], ["IVIG infusion", "TREATMENT", 59, 72], ["non-KS controls", "TREATMENT", 114, 129], ["other febrile illnesses", "PROBLEM", 142, 165]]], ["The results showed no difference in the throat flora between KS and febrile controls even in the mean mitogenic activity of bacteria isolated (85) .WHAT IS KNOWN ABOUT MICROBIOTA AND KAWASAKI SYNDROMEThe gastrointestinal tract could be one of the primary sites of entry of bacterial toxins in children with KS, and a perturbation in the intestinal microbiota has been linked to the disease's pathophysiology in another study by Yamashiro et al. (86) who investigated the microflora of the small intestine in 15 Japanese patients with KS.", [["throat flora", "ANATOMY", 40, 52], ["KS", "ANATOMY", 61, 63], ["gastrointestinal tract", "ANATOMY", 204, 226], ["sites", "ANATOMY", 255, 260], ["KS", "ANATOMY", 307, 309], ["intestinal", "ANATOMY", 337, 347], ["small intestine", "ANATOMY", 489, 504], ["KS", "ANATOMY", 534, 536], ["febrile", "DISEASE", 68, 75], ["gastrointestinal tract", "DISEASE", 204, 226], ["KS", "DISEASE", 307, 309], ["KS", "DISEASE", 534, 536], ["throat", "ORGANISM_SUBDIVISION", 40, 46], ["gastrointestinal tract", "ORGAN", 204, 226], ["children", "ORGANISM", 293, 301], ["intestinal microbiota", "MULTI-TISSUE_STRUCTURE", 337, 358], ["small intestine", "ORGAN", 489, 504], ["patients", "ORGANISM", 520, 528], ["children", "SPECIES", 293, 301], ["patients", "SPECIES", 520, 528], ["the throat flora", "PROBLEM", 36, 52], ["febrile controls", "PROBLEM", 68, 84], ["bacteria", "PROBLEM", 124, 132], ["KAWASAKI SYNDROME", "PROBLEM", 183, 200], ["bacterial toxins", "PROBLEM", 273, 289], ["KS", "TEST", 307, 309], ["a perturbation in the intestinal microbiota", "PROBLEM", 315, 358], ["the disease's pathophysiology", "PROBLEM", 378, 407], ["another study", "TEST", 411, 424], ["no", "UNCERTAINTY", 19, 21], ["difference", "OBSERVATION_MODIFIER", 22, 32], ["throat", "ANATOMY", 40, 46], ["gastrointestinal tract", "ANATOMY", 204, 226], ["bacterial toxins", "OBSERVATION", 273, 289], ["intestinal microbiota", "ANATOMY", 337, 358], ["small intestine", "ANATOMY", 489, 504], ["15 Japanese", "OBSERVATION_MODIFIER", 508, 519]]], ["The range of bacterial species isolated from jejunal biopsies was characterized by a wider variety of Gram-positive cocci in the acute phase of KS.", [["jejunal biopsies", "ANATOMY", 45, 61], ["KS", "ANATOMY", 144, 146], ["KS", "DISEASE", 144, 146], ["jejunal biopsies", "MULTI-TISSUE_STRUCTURE", 45, 61], ["Gram", "GENE_OR_GENE_PRODUCT", 102, 106], ["bacterial species", "PROBLEM", 13, 30], ["jejunal biopsies", "TEST", 45, 61], ["Gram-positive cocci", "PROBLEM", 102, 121], ["the acute phase of KS", "PROBLEM", 125, 146], ["range", "OBSERVATION_MODIFIER", 4, 9], ["bacterial species", "OBSERVATION", 13, 30], ["jejunal", "ANATOMY", 45, 52], ["biopsies", "OBSERVATION", 53, 61], ["positive cocci", "OBSERVATION", 107, 121], ["acute phase", "OBSERVATION_MODIFIER", 129, 140], ["KS", "OBSERVATION", 144, 146]]], ["Notably, 5 kinds of streptococci (Streptococcus salivarius, Streptococcus mitis, Streptococcus oralis, Streptococcus sangius, and Gemella haemolysans) and 2 kinds of staphylococci (Staphylococcus capitis and Staphylococcus hyicus) were isolated only from KS patients, suggesting that some antigens inducing a delayed-type hypersensitivity reaction in the mucosa might inundate the body by breaching the barrier of the small intestinal mucosa of KS patients (86) .", [["KS", "ANATOMY", 255, 257], ["mucosa", "ANATOMY", 355, 361], ["body", "ANATOMY", 381, 385], ["small intestinal mucosa", "ANATOMY", 418, 441], ["KS", "ANATOMY", 445, 447], ["streptococci", "CHEMICAL", 20, 32], ["staphylococci", "DISEASE", 166, 179], ["Staphylococcus capitis", "DISEASE", 181, 203], ["hypersensitivity", "DISEASE", 322, 338], ["streptococci", "ORGANISM", 20, 32], ["Streptococcus salivarius", "ORGANISM", 34, 58], ["Streptococcus mitis", "ORGANISM", 60, 79], ["Streptococcus oralis", "ORGANISM", 81, 101], ["Streptococcus sangius", "ORGANISM", 103, 124], ["Gemella haemolysans", "ORGANISM", 130, 149], ["staphylococci", "CANCER", 166, 179], ["Staphylococcus capitis", "ORGANISM", 181, 203], ["Staphylococcus hyicus", "ORGANISM", 208, 229], ["patients", "ORGANISM", 258, 266], ["mucosa", "MULTI-TISSUE_STRUCTURE", 355, 361], ["body", "ORGANISM_SUBDIVISION", 381, 385], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 424, 441], ["patients", "ORGANISM", 448, 456], ["Streptococcus salivarius", "SPECIES", 34, 58], ["Streptococcus mitis", "SPECIES", 60, 79], ["Streptococcus oralis", "SPECIES", 81, 101], ["Streptococcus sangius", "SPECIES", 103, 124], ["Gemella haemolysans", "SPECIES", 130, 149], ["Staphylococcus capitis", "SPECIES", 181, 203], ["Staphylococcus hyicus", "SPECIES", 208, 229], ["patients", "SPECIES", 258, 266], ["patients", "SPECIES", 448, 456], ["Streptococcus salivarius", "SPECIES", 34, 58], ["Streptococcus mitis", "SPECIES", 60, 79], ["Streptococcus oralis", "SPECIES", 81, 101], ["Streptococcus sangius", "SPECIES", 103, 124], ["Gemella haemolysans", "SPECIES", 130, 149], ["Staphylococcus capitis", "SPECIES", 181, 203], ["Staphylococcus hyicus", "SPECIES", 208, 229], ["streptococci", "PROBLEM", 20, 32], ["Streptococcus salivarius", "PROBLEM", 34, 58], ["Streptococcus mitis", "PROBLEM", 60, 79], ["Streptococcus oralis", "TEST", 81, 101], ["Streptococcus sangius", "TEST", 103, 124], ["Gemella haemolysans", "TEST", 130, 149], ["staphylococci", "PROBLEM", 166, 179], ["Staphylococcus capitis", "PROBLEM", 181, 203], ["Staphylococcus hyicus", "PROBLEM", 208, 229], ["some antigens", "PROBLEM", 284, 297], ["a delayed-type hypersensitivity reaction", "PROBLEM", 307, 347], ["5 kinds", "OBSERVATION_MODIFIER", 9, 16], ["streptococci", "OBSERVATION", 20, 32], ["staphylococci", "OBSERVATION", 166, 179], ["hypersensitivity reaction", "OBSERVATION", 322, 347], ["mucosa", "ANATOMY", 355, 361], ["small", "OBSERVATION_MODIFIER", 418, 423], ["intestinal mucosa", "ANATOMY", 424, 441]]], ["In fact, Nagata et al. (87) investigated cell surface phenotypes of mononuclear cells and enterocytes in the jejunal mucosa of 16 Japanese patients with KS and in 10 patients with diarrhea due to cow's milk protein intolerance.", [["cell surface", "ANATOMY", 41, 53], ["mononuclear cells", "ANATOMY", 68, 85], ["enterocytes", "ANATOMY", 90, 101], ["jejunal mucosa", "ANATOMY", 109, 123], ["KS", "ANATOMY", 153, 155], ["KS", "DISEASE", 153, 155], ["diarrhea", "DISEASE", 180, 188], ["cell", "CELL", 41, 45], ["mononuclear cells", "CELL", 68, 85], ["enterocytes", "CELL", 90, 101], ["jejunal mucosa", "MULTI-TISSUE_STRUCTURE", 109, 123], ["patients", "ORGANISM", 139, 147], ["patients", "ORGANISM", 166, 174], ["cow", "ORGANISM", 196, 199], ["milk", "ORGANISM_SUBSTANCE", 202, 206], ["mononuclear cells", "CELL_TYPE", 68, 85], ["enterocytes", "CELL_TYPE", 90, 101], ["patients", "SPECIES", 139, 147], ["patients", "SPECIES", 166, 174], ["cow", "SPECIES", 196, 199], ["cow", "SPECIES", 196, 199], ["cell surface phenotypes of mononuclear cells", "PROBLEM", 41, 85], ["enterocytes in the jejunal mucosa", "PROBLEM", 90, 123], ["KS", "TEST", 153, 155], ["diarrhea", "PROBLEM", 180, 188], ["cow's milk protein intolerance", "PROBLEM", 196, 226], ["mononuclear cells", "OBSERVATION", 68, 85], ["enterocytes", "ANATOMY", 90, 101], ["jejunal mucosa", "ANATOMY", 109, 123], ["16 Japanese", "OBSERVATION_MODIFIER", 127, 138]]], ["Both HLA-DR+CD3+ and DR+CD4+ cells were significantly increased, and CD8+ cells significantly reduced in the lamina propria of KS patients during the acute phase compared with patients with cow's milk protein intolerance.", [["HLA-DR+CD3+ and DR+CD4+ cells", "ANATOMY", 5, 34], ["CD8+ cells", "ANATOMY", 69, 79], ["lamina propria", "ANATOMY", 109, 123], ["KS", "ANATOMY", 127, 129], ["milk", "ANATOMY", 196, 200], ["HLA-DR", "GENE_OR_GENE_PRODUCT", 5, 11], ["CD3", "GENE_OR_GENE_PRODUCT", 12, 15], ["DR", "GENE_OR_GENE_PRODUCT", 21, 23], ["CD8", "GENE_OR_GENE_PRODUCT", 69, 72], ["lamina propria", "TISSUE", 109, 123], ["patients", "ORGANISM", 130, 138], ["patients", "ORGANISM", 176, 184], ["cow", "ORGANISM_SUBDIVISION", 190, 193], ["milk", "ORGANISM_SUBSTANCE", 196, 200], ["DR", "PROTEIN", 9, 11], ["CD3", "PROTEIN", 12, 15], ["DR", "PROTEIN", 21, 23], ["CD4", "PROTEIN", 24, 27], ["CD8", "PROTEIN", 69, 72], ["patients", "SPECIES", 130, 138], ["patients", "SPECIES", 176, 184], ["cow", "SPECIES", 190, 193], ["cow", "SPECIES", 190, 193], ["Both HLA", "TEST", 0, 8], ["CD3", "TEST", 12, 15], ["DR", "TEST", 21, 23], ["CD4+ cells", "PROBLEM", 24, 34], ["CD8+ cells", "PROBLEM", 69, 79], ["cow's milk protein intolerance", "PROBLEM", 190, 220], ["HLA", "ANATOMY", 5, 8], ["CD3", "ANATOMY", 12, 15], ["CD4+ cells", "OBSERVATION", 24, 34], ["significantly", "OBSERVATION_MODIFIER", 40, 53], ["increased", "OBSERVATION_MODIFIER", 54, 63], ["CD8+ cells", "OBSERVATION", 69, 79], ["significantly", "OBSERVATION_MODIFIER", 80, 93], ["reduced", "OBSERVATION_MODIFIER", 94, 101], ["lamina", "ANATOMY_MODIFIER", 109, 115], ["propria", "ANATOMY_MODIFIER", 116, 123]]], ["These cell patterns returned to normal in the convalescent phase of KS.", [["cell", "ANATOMY", 6, 10], ["KS", "ANATOMY", 68, 70], ["KS", "DISEASE", 68, 70], ["cell", "CELL", 6, 10], ["These cell patterns", "TEST", 0, 19], ["normal", "OBSERVATION", 32, 38], ["convalescent phase", "OBSERVATION_MODIFIER", 46, 64]]], ["The authors concluded that a delayed-type hypersensitivity reaction was indeed present in the small intestinal mucosa of KS patients (87) .WHAT IS KNOWN ABOUT MICROBIOTA AND KAWASAKI SYNDROMEDue to the fact that the gastrointestinal tract is the largest interface between microbial factors and their host, containing the largest proportion of bacteria and the largest amount of lymphoid tissue in the body, it was hypothesized by Eladawy et al. that the intestinal milieu could be altered in children with KS, and indeed KS patients have a higher incidence of gastrointestinal symptoms and complications (88) .", [["small intestinal mucosa", "ANATOMY", 94, 117], ["KS", "ANATOMY", 121, 123], ["gastrointestinal tract", "ANATOMY", 216, 238], ["lymphoid tissue", "ANATOMY", 378, 393], ["body", "ANATOMY", 401, 405], ["intestinal", "ANATOMY", 454, 464], ["KS", "ANATOMY", 506, 508], ["KS", "ANATOMY", 521, 523], ["gastrointestinal", "ANATOMY", 560, 576], ["hypersensitivity", "DISEASE", 42, 58], ["gastrointestinal tract", "DISEASE", 216, 238], ["KS", "DISEASE", 506, 508], ["gastrointestinal symptoms", "DISEASE", 560, 585], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 100, 117], ["patients", "ORGANISM", 124, 132], ["gastrointestinal tract", "ORGAN", 216, 238], ["lymphoid tissue", "TISSUE", 378, 393], ["body", "ORGANISM_SUBDIVISION", 401, 405], ["intestinal", "ORGAN", 454, 464], ["children", "ORGANISM", 492, 500], ["patients", "ORGANISM", 524, 532], ["gastrointestinal", "ORGAN", 560, 576], ["microbial factors", "PROTEIN", 272, 289], ["patients", "SPECIES", 124, 132], ["children", "SPECIES", 492, 500], ["patients", "SPECIES", 524, 532], ["a delayed-type hypersensitivity reaction", "PROBLEM", 27, 67], ["the gastrointestinal tract", "PROBLEM", 212, 238], ["bacteria", "PROBLEM", 343, 351], ["lymphoid tissue in the body", "PROBLEM", 378, 405], ["gastrointestinal symptoms", "PROBLEM", 560, 585], ["complications", "PROBLEM", 590, 603], ["small", "ANATOMY_MODIFIER", 94, 99], ["intestinal mucosa", "ANATOMY", 100, 117], ["gastrointestinal tract", "ANATOMY", 216, 238], ["largest", "OBSERVATION_MODIFIER", 246, 253], ["microbial factors", "OBSERVATION", 272, 289], ["largest", "OBSERVATION_MODIFIER", 321, 328], ["bacteria", "OBSERVATION", 343, 351], ["largest", "OBSERVATION_MODIFIER", 360, 367], ["amount", "OBSERVATION_MODIFIER", 368, 374], ["lymphoid tissue", "OBSERVATION", 378, 393], ["body", "ANATOMY", 401, 405], ["intestinal", "ANATOMY", 454, 464], ["altered", "OBSERVATION_MODIFIER", 481, 488], ["gastrointestinal", "ANATOMY", 560, 576]]], ["Specifically, Takeshita et al. (89) evaluated 20 patients with KS, 20 patients with acute febrile diseases and 20 healthy children, finding that the incidence of Lactobacilli isolated from KS patients (2/20, 10%) was significantly lower (p < 0.001) than in the other cohorts.", [["KS", "ANATOMY", 63, 65], ["KS", "ANATOMY", 189, 191], ["KS", "DISEASE", 63, 65], ["acute febrile diseases", "DISEASE", 84, 106], ["Lactobacilli", "CHEMICAL", 162, 174], ["patients", "ORGANISM", 49, 57], ["patients", "ORGANISM", 70, 78], ["children", "ORGANISM", 122, 130], ["Lactobacilli", "ORGANISM", 162, 174], ["KS", "ORGANISM", 189, 191], ["patients", "ORGANISM", 192, 200], ["patients", "SPECIES", 49, 57], ["patients", "SPECIES", 70, 78], ["children", "SPECIES", 122, 130], ["patients", "SPECIES", 192, 200], ["acute febrile diseases", "PROBLEM", 84, 106], ["Lactobacilli", "TREATMENT", 162, 174], ["acute", "OBSERVATION_MODIFIER", 84, 89], ["febrile", "OBSERVATION", 90, 97]]], ["Moreover, no significant differences in the presence of Staphylococcus, Streptococcus, Enterococcus, Enterobacteriaceae, Bifidobacterium, Clostridium, Veillonella, or Bacteroides were found among the three groups.", [["Staphylococcus, Streptococcus", "ORGANISM", 56, 85], ["Bifidobacterium", "SIMPLE_CHEMICAL", 121, 136], ["Veillonella", "SIMPLE_CHEMICAL", 151, 162], ["Bacteroides", "GENE_OR_GENE_PRODUCT", 167, 178], ["Staphylococcus", "PROBLEM", 56, 70], ["Streptococcus", "PROBLEM", 72, 85], ["Enterococcus", "PROBLEM", 87, 99], ["Enterobacteriaceae", "PROBLEM", 101, 119], ["Bifidobacterium", "PROBLEM", 121, 136], ["Clostridium", "PROBLEM", 138, 149], ["Veillonella", "PROBLEM", 151, 162], ["Bacteroides", "PROBLEM", 167, 178], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["Staphylococcus", "OBSERVATION", 56, 70]]], ["Conversely, the presence of Eubacterium and Peptostreptococcus was significantly higher in KS patients than in patients with other febrile diseases (p < 0.01 and p < 0.05, respectively), though no significant differences were observed between KS patients and healthy children (89) .", [["KS", "ANATOMY", 91, 93], ["KS", "ANATOMY", 243, 245], ["febrile diseases", "DISEASE", 131, 147], ["Eubacterium", "GENE_OR_GENE_PRODUCT", 28, 39], ["Peptostreptococcus", "GENE_OR_GENE_PRODUCT", 44, 62], ["patients", "ORGANISM", 94, 102], ["patients", "ORGANISM", 111, 119], ["patients", "ORGANISM", 246, 254], ["children", "ORGANISM", 267, 275], ["patients", "SPECIES", 94, 102], ["patients", "SPECIES", 111, 119], ["patients", "SPECIES", 246, 254], ["children", "SPECIES", 267, 275], ["Eubacterium", "PROBLEM", 28, 39], ["Peptostreptococcus", "PROBLEM", 44, 62], ["other febrile diseases", "PROBLEM", 125, 147], ["Eubacterium", "OBSERVATION", 28, 39], ["Peptostreptococcus", "OBSERVATION", 44, 62], ["higher", "OBSERVATION_MODIFIER", 81, 87], ["no", "UNCERTAINTY", 194, 196], ["significant", "OBSERVATION_MODIFIER", 197, 208]]], ["This observation confirmed that the majority of Lactobacillus species are anti-inflammatory and beneficial for health, particularly during the first years of life, due to their action in protecting against colitis, reducing pro-inflammatory cytokines such as TNF-\u03b1, IL-1, or IL-6, and increasing the subsets of regulatory T cells (90) .", [["regulatory T cells", "ANATOMY", 311, 329], ["colitis", "DISEASE", 206, 213], ["Lactobacillus species", "ORGANISM", 48, 69], ["colitis", "PATHOLOGICAL_FORMATION", 206, 213], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 259, 264], ["IL-1", "GENE_OR_GENE_PRODUCT", 266, 270], ["IL-6", "GENE_OR_GENE_PRODUCT", 275, 279], ["regulatory T cells", "CELL", 311, 329], ["pro-inflammatory cytokines", "PROTEIN", 224, 250], ["TNF", "PROTEIN", 259, 262], ["IL-6", "PROTEIN", 275, 279], ["regulatory T cells", "CELL_TYPE", 311, 329], ["This observation", "TEST", 0, 16], ["Lactobacillus species", "PROBLEM", 48, 69], ["colitis", "PROBLEM", 206, 213], ["pro-inflammatory cytokines", "TEST", 224, 250], ["TNF", "TEST", 259, 262], ["IL", "TEST", 266, 268], ["regulatory T cells", "TREATMENT", 311, 329], ["Lactobacillus species", "OBSERVATION", 48, 69]]], ["In fact, several studies have largely described the specific action of Lactobacilli in maintaining the epithelial homeostasis of the gut and their striking anti-inflammatory potential (91, 92) .", [["epithelial", "ANATOMY", 103, 113], ["gut", "ANATOMY", 133, 136], ["Lactobacilli", "CHEMICAL", 71, 83], ["Lactobacilli", "SIMPLE_CHEMICAL", 71, 83], ["epithelial", "TISSUE", 103, 113], ["gut", "ORGAN", 133, 136], ["several studies", "TEST", 9, 24], ["Lactobacilli", "TREATMENT", 71, 83], ["epithelial homeostasis", "OBSERVATION", 103, 125], ["gut", "ANATOMY", 133, 136]]], ["Nagata et al. (93) also studied the role of the gut microbiota in KS pathogenesis via SAgs and heat shock proteins (Hsps) produced by gut bacteria: the authors evaluated Sags and Hsps released by microorganisms isolated from the jejunal mucosa of 19 children with KS compared with 15 age-matched healthy controls, identifying 13 strains of Gram-negative microbes from patients with KS, which produced a large amount of Hsp60, having the power to induce an over-secretion of proinflammatory cytokines.", [["gut microbiota", "ANATOMY", 48, 62], ["KS", "ANATOMY", 66, 68], ["jejunal mucosa", "ANATOMY", 229, 243], ["KS", "ANATOMY", 264, 266], ["KS", "ANATOMY", 382, 384], ["KS", "DISEASE", 264, 266], ["KS", "DISEASE", 382, 384], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 48, 62], ["SAgs", "GENE_OR_GENE_PRODUCT", 86, 90], ["heat shock proteins", "GENE_OR_GENE_PRODUCT", 95, 114], ["Hsps", "GENE_OR_GENE_PRODUCT", 116, 120], ["Sags", "GENE_OR_GENE_PRODUCT", 170, 174], ["Hsps", "GENE_OR_GENE_PRODUCT", 179, 183], ["jejunal mucosa", "MULTI-TISSUE_STRUCTURE", 229, 243], ["children", "ORGANISM", 250, 258], ["Gram", "GENE_OR_GENE_PRODUCT", 340, 344], ["patients", "ORGANISM", 368, 376], ["Hsp60", "GENE_OR_GENE_PRODUCT", 419, 424], ["SAgs", "PROTEIN", 86, 90], ["heat shock proteins", "PROTEIN", 95, 114], ["Hsps", "PROTEIN", 116, 120], ["Sags", "PROTEIN", 170, 174], ["Hsps", "PROTEIN", 179, 183], ["Hsp60", "PROTEIN", 419, 424], ["proinflammatory cytokines", "PROTEIN", 474, 499], ["children", "SPECIES", 250, 258], ["patients", "SPECIES", 368, 376], ["heat shock proteins", "PROBLEM", 95, 114], ["Hsps", "TEST", 116, 120], ["gut bacteria", "PROBLEM", 134, 146], ["KS", "TEST", 264, 266], ["Gram", "TEST", 340, 344], ["KS", "TEST", 382, 384], ["Hsp60", "PROBLEM", 419, 424], ["proinflammatory cytokines", "PROBLEM", 474, 499], ["gut microbiota", "ANATOMY", 48, 62], ["gut", "ANATOMY", 134, 137], ["bacteria", "OBSERVATION", 138, 146], ["jejunal mucosa", "ANATOMY", 229, 243], ["negative microbes", "OBSERVATION_MODIFIER", 345, 362], ["large", "OBSERVATION_MODIFIER", 403, 408], ["amount", "OBSERVATION_MODIFIER", 409, 415], ["proinflammatory cytokines", "OBSERVATION", 474, 499]]], ["They also identified 18 strains of Grampositive cocci with SAg properties which induced the expansion of V\u03b22 T cells in vitro (93) .", [["V\u03b22 T cells", "ANATOMY", 105, 116], ["Grampositive cocci", "CELL", 35, 53], ["SAg", "ORGANISM", 59, 62], ["V\u03b22 T cells", "CELL", 105, 116], ["V\u03b22 T cells", "CELL_TYPE", 105, 116], ["Grampositive cocci", "PROBLEM", 35, 53], ["SAg properties", "PROBLEM", 59, 73], ["cocci", "OBSERVATION", 48, 53], ["expansion", "OBSERVATION_MODIFIER", 92, 101]]], ["This microbiological analysis disclosed different causative bacteria with a final common pathway of immune activation, which might contribute to the final development of KS.WHAT IS KNOWN ABOUT MICROBIOTA AND KAWASAKI SYNDROMEIn order to evaluate the differential microbiota composition of KS patients, Kinumaki et al. (94) performed a metagenomic analysis using non-culture-based methods on feces.", [["KS", "ANATOMY", 170, 172], ["KS", "ANATOMY", 289, 291], ["feces", "ANATOMY", 391, 396], ["KS", "DISEASE", 170, 172], ["KS", "CANCER", 170, 172], ["patients", "ORGANISM", 292, 300], ["feces", "ORGANISM_SUBDIVISION", 391, 396], ["patients", "SPECIES", 292, 300], ["This microbiological analysis", "TEST", 0, 29], ["different causative bacteria", "PROBLEM", 40, 68], ["immune activation", "PROBLEM", 100, 117], ["a metagenomic analysis", "TEST", 333, 355], ["non-culture", "TEST", 362, 373], ["immune activation", "OBSERVATION", 100, 117], ["KS", "OBSERVATION", 170, 172]]], ["Their study included 28 KS patients (15 males and 13 females, aged 1-114 months, with a median age of 25 months); the time of admission to the study was defined as the acute phase, while 4-6 months after the onset of KS was considered as the nonacute phase.", [["KS", "ANATOMY", 24, 26], ["KS", "ANATOMY", 217, 219], ["KS", "DISEASE", 217, 219], ["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35], ["Their study", "TEST", 0, 11], ["the study", "TEST", 139, 148], ["KS", "TEST", 217, 219]]], ["The authors collected a total of 56 samples\u221228 samples each for both acute and non-acute phases.", [["samples", "ANATOMY", 36, 43], ["samples", "ANATOMY", 47, 54], ["both acute and non-acute phases", "PROBLEM", 64, 95]]], ["It was demonstrated that the genera Ruminococcus, Roseburia, and Faecalibacterium were mostly predominant during the nonacute phase, while a higher presence of Streptococcus spp., including Streptococcus pneumoniae, pseudopneumoniae, mitis, oralis, gordonii, and sanguinis, was detected in the fecal samples during the acute phase (94) .WHAT IS KNOWN ABOUT MICROBIOTA AND KAWASAKI SYNDROMEThis novel interpretation of a disease can be shared by other conditions, as liver cirrhosis and Sj\u00f6gren syndrome, in which major changes of gut microbiota with higher proportions of Streptococcus spp. have been demonstrated (95, 96) .", [["fecal samples", "ANATOMY", 294, 307], ["liver cirrhosis", "ANATOMY", 466, 481], ["gut microbiota", "ANATOMY", 530, 544], ["Streptococcus spp.", "DISEASE", 160, 178], ["Streptococcus pneumoniae, pseudopneumoniae", "DISEASE", 190, 232], ["liver cirrhosis", "DISEASE", 466, 481], ["Sj\u00f6gren syndrome", "DISEASE", 486, 502], ["Ruminococcus", "GENE_OR_GENE_PRODUCT", 36, 48], ["Roseburia", "GENE_OR_GENE_PRODUCT", 50, 59], ["Faecalibacterium", "GENE_OR_GENE_PRODUCT", 65, 81], ["Streptococcus spp.", "ORGANISM", 160, 178], ["Streptococcus pneumoniae", "ORGANISM", 190, 214], ["mitis, oralis", "ORGANISM", 234, 247], ["gordonii", "ORGANISM", 249, 257], ["sanguinis", "ORGANISM", 263, 272], ["fecal samples", "ORGANISM_SUBSTANCE", 294, 307], ["liver", "ORGAN", 466, 471], ["gut", "ORGANISM_SUBDIVISION", 530, 533], ["Streptococcus spp", "ORGANISM", 572, 589], ["Streptococcus spp.", "SPECIES", 160, 178], ["Streptococcus pneumoniae", "SPECIES", 190, 214], ["pseudopneumoniae", "SPECIES", 216, 232], ["mitis, oralis", "SPECIES", 234, 247], ["gordonii", "SPECIES", 249, 257], ["sanguinis", "SPECIES", 263, 272], ["Streptococcus spp", "SPECIES", 572, 589], ["Streptococcus spp.", "SPECIES", 160, 178], ["Streptococcus pneumoniae", "SPECIES", 190, 214], ["the genera Ruminococcus", "TEST", 25, 48], ["Roseburia", "TEST", 50, 59], ["Faecalibacterium", "PROBLEM", 65, 81], ["Streptococcus spp.", "PROBLEM", 160, 178], ["Streptococcus pneumoniae", "PROBLEM", 190, 214], ["pseudopneumoniae", "PROBLEM", 216, 232], ["mitis", "PROBLEM", 234, 239], ["sanguinis", "PROBLEM", 263, 272], ["the fecal samples", "TEST", 290, 307], ["a disease", "PROBLEM", 418, 427], ["liver cirrhosis", "PROBLEM", 466, 481], ["Sj\u00f6gren syndrome", "PROBLEM", 486, 502], ["Streptococcus spp", "PROBLEM", 572, 589], ["genera Ruminococcus", "OBSERVATION", 29, 48], ["Streptococcus spp.", "OBSERVATION", 160, 178], ["Streptococcus pneumoniae", "OBSERVATION", 190, 214], ["mitis", "OBSERVATION", 234, 239], ["fecal", "ANATOMY", 294, 299], ["disease", "OBSERVATION", 420, 427], ["liver", "ANATOMY", 466, 471], ["cirrhosis", "OBSERVATION", 472, 481], ["Sj\u00f6gren syndrome", "OBSERVATION", 486, 502], ["Streptococcus spp", "OBSERVATION", 572, 589]]], ["These findings taken as a whole suggest that many other immune-mediated disorders are likely to be connected to an abnormal bacterial colonization of the intestinal tract, with a main role for Streptococcus spp., and that changes in the gut microflora composition might promote systemic and extra-intestinal inflammation.", [["intestinal tract", "ANATOMY", 154, 170], ["gut microflora", "ANATOMY", 237, 251], ["inflammation", "DISEASE", 308, 320], ["intestinal tract", "ORGANISM_SUBDIVISION", 154, 170], ["Streptococcus spp.", "ORGANISM", 193, 211], ["gut microflora", "MULTI-TISSUE_STRUCTURE", 237, 251], ["Streptococcus spp.", "SPECIES", 193, 211], ["Streptococcus spp.", "SPECIES", 193, 211], ["many other immune-mediated disorders", "PROBLEM", 45, 81], ["an abnormal bacterial colonization of the intestinal tract", "PROBLEM", 112, 170], ["Streptococcus spp.", "PROBLEM", 193, 211], ["the gut microflora composition", "TREATMENT", 233, 263], ["systemic and extra-intestinal inflammation", "PROBLEM", 278, 320], ["abnormal", "OBSERVATION_MODIFIER", 115, 123], ["bacterial colonization", "OBSERVATION", 124, 146], ["intestinal tract", "ANATOMY", 154, 170], ["systemic", "OBSERVATION_MODIFIER", 278, 286], ["extra-intestinal", "ANATOMY", 291, 307], ["inflammation", "OBSERVATION", 308, 320]]], ["Therefore, all presented studies confirm the concept that an imbalance in the gut microbiota might directly or indirectly interfere with the normal functions of the immune system, and that the interaction with other environmental factors, mainly infectious agents, might lead to the final development of KS.", [["gut microbiota", "ANATOMY", 78, 92], ["immune system", "ANATOMY", 165, 178], ["KS", "ANATOMY", 304, 306], ["KS", "DISEASE", 304, 306], ["gut", "ORGANISM_SUBDIVISION", 78, 81], ["immune system", "ANATOMICAL_SYSTEM", 165, 178], ["KS", "CANCER", 304, 306], ["all presented studies", "TEST", 11, 32], ["an imbalance", "PROBLEM", 58, 70], ["imbalance", "OBSERVATION", 61, 70], ["KS", "OBSERVATION", 304, 306]]], ["Table 1 shows the characteristics of the microbiota in children with KS, as emerging by the most relevant studies dedicated to this issue.CONCLUSIVE REMARKS AND FUTURE PERSPECTIVESAs no etiologic agent has ever been accused of being directly involved in the etiology of KS, basic research evaluating the pathogenic mechanisms of this disease will probably provide better therapies and probably consent to identify the most vulnerable hosts and protect them.", [["KS", "ANATOMY", 69, 71], ["KS", "ANATOMY", 270, 272], ["KS", "DISEASE", 69, 71], ["KS", "DISEASE", 270, 272], ["children", "ORGANISM", 55, 63], ["children", "SPECIES", 55, 63], ["basic research", "TEST", 274, 288], ["this disease", "PROBLEM", 329, 341]]], ["A potential relationship between eubiosis and the protean functions of immunity has been contemplated by different studies, and conversely a relationship should exist between dysbiosis and immunity dysfunction shown by various diseases (97) .", [["eubiosis", "DISEASE", 33, 41], ["dysbiosis", "DISEASE", 175, 184], ["immunity dysfunction", "DISEASE", 189, 209], ["different studies", "TEST", 105, 122], ["dysbiosis", "PROBLEM", 175, 184], ["immunity dysfunction", "PROBLEM", 189, 209], ["various diseases", "PROBLEM", 219, 235]]], ["It is strengthened that heterogeneity and abnormalities in the intestinal microflora composition may trigger or contribute to the development of specific diseases, and an increasing amount of research and microbiologic observations have led to a role of the intestinal microbiota for KS to be postulated.", [["intestinal microflora", "ANATOMY", 63, 84], ["intestinal", "ANATOMY", 258, 268], ["KS", "ANATOMY", 284, 286], ["intestinal microflora", "MULTI-TISSUE_STRUCTURE", 63, 84], ["intestinal microbiota", "MULTI-TISSUE_STRUCTURE", 258, 279], ["abnormalities in the intestinal microflora composition", "PROBLEM", 42, 96], ["specific diseases", "PROBLEM", 145, 162], ["microbiologic observations", "TEST", 205, 231], ["KS", "PROBLEM", 284, 286], ["heterogeneity", "OBSERVATION_MODIFIER", 24, 37], ["abnormalities", "OBSERVATION", 42, 55], ["intestinal microflora", "ANATOMY", 63, 84], ["specific", "OBSERVATION_MODIFIER", 145, 153], ["diseases", "OBSERVATION", 154, 162], ["increasing", "OBSERVATION_MODIFIER", 171, 181], ["amount", "OBSERVATION_MODIFIER", 182, 188], ["intestinal", "ANATOMY", 258, 268]]], ["The principal obstacle of today's medical literature is to understand if the microbiota modification during KS can cause the disease or if it is a mark and a consequence of the disease itself, and if modulating the microbiota/microbiome might represent a future target of therapy in KS.", [["KS", "ANATOMY", 108, 110], ["KS", "ANATOMY", 283, 285], ["KS", "DISEASE", 283, 285], ["KS", "CANCER", 283, 285], ["the disease", "PROBLEM", 121, 132], ["the disease itself", "PROBLEM", 173, 191], ["therapy", "TREATMENT", 272, 279], ["principal", "OBSERVATION_MODIFIER", 4, 13], ["obstacle", "OBSERVATION_MODIFIER", 14, 22], ["disease", "OBSERVATION", 125, 132], ["disease", "OBSERVATION", 177, 184]]], ["This raises the hypothesis of targeting intestinal microflora in order to restore eubiosis through the rational use of antibiotics, xenobiotics, probiotics and nutrients.", [["intestinal microflora", "ANATOMY", 40, 61], ["intestinal microflora", "MULTI-TISSUE_STRUCTURE", 40, 61], ["intestinal microflora", "TREATMENT", 40, 61], ["antibiotics", "TREATMENT", 119, 130], ["xenobiotics", "TREATMENT", 132, 143], ["probiotics", "TREATMENT", 145, 155], ["intestinal", "ANATOMY", 40, 50]]], ["While multicenter trials and registries may allow us to improve the general outcome of KS, further in-depth analysis in larger cohorts of affected children will probably unravel the tangled pathogenesis of this mysterious disorder and find new targets for identifying disease-modifying agents or more specific therapies.AUTHOR CONTRIBUTIONSSE, IP, and DR contributed to all stages of the preparation of this manuscript, including conception and writing.", [["KS", "ANATOMY", 87, 89], ["mysterious disorder", "DISEASE", 211, 230], ["children", "ORGANISM", 147, 155], ["children", "SPECIES", 147, 155], ["further in-depth analysis", "TEST", 91, 116], ["this mysterious disorder", "PROBLEM", 206, 230], ["disease", "PROBLEM", 268, 275], ["modifying agents", "TREATMENT", 276, 292], ["specific therapies", "TREATMENT", 301, 319]]]], "PMC7096093": [["Neue tumorspezifische SubstanzenDie auff\u00e4lligste Entwicklung in der modernen Onkologie ist die Vielzahl neu zugelassener Substanzen, die ihre antitumor\u00f6se Wirkung weniger aufgrund konventioneller zytotoxischer Wirkmechanismen, sondern vielmehr aufgrund zellbiologischer Mechanismen wie Signaltransduktionshemmung oder Apoptoseregulation entfalten.", [["Neue tumorspezifische SubstanzenDie", "TREATMENT", 0, 35]]], ["Diese gezielt auf zellbiologische Prozesse in Tumorzellen einwirkenden Substanzen werden daher auch als \u201etargeted therapies\u201c bezeichnet; sie nehmen neben \u00e4lteren und neueren \u201eChemotherapeutika\u201c (dieser Begriff bezeichnet im onkologischen Sinn tumorwirksame Medikamente, die gegen ubiquit\u00e4r vorhandene Zellteilungsvorg\u00e4nge und damit allgemein zytotoxisch in Abh\u00e4ngigkeit vom Proliferationsgrad wirken) eine zunehmend bedeutsame Stellung ein.", [["Diese gezielt auf zellbiologische Prozesse in Tumorzellen einwirkenden Substanzen werden daher auch als \u201etargeted therapies\u201c bezeichnet; sie nehmen neben \u00e4lteren und neueren \u201eChemotherapeutika\u201c (dieser Begriff bezeichnet im onkologischen Sinn tumorwirksame Medikamente, die gegen ubiquit\u00e4r vorhandene Zellteilungsvorg\u00e4nge und damit allgemein zytotoxisch in Abh\u00e4ngigkeit vom Proliferationsgrad wirken) eine zunehmend bedeutsame Stellung ein", "SPECIES", 0, 439], ["Diese gezielt auf zellbiologische Prozesse", "TREATMENT", 0, 42], ["bezeichnet", "TREATMENT", 125, 135], ["dieser Begriff bezeichnet", "TREATMENT", 195, 220], ["Sinn tumorwirksame Medikamente", "TREATMENT", 238, 268], ["vorhandene Zellteilungsvorg\u00e4nge", "TREATMENT", 290, 321], ["zytotoxisch", "TREATMENT", 342, 353]]], ["Der Begriff der Targeted therapies umfasst dabei eine Vielzahl strukturell uneinheitlicher Substanzen, z.", [["umfasst dabei eine Vielzahl", "TREATMENT", 35, 62]]], ["B. monoklonale Antik\u00f6rper gegen zellwachstumsrelevante Rezeptoren und Liganden, peroral applizierbare Tyrosinkinaseinhibitoren (TKI), \u201emultitargeted\u201c TKI oder Serin-/Threonin-Kinase-Inhibitoren.", [["Liganden", "CHEMICAL", 70, 78], ["B. monoklonale", "SPECIES", 0, 14], ["B. monoklonale Antik\u00f6rper gegen zellwachstumsrelevante Rezeptoren", "TREATMENT", 0, 65], ["peroral applizierbare Tyrosinkinaseinhibitoren (TKI", "TREATMENT", 80, 131], ["\u201emultitargeted\u201c TKI", "TREATMENT", 134, 153], ["Serin", "TEST", 159, 164], ["Threonin", "TREATMENT", 166, 174], ["Inhibitoren", "TREATMENT", 182, 193]]], ["Deren zielgerichtetes Wirken impliziert einen bedeutsamen Paradigmenwechsel in der Onkologie, in der vormals eine m\u00f6glichst dosisdichte Gabe der breit zytotoxisch wirkenden Chemotherapeutika im Vordergrund stand.", [["Deren zielgerichtetes", "TREATMENT", 0, 21]]], ["Diese in der Regel besser kontrollierbaren Toxizit\u00e4tsprofile wirken sich auch auf die g\u00e4ngigen Tumortherapiesequenzen z.", [["Diese in der Regel besser kontrollierbaren Toxizit\u00e4tsprofile", "TREATMENT", 0, 60]]], ["B. im sp\u00e4ten Krankheitsverlauf aus.", [["Krankheitsverlauf aus", "OBSERVATION", 13, 34]]], ["Eine Anzahl dieser Substanzen zeichnet sich eher durch eine klinisch relevante, symptomkontrollierte Tumorstabilisierung als durch eine morphometrisch fassbare Tumorgr\u00f6\u00dfenreduktion aus, sodass in der Onkologie zunehmend klinisch gepr\u00e4gte Zielkriterien (\u201etime to progression\u201c, \u201estable disease\u201c, \u201eclinical benefit response\u201c) genutzt werden [2].Neue tumorspezifische SubstanzenF\u00fcr die An\u00e4sthesiologie bedeutet diese Entwicklung eine Besonderheit in der Einsch\u00e4tzung der Narkosef\u00e4higkeit und perioperativen an\u00e4sthesiologischen F\u00fchrung einer zuvor nichtexistenten Gruppe von Patienten mit Tumorerkrankungen, die sich selbst im fortgeschrittenen Erkrankungsverlauf unter medikament\u00f6ser Tumortherapie befinden k\u00f6nnen oder \u2013 nach intensiver Vorbehandlung \u2013 als tumorfrei gelten.", [["Neue tumorspezifische SubstanzenF\u00fcr die An\u00e4sthesiologie bedeutet diese Entwicklung eine Besonderheit in der Einsch\u00e4tzung der Narkosef\u00e4higkeit und perioperativen an\u00e4sthesiologischen F\u00fchrung einer zuvor nichtexistenten Gruppe von Patienten mit Tumorerkrankungen, die sich selbst im fortgeschrittenen Erkrankungsverlauf unter medikament\u00f6ser Tumortherapie befinden k\u00f6nnen oder \u2013 nach intensiver Vorbehandlung \u2013 als tumorfrei gelten", "SPECIES", 342, 769], ["Eine Anzahl dieser", "TREATMENT", 0, 18], ["Substanzen zeichnet sich eher durch eine klinisch", "TREATMENT", 19, 68], ["symptomkontrollierte Tumorstabilisierung als durch eine morphometrisch", "TREATMENT", 80, 150], ["Zielkriterien", "TREATMENT", 238, 251], ["\u201estable disease", "PROBLEM", 276, 291], ["Neue tumorspezifische SubstanzenF\u00fcr die", "TREATMENT", 342, 381]]], ["Die an\u00e4sthesiologische pr\u00e4operative Einsch\u00e4tzung, die Durchf\u00fchrung der An\u00e4sthesie, aber auch die postoperative Betreuung erfordern eine zunehmend genauere Differenzierung des zugrunde liegenden onkologischen Therapiekonzeptes, der applizierten Substanzgruppe und ihrer pharmakologischen Eigenschaften bzw.", [["postoperative Betreuung erfordern eine zunehmend", "TREATMENT", 97, 145], ["Differenzierung des zugrunde liegenden onkologischen Therapiekonzeptes", "TREATMENT", 155, 225]]], ["Nebenwirkungen.Neue tumorspezifische SubstanzenF\u00fcr die Tumorschmerztherapie implizieren diese Tumortherapieoptionen und deren klinisch orientierte Zielkriterien eine deutliche Erweiterung der zur Verf\u00fcgung stehenden analgetisch wirksamen Behandlungsoptionen, die in der interdisziplin\u00e4ren Zusammenarbeit zwischen Schmerztherapeuten und Onkologen bedacht werden sollten.Neue tumorspezifische SubstanzenIn Tab.", [["Nebenwirkungen", "CHEMICAL", 0, 14], ["Neue tumorspezifische SubstanzenF\u00fcr die Tumorschmerztherapie implizieren diese Tumortherapieoptionen und deren klinisch orientierte Zielkriterien eine deutliche Erweiterung der zur Verf\u00fcgung stehenden analgetisch wirksamen Behandlungsoptionen, die in der interdisziplin\u00e4ren Zusammenarbeit zwischen Schmerztherapeuten und Onkologen bedacht werden sollten", "SPECIES", 15, 368], ["Neue tumorspezifische SubstanzenF\u00fcr die", "TREATMENT", 15, 54], ["Tumortherapieoptionen und deren klinisch", "TREATMENT", 94, 134], ["Zielkriterien eine deutliche", "TREATMENT", 147, 175], ["Zusammenarbeit zwischen Schmerztherapeuten", "TREATMENT", 289, 331]]], ["1 werden \u00e4ltere und neuere, konventionell zytotoxische und neue \u201ezielgerichtete\u201c Substanzgruppen sowie einige ihrer im an\u00e4sthesiologischen Kontext relevanten Wirkungen beispielhaft aufgef\u00fchrt.Neue tumorspezifische SubstanzenEine Vielzahl der in Tab.", [["Substanzgruppen", "TREATMENT", 81, 96]]], ["1 genannten Wirkungen und Nebenwirkungen kann perioperatives, intensivmedizinisches, aber auch notfallmedizinisches Management beeinflussen.", [["intensivmedizinisches", "TREATMENT", 62, 83]]], ["So steht zu erwarten, dass im Rahmen der zunehmend ambulant \u00fcber Port- und Pumpensysteme applizierten Tumortherapien z.", [["ambulant \u00fcber Port", "TREATMENT", 51, 69]]], ["B. Koronarisch\u00e4mien unter 5-Fluorouracil (5FU) oder anaphylaktische Sp\u00e4treaktionen nach Erstgaben von Antik\u00f6rpern das Spektrum not\u00e4rztlicher Eins\u00e4tze beeinflussen werden.", [["5-Fluorouracil", "CHEMICAL", 26, 40], ["5FU", "CHEMICAL", 42, 45], ["5-Fluorouracil", "CHEMICAL", 26, 40], ["5FU", "CHEMICAL", 42, 45], ["5-Fluorouracil", "SIMPLE_CHEMICAL", 26, 40], ["5FU", "SIMPLE_CHEMICAL", 42, 45], ["Fluorouracil (5FU)", "TREATMENT", 28, 46], ["anaphylaktische", "TREATMENT", 52, 67], ["Sp\u00e4treaktionen nach Erstgaben", "TREATMENT", 68, 97]]], ["Aus infektiologischer Perspektive sind die verschiedenen krankheitsassoziierten oder medikament\u00f6s induzierten Immundefektsyndrome mit einer notwendigen Ber\u00fccksichtigung atypischer, viraler oder Pilzerreger bei der empirischen Antibiotikaauswahl von Interesse.", [["Aus infektiologischer", "PROBLEM", 0, 21]]], ["In der operativen Intensivmedizin sind die potenziellen Nebenwirkungen des \u201eVascular-endothelial-growth-factor\u201c- (VEGF-)Antik\u00f6rpers Bevacizumab von Bedeutung, die entsprechend der antiangiogenetischen Wirkung eine arterielle Hypertonie (laut Fachinformation bis zu 34% der F\u00e4lle), schwerere Blutungen, Grad 3\u20135 der National Cancer Institute-Common Toxicity Criteria (NCI-CTC; in 0,4\u20135% der F\u00e4lle), Epistaxis (in 20\u201340% der F\u00e4lle), Wundheilungsst\u00f6rungen oder Perforationen des Magen-Darm-Traktes (in 0,2\u20131% der F\u00e4lle) umfassen k\u00f6nnen (http://www.fachinfo.de; [3, 4]).", [["Cancer", "DISEASE", 324, 330], ["Toxicity", "DISEASE", 348, 356], ["VEGF", "PROTEIN", 114, 118], ["der antiangiogenetischen Wirkung eine arterielle Hypertonie (laut Fachinformation bis zu 34% der F\u00e4lle)", "SPECIES", 176, 279], ["factor\u201c", "TEST", 104, 111], ["VEGF", "TEST", 114, 118], ["Antik\u00f6rpers Bevacizumab von Bedeutung", "TREATMENT", 120, 157], ["Hypertonie", "TEST", 225, 235], ["CTC", "TEST", 371, 374], ["Epistaxis", "PROBLEM", 398, 407], ["Vascular", "ANATOMY", 76, 84], ["endothelial", "ANATOMY", 85, 96], ["Epistaxis", "OBSERVATION", 398, 407]]], ["Die protrahierte physiologische Wirkung kann bis zu 12 Wochen (4 Halbwertszeiten) nach Absetzen der Substanz andauern; dennoch wurde auch eine gastrointestinale Perforation unter Bevacizumab 10 Monate postoperativ beschrieben [5].", [["Die protrahierte physiologische", "TREATMENT", 0, 31], ["kann bis zu", "TREATMENT", 40, 51], ["dennoch wurde", "TREATMENT", 119, 132], ["Perforation", "PROBLEM", 161, 172], ["Bevacizumab", "TREATMENT", 179, 190]]], ["Die nur teilweise reversiblen peripheren Polyneuropathien nach Gabe von Platinderivaten, Vinca-Alkaloiden, Taxanen oder Thalidomid/Lenalidomid, die allesamt zunehmende Verbreitung durch erweiterte Indikationsspektren finden, k\u00f6nnen die nachfolgende Option zur Regionalan\u00e4sthesie durch Beeintr\u00e4chtigung des neurophysiologischen Monitorings verhindern.Neue tumorspezifische SubstanzenNebenwirkungen und Arzneimittelinteraktionen nehmen bei der Applikation von Tumortherapeutika einen hohen Stellenwert ein; durch diese sind Krebspatienten in hohem Ma\u00df gef\u00e4hrdet.", [["Die nur teilweise reversiblen peripheren Polyneuropathien nach Gabe von Platinderivaten, Vinca-Alkaloiden, Taxanen oder Thalidomid/Lenalidomid, die allesamt zunehmende Verbreitung durch erweiterte Indikationsspektren finden, k\u00f6nnen die nachfolgende Option zur Regionalan\u00e4sthesie durch Beeintr\u00e4chtigung des neurophysiologischen Monitorings verhindern", "SPECIES", 0, 349], ["Neue tumorspezifische SubstanzenNebenwirkungen und Arzneimittelinteraktionen nehmen bei der Applikation von Tumortherapeutika einen hohen Stellenwert ein; durch diese sind Krebspatienten in hohem Ma\u00df gef\u00e4hrdet", "SPECIES", 350, 559], ["Vinca", "TREATMENT", 89, 94], ["Alkaloiden", "TREATMENT", 95, 105], ["Taxanen", "TREATMENT", 107, 114], ["Thalidomid", "TREATMENT", 120, 130], ["Lenalidomid", "TREATMENT", 131, 142], ["Neue tumorspezifische SubstanzenNebenwirkungen", "TREATMENT", 350, 396]]], ["Neben wechselseitigen Medikamenteneinfl\u00fcssen auf die intestinale Resorption (bei oraler Anwendung), auf die Metabolisierung zur Aktivierung von \u201epro-drugs\u201c (wie z.", [["Neben wechselseitigen Medikamenteneinfl\u00fcssen auf die intestinale Resorption (bei oraler Anwendung), auf die Metabolisierung zur Aktivierung von \u201epro-drugs\u201c (wie z.", "SPECIES", 0, 163], ["Resorption (bei oraler Anwendung", "TREATMENT", 65, 97]]], ["Als Schnittstelle f\u00fcr Arzneimittelinteraktionen erweist sich hierbei die Subgruppe CyP450 3 A4/A5 des Zytochrom-P-Enzymsystems, mithilfe deren viele klassische Zytostatika, nichtzytotoxische Targeted therapies, tumorwirksame Hormonpr\u00e4parate und in der Supportivtherapie eingesetzte Medikamente (Dexamethason, Makrolidantibiotika, Azolantimykotika) metabolisiert werden.", [["Arzneimittelinteraktionen erweist sich hierbei die Subgruppe CyP450 3 A4/A5 des Zytochrom-P-Enzymsystems", "SPECIES", 22, 126], ["Schnittstelle", "TEST", 4, 17], ["Arzneimittelinteraktionen", "TEST", 22, 47], ["sich", "TEST", 56, 60], ["A4", "TEST", 92, 94], ["Zytochrom", "TEST", 102, 111], ["Enzymsystems", "TREATMENT", 114, 126], ["mithilfe", "TREATMENT", 128, 136], ["Targeted therapies", "TREATMENT", 191, 209], ["tumorwirksame Hormonpr\u00e4parate", "TREATMENT", 211, 240], ["Medikamente (Dexamethason", "TREATMENT", 282, 307], ["Makrolidantibiotika", "TREATMENT", 309, 328]]], ["Von den bekannten CyP450-Enzyminduktoren finden vor allem Johanniskraut [6] und Dexamethason bei Tumorpatienten Anwendung, w\u00e4hrend der Einsatz \u201eklassischer\u201c Enzyminduktoren wie Rifampicin oder Phenytoin eine Rarit\u00e4t bleibt.", [["Rifampicin", "CHEMICAL", 177, 187], ["Phenytoin", "CHEMICAL", 193, 202], ["Rifampicin", "CHEMICAL", 177, 187], ["Phenytoin", "CHEMICAL", 193, 202], ["Enzyminduktoren", "TREATMENT", 157, 172], ["Rifampicin", "TREATMENT", 177, 187], ["Phenytoin eine Rarit\u00e4t bleibt", "TREATMENT", 193, 222]]], ["Von den bekannten Hemmstoffen des CyP450-Systems kommen in der Tumortherapie vor allem Allopurinol, Ciprofloxacin, Makrolidantibiotika, Azolantimykotika (insbesondere Ketoconazol), \u00f6strogenhaltige Pr\u00e4parationen oder Interferon-\u03b1 zum Einsatz, unter denen eine verst\u00e4rkte Wirkung z.", [["Allopurinol", "CHEMICAL", 87, 98], ["Ciprofloxacin", "CHEMICAL", 100, 113], ["Allopurinol", "CHEMICAL", 87, 98], ["Ciprofloxacin", "CHEMICAL", 100, 113], ["Ciprofloxacin", "SIMPLE_CHEMICAL", 100, 113], ["Hemmstoffen des CyP450", "TREATMENT", 18, 40], ["Allopurinol", "TREATMENT", 87, 98], ["Ciprofloxacin", "TREATMENT", 100, 113], ["Makrolidantibiotika", "TREATMENT", 115, 134], ["Azolantimykotika (insbesondere Ketoconazol)", "TREATMENT", 136, 179], ["\u00f6strogenhaltige Pr\u00e4parationen", "TREATMENT", 181, 210], ["Interferon", "TREATMENT", 216, 226], ["zum Einsatz", "TREATMENT", 229, 240]]], ["B. von Benzodiazepinen, Fentanyl oder auch von Zytostatika beobachtet werden kann ([7, 8]; Tab.", [["Fentanyl", "CHEMICAL", 24, 32], ["Fentanyl", "CHEMICAL", 24, 32], ["Fentanyl oder auch von Zytostatika beobachtet", "TREATMENT", 24, 69]]], ["B.:kumulative Nephro- (und Oto-)Toxizit\u00e4t bei der Kombination von Cisplatin/Carboplatin mit Schleifendiuretika, Aminoglykosiden, Cephalosporinen und i.v.-R\u00f6ntgenkontrastmitteln (bei der ausgepr\u00e4gten Begleithydratation zur Infusion von Cisplatin und der damit verbundenen hohen Volumenbelastung sollten f\u00fcr eine eventuell notwendige forcierte Diurese keine Schleifendiuretika, sondern z.", [["Cisplatin", "CHEMICAL", 66, 75], ["Carboplatin", "CHEMICAL", 76, 87], ["Cisplatin", "CHEMICAL", 235, 244], ["B.:kumulative Nephro- (und Oto-)Toxizit\u00e4t bei der Kombination von Cisplatin/Carboplatin mit Schleifendiuretika, Aminoglykosiden, Cephalosporinen und i.v.-R\u00f6ntgenkontrastmitteln (bei der ausgepr\u00e4gten Begleithydratation zur Infusion von Cisplatin und der damit verbundenen hohen Volumenbelastung sollten f\u00fcr eine eventuell notwendige forcierte Diurese keine Schleifendiuretika, sondern z.", "SPECIES", 0, 386], ["kumulative Nephro", "TREATMENT", 3, 20], ["Toxizit\u00e4t bei der Kombination von Cisplatin", "TREATMENT", 32, 75], ["Carboplatin mit Schleifendiuretika", "TREATMENT", 76, 110], ["Aminoglykosiden", "TREATMENT", 112, 127], ["Cephalosporinen", "TREATMENT", 129, 144], ["R\u00f6ntgenkontrastmitteln (bei der ausgepr\u00e4gten Begleithydratation zur Infusion von Cisplatin", "TREATMENT", 154, 244], ["Volumenbelastung sollten", "TREATMENT", 277, 301]]], ["B. D-Mannitol eingesetzt werden);kompetitive Hemmung des Docetaxelmetabolismus durch Makrolide, Azole, aber auch Midazolam;kompetitive Hemmung des renalen tubul\u00e4ren S\u00e4ure-\u201ecarriers\u201c durch Piperacillin, Probenecid oder nichtsteroidale Antiphlogistika (NSAID) mit erh\u00f6hter Toxizit\u00e4t von Antifolaten wie Metothrexat, Raltitrexed oder Pemetrexed;massiv erh\u00f6hte (potenziell letale) Plasmakonzentration von 5FU bei gleichzeitiger Gabe der gegen Herpes-simplex-Virus (HSV) und Herpes-zoster-Virus (VZV) eingesetzten Nukleosidanaloga Brivudin und Sorivudin durch Hemmung des 5FU abbauenden Enzyms Dihydropyrimidindehydrogenase;kumulative Organtoxizit\u00e4t (Knochenmark, Lunge u. a.) durch Kombination mehrerer Chemotherapeutika, auch mit begleitender Strahlentherapie;gest\u00f6rte hepatische Elimination von Zytostatika durch potenziell hepatotoxische Medikamente (wie sie auch in der An\u00e4sthesie und Intensivmedizin eingesetzt werden).", [["5FU", "CHEMICAL", 401, 404], ["Herpes-simplex-Virus", "DISEASE", 439, 459], ["zoster", "DISEASE", 477, 483], ["5FU", "CHEMICAL", 567, 570], ["Herpes-simplex-Virus", "ORGANISM", 439, 459], ["HSV", "ORGANISM", 461, 464], ["Herpes-zoster-Virus", "ORGANISM", 470, 489], ["VZV", "ORGANISM", 491, 494], ["Herpes", "SPECIES", 439, 445], ["Hemmung des Docetaxelmetabolismus durch Makrolide, Azole, aber auch Midazolam;kompetitive Hemmung des renalen tubul\u00e4ren S\u00e4ure-\u201ecarriers\u201c durch Piperacillin, Probenecid oder nichtsteroidale Antiphlogistika (NSAID) mit erh\u00f6hter Toxizit\u00e4t von Antifolaten wie Metothrexat, Raltitrexed oder Pemetrexed;massiv erh\u00f6hte (potenziell letale) Plasmakonzentration von 5FU bei gleichzeitiger Gabe der gegen Herpes-simplex-Virus (HSV) und Herpes-zoster-Virus (VZV) eingesetzten Nukleosidanaloga Brivudin und Sorivudin durch Hemmung des 5FU abbauenden Enzyms Dihydropyrimidindehydrogenase;kumulative Organtoxizit\u00e4t (Knochenmark, Lunge u. a.) durch Kombination mehrerer Chemotherapeutika, auch mit begleitender Strahlentherapie;gest\u00f6rte hepatische Elimination von Zytostatika durch potenziell hepatotoxische Medikamente (wie sie auch in der An\u00e4sthesie und Intensivmedizin eingesetzt werden", "SPECIES", 45, 918], ["Mannitol eingesetzt werden", "TREATMENT", 5, 31], ["kompetitive Hemmung des Docetaxelmetabolismus durch Makrolide", "TREATMENT", 33, 94], ["Azole", "TREATMENT", 96, 101], ["Midazolam", "TREATMENT", 113, 122], ["kompetitive Hemmung des", "TREATMENT", 123, 146], ["tubul\u00e4ren S\u00e4ure-\u201ecarriers", "TREATMENT", 155, 180], ["Piperacillin", "TREATMENT", 188, 200], ["Probenecid oder nichtsteroidale Antiphlogistika (NSAID)", "TREATMENT", 202, 257], ["von Antifolaten wie Metothrexat", "TREATMENT", 281, 312], ["Raltitrexed oder Pemetrexed", "TREATMENT", 314, 341], ["massiv erh\u00f6hte (potenziell letale", "TREATMENT", 342, 375], ["Plasmakonzentration von 5FU bei gleichzeitiger", "TEST", 377, 423], ["Herpes", "TEST", 439, 445], ["zoster", "PROBLEM", 477, 483], ["Virus (VZV) eingesetzten", "TREATMENT", 484, 508], ["Brivudin", "TREATMENT", 526, 534], ["Sorivudin durch Hemmung des", "TREATMENT", 539, 566], ["5FU abbauenden Enzyms Dihydropyrimidindehydrogenase", "TREATMENT", 567, 618], ["kumulative Organtoxizit\u00e4t (Knochenmark", "TREATMENT", 619, 657], ["auch mit begleitender Strahlentherapie", "TREATMENT", 718, 756]]]], "d7654417288363a343f32de99e2af98a3d3c9266": [["The ongoing COVID-19 pandemic has produced an unprecedented health and economic crisis, urging for the development of adapted actions aimed at monitoring the spread of the new coronavirus.", [["coronavirus", "DISEASE", 176, 187], ["coronavirus", "ORGANISM", 176, 187], ["The ongoing COVID", "TEST", 0, 17], ["economic crisis", "PROBLEM", 71, 86], ["the new coronavirus", "PROBLEM", 168, 187]]], ["No country remained untouched, and all of them experienced a propagation mechanism that is basically universal in the onset phase: each infected person happened to infect in average more than one other person, leading to an initial exponential growth.IntroductionThe strength of the spread is quantified by the so-called reproduction number which measures how many people can be contaminated by an infected person.", [["people", "ORGANISM", 365, 371], ["person", "SPECIES", 145, 151], ["person", "SPECIES", 202, 208], ["people", "SPECIES", 365, 371], ["person", "SPECIES", 407, 413], ["an initial exponential growth", "PROBLEM", 221, 250], ["untouched", "OBSERVATION", 20, 29], ["infected", "OBSERVATION", 136, 144], ["infected", "OBSERVATION", 398, 406]]], ["In the early phase where the growth is exponential, this is referred to as R 0 (for COVID-19, R 0 \u223c 3 [13, 23] ).", [["COVID", "TEST", 84, 89], ["early phase", "OBSERVATION_MODIFIER", 7, 18], ["growth", "OBSERVATION_MODIFIER", 29, 35], ["exponential", "OBSERVATION_MODIFIER", 39, 50]]], ["As the pandemic develops and because more people get infected, the effective reproduction number evolves, hence becoming a function of time hereafter labeled R(t).", [["people", "ORGANISM", 42, 48], ["people", "SPECIES", 42, 48]]], ["This can indeed end up with the extinction of the pandemic, R(t) \u2192 0, at the expense though of the contamination of a very large percentage of the total population, and of potentially dramatic consequences.IntroductionRather than letting the pandemic develop until the reproduction number would eventually decrease below unity (in which case the spread would cease by itself), an active strategy amounts to take actions so as to limit contacts between individuals.", [["very", "OBSERVATION_MODIFIER", 118, 122], ["large", "OBSERVATION_MODIFIER", 123, 128], ["percentage", "OBSERVATION_MODIFIER", 129, 139], ["total", "OBSERVATION_MODIFIER", 147, 152], ["population", "OBSERVATION", 153, 163], ["dramatic", "OBSERVATION_MODIFIER", 184, 192]]], ["Monitoring and estimating R(t) raises however a series of issues related to pandemic data modeling, to parameter estimation techniques and to data availability.", [["Monitoring", "TEST", 0, 10], ["pandemic data modeling", "TEST", 76, 98], ["parameter estimation techniques", "TEST", 103, 134]]], ["Concerning the mathematical modeling of infectious diseases, the most celebrated The questions of modeling and estimation, be they fully parametric or semi-parametric, are intimately intertwined with that of data availability.", [["infectious diseases", "DISEASE", 40, 59], ["infectious diseases", "PROBLEM", 40, 59], ["infectious", "OBSERVATION", 40, 50]]], ["There is first the nature of the incidence data used in the analysis (reported infected cases, hospitalizations, deaths) and the database they are extracted from.", [["deaths", "DISEASE", 113, 119], ["the analysis", "TEST", 56, 68]]], ["Next, there is the granularity of the data (whole country, regions, smaller units) and the specificities that can be attached to a specific choice as well as the comparisons that can be envisioned.", [["granularity", "OBSERVATION", 19, 30], ["smaller", "OBSERVATION_MODIFIER", 68, 75]]], ["In this respect, it is worth remarking that most analyses reported in the literature are based on (possibly multiple) univariate time series, whereas genuinely multivariate analyses (e.g., a joint analysis of the same type of data in different countries in order to compare health policies) might prove more informative.IntroductionGoal, contributions and outlines.", [["multivariate analyses", "TEST", 160, 181], ["a joint analysis", "TEST", 189, 205], ["joint", "ANATOMY", 191, 196]]], ["For that category of research work motivated by contributing in emergency to the societal stake of monitoring the pandemic evolution in realtime, or at least, on a daily basis, there are two classes of challenges: ensuring a robust and regular access to relevant data; rapidly developing analysis/estimation tools that are theoretically sound, practically usable on data actually available, and that may contribute to improving current monitoring strategies.", [["rapidly developing analysis", "PROBLEM", 269, 296], ["estimation tools", "TEST", 297, 313]]], ["In that spirit, the overarching goal of the present work is twofold: (1) proposing a new, more versatile framework for the estimation of R(t) within the semi-parametric model of [11, 25] , reformulating its estimation as an inverse problem whose functional is minimized by using non smooth proximal-based convex optimization; (2) inserting this approach in an extended multivariate framework, with applications to various, complementary datasets corresponding both to different incidence data and to different geographical regions.IntroductionThe data used here were collected from three different databases (Johns Hopkins University, European Centre for Disease Prevention and Control, and Sant\u00e9-Publique-France).", [["non smooth proximal-based convex optimization", "TREATMENT", 279, 324], ["this approach", "TREATMENT", 340, 353], ["an extended multivariate framework", "TREATMENT", 357, 391], ["applications", "TREATMENT", 398, 410], ["Disease Prevention", "TREATMENT", 655, 673], ["Sant\u00e9", "TEST", 691, 696]]], ["While incidence data reported essentially consist of the number of infected, hospitalized, dead and recovered persons, the three databases are very heterogenous with respect to starting date of data availability, geographical granularity, and data quality (outliers, misreporting,. . . ).", [["persons", "SPECIES", 110, 117], ["very heterogenous", "PROBLEM", 143, 160], ["infected", "OBSERVATION", 67, 75], ["heterogenous", "OBSERVATION", 148, 160]]], ["In the present work, it has been chosen to work with the number of daily new infections as incidence data, thus labeled z(t) in the remainder of the work.", [["infections", "DISEASE", 77, 87]]], ["The number of daily new infections may however be directly read as reported in databases, or recomputed from other available data (such as hospitalization numbers).", [["infections", "DISEASE", 24, 34], ["daily new infections", "PROBLEM", 14, 34], ["new", "OBSERVATION_MODIFIER", 20, 23], ["infections", "OBSERVATION", 24, 34]]], ["Section 3 presents the semi-parametric model for R(t) (cf. Section 3.1) and how its estimation can be phrased within a non smooth proximal-based convex optimization framework, intentionally designed to enforce piecewise linearity in the estimation of R(t) via temporal regularization, as well as piecewise constancy in spatial variations of R(t) by graph-based regularization (cf. Section 3.2).", [["temporal regularization", "TREATMENT", 260, 283]]], ["Proximal-operator based algorithms for the minimization for the corresponding functionals are detailed in Section 3.3.", [["Proximal-operator based algorithms", "TREATMENT", 0, 34]]], ["These estimation tools have been first illustrated at work on synthetic data, constructed from different models and simulating several scenarii (cf. Section 3.4).", [["These estimation tools", "TEST", 0, 22], ["synthetic data", "TEST", 62, 76]]], ["First, the number of daily new infections for many different countries across the world were analyzed independently (cf. Section 4.3).", [["infections", "DISEASE", 31, 41], ["daily new infections", "PROBLEM", 21, 41], ["new", "OBSERVATION_MODIFIER", 27, 30], ["infections", "OBSERVATION", 31, 41]]], ["Second, focusing on France only, the number of daily new infections per continental France d\u00e9partements (d\u00e9partements constitute usual entities organizing the administrative life in France) were analyzed both independently and in a multivariate setting, illustrating the benefit of this latter formulation (cf. Section 4.4).", [["infections", "DISEASE", 57, 67], ["daily new infections", "PROBLEM", 47, 67], ["this latter formulation", "TREATMENT", 282, 305], ["new", "OBSERVATION_MODIFIER", 53, 56], ["infections", "OBSERVATION", 57, 67]]], ["Discussions, perpectives and potential improvements are discussed in Section 5.DatasetsTo enable a relevant study of the pandemic, it is essential to have at disposal robust and automated accesses to reliable databasets where pandemic-related data are made available by relevant authorities, on a regular basis.", [["a relevant study", "TEST", 97, 113]]], ["In the present study, three sources of data were systematically used.DatasetsSource1(JHU) Johns Hopkins University 1 provides access to the cumulated daily reports of the number of infected, deceased and recovered persons, on a per country basis, for a large number of countries worldwide, essentially since inception of the COVID-19 crisis (January 1st, 2020).DatasetsSource2(ECDPC) The European Centre for Disease Prevention and Control 2 provides similar information.DatasetsSource3(SPF) Sant\u00e9-Publique-France 3 focuses on France only.", [["persons", "SPECIES", 214, 221], ["the present study", "TEST", 3, 20], ["the COVID", "TEST", 321, 330], ["DatasetsSource2(ECDPC", "TREATMENT", 361, 382], ["The European Centre", "TREATMENT", 384, 403], ["Disease Prevention", "TREATMENT", 408, 426], ["DatasetsSource3(SPF", "TREATMENT", 470, 489], ["infected", "OBSERVATION", 181, 189], ["large", "OBSERVATION_MODIFIER", 253, 258]]], ["It makes available on a daily basis a rich variety of pandemic-documented data across the France territory on a per d\u00e9partement-basis, d\u00e9partements consisting of the usual granularity of geographical units (of roughly comparable sizes), used in France to address most administrative issues (an equivalent of counties for other countries).", [["geographical units", "TREATMENT", 187, 205]]], ["Source3(SPF) data are mostly based on hospital records, such as the daily reports of the number of currently hospitalized persons, together with the cumulated numbers of deceased and recovered persons with breakdowns by age and gender.", [["persons", "ORGANISM", 122, 129], ["persons", "SPECIES", 122, 129], ["persons", "SPECIES", 193, 200]]], ["Elementary algebra enables us to derive the daily number of new hospitalizations, used as a (delayed) proxy for daily new infections, assuming that a constant fraction of infected people is hospitalized.", [["infections", "DISEASE", 122, 132], ["people", "ORGANISM", 180, 186], ["people", "SPECIES", 180, 186], ["daily new infections", "PROBLEM", 112, 132], ["infections", "OBSERVATION", 122, 132], ["infected", "OBSERVATION", 171, 179]]], ["Data are however available only after March 20th.DatasetsData were (and still are) automatically downloaded on a daily basis, using MATLAB routines, written by ourselves and available upon request.Time seriesThe data available on the different data repositories used here are strongly affected by outliers, which may stem from inaccuracy or misreporting in per country reporting procedures, or from changes in the way counts are collected, aggregated, and reported.", [["DatasetsData", "TEST", 49, 61], ["The data", "TEST", 208, 216], ["the way counts", "TEST", 410, 424]]], ["In the present work, it has been chosen to preprocess data for outlier removal by applying to the raw time series a nonlinear filtering, consisting of a slidingmedian over a 7-day window: outliers defined as \u00b12.5 standard deviation are replaced by window median to yield the pre-processed time series z(t), from which the reproduction number R(t) is estimated.", [["outlier removal", "TREATMENT", 63, 78]]], ["Examples of raw and pre-processed time series are illustrated in the figures throughout Section 4.Time seriesCountries are studied independently (cf. Section 4.3), and the estimation procedure is thus applied independently to each time series z(t) of size T , the number of days available for analysis.Time seriesTo each continental France d\u00e9partement is associated a time series z d (t) of size T , where 1 \u2264 d \u2264 D = 94 indexes the d\u00e9partement.", [["Section", "TEST", 150, 157], ["the estimation procedure", "TREATMENT", 168, 192], ["analysis", "TEST", 293, 301]]], ["These time series are collected and stacked in a matrix of size D \u00d7 T , and are analyzed both independently and jointly (cf. Section 4.4).Time seriesEstimation of R(t) is performed daily, with T thus increasing every day.6.", [["size", "OBSERVATION_MODIFIER", 59, 63]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)6The copyright holder for this preprint this version posted June 12, 2020. .Data modelingAs mentioned in Introduction, epidemiological data are often modeled by SIR models and variants, devised to account for the detailed mechanisms driving the epidemic outbreak.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 200, 220], ["Data modeling", "TEST", 275, 288], ["epidemiological data", "TEST", 318, 338], ["med", "ANATOMY", 102, 105]]], ["Although they can be used for envisioning the impact of possible scenarii in the future development of an on-going epidemic [13] , such models, because they require the full estimation of numerous parameters, are often used a posteriori (e.g., long after the epidemic) with consolidated and accurate datasets.", [["scenarii", "TREATMENT", 65, 73]]], ["During the spread phase and in order to account for the on-line/on-the-fly need to monitor the pandemic and to offer some robustness to partial/incomplete/noisy data, less detailed semi-parametric models focusing on the only estimation of the time-dependent reproduction number can be preferred [26, 18, 11] .Data modelingLet R(t) denote the instantaneous reproduction number to be estimated and z(t) be the number of daily new infections.", [["infections", "DISEASE", 428, 438], ["Let R", "GENE_OR_GENE_PRODUCT", 322, 327], ["new infections", "PROBLEM", 424, 438], ["new", "OBSERVATION_MODIFIER", 424, 427], ["infections", "OBSERVATION", 428, 438]]], ["It has been proposed in [11, 25] that {z(t), t = 1, . . . , T } can be modeled as a nonstationary time series consisting of a collection of random variables, each drawn from a Poisson distribution P pt whose parameter p t depends on the past observations of z(t), on the current value of R(t), and on the serial interval function \u03a6(\u00b7):Data modelingThe serial interval function \u03a6(\u00b7) constitutes a key ingredient of the model, whose importance and role in pandemic evolution has been mentioned in Introduction.", [["{z(t)", "SIMPLE_CHEMICAL", 38, 43], ["a collection of random variables", "PROBLEM", 124, 156], ["The serial interval function", "TEST", 348, 376]]], ["It is assumed to be independent of calendar time (i.e., constant across the epidemic outbreak), and, importantly, independent of R(t), whose role is to account for the time dependencies in pandemic propagation mechanisms.Data modelingFor the COVID-19 pandemic, several studies have empirically estimated the serial interval function \u03a6(\u00b7) [16, 22] .", [["Data modeling", "TEST", 221, 234], ["the COVID", "TEST", 238, 247], ["several studies", "TEST", 261, 276], ["the serial interval function", "TEST", 304, 332], ["assumed to be", "UNCERTAINTY", 6, 19]]], ["For convenience, \u03a6(\u00b7) has been modeled as a Gamma distribution, with shape and rate parameters 1.87 and 0.28, respectively (corresponding to mean and standard deviations of 6.6 and 3.5 days, see [14] and references therein).", [["rate parameters", "TEST", 79, 94], ["mean", "TEST", 141, 145]]], ["These choices and assumptions have been followed and used here, and the corresponding function is illustrated in Fig. 1 .Data modelingIn essence, the model in Eq.", [["Data modeling", "TEST", 121, 134]]], ["(2) is univariate (only one time series is modeled at a time), and based on a Poisson marginal distribution.", [["marginal distribution", "OBSERVATION", 86, 107]]], ["It is also nonstationary, as the Poisson rate evolves along time.", [["the Poisson rate", "TEST", 29, 45]]], ["The key ingredient of this model consists of the Poisson rate evolving as a weighted moving average of past observations, which is qualitatively based on the following rationale: when z(t)/ s\u22651 \u03a6(s)z(t \u2212 s) is above 1, the epidemic is growing and, conversely, when this ratio is below 1, it decreases and eventually vanishes.7.", [["z(t \u2212 s", "TEST", 198, 205], ["the epidemic", "TEST", 219, 231], ["this ratio", "TEST", 265, 275], ["epidemic", "OBSERVATION", 223, 231]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)7The copyright holder for this preprint this version posted June 12, 2020.Estimation via non-smooth convex optimisationIn order to estimate R(t), and instead of using Bayesian frameworks that are considered state-of-the-art tools for epidemic evolution analysis, we propose and promote here an alternative approach based on an inverse problem formulation.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 200, 220], ["epidemic evolution analysis", "TEST", 433, 460], ["an alternative approach", "TREATMENT", 490, 513], ["an inverse problem formulation", "TREATMENT", 523, 553], ["med", "ANATOMY", 102, 105]]], ["Its main principle is to assume some form of temporal regularity in the evolution of R(t) (below we use a piecewise linear model).", [["temporal regularity", "PROBLEM", 45, 64], ["a piecewise linear model)", "TREATMENT", 104, 129], ["main", "OBSERVATION_MODIFIER", 4, 8], ["temporal", "OBSERVATION_MODIFIER", 45, 53], ["regularity", "OBSERVATION", 54, 64]]], ["In the case of a joint estimation of R(t) across several continental France d\u00e9partements, we further assume some form of spatial regularity, i.e., that the values of R(t) for neighboring d\u00e9partements are similar.Estimation via non-smooth convex optimisationUnivariate setting.", [["a joint estimation", "TEST", 15, 33], ["joint", "ANATOMY", 17, 22], ["spatial regularity", "OBSERVATION", 121, 139]]], ["For a single country, or a single d\u00e9partement, the observed (possibly pre-processed) data {z(t),Estimation via non-smooth convex optimisationRecalling that the Poisson law is P(Z = n|p) = p n n! e \u2212p for each integer n \u2265 0, the negative log-likelihood of observing z given a vector p \u2208 R T of Poisson parameters p t isEstimation via non-smooth convex optimisationwhere r \u2208 R T is the (unknown) vector of values of R(t).", [["P", "DNA", 175, 176], ["a vector", "TREATMENT", 273, 281], ["Poisson parameters", "TEST", 293, 311]]], ["Up to an additive term independent of p, this is equal to the KL-divergence (cf. Section 5.4. in [21] ):Estimation via non-smooth convex optimisationGiven the vector of observed values z, the serial interval function \u03a6(\u00b7), and the number of days T , the vector p given by (2) reads p = r \u03a6z, with the entrywise product and \u03a6 \u2208 R T \u00d7T the matrix with entries \u03a6 ij = \u03a6(i \u2212 j).8.", [["KL", "GENE_OR_GENE_PRODUCT", 62, 64], ["matrix", "CELLULAR_COMPONENT", 338, 344], ["KL", "PROTEIN", 62, 64], ["\u03a6", "PROTEIN", 323, 324], ["Section", "TEST", 81, 88], ["the serial interval function", "TEST", 188, 216], ["the entrywise product", "TEST", 297, 318], ["ij", "ANATOMY", 360, 362]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 12, 2020. .(which was not certified by peer review)Maximum likelihood estimation of r (i.e., minimization of the negative log-likelihood) leads to an optimization problem min r D KL (z | r \u03a6z) which does not ensure any regularity of R(t).", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["an optimization problem", "TEST", 409, 432], ["med", "ANATOMY", 102, 105]]], ["To ensure temporal regularity, we propose a penalized approach using r = arg min r D KL (z | r \u03a6z) + \u2126(r) where \u2126 denotes a penalty function.(which was not certified by peer review)Here we wish to promote a piecewise affine and continuous behavior, which may be accomplished [7, 12] using \u2126(r) = \u03bb time D 2 r 1 , where D 2 is the matrix associated with a Laplacian filter (second order discrete temporal derivatives), \u00b7 1 denotes the 1 -norm (i.e., the sum of the absolute values of all entries), and \u03bb time is a penalty factor to be tuned.", [["matrix", "CELLULAR_COMPONENT", 330, 336], ["a penalized approach", "TREATMENT", 42, 62], ["a piecewise affine", "TREATMENT", 205, 223], ["a Laplacian filter", "TREATMENT", 353, 371], ["a penalty factor", "PROBLEM", 511, 527], ["penalty function", "OBSERVATION", 124, 140], ["Laplacian filter", "OBSERVATION", 355, 371]]], ["In the case of multiple d\u00e9partements, we consider multiple vectors (z d \u2208 R T , 1 \u2264 d \u2264 D) associated to the D time series, and multiple vectors of(which was not certified by peer review), which can be gathered into matrices: a data matrix Z \u2208 R T \u00d7D whose columns are z d and a matrix of unknown R \u2208 R T \u00d7D whose columns are the quantities to be estimated r d .", [["multiple vectors", "TREATMENT", 50, 66], ["a data matrix", "TEST", 226, 239], ["Z", "TEST", 240, 241]]], ["A first possibility is to proceed to independent estimation of the (r d \u2208 R T , 1 \u2264 d \u2264 D) by addressing the separate optimization problems(which was not certified by peer review)which can be equivalently rewritten into a matrix form:(which was not certified by peer review)where(which was not certified by peer review), the sum of the absolute values of all its entries.(which was not certified by peer review)An alternative is to estimate jointly the (r d \u2208 R T , 1 \u2264 d \u2264 D) using a penalty function promoting spatial regularity.", [["the (r d \u2208 R T", "TREATMENT", 63, 77], ["a penalty function", "TREATMENT", 483, 501], ["spatial regularity", "OBSERVATION", 512, 530]]], ["To account for spatial regularity, we use a spatial analogue of D 2 promoting spatially piecewise constant solutions.", [["spatial regularity", "PROBLEM", 15, 33], ["a spatial analogue of D 2 promoting spatially piecewise constant solutions", "TREATMENT", 42, 116], ["spatial regularity", "OBSERVATION", 15, 33]]], ["The D continental France d\u00e9partements can be considered as the vertices of a graph, where edges are present between adjacent d\u00e9partements.", [["The D continental France d\u00e9partements", "TREATMENT", 0, 37]]], ["From the adjacency matrix A \u2208 R D\u00d7D of this graph (A ij = 1 if there is an edge e = (i, j) in the graph, A ij = 0 otherwise), the global variation of the function on the graphs can be computed as ij A ij (R ti \u2212 R tj ) 2 and it is known that this can be accessed through the so-called (combinatorial) Laplacian of the graph: [24] .", [["this graph", "TEST", 39, 49], ["A ij", "TREATMENT", 51, 55], ["an edge e", "TEST", 72, 81], ["the graph", "TEST", 94, 103], ["A ij", "TREATMENT", 105, 109], ["ij A ij (R ti \u2212 R tj )", "TREATMENT", 196, 218], ["ij", "ANATOMY", 53, 55], ["ij", "ANATOMY", 107, 109], ["ij", "ANATOMY", 196, 198], ["ij", "ANATOMY", 201, 203]]], ["However, in order to promote smoothness over the graphs while keeping some sparse discontinuities on some edges, it is preferable to regularize using a Total Variation on the graph, which amounts to 9 .", [["the graphs", "TEST", 45, 55], ["some sparse discontinuities on some edges", "PROBLEM", 70, 111], ["the graph", "TEST", 171, 180], ["smoothness", "OBSERVATION_MODIFIER", 29, 39], ["sparse", "OBSERVATION_MODIFIER", 75, 81], ["discontinuities", "OBSERVATION_MODIFIER", 82, 97], ["some edges", "OBSERVATION_MODIFIER", 101, 111]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 12, 2020. . https://doi.org/10.1101/2020.06.10.20127365 doi: medRxiv preprint take the 1 -norm of these gradients (R ti \u2212 R tj ) on all existing edges.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["medRxiv", "TREATMENT", 323, 330], ["these gradients", "TREATMENT", 360, 375], ["R ti \u2212 R tj", "TREATMENT", 377, 388], ["med", "ANATOMY", 102, 105], ["tj", "ANATOMY", 386, 388], ["edges", "OBSERVATION_MODIFIER", 407, 412]]], ["For that, let us introduce the incidence matrix B \u2208 R E\u00d7D such that L = B B where E is the number of edges and, on each line representing an existing edge e = (i, j), we set B e,i = 1 and B e,j = \u22121.(which was not certified by peer review)where r(t) \u2208 R D is the t-th row of R, which gathers the values across all d\u00e9partements at a given time t.", [["incidence matrix B \u2208 R E\u00d7D", "PROTEIN", 31, 57], ["L = B B", "PROTEIN", 68, 75], ["the incidence matrix", "TREATMENT", 27, 47]]], ["From that, we can define the regularized optimization problem:(which was not certified by peer review)Optimization problems (6) and (7) involve convex, lower semi-continuous, proper and non-negative functions, hence their set of minimizers is non-empty and convex [2] .", [["Optimization problems (6) and (7) involve convex", "PROBLEM", 102, 150]]], ["By the known sparsitypromoting properties of 1 regularizers and their variants, the corresponding solutions are such that D 2 R and/or RB are sparse matrices, in the sense that these matrices of (second order temporal or first order spatial) derivatives have many zero entries.", [["D 2 R", "GENE_OR_GENE_PRODUCT", 122, 127], ["RB", "PROTEIN", 135, 137]]], ["The higher the penalty factors \u03bb time and \u03bb space , the more zeroes in these matrices.", [["penalty factors", "PROTEIN", 15, 30], ["higher", "OBSERVATION_MODIFIER", 4, 10], ["penalty", "OBSERVATION_MODIFIER", 15, 22]]], ["When \u03bb space is large enough, RB is exactly zero, which implies that r(t) is constant at each time since the graph of d\u00e9partements is connected.", [["RB", "PROTEIN", 30, 32], ["large", "OBSERVATION_MODIFIER", 16, 21]]], ["How to tune such parameters is further discussed in Section 4.1.Optimization using a proximal algorithmThe considered optimization problems are of the formOptimization using a proximal algorithmwhere F and G m are proper lower semi-continuous convex, and K m are bounded linear operators.", [["G m", "GENE_OR_GENE_PRODUCT", 206, 209], ["a proximal algorithm", "TEST", 83, 103], ["optimization problems", "PROBLEM", 118, 139], ["lower", "ANATOMY_MODIFIER", 221, 226], ["linear", "OBSERVATION_MODIFIER", 271, 277]]], ["To handle the lack of smoothness of Lipschitz differentiability for the considered functions F and G m , these approaches rely on their proximity operators.", [["G m", "GENE_OR_GENE_PRODUCT", 99, 102], ["Lipschitz differentiability", "PROBLEM", 36, 63]]], ["We recall that the proximity operator of a convex, lower semi-continuous function \u03d5 is defined as [17] prox \u03d5 (y) = arg min10.", [["min10", "PROTEIN", 120, 125]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 12, 2020. . https://doi.org/10.1101/2020.06.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["1 , m = 1, 2, and K 1 (R) := \u03bb time D 2 R,(which was not certified by peer review)The proximity operators associated to G m read:(which was not certified by peer review)where (.) + = max(0, .).", [["K", "TEST", 18, 19]]], ["The adjoint of K m , denoted K * m , is given by(which was not certified by peer review)The sequence (R (k+1) ) k\u2208N converges to a minimizer of (7) (cf. Thm 8.2 of [10] ).(which was not certified by peer review)Algorithm 1: Chambolle-Pock with multiple penalization terms Input: data Z, tolerance > 0;11.", [["The sequence", "TEST", 88, 100], ["k", "TEST", 105, 106], ["k", "TEST", 112, 113]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 12, 2020. . https://doi.org/10.1101/2020.06.10.20127365 doi: medRxiv preprintEstimation on synthetic dataTo assess the relevance and performance of the proposed estimation procedure detailed above, it is first applied to two different synthetic time series z(t).", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["the proposed estimation procedure", "TREATMENT", 410, 443], ["med", "ANATOMY", 102, 105]]], ["For such models, R(t) can be theoretically related to the time scale parameters entering their definition, as the ratio between the infection time scale and the quitting infection (be it by death or recovery) time scale.", [["infection", "DISEASE", 132, 141], ["infection", "DISEASE", 170, 179], ["death", "DISEASE", 190, 195], ["the ratio", "TEST", 110, 119], ["the infection time scale", "PROBLEM", 128, 152], ["the quitting infection", "PROBLEM", 157, 179], ["infection", "OBSERVATION", 132, 141]]], ["The theoretical serial function \u03a6 associated to that model and to its parameters is computed analytically (cf., e.g., [6] ) and used in the estimation procedure.Estimation on synthetic dataFor both cases, the same a priori prescribed function R(t), to be estimated, is chosen as constant (R = 2.2) over the first 45 days to model the epidemic outbreak, followed by a linear decrease (till below 1) over the next 45 days to model lockdown benefits, and finally an abrupt linear increase for the last 10 days, modeling a possible outbreak at when lockdown is lifted.", [["\u03a6", "PROTEIN", 32, 33], ["the estimation procedure", "TREATMENT", 136, 160], ["Estimation on synthetic data", "TEST", 161, 189], ["a linear decrease", "PROBLEM", 365, 382], ["an abrupt linear increase", "PROBLEM", 460, 485], ["epidemic", "OBSERVATION_MODIFIER", 334, 342], ["outbreak", "OBSERVATION", 343, 351], ["abrupt", "OBSERVATION_MODIFIER", 463, 469], ["linear", "OBSERVATION_MODIFIER", 470, 476], ["increase", "OBSERVATION_MODIFIER", 477, 485], ["possible", "UNCERTAINTY", 519, 527], ["outbreak", "OBSERVATION_MODIFIER", 528, 536]]], ["Additive Gaussian noise is superimposed to the data produced by the models to account for outliers and misreporting.", [["Additive Gaussian noise", "PROBLEM", 0, 23], ["Gaussian noise", "OBSERVATION", 9, 23]]], ["For both cases, the proposed estimation procedure (obtained with \u03bb time set to the same values as those used to analyze real data in Section 4) outperforms the naive estimates (1), which turn out to be very irregular (cf. Fig. 2 ).", [["the proposed estimation procedure", "TREATMENT", 16, 49], ["very irregular", "PROBLEM", 202, 216]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 12, 2020. . https://doi.org/10.1101/2020.06.10.20127365 doi: medRxiv preprint well the three different phases of R(t) (stable, decreasing and increasing, with notably a rapid and accurate reaction to the increasing change in the 10 last days.COVID-19 reproduction number time evolutionsThe present section aims to apply the models and estimation tools proposed in Section 3 to the data described in Section 2.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["medRxiv", "TREATMENT", 323, 330], ["a rapid and accurate reaction", "PROBLEM", 429, 458], ["the increasing change", "PROBLEM", 462, 483], ["COVID", "TEST", 504, 509], ["med", "ANATOMY", 102, 105], ["stable", "OBSERVATION_MODIFIER", 381, 387], ["decreasing", "OBSERVATION_MODIFIER", 389, 399], ["increasing", "OBSERVATION_MODIFIER", 404, 414], ["rapid", "OBSERVATION_MODIFIER", 431, 436], ["increasing", "OBSERVATION_MODIFIER", 466, 476], ["change", "OBSERVATION_MODIFIER", 477, 483]]], ["First, methodological issues are addressed related to tuning the hyperparameter(s) \u03bb time or (\u03bb time , \u03bb space ) in univariate and multivariate settings, and to comparing the consistency between different estimates of R obtained from the same incidence data yet downloaded from different repositories.", [["methodological issues", "PROBLEM", 7, 28]]], ["Then, the estimation tools are applied to the estimation of R(t) independently for numerous countries (cf. Section 4.3) and jointly for the 94 continental France d\u00e9partements (cf. Section 4.4).Regularization hyperparameter tuningA critical issue associated with the practical use of the estimates based on the optimization problems (5) and (7) lies in the tuning of the hyperparameters balancing data fidelity terms and penalization terms.", [["the estimation tools", "TEST", 6, 26], ["Section", "TEST", 107, 114]]], ["While automated and data-driven procedures can be devised, following works such as [20] and references therein, let us analyze the forms of the functional to be minimized, so as to compute relevant orders of magnitude for these hyperparameters.Regularization hyperparameter tuningLet us start with the univariate estimation (5).", [["driven procedures", "TREATMENT", 25, 42], ["these hyperparameters", "TREATMENT", 222, 243], ["the univariate estimation", "TEST", 298, 323]]], ["Using \u03bb time = 0 implies no regularization and the achieved estimate turns out to be as noisy as the one obtained with a naive estimator (cf. Eq.", [["regularization", "TREATMENT", 28, 42]]], ["However, a careful analysis of the functional to minimize shows that the data fidelity term (9), based on a Kullback-Leibler divergence, scales proportionally to the input incidence data z while the penalization term, based on the regularization of R(t), is independent of the actual values of z.", [["a careful analysis", "TEST", 9, 27], ["the penalization term", "PROBLEM", 195, 216]]], ["Therefore, the same estimate for R(t) is obtained if we replace z with \u03b1 \u00d7 z and \u03bb with \u03b1 \u00d7 \u03bb.", [["\u03b1", "PROTEIN", 71, 72], ["\u03bb", "PROTEIN", 81, 82], ["\u03b1", "PROTEIN", 88, 89]]], ["Because orders of magnitude of z are different amongst countries (either because of differences in population size, or of pandemic impact), this critical observation leads us to apply the estimate not to the raw data z but to a normalized version z/std(z), alleviating the burden of selecting one \u03bb time per country, instead enabling to select one same \u03bb time for all countries and further permitting to compare the estimated R(t)'s across countries for equivalent levels of regularization.Regularization hyperparameter tuningConsidering now the graph-based spatially-regularized estimates (7) while keeping fixed \u03bb time , the different R(t) are analyzed independently for each d\u00e9partement when 13 .", [["Regularization hyperparameter tuning", "TREATMENT", 490, 526], ["the graph", "TEST", 542, 551], ["size", "OBSERVATION_MODIFIER", 110, 114]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 12, 2020. . \u03bb space = 0.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["Conversely, choosing a large enough \u03bb space yields exactly identical estimates across d\u00e9partments that are, satisfactorily, very close to what is obtained from data aggregated over France prior to estimation.", [["a large enough \u03bb space", "PROBLEM", 21, 43]]], ["Further, the connectivity graph amongst the 94 continental France d\u00e9partements leads to an adjacency matrix with 475 non-zero off-diagonal entries (set to the value 1, associated to as many edges in the graph).", [["matrix", "CELLULAR_COMPONENT", 101, 107], ["475 non-zero off-diagonal entries", "DNA", 113, 146], ["the connectivity graph", "TEST", 9, 31], ["an adjacency matrix", "PROBLEM", 88, 107]]], ["Therefore, a careful examination of (7) shows that the spatial and temporal regularizations have equivalent weights when \u03bb time and \u03bb time are chosen such that(which was not certified by peer review)The use of z/std(z) and of (10) above gives a relevant first-order guess to the tuning of \u03bb time and of (\u03bb time , \u03bb space ).Estimate consistency using different repository sourcesWhen undertaking such work dedicated to on-going events, to daily evolutions, and to a real stake in forecasting future trends, a solid access to reliable data is critical.", [["a careful examination", "TEST", 11, 32], ["the spatial and temporal regularizations", "PROBLEM", 51, 91], ["z/std(z)", "TREATMENT", 210, 218]]], ["Source1(JHU) and Source2(ECDPC) provide cumulated numbers of confirmed cases counted at national levels and (in principle) including all reported cases from any source (hospital, death at home or in care homes. . . ).", [["death", "DISEASE", 179, 184]]], ["Source3(SPF) does not report that same number, but a collection of other figures related to hospital counts only, from which a daily number of new hospitalizations can be reconstructed and used as a proxy for daily new infections.", [["infections", "DISEASE", 219, 229], ["a collection of other figures", "PROBLEM", 51, 80], ["hospital counts", "TEST", 92, 107], ["daily new infections", "PROBLEM", 209, 229], ["infections", "OBSERVATION", 219, 229]]], ["The corresponding raw and (sliding-median) preprocessed data, illustrated in Fig. 3 , show overall comparable shapes and evolutions, yet with clearly visible discrepancies of two kinds.", [["overall", "OBSERVATION_MODIFIER", 91, 98], ["comparable", "OBSERVATION_MODIFIER", 99, 109], ["shapes", "OBSERVATION_MODIFIER", 110, 116], ["visible", "OBSERVATION_MODIFIER", 150, 157], ["discrepancies", "OBSERVATION", 158, 171], ["two kinds", "ANATOMY_MODIFIER", 175, 184]]], ["Those can result from miscounts, from pointwise incorporations of new figures, such as the progressive inclusion of cases from EHPAD (care homes) in France, or from corrections of previous erroneous reports.", [["EHPAD", "DISEASE", 127, 132], ["miscounts", "PROBLEM", 22, 31], ["new", "OBSERVATION_MODIFIER", 66, 69]]], ["Conversely, data from Source3(SPF), based on hospital reports, suffer from far less outliers, yet at the cost of providing only partial figures.", [["partial", "OBSERVATION_MODIFIER", 128, 135], ["figures", "OBSERVATION", 136, 143]]], ["As discussed in Section 2.2, it has been chosen here to preprocess outliers, on the basis of a sliding median procedure, prior to conducting the estimation of R(t).", [["a sliding median procedure", "TREATMENT", 93, 119]]], ["Second, in France, as in numerous other countries worldwide, the procedure on which confirmed case counts are based, changed several times during the pandemic period, yielding possibly some artificial increase in the local average number of daily new confirmed cases.", [["the procedure", "TREATMENT", 61, 74], ["case counts", "TEST", 94, 105], ["some artificial increase", "PROBLEM", 185, 209], ["possibly", "UNCERTAINTY", 176, 184], ["some", "OBSERVATION_MODIFIER", 185, 189], ["artificial", "OBSERVATION_MODIFIER", 190, 200], ["increase", "OBSERVATION_MODIFIER", 201, 209]]], ["This has notably been the case for France, prior to the end of the lockdown period (mid-May), when the number of tests performed has regularly increased for about two weeks, or more recently early June when the count procedures 14 .", [["tests", "TEST", 113, 118], ["the count procedures", "TEST", 207, 227], ["increased", "OBSERVATION_MODIFIER", 143, 152]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 12, 2020. . has been changed again, likely because of the massive use of serology tests.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["serology tests", "TEST", 335, 349], ["med", "ANATOMY", 102, 105], ["massive", "OBSERVATION_MODIFIER", 320, 327]]], ["Because the estimate of R(t) essentially relies on comparing a daily number against a past moving average, these changes lead to significant biases that cannot be easily accounted for, but vanishes after some duration controlled by the typical width of the serial distribution \u03a6 (of the order of ten days).", [["significant biases", "PROBLEM", 129, 147]]], ["Overall shapes in the time evolution of estimates are consistent, For instance, the three sources led to estimates showing a mild yet clear increase of R(t) for the period ranging from early May to May 20th, likely corresponding to a bias induced by the regular increase of tests actually performed in France.", [["tests", "TEST", 274, 279], ["shapes", "OBSERVATION_MODIFIER", 8, 14], ["mild", "OBSERVATION_MODIFIER", 125, 129], ["clear", "OBSERVATION_MODIFIER", 134, 139], ["increase", "OBSERVATION_MODIFIER", 140, 148]]], ["These comparisons however also clearly show that estimates are impacted by outliers and thus do depend on preprocessing.", [["impacted", "OBSERVATION", 63, 71]]], ["These considerations led to the final choice, used hereafter, of a threshold of \u00b12.5 std, in the sliding median denoising of Section 2.2.MarApr15.", [["MarApr15", "CHEMICAL", 137, 145], ["MarApr15", "GENE_OR_GENE_PRODUCT", 137, 145], ["MarApr15", "PROTEIN", 137, 145], ["MarApr15", "TREATMENT", 137, 145]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 12, 2020. .Confirmed infection cases across the worldTo report estimated R(t)'s for different countries, data from Source2(ECDPC) are used as they are of better quality than data from Source1(JHU), and because hospital-based data (as in Source3(SPF)) are not easily available for numerous different countries.", [["CC", "CHEMICAL", 0, 2], ["infection", "DISEASE", 283, 292], ["The copyright holder", "TREATMENT", 198, 218], ["infection cases", "PROBLEM", 283, 298], ["med", "ANATOMY", 102, 105], ["infection", "OBSERVATION", 283, 292]]], ["Visual inspection led us to choose, uniformly for all countries, two values of the temporal regularization parameter: \u03bb time = 50 to produce a strongly-regularized, hence slowly varying estimate, and \u03bb time = 3.5 for a milder regularization, and hence a more reactive estimate.", [["Visual inspection", "TEST", 0, 17], ["a milder regularization", "PROBLEM", 217, 240]]], ["These estimates being by construction designed to favor piecewise linear behaviors, local trends can be estimated by computing (robust) estimates of the derivatives\u03b2(t) ofR(t).", [["piecewise linear behaviors", "PROBLEM", 56, 82]]], ["The slow and less slow estimates ofR(t) thus provide a slow and less slow estimate of the local trends.", [["slow", "OBSERVATION_MODIFIER", 4, 8], ["less", "OBSERVATION_MODIFIER", 13, 17], ["slow", "OBSERVATION_MODIFIER", 18, 22]]], ["Intuitively, these local trends can be seen as predictors for the forthcoming value of R:R(t + n) =R(t) + n\u03b2(t).", [["R:R", "SIMPLE_CHEMICAL", 87, 90], ["the forthcoming value", "TEST", 62, 83]]], ["Let us start by inspecting again data for France, further comparing estimates stemming from data in Source2(ECDPC) or in Source3(SPF) (cf. Fig. 4) .", [["Source2", "TEST", 100, 107], ["ECDPC", "TEST", 108, 113]]], ["As discussed earlier, data from Source2(ECDPC) show far more outliers that data from Source3(SPF), thus impacting estimation of R and \u03b2.", [["R", "GENE_OR_GENE_PRODUCT", 128, 129], ["ECDPC", "TEST", 40, 45], ["Source3", "TEST", 85, 92]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 12, 2020. . are significant, as data from Source2(ECDPC) yields, for June 9th, estimates of R slightly above 1, while that from Source3(SPF) remain steadily around 0.75, with no or mild local trends.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["Source2", "TEST", 304, 311], ["Source3", "TEST", 390, 397], ["SPF", "TEST", 398, 401], ["med", "ANATOMY", 102, 105], ["significant", "OBSERVATION_MODIFIER", 278, 289], ["mild", "OBSERVATION_MODIFIER", 443, 447]]], ["Again, this might be because late May, France has started massive serology testing, mostly performed outside hospitals.", [["massive serology testing", "TEST", 58, 82]]], ["This yielded an abrupt increase in the number of new confirmed cases, biasing upward the estimates of R(t).", [["an abrupt increase", "PROBLEM", 13, 31], ["abrupt", "OBSERVATION_MODIFIER", 16, 22], ["increase", "OBSERVATION_MODIFIER", 23, 31], ["new", "OBSERVATION_MODIFIER", 49, 52], ["upward", "OBSERVATION_MODIFIER", 78, 84]]], ["However, the short-term local trend for June 9th goes also downward, suggesting that the model is incorporating these irregularities and that estimates will return to unbiased after an estimation time controlled by the typical width of the serial distribution \u03a6 (of the order of ten days).", [["these irregularities", "PROBLEM", 112, 132], ["short", "OBSERVATION_MODIFIER", 13, 18], ["irregularities", "OBSERVATION", 118, 132], ["width", "OBSERVATION_MODIFIER", 227, 232]]], ["This recent increase is not seen in Source3(SPF)-based estimates that remain very stable, potentially suggesting that hospital-based data are much less sensitive to changes in the count policies.", [["increase", "OBSERVATION_MODIFIER", 12, 20], ["not seen", "UNCERTAINTY", 24, 32], ["very", "OBSERVATION_MODIFIER", 77, 81], ["stable", "OBSERVATION", 82, 88]]], ["As of June 9th (time of writing), Fig. 5 shows that for most European countries, the pandemic seems to remain under control despite lifting of the lockdown,17.", [["the pandemic", "PROBLEM", 81, 93]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 12, 2020. . with (slowly varying) estimates of R remaining stable below 1, ranging from 0.7 to 0.8 depending on countries, and (slowly varying) trends around 0.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105], ["stable", "OBSERVATION_MODIFIER", 321, 327]]], ["Sweden and Portugal (not shown here) display less favorable patterns, as well as, to a lesser extent, The Netherlands, raising the question of whether this might be a potential consequence of less stringent lockdown rules compared to neighboring European countries.", [["less stringent lockdown rules", "PROBLEM", 192, 221], ["less favorable", "OBSERVATION_MODIFIER", 45, 59], ["lesser extent", "OBSERVATION_MODIFIER", 87, 100]]], ["Fig. 6 shows that whileR for Canada is clearly below 1 since early May, with a negative local trend, the USA are still bouncing back and forth around 1.", [["the USA", "TEST", 101, 108]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 12, 2020.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["Phase-space representation To complement Figs.", [["space representation", "OBSERVATION", 6, 26]]], ["Interestingly, European countries display a C-shape trajectory, starting with R > 1 with negative trends (lockdown effects), thus reaching the safe zone (R < 1) but eventually performing a U-turn with a slow increase of local trends till positive.", [["a C-shape trajectory", "PROBLEM", 42, 62], ["a U-turn", "TREATMENT", 187, 195], ["a slow increase of local trends", "PROBLEM", 201, 232]]], ["This results in a mild but clear re-increase of R, yet with most values below 1 today, except for France (see comments above) and Sweden.", [["a mild but clear re-increase of R", "PROBLEM", 16, 49], ["mild", "OBSERVATION_MODIFIER", 18, 22], ["clear", "OBSERVATION_MODIFIER", 27, 32], ["re-increase", "OBSERVATION_MODIFIER", 33, 44]]], ["The USA display a similar C-shape though almost concentrated on the edge point R(t) = 1, \u03b2 = 0, while Canada does return to the safe zone with a specific pattern.", [["The USA", "TEST", 0, 7], ["a similar C-shape", "PROBLEM", 16, 33], ["similar", "OBSERVATION_MODIFIER", 18, 25], ["shape", "OBSERVATION_MODIFIER", 28, 33], ["almost", "OBSERVATION_MODIFIER", 41, 47], ["concentrated", "OBSERVATION_MODIFIER", 48, 60]]], ["South-American countries, obviously at an earlier stage of the pandemic, show an inverted C-shape pattern, with trajectory evolving from the bad top right corner, to the controlling phase (negative local trend, with decreasing R still above 1 though).", [["an inverted C-shape pattern", "PROBLEM", 78, 105], ["-shape", "OBSERVATION_MODIFIER", 91, 97], ["trajectory", "OBSERVATION_MODIFIER", 112, 122], ["right", "ANATOMY_MODIFIER", 149, 154], ["corner", "ANATOMY_MODIFIER", 155, 161]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 12, 2020. and African countries essentially confirm these C-shaped trajectories.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["these C-shaped trajectories", "PROBLEM", 314, 341], ["med", "ANATOMY", 102, 105]]], ["Envisioning these phase-space plots as pertaining to different stages of the pandemic (rather than to different countries), this suggests that COVID-19 pandemic trajectory ressembles a counter-clock wise circle, starting from the bad top right corner (R above 1 and positive trends), evolving, likely by lockdown impact, towards the bottom right corner (R still above 1 but negative trends) and finally to the safe bottom left corner (R below1 and negative then null trend).", [["R below1", "PROTEIN", 435, 443], ["space plots", "PROBLEM", 24, 35], ["the pandemic", "PROBLEM", 73, 85], ["COVID", "TEST", 143, 148], ["a counter-clock wise circle", "TREATMENT", 183, 210], ["right", "ANATOMY_MODIFIER", 238, 243], ["corner", "ANATOMY_MODIFIER", 244, 250], ["bottom", "ANATOMY_MODIFIER", 333, 339], ["right", "ANATOMY_MODIFIER", 340, 345], ["corner", "ANATOMY_MODIFIER", 346, 352]]], ["As of June 9th, it can be only expected that trajectories will not close the loop and reach back the bad top right corner and the R = 1 limit.20.", [["loop", "OBSERVATION", 77, 81], ["bad", "OBSERVATION", 101, 104], ["right", "ANATOMY_MODIFIER", 109, 114], ["corner", "ANATOMY_MODIFIER", 115, 121]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 12, 2020. .", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["Figure 9 -Phase-space evolution reconstructed from averaged slowly varying estimates of R and \u03b2, per continent.", [["Figure", "TEST", 0, 6], ["slowly", "OBSERVATION_MODIFIER", 60, 66], ["varying", "OBSERVATION_MODIFIER", 67, 74]]], ["The name of the country is written at the last day of the trajectory, also marked by larger size empty symbol.", [["marked", "OBSERVATION_MODIFIER", 75, 81], ["larger", "OBSERVATION_MODIFIER", 85, 91], ["size", "OBSERVATION_MODIFIER", 92, 96], ["empty symbol", "OBSERVATION", 97, 109]]], ["Data from Source2(ECDPC).21.", [["ECDPC", "TEST", 18, 23]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 12, 2020. . https://doi.org/10.1101/2020.06.10.20127365 doi: medRxiv preprintContinental France d\u00e9partements: regularized joint estimatesThere is further interest in focusing the analysis on the potential heterogeneity in the epidemic propagation across a given territory, governed by the same sanitary rules and health care system.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["medRxiv", "TREATMENT", 323, 330], ["regularized joint estimates", "TREATMENT", 372, 399], ["the analysis", "TEST", 437, 449], ["med", "ANATOMY", 102, 105], ["joint", "ANATOMY", 384, 389]]], ["This can be achieved by estimating a set of localR(t)'s for different provinces and regions [14] .", [["localR(t)'s", "TREATMENT", 44, 55]]], ["Such a study is made possible by the data from Source3(SPF), that provides hospital-based data for each of the continental France d\u00e9partements.", [["a study", "TEST", 5, 12]]], ["Fig. 4 (right) already reported the slow and fast varying estimates of R and local trends computed from data aggregated over the whole France.", [["right", "ANATOMY_MODIFIER", 8, 13]]], ["To further study the variability across the continental France territory, the graph-based, joint spatial and temporal regularization described in Eq.", [["further study", "TEST", 3, 16], ["joint spatial and temporal regularization", "PROBLEM", 91, 132], ["continental", "OBSERVATION_MODIFIER", 44, 55], ["joint", "ANATOMY", 91, 96], ["temporal regularization", "OBSERVATION", 109, 132]]], ["The two choices for \u03bb time leading to slow and less slow estimates were kept for this joint study.", [["slow and less slow estimates", "PROBLEM", 38, 66], ["this joint study", "TEST", 81, 97], ["joint", "ANATOMY", 86, 91]]], ["Using (10) as a guideline, empirical analyses led to set \u03bb space = 0.025, thus selecting spatial regularization to weight one-fourth of the temporal regularization.Continental France d\u00e9partements: regularized joint estimatesFirst, Fig. 10 (top row) maps and compares for June 9th (chosen arbitrarily as the day of writing) per-d\u00e9partement estimates, obtained when d\u00e9partements are analyzed either independently (R Indep using Eq.", [["empirical analyses", "TEST", 27, 45], ["the temporal regularization", "TREATMENT", 136, 163], ["regularized joint estimates", "TREATMENT", 197, 224], ["temporal regularization", "OBSERVATION", 140, 163], ["joint", "ANATOMY", 209, 214]]], ["6, left plot) or jointly (R Joint using Eq.", [["left", "ANATOMY_MODIFIER", 3, 7], ["Joint", "ANATOMY", 28, 33]]], ["7, right plot).", [["right", "ANATOMY_MODIFIER", 3, 8]]], ["While the means ofR Indep andR Joint are of the same order ( 0.58 and 0.63 respectively) the standard deviations drop down from 0.40 to 0.14, thus indicating a significant decrease in the variability across departments.", [["the standard deviations drop", "TEST", 89, 117], ["a significant decrease in the variability across departments", "PROBLEM", 158, 218], ["Joint", "ANATOMY", 31, 36], ["significant", "OBSERVATION_MODIFIER", 160, 171], ["decrease", "OBSERVATION_MODIFIER", 172, 180], ["variability", "OBSERVATION_MODIFIER", 188, 199]]], ["This is further complemented by the visual inspection of the maps which reveals reduced discrepancies across neighboring departments, as induced by the estimation procedure.Continental France d\u00e9partements: regularized joint estimatesIn a second step, short and long-term trends are automatically extracted fromR Indep andR Joint and short-term trends are displayed in the bottom row of Fig. 10 (left and right, respectively).", [["the visual inspection", "TEST", 32, 53], ["the maps", "TEST", 57, 65], ["reduced discrepancies", "PROBLEM", 80, 101], ["the estimation procedure", "TREATMENT", 148, 172], ["regularized joint estimates", "TREATMENT", 206, 233], ["short and long-term trends", "PROBLEM", 251, 277], ["reduced", "OBSERVATION_MODIFIER", 80, 87], ["discrepancies", "OBSERVATION", 88, 101], ["joint", "ANATOMY", 218, 223], ["Joint", "ANATOMY", 323, 328], ["left", "ANATOMY_MODIFIER", 395, 399], ["right", "ANATOMY_MODIFIER", 404, 409]]], ["This evidences again a reduced variability across neighboring departments, though much less than that observed forR Indep andR Joint , likely suggesting that trends on R per se are more robust quantities to estimate than single R's.", [["a reduced variability", "PROBLEM", 21, 42], ["reduced", "OBSERVATION_MODIFIER", 23, 30], ["variability", "OBSERVATION_MODIFIER", 31, 42], ["Joint", "ANATOMY", 127, 132], ["likely suggesting", "UNCERTAINTY", 135, 152]]], ["For June 9th, Fig. 10 also indicates globally mild decreasing trends (\u22120.007\u00b10.010 per day, on average) everywhere across France, thus confirming the trend estimated on data aggregated over all France (cf. Fig. 4, right plot) .Continental France d\u00e9partements: regularized joint estimatesA video animation, available at perso.ens-lyon.fr/patrice.abry/DeptRegul.mp4 and updated on a daily basis (see also barthes.enssib.fr/coronavirus/IXXI-SiSyPhe/), reports further comparisons betweenR Indep andR Joint and their evolution along time for the whole period of data availability.", [["coronavirus", "ORGANISM", 421, 432], ["patrice.abry", "PROTEIN", 337, 349], ["DeptRegul.mp4", "DNA", 350, 363], ["IXXI", "PROTEIN", 433, 437], ["globally mild decreasing trends", "PROBLEM", 37, 68], ["enssib", "TEST", 411, 417], ["globally", "OBSERVATION_MODIFIER", 37, 45], ["mild", "OBSERVATION_MODIFIER", 46, 50], ["decreasing", "OBSERVATION_MODIFIER", 51, 61], ["right", "ANATOMY_MODIFIER", 214, 219], ["joint", "ANATOMY", 272, 277], ["lyon", "OBSERVATION", 329, 333], ["Joint", "ANATOMY", 497, 502]]], ["Maps for selected days are also displayed in Fig. 11 (with identical colormaps and colorbars across time).", [["Maps", "TEST", 0, 4]]], ["Fig. 11 shows that until late March (lockdown took place in France on March, 17th),R Joint was uniformly above 1.5 (chosen as the upper 22 .", [["Joint", "ANATOMY", 85, 90], ["upper", "ANATOMY_MODIFIER", 130, 135]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 12, 2020. . limit of the colorbar to permit to see variations during the lockdown and post-lockdown periods), indicating a rapid evolution of the epidemic across entire France.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["post-lockdown periods", "TREATMENT", 348, 369], ["med", "ANATOMY", 102, 105], ["rapid", "OBSERVATION_MODIFIER", 385, 390], ["epidemic", "OBSERVATION_MODIFIER", 408, 416]]], ["A slowdown of the epidemic evolution is visible as early as the first days of April (with overall decreases ofR Joint , and a clear North vs. South gradient).", [["overall decreases ofR Joint", "PROBLEM", 90, 117], ["South gradient", "TEST", 142, 156], ["slowdown", "OBSERVATION_MODIFIER", 2, 10], ["epidemic", "OBSERVATION_MODIFIER", 18, 26], ["visible", "OBSERVATION_MODIFIER", 40, 47], ["decreases", "OBSERVATION_MODIFIER", 98, 107], ["Joint", "ANATOMY", 112, 117], ["gradient", "OBSERVATION_MODIFIER", 148, 156]]], ["During April, this gradient rotates slightly and aligns on a North-East vs. South-West direction and globally decreases in amplitude.", [["this gradient rotates slightly", "PROBLEM", 14, 44], ["globally decreases in amplitude", "PROBLEM", 101, 132], ["globally", "OBSERVATION_MODIFIER", 101, 109], ["decreases", "OBSERVATION_MODIFIER", 110, 119], ["amplitude", "OBSERVATION_MODIFIER", 123, 132]]], ["Interestingly, in May, this gradient has reversed direction from South-West to North-East, though with very mild amplitude.(which was not certified by peer review)As of today (June 9th), the pandemic, viewed Hospital-based data from Source3(SPF), seems under control for the whole continental France.", [["very mild amplitude", "PROBLEM", 103, 122], ["mild", "OBSERVATION_MODIFIER", 108, 112], ["amplitude", "OBSERVATION_MODIFIER", 113, 122]]], ["Fast varying estimates of reproduction numbers R (top) and trends \u03b2 (bottom) for independent (left) and spatial graph-based regularized estimates (right).", [["spatial graph", "TEST", 104, 117], ["left", "ANATOMY_MODIFIER", 94, 98], ["right", "ANATOMY_MODIFIER", 147, 152]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 12, 2020. .", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["Figure 11 -Graph-based spatially regularized estimates of the reproduction number R for the 94 continental France d\u00e9partments, as a function of days.", [["Figure", "TEST", 0, 6]]], ["Movie animations for the whole period are made available at perso.ens-lyon.fr/patrice.abry/DeptRegul.mp4 or barthes.enssib.fr/coronavirus/IXXI-SiSyPhe/, and updated on a regular basis.", [["DeptRegul.mp4", "GENE_OR_GENE_PRODUCT", 91, 104], ["coronavirus", "ORGANISM", 126, 137], ["IXXI", "GENE_OR_GENE_PRODUCT", 138, 142], ["patrice.abry", "PROTEIN", 78, 90], ["DeptRegul.mp4", "DNA", 91, 104], ["IXXI", "PROTEIN", 138, 142], ["SiSyPhe", "PROTEIN", 143, 150], ["DeptRegul.mp4", "TREATMENT", 91, 104], ["barthes", "TREATMENT", 108, 115], ["lyon", "OBSERVATION", 70, 74]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 12, 2020. . https://doi.org/10.1101/2020.06.10.20127365 doi: medRxiv preprintConclusions and perspectivesThe estimation of reproduction numbers constitutes a classical task in assessing the status of a pandemic.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["medRxiv", "TREATMENT", 323, 330], ["a pandemic", "PROBLEM", 462, 472], ["med", "ANATOMY", 102, 105]]], ["This calls for a triplet of constraints: i) robust access to fast-collected data ; ii) semi-parametric models for such data that focus on a subset of critical parameters ; iii) estimation procedures that are elaborated enough to yield robust estimates and versatile enough to be used in quasi-real time (daily basis) and applied to (often-limited in quality and quantity) available data.", [["estimation procedures", "TREATMENT", 177, 198]]], ["In that spirit, making use of a robust nonstationary Poisson-distribution based semi-parametric model proven robust in the literature for epidemic analysis, we developed an original estimation procedure to favor piecewise regular estimation of the evolution of the reproduction number, both along time and across space.", [["epidemic analysis", "TEST", 138, 155], ["an original estimation procedure", "TREATMENT", 170, 202]]], ["This was constructed as an inverse problem formulation designed to achieve robustness in the estimation by enforcing time and space smoothness through regularization while permitting fast enough temporal and spatial evolutions and solved using used proximal operators and nonsmooth convex optimization.", [["an inverse problem formulation", "TREATMENT", 24, 54], ["space smoothness through regularization", "TREATMENT", 126, 165], ["proximal operators", "TREATMENT", 249, 267], ["nonsmooth convex optimization", "TREATMENT", 272, 301]]], ["The proposed tools were applied to pandemic incidence data consisting of daily counts of new infections, from several databases providing data either worldwide on an aggregated per-country basis or, for France only, based on the sole hospital counts, spread across the French territory.", [["infections", "DISEASE", 93, 103], ["pandemic incidence data", "PROBLEM", 35, 58], ["new infections", "PROBLEM", 89, 103], ["new", "OBSERVATION_MODIFIER", 89, 92], ["infections", "OBSERVATION", 93, 103]]], ["They permitted to reveal interesting patterns on the state of the pandemic across the world as well as to assess variability across one single territory governed by the same (health care and politics) rules.Conclusions and perspectivesAt the practical level, this tool can be applied to time series of incidence data, reported, e.g., for a given country.", [["incidence data", "TEST", 302, 316]]], ["Importantly, this tool can be used everyday easily as an on-the-fly monitoring procedure for assessing the current state of the pandemic and predict its short-term future evolution.", [["the-fly monitoring procedure", "TREATMENT", 60, 88], ["the pandemic", "PROBLEM", 124, 136], ["pandemic", "OBSERVATION", 128, 136], ["short-term", "OBSERVATION_MODIFIER", 153, 163]]], ["Indeed, the tool also provides local trends \u03b2, whose last value can be used to forecast short-term future values of R and thus to detect a sudden increase of the pandemic.Conclusions and perspectivesThe tools can be made available upon motivated request.", [["a sudden increase of the pandemic", "PROBLEM", 137, 170]]], ["Achieved estimations are updated on a daily basis at perso.ens-lyon.fr/patrice.abry (see also barthes.enssib.fr/coronavirus/IXXI-SiSyPhe/).25.", [["enssib", "GENE_OR_GENE_PRODUCT", 102, 108], ["coronavirus", "ORGANISM", 112, 123], ["IXXI", "GENE_OR_GENE_PRODUCT", 124, 128], ["enssib", "PROTEIN", 102, 108], ["IXXI", "PROTEIN", 124, 128], ["enssib", "TEST", 102, 108], ["lyon", "OBSERVATION", 63, 67]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)25The copyright holder for this preprint this version posted June 12, 2020. .", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["At the methodological level, the tool can be further improved in several ways.", [["improved", "OBSERVATION", 53, 61]]], ["Instead of using \u2126(R) := \u03bb time D 2 R 1 + \u03bb space RB 1 , for the joint time and space regularization, another possible choice is to directly consider the matrix D 2 RB of joint spatiotemporal derivatives, and to promote sparsity with an 1 -norm, or structured sparsity with a mixed norm 1,2 , e.g., D 2 RB 1,2 = t (D 2 RB )(t) 2 .", [["RB 1", "PROTEIN", 50, 54], ["RB", "PROTEIN", 165, 167], ["space regularization", "TREATMENT", 80, 100], ["the matrix D 2 RB of joint spatiotemporal derivatives", "TREATMENT", 150, 203], ["joint", "ANATOMY", 65, 70], ["joint", "ANATOMY", 171, 176]]], ["They can be combined into a single step at the cost of increasing the representation space permitting to split observation in true data and outliers, by adding to the functional to minimize an extra regularization term and devising the corresponding optimization procedure, which becomes nonconvex, and hence far more complicated to address.", [["an extra regularization term", "TREATMENT", 190, 218], ["the corresponding optimization procedure", "TREATMENT", 232, 272]]], ["Finally, when an epidemic model suggests a way to make use of several time series (such as, e.g., infected and deceased) for one same territory, the tool can straightforwardly be extended into a multivariate setting by a mild adaptation of optimization problems (6) and (7), replacing the Kullback-Leibler divergence D KL (Z | R \u03a6Z) by I i=1 D KL (Z i | R \u03a6Z i ).", [["Kullback-Leibler divergence D KL", "PROTEIN", 289, 321], ["a mild adaptation of optimization problems", "PROBLEM", 219, 261], ["the Kullback", "TEST", 285, 297], ["Z i", "TEST", 348, 351], ["mild", "OBSERVATION_MODIFIER", 221, 225]]], ["Finally, automating a data-driven tuning of the regularization hyperparameters constitutes another important research track.", [["the regularization hyperparameters", "TREATMENT", 44, 78]]]], "335a5a9080f930aae6c278ceca49533cb77fb7fe": [["The European cattle was domesticated 10 000 years ago in eastern Turkey, 1000 years later potteryassociated milk fats identify cattle-based dairy activity in western Turkey.", [["milk fats", "ANATOMY", 108, 117], ["cattle", "ORGANISM", 13, 19], ["milk", "ORGANISM", 108, 112], ["fats", "ORGANISM_SUBDIVISION", 113, 117], ["dairy", "ORGANISM_SUBDIVISION", 140, 145], ["cattle", "SPECIES", 13, 19], ["milk", "SPECIES", 108, 112], ["cattle", "SPECIES", 127, 133], ["cattle", "SPECIES", 13, 19], ["cattle", "SPECIES", 127, 133]]], ["Subsequently, the Indo-European language, domesticated animals and plants travel as a Neolithic package along two major routes across Europe.", [["Indo", "CHEMICAL", 18, 22], ["the Indo", "TREATMENT", 14, 22], ["a Neolithic package", "TREATMENT", 84, 103]]], ["A striking south-east to north-west gradient of a mutation in the current European population (lactase persistence into adulthood) documents the expansion of a Neolithic dairy culture into a Mesolithic hunter society.", [["lactase", "GENE_OR_GENE_PRODUCT", 95, 102], ["a mutation", "PROBLEM", 48, 58], ["a Neolithic dairy culture", "TEST", 158, 183], ["expansion", "OBSERVATION_MODIFIER", 145, 154]]], ["Using oral tradition (myths), archaeological and written historical evidence and biological data, it is asked whether highly transmissible viral diseases like measles and smallpox entered during the Neolithic from domesticated animals into the human population.", [["oral", "ANATOMY", 6, 10], ["viral diseases", "DISEASE", 139, 153], ["measles and smallpox", "DISEASE", 159, 179], ["oral", "ORGANISM_SUBDIVISION", 6, 10], ["human", "ORGANISM", 244, 249], ["human", "SPECIES", 244, 249], ["human", "SPECIES", 244, 249], ["highly transmissible viral diseases", "PROBLEM", 118, 153], ["measles", "PROBLEM", 159, 166], ["smallpox", "TREATMENT", 171, 179]]], ["The bovine origin of paramyxovirus infections is likely; smallpox comes from camels or from rodents via cattle while mycobacteria and Helicobacter infected humans already before the Neolithic.", [["paramyxovirus infections", "DISEASE", 21, 45], ["Helicobacter infected", "DISEASE", 134, 155], ["bovine", "ORGANISM", 4, 10], ["paramyxovirus", "ORGANISM", 21, 34], ["camels", "ORGANISM_SUBDIVISION", 77, 83], ["cattle", "ORGANISM", 104, 110], ["Helicobacter", "ORGANISM", 134, 146], ["humans", "ORGANISM", 156, 162], ["bovine", "SPECIES", 4, 10], ["cattle", "SPECIES", 104, 110], ["humans", "SPECIES", 156, 162], ["cattle", "SPECIES", 104, 110], ["humans", "SPECIES", 156, 162], ["paramyxovirus infections", "PROBLEM", 21, 45], ["smallpox", "PROBLEM", 57, 65], ["mycobacteria", "PROBLEM", 117, 129], ["Helicobacter infected humans", "PROBLEM", 134, 162], ["bovine origin", "OBSERVATION_MODIFIER", 4, 17], ["paramyxovirus infections", "OBSERVATION", 21, 45], ["is likely", "UNCERTAINTY", 46, 55], ["Helicobacter infected", "OBSERVATION", 134, 155]]], ["The current global environmental changes will lead to another highly dynamic phase of viral transmissions into the human population.", [["human", "ORGANISM", 115, 120], ["human", "SPECIES", 115, 120], ["human", "SPECIES", 115, 120]]]], "PMC7264671": [["We outline the current measures being used to contain the outbreak and how the experience of the SARS epidemic may have influenced the response in Hong Kong.", [["SARS", "DISEASE", 97, 101], ["the current measures", "TREATMENT", 11, 31], ["the SARS epidemic", "PROBLEM", 93, 110]]], ["We also discuss the potential mental health ill\u2010effects of the pandemic and its impact on mental health nursing locally.RELEVANCE STATEMENTThis editorial provides an overview of the impact of COVID\u201019 on mental health and mental health nursing in Hong Kong.", [["COVID\u2010", "TREATMENT", 192, 198]]], ["The potential consequences of the pandemic for mental health nurses and future research are outlined.COVID\u201019 AND THE CURRENT SITUATION IN HONG KONGAt the time of writing (mid\u2010April 2020), the current number of people in Hong Kong diagnosed as infected by the virus (SARS\u2010CoV\u20102) that causes COVID\u201019 stands at 1,011.", [["SARS", "DISEASE", 267, 271], ["people", "ORGANISM", 211, 217], ["people", "SPECIES", 211, 217], ["the virus", "PROBLEM", 256, 265]]], ["Despite Hong Kong's proximity to mainland China, the huge numbers of Chinese tourists and business visitors, and Hong Kong's position as a major international transport hub, to date, only four people have lost their lives to COVID\u201019.", [["people", "ORGANISM", 193, 199], ["people", "SPECIES", 193, 199], ["huge", "OBSERVATION_MODIFIER", 53, 57]]], ["Concerns about Hong Kong becoming an epicentre for the COVID\u201019 outbreak were compounded by the fact that Hong Kong is an extremely densely populated region, with a total population of 7.48 million residing in an area of 1,004 km2 and hence is particularly conducive to the spread of a highly contagious virus.COVID\u201019 AND THE CURRENT SITUATION IN HONG KONGDespite the numbers of infections and COVID\u201019 deaths being relatively low, people in Hong Kong have been facing prolonged fear and restrictions on their daily lives since mid\u2010January 2020.", [["infections", "DISEASE", 380, 390], ["COVID", "DISEASE", 395, 400], ["deaths", "DISEASE", 404, 410], ["people", "SPECIES", 433, 439], ["a highly contagious virus", "PROBLEM", 284, 309], ["infections", "PROBLEM", 380, 390], ["extremely", "OBSERVATION_MODIFIER", 122, 131], ["densely", "OBSERVATION_MODIFIER", 132, 139], ["populated", "OBSERVATION", 140, 149], ["infections", "OBSERVATION", 380, 390]]], ["While some governments were minimizing the risk of the virus, the HK government began to provide social distancing advice and implementing border restriction measures on 26 January 2020 (Information Services Department, 2020a).", [["the virus", "PROBLEM", 51, 60], ["border restriction measures", "TREATMENT", 139, 166]]], ["Due to the rapidly growing number of COVID\u201019 patients in Hong Kong, the Hospital Authority (HA) activated the Emergency Response Level on 25 January 2020 (Hospital Authority, 2020a).", [["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54]]], ["All hospital visiting was suspended, and non\u2010urgent outpatient specialist appointments/surgery was re\u2010scheduled.", [["surgery", "TREATMENT", 87, 94]]], ["These preventive measures aimed to reduce COVID\u201019 infection rates and reduce the risk of the healthcare system becoming overwhelmed.COVID\u201019 AND THE CURRENT SITUATION IN HONG KONGInitially, the measures put in place by the local government to control the spread of the virus were far less restrictive than many other areas of the world, consisting of social distancing, border restrictions, school/university closures, encouraging working from home, promoting frequent hand washing and encouraging wearing masks in public (CHP, 2020).", [["hand", "ANATOMY", 470, 474], ["infection", "DISEASE", 51, 60], ["hand", "ORGANISM_SUBDIVISION", 470, 474], ["COVID\u2010", "TREATMENT", 42, 48], ["infection rates", "PROBLEM", 51, 66], ["the measures", "TREATMENT", 191, 203], ["the virus", "PROBLEM", 266, 275], ["frequent hand washing", "TREATMENT", 461, 482], ["infection", "OBSERVATION", 51, 60], ["virus", "OBSERVATION", 270, 275]]], ["However, due to a rapid increase in confirmed COVID\u201019 cases, the government decided to impose Prevention and Control of Disease Regulations from 28 March 2020 to 23 April 2020.", [["a rapid increase", "PROBLEM", 16, 32], ["Disease Regulations", "TREATMENT", 121, 140]]], ["Although a total \u201clockdown\u201d was not imposed, restaurants were required to run at half\u2010capacity, group gatherings were limited to four people, and bars, beauty parlours, and other leisure venues were closed.", [["people", "ORGANISM", 134, 140], ["people", "SPECIES", 134, 140]]], ["Anyone contravening these regulations is subject to fines and imprisonment, but generally, the majority of local people have been complying with regulations and advice.COVID\u201019 AND THE CURRENT SITUATION IN HONG KONGThese more stringent preventive measures seem to have been effective to reduce the transmission of COVID\u201019 because new infections have been declining for two weeks at the time of writing.", [["COVID", "DISEASE", 314, 319], ["infections", "DISEASE", 335, 345], ["people", "ORGANISM", 113, 119], ["people", "SPECIES", 113, 119], ["HONG KONGThese more stringent preventive measures", "TREATMENT", 206, 255], ["COVID\u2010", "TREATMENT", 314, 320], ["new infections", "PROBLEM", 331, 345], ["new", "OBSERVATION_MODIFIER", 331, 334], ["infections", "OBSERVATION", 335, 345]]], ["However, the government are warning the population not to become complacent due to the risk of a third wave of local infection due to imported cases.", [["infection", "DISEASE", 117, 126], ["local infection", "PROBLEM", 111, 126], ["local", "OBSERVATION_MODIFIER", 111, 116], ["infection", "OBSERVATION", 117, 126]]], ["This is a real concern given that Hong Kong has experienced restrictions for almost three months, resulting in some people becoming frustrated by the lack of social contact.COVID\u201019 AND THE CURRENT SITUATION IN HONG KONGIt is likely that the Severe Acute Respiratory Syndrome (SARS) epidemic of 2003 influenced the government's and the public's response to COVID\u201019.", [["Acute Respiratory Syndrome", "DISEASE", 249, 275], ["SARS", "DISEASE", 277, 281], ["people", "ORGANISM", 116, 122], ["people", "SPECIES", 116, 122], ["the Severe Acute Respiratory Syndrome", "PROBLEM", 238, 275], ["Severe", "OBSERVATION_MODIFIER", 242, 248], ["Acute", "OBSERVATION_MODIFIER", 249, 254], ["Respiratory Syndrome", "OBSERVATION", 255, 275]]], ["In 2003, Hong Kong was the epicentre of SARS outbreak with a total of 1,750 confirmed cases and 286 deaths, eight of these fatalities were healthcare professionals (Lee, 2003).", [["SARS", "DISEASE", 40, 44], ["deaths", "DISEASE", 100, 106], ["fatalities", "DISEASE", 123, 133], ["SARS outbreak", "PROBLEM", 40, 53]]], ["The SARS epidemic also resulted in severe financial decline locally, which harmed mental health (Liu et al., 2012).", [["SARS", "DISEASE", 4, 8], ["The SARS epidemic", "PROBLEM", 0, 17], ["severe financial decline locally", "PROBLEM", 35, 67], ["severe", "OBSERVATION_MODIFIER", 35, 41]]], ["The impact of SARS resulted in profound changes in the way Hong Kong people maintained self\u2010hygiene, such as the routine wearing of face masks when unwell.", [["SARS", "DISEASE", 14, 18], ["people", "ORGANISM", 69, 75], ["people", "SPECIES", 69, 75], ["SARS", "PROBLEM", 14, 18], ["profound changes", "PROBLEM", 31, 47], ["self\u2010hygiene", "TREATMENT", 87, 99], ["face masks", "TREATMENT", 132, 142], ["unwell", "PROBLEM", 148, 154], ["SARS", "OBSERVATION", 14, 18], ["profound", "OBSERVATION_MODIFIER", 31, 39], ["changes", "OBSERVATION", 40, 47]]], ["The wearing of masks during COVID\u201019 has become so entrenched in daily life that virtually everyone will use one when leaving home and the few people who do not comply with this social norm are sometimes chastised and ostracized.", [["people", "ORGANISM", 143, 149], ["people", "SPECIES", 143, 149], ["masks during COVID\u2010", "TREATMENT", 15, 34]]], ["Despite the damaging aspects of the SARS cloud sitting over Hong Kong for 17 years, it is possible there was a silver lining, as these past experiences seem to have increased perceptions of COVID\u201019 severity and susceptibility, and thus, the Hong Kong population may have been better prepared for the outbreak.COVID\u201019 MENTAL HEALTH CHALLENGESHong Kong may face a range of mental health challenges resulting from COVID\u201019.", [["SARS", "DISEASE", 36, 40], ["silver", "CHEMICAL", 111, 117], ["silver lining", "OBSERVATION", 111, 124], ["increased", "OBSERVATION_MODIFIER", 165, 174]]], ["It is becoming apparent that stringent preventive measures, especially the social distancing and prolonged quarantines, may have a negative impact on the general population's physical and mental well\u2010being, inter\u2010familial relationships and social/emotional support networks.", [["stringent preventive measures", "TREATMENT", 29, 58]]], ["Whether these COVID\u201019 preventive measures will increase the likelihood of psychiatric morbidity requires further investigation.", [["psychiatric", "DISEASE", 75, 86], ["these COVID\u2010", "TREATMENT", 8, 20], ["preventive measures", "TREATMENT", 23, 42], ["psychiatric morbidity", "PROBLEM", 75, 96], ["further investigation", "TEST", 106, 127]]], ["Limited local evidence suggests that anxiety levels are rising, a recent cross\u2010sectional study involving 1,168 Hong Kong citizens reported that respondents had a high perceived susceptibility (88%) of contracting COVID\u201019 and the mean anxiety level was 8.82 (borderline abnormal) using the Hospital Anxiety and Depression Scale (CUHK, 2020).COVID\u201019 MENTAL HEALTH CHALLENGESIn addition to COVID\u201019 infection\u2010related anxiety, it is foreseeable that Hong Kong and many other countries will be confronted with a major economic recession, which will have a direct detrimental impact on mental health.", [["anxiety", "DISEASE", 37, 44], ["COVID", "DISEASE", 213, 218], ["anxiety", "DISEASE", 235, 242], ["Anxiety and Depression", "DISEASE", 299, 321], ["anxiety", "DISEASE", 416, 423], ["anxiety levels", "PROBLEM", 37, 51], ["a recent cross\u2010sectional study", "TEST", 64, 94], ["contracting COVID\u2010", "TEST", 201, 219], ["the mean anxiety level", "TEST", 226, 248], ["borderline abnormal)", "PROBLEM", 259, 279], ["anxiety", "PROBLEM", 416, 423], ["rising", "OBSERVATION_MODIFIER", 56, 62]]], ["Although the local government has offered some short\u2010term financial assistance to reduce the financial burden of COVID\u201019, the long\u2010term economic damage should not be underestimated.", [["COVID", "DISEASE", 113, 118], ["some short\u2010term financial assistance", "TREATMENT", 42, 78], ["COVID\u2010", "TREATMENT", 113, 119], ["the long\u2010term economic damage", "PROBLEM", 123, 152]]], ["These financial challenges in Hong Kong are also compounded by the huge reductions in tourist visitors due to the social movement and associated anti\u2010government protests that have been apparent since June 2019.COVID\u201019 MENTAL HEALTH CHALLENGESThe mental health of mental health nurses and other healthcare professionals may also be an area that requires additional resources and attention.", [["associated anti\u2010government protests", "PROBLEM", 134, 169]]], ["It is reasonable to assume that the anxiety and stress levels among health professionals are proportionally higher than that of the general population due to direct contact with infected patients.", [["anxiety", "DISEASE", 36, 43], ["patients", "ORGANISM", 187, 195], ["patients", "SPECIES", 187, 195], ["the anxiety and stress levels", "PROBLEM", 32, 61]]], ["Without any disease epidemic, the healthcare system in Hong Kong is already struggling with shortages of hospital beds, a lack of staff and scant resources in both general and psychiatric clinical settings (Cheung & Yip, 2015).", [["psychiatric", "DISEASE", 176, 187], ["any disease epidemic", "PROBLEM", 8, 28], ["disease", "OBSERVATION", 12, 19]]], ["This may explain why frontline nurses are exceptionally vulnerable to fatigue, burnout (Wang, Okoli, et al., 2020), mental exhaustion, poor staff morale, decision control/autonomy, lower quality of life and poor job satisfaction (Cheung & Yip, 2015).", [["fatigue", "DISEASE", 70, 77], ["burnout", "DISEASE", 79, 86], ["fatigue", "PROBLEM", 70, 77], ["burnout", "PROBLEM", 79, 86], ["mental exhaustion", "PROBLEM", 116, 133]]], ["Also, nurses caring for COVID\u201019 cases may have a higher risk of developing burnout, anxiety and depression than other allied health professionals (Lai et al., 2020).", [["burnout", "DISEASE", 76, 83], ["anxiety", "DISEASE", 85, 92], ["depression", "DISEASE", 97, 107], ["anxiety", "PROBLEM", 85, 92], ["depression", "PROBLEM", 97, 107], ["burnout", "OBSERVATION", 76, 83]]], ["Recent research conducted in mainland China also highlights the negative impact of COVID\u201019 pandemic on frontline healthcare workers including increased levels of anxiety (Shanafelt, Ripp, & Trockel, 2020), depression (Xiang et al., 2020), post\u2010traumatic stress symptoms, loneliness and powerlessness (Xiang et al., 2020).", [["anxiety", "DISEASE", 163, 170], ["depression", "DISEASE", 207, 217], ["post\u2010traumatic stress symptoms", "DISEASE", 240, 270], ["loneliness", "DISEASE", 272, 282], ["powerlessness", "DISEASE", 287, 300], ["anxiety", "PROBLEM", 163, 170], ["depression", "PROBLEM", 207, 217], ["post\u2010traumatic stress symptoms", "PROBLEM", 240, 270], ["loneliness", "PROBLEM", 272, 282], ["powerlessness", "PROBLEM", 287, 300]]], ["Based on experience with SARS, many frontline healthcare professionals will experience psychological damage due to COVID\u201019.", [["SARS", "DISEASE", 25, 29], ["psychological damage", "DISEASE", 87, 107], ["SARS", "PROBLEM", 25, 29], ["psychological damage", "PROBLEM", 87, 107], ["COVID\u2010", "TREATMENT", 115, 121]]], ["Studies showed that 90% of the frontline medical personnel who worked in high\u2010risk clinical settings reported psychological symptoms (Chua et al., 2004) and some nurses who experienced SARS still required mental health treatment for their depressive/post\u2010traumatic stress symptoms after several years (Liu et al., 2012).IMPACT ON MENTAL HEALTH SERVICES, EDUCATION AND RESEARCHLocal mental health services are now inevitably affected by the COVID\u201019 pandemic.", [["SARS", "DISEASE", 185, 189], ["depressive", "DISEASE", 239, 249], ["Studies", "TEST", 0, 7], ["psychological symptoms", "PROBLEM", 110, 132], ["SARS", "PROBLEM", 185, 189], ["mental health treatment", "TREATMENT", 205, 228], ["their depressive/post\u2010traumatic stress symptoms", "PROBLEM", 233, 280], ["pandemic", "PROBLEM", 449, 457]]], ["Psychiatric Day Hospitals are currently only operated for a half\u2010day, restricted to a small number of day patients or temporarily closed.", [["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114]]], ["Besides, community mental health clinical services have also been impacted, for example outreach visits were suspended in mid\u2010February 2020 (Hospital Authority, 2020b) and replaced by telephone contacts by community psychiatric nurses (except for crisis interventions).IMPACT ON MENTAL HEALTH SERVICES, EDUCATION AND RESEARCHMeasures put in place to reduce the risk of infection within inpatient units consisted of closing wards to all visitors, provision of face masks for all staff and patients, and newly admitted patients being isolated on selected admission wards for 14 days before being transferred to other units.", [["psychiatric", "DISEASE", 216, 227], ["infection", "DISEASE", 369, 378], ["patients", "ORGANISM", 488, 496], ["patients", "ORGANISM", 517, 525], ["patients", "SPECIES", 488, 496], ["patients", "SPECIES", 517, 525], ["crisis interventions", "TREATMENT", 247, 267], ["RESEARCHMeasures", "TREATMENT", 317, 333], ["infection", "PROBLEM", 369, 378], ["infection", "OBSERVATION", 369, 378]]], ["Due to the suspension of visiting, psychiatric patients were allowed to maintain social contact with their family members online to reduce perceived loneliness and abandonment and maintain bonds between patients\u2019 and their families.", [["psychiatric", "DISEASE", 35, 46], ["patients", "ORGANISM", 47, 55], ["patients", "ORGANISM", 203, 211], ["patients", "SPECIES", 47, 55], ["patients", "SPECIES", 203, 211]]], ["The consequences of a temporary reduction in clinical and supportive services remain to be seen, but it is logical to assume that recovery rates may be damaged, particularly for those people with a severe mental illness who require regular and consistent community\u2010based support.IMPACT ON MENTAL HEALTH SERVICES, EDUCATION AND RESEARCHHong Kong mental health nursing academics and students have also experienced disruption and stress due to COVID\u201019.", [["people", "SPECIES", 184, 190], ["a temporary reduction", "TREATMENT", 20, 41], ["supportive services", "TREATMENT", 58, 77], ["a severe mental illness", "PROBLEM", 196, 219], ["stress", "PROBLEM", 427, 433], ["temporary", "OBSERVATION_MODIFIER", 22, 31], ["reduction", "OBSERVATION_MODIFIER", 32, 41]]], ["Students are understandably very anxious about how and when their clinical placement hours will be made up.", [["very anxious", "PROBLEM", 28, 40]]], ["Mental health nurse researchers are facing mounting stressors as all data collection and participant recruitment have been suspended since late January, resulting in financial concerns associated with paying full\u2010time research staff who have no work to do on suspended clinical trials.THE FUTUREThe real\u2010world impact of COVID\u201019 on the mental health of the public, nursing staff, students and academics is currently unclear.", [["COVID\u2010", "TREATMENT", 320, 326]]], ["However, based on the experience of SARS and the limited empirical and anecdotal evidence, we may be facing the possibility of a mental health epidemic in Hong Kong.", [["SARS", "DISEASE", 36, 40], ["SARS", "PROBLEM", 36, 40]]], ["We hope that the COVID\u201019 crisis may provide the impetus for the local government to place more emphasis on the allocation of financial resources to mental health services and staff support programmes.", [["the COVID\u2010", "TREATMENT", 13, 23]]], ["However, the degree of mental health research evidence is currently inadequate to inform a measured response.", [["degree", "OBSERVATION_MODIFIER", 13, 19]]], ["For example, recent research conducted in China has focused on psychological responses towards COVID\u201019 in the general population (Wang, Okoli, et al., 2020), the levels of depression and quality of life in suspected COVID\u201019 cases (Nguyen et al., 2020) and the importance of wearing masks to combat COVID\u201019 infection (Lam et al., 2020).", [["depression", "DISEASE", 173, 183], ["COVID", "DISEASE", 217, 222], ["infection", "DISEASE", 309, 318], ["depression", "PROBLEM", 173, 183]]], ["There seems to be a paucity of local studies examining the impact of COVID\u201019 on mental well\u2010being (Sj\u00f6berg et al., 2020); therefore, timely research examining the mental health status of health professionals, mental health service users and the general population in Hong Kong is urgently needed (Xiang et al., 2020).CONCLUSIONBased on earlier experiences of SARS and the limited recent evidence, the direct impact of COVID\u201019 on the mental health of the population, mental health service users and nurses is predicted to be a major issue in Hong Kong.", [["SARS", "DISEASE", 360, 364], ["local studies", "TEST", 31, 44], ["COVID\u2010", "TREATMENT", 69, 75], ["SARS", "PROBLEM", 360, 364]]], ["Thankfully, the preventative measures seem to have been relatively effective and the infection rate curve has downturned in Hong Kong; however, the potential for a major economic recession and the resulting long\u2010lasting damage on mental well\u2010being should not be underestimated.", [["infection", "DISEASE", 85, 94], ["the infection rate curve", "PROBLEM", 81, 105], ["a major economic recession", "PROBLEM", 162, 188], ["the resulting long\u2010lasting damage", "PROBLEM", 193, 226], ["mental well\u2010being", "TREATMENT", 230, 247], ["effective", "OBSERVATION_MODIFIER", 67, 76], ["infection", "OBSERVATION", 85, 94], ["economic", "OBSERVATION_MODIFIER", 170, 178], ["recession", "OBSERVATION", 179, 188]]]], "1b508c6b36e9102ead78cacdab3e3ca484df8a7c": [["Table S1 shows the COVID-19 data per participating country during the study period, data on travel restrictions, and policy for retinoblastoma patients.", [["retinoblastoma", "ANATOMY", 128, 142], ["retinoblastoma", "DISEASE", 128, 142], ["patients", "ORGANISM", 143, 151], ["patients", "SPECIES", 143, 151], ["the COVID", "TEST", 15, 24], ["the study", "TEST", 66, 75], ["retinoblastoma", "PROBLEM", 128, 142], ["retinoblastoma", "OBSERVATION", 128, 142]]], ["In 51 countries (54.3%), there were fewer than 100 COVID-19-positive cases per average day; in 30 countries (31.9%), there were between 100 and 999 new positive cases; and in 9 (9.6%) countries, there were between 1000 and 10 000 new positive cases per day.", [["COVID", "TEST", 51, 56]]], ["In terms of deaths, no cases were reported in 23 (24.5%) of the participating countries; in 50 (53.2%) countries, there were 1 to 9 deaths per day on average; and in 17 (18.1%) countries; there were between 10 and 499 deaths per day on average.", [["deaths", "DISEASE", 12, 18], ["deaths", "DISEASE", 132, 138], ["deaths", "DISEASE", 218, 224]]], ["In Overall, 16 (8.3%) centers reported that retinoblastoma management was disrupted due to personnel being quarantined or sick (i.e., COVID-19 positive), 11 (5.7%) due to personnel being needed elsewhere, 7 (3.6%) due to equipment being needed elsewhere/missing, 40 (20.6%) due to a combination of factors, and 120 (61.9%) reported no disruption.CONFLICTS OF INTERESTWe declare no competing interests relevant to the present work.", [["retinoblastoma", "ANATOMY", 44, 58], ["retinoblastoma", "DISEASE", 44, 58], ["retinoblastoma", "CANCER", 44, 58], ["retinoblastoma management", "TREATMENT", 44, 69], ["COVID", "TEST", 134, 139], ["disruption", "PROBLEM", 335, 345], ["retinoblastoma", "OBSERVATION", 44, 58], ["no", "UNCERTAINTY", 332, 334], ["disruption", "OBSERVATION", 335, 345]]], ["Allen Foster 1 on behalf of the Global Retinoblastoma Study Group", [["Retinoblastoma", "DISEASE", 39, 53], ["Retinoblastoma", "OBSERVATION", 39, 53]]]], "4f704c5b425905a6a1d4f37cd2663c01c3b82048": [["Sensors in buildings and applicationsIndoor air quality has been a major concern since the 1970s, and is a major objective for the Environmental Protection Agency (EPA), the National Institute for Occupational Safety and Health (NIOSH), and the American Society of Heating Refrigeration and Air Conditioning Engineers (ASHRAE).", [["Heating Refrigeration", "TREATMENT", 265, 286]]], ["People in the western world can spend up to 90% of their lives indoors [1, 2] .", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6]]], ["Leaky roofs, problems with the HVAC systems, construction of overly tight buildings, the use of synthetic building materials, and chemical based personal care products are primary causes for a variety of health related problems.", [["Leaky roofs", "PROBLEM", 0, 11], ["the HVAC systems", "TREATMENT", 27, 43], ["synthetic building materials", "TREATMENT", 96, 124], ["roofs", "OBSERVATION", 6, 11]]], ["The exposure to air pollutants (CO2, VOCs, CO, radon, mold, atmospheric particulate matter, and microbial contaminants) may lead to immediate or long-term effects health issues.", [["CO2, VOCs, CO, radon, mold", "CHEMICAL", 32, 58], ["CO2", "CHEMICAL", 32, 35], ["CO", "CHEMICAL", 43, 45], ["CO2", "SIMPLE_CHEMICAL", 32, 35], ["CO", "SIMPLE_CHEMICAL", 43, 45], ["radon", "SIMPLE_CHEMICAL", 47, 52], ["air pollutants (CO2, VOCs, CO, radon, mold, atmospheric particulate matter", "PROBLEM", 16, 90], ["long-term effects health issues", "PROBLEM", 145, 176], ["air pollutants", "OBSERVATION", 16, 30]]], ["Immediate symptoms may be as mild as headaches, dizziness, fatigue, and irritation of the sinuses [3] .", [["sinuses", "ANATOMY", 90, 97], ["headaches", "DISEASE", 37, 46], ["dizziness", "DISEASE", 48, 57], ["fatigue", "DISEASE", 59, 66], ["irritation of the sinuses", "DISEASE", 72, 97], ["Immediate symptoms", "PROBLEM", 0, 18], ["mild as headaches", "PROBLEM", 29, 46], ["dizziness", "PROBLEM", 48, 57], ["fatigue", "PROBLEM", 59, 66], ["irritation of the sinuses", "PROBLEM", 72, 97], ["mild", "OBSERVATION_MODIFIER", 29, 33], ["sinuses", "ANATOMY", 90, 97]]], ["People most susceptible to these air pollutants include the young, the elderly, and the chronically ill [3] .", [["chronically ill", "DISEASE", 88, 103], ["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6], ["these air pollutants", "PROBLEM", 27, 47], ["air pollutants", "OBSERVATION", 33, 47]]], ["These effects may also be amplified for people suffering from asthma, which affects approximately 26 million people in the US [4] , resulting in 2 million hospital visits in 2010 [3] , and costing Americans approximately \u00de, is known as the PF-operator.", [["asthma", "DISEASE", 62, 68], ["people", "ORGANISM", 40, 46], ["people", "ORGANISM", 109, 115], ["people", "SPECIES", 40, 46], ["people", "SPECIES", 109, 115], ["asthma", "PROBLEM", 62, 68], ["asthma", "OBSERVATION", 62, 68]]], ["This can be mathematically expressed in terms of the output equations, Y\u00f0x; t\u00de Y\u00f0x; t\u00de \u00bc l k \u00f0x\u00de4\u00f0x; t\u00de; k \u00bc fj; lg (5) where l k \u00f0x\u00de is the indicator function for the sensor location (the indicator function is zero everywhere except in a finite region around a sensor, i.e. in the 'sensing' volume).Representing a vector field as a Markov matrixAlthough scalar transport by solving the PDE has been a popular method for determining contaminant concentrations, the method has recently been pointed out to have some limitations [38] .", [["Y\u00f0x", "PROTEIN", 79, 82], ["\u00f0x\u00de4\u00f0x", "PROTEIN", 93, 99], ["PDE", "PROTEIN", 387, 390], ["the output equations", "TEST", 49, 69], ["Y\u00f0x", "TEST", 71, 74], ["Y\u00f0x", "TEST", 79, 82], ["t\u00de", "TEST", 84, 86], ["\u00f0x\u00de4\u00f0x", "TEST", 93, 99], ["t\u00de", "TEST", 101, 103], ["lg", "TEST", 113, 115], ["l k \u00f0x\u00de", "TEST", 126, 133], ["a Markov matrixAlthough scalar transport", "TREATMENT", 331, 371], ["a popular method", "TREATMENT", 400, 416], ["lg", "ANATOMY", 113, 115]]], ["These limitations include loading a potentially large amount of data into memory, solving a PDE, which can be time consuming for real-time decision making, and may require specialized software packages or commercial software.", [["a PDE", "TREATMENT", 90, 95]]], ["As a result of these limitations the discrete finite dimensional PF operator has become of interest (Fig. 2) .", [["the discrete finite dimensional PF operator", "TREATMENT", 33, 76]]], ["The discrete finite dimensional PF-operator breaks up the domain into a set of cells fu 1 ; \u2026; u n g.", [["cells", "ANATOMY", 79, 84], ["cells", "CELL", 79, 84], ["The discrete finite dimensional PF", "PROBLEM", 0, 34], ["discrete", "OBSERVATION_MODIFIER", 4, 12], ["finite", "OBSERVATION_MODIFIER", 13, 19]]], ["These cells are also called states.", [["cells", "ANATOMY", 6, 11], ["cells", "CELL", 6, 11]]], ["The movement of contaminants over some time interval is represented as a (probabilistic) transition from an initial state i, to a final state, j.", [["movement", "OBSERVATION_MODIFIER", 4, 12]]], ["The collection of all these probabilistic transitions over a time period in the domain is the discrete finite dimensional PF-operator and corresponds to a Markov matrix (also viewed as an adjacency or transition matrix), Eq.", [["matrix", "CELLULAR_COMPONENT", 212, 218], ["a Markov matrix", "PROBLEM", 153, 168], ["an adjacency or transition matrix", "TREATMENT", 185, 218], ["collection", "OBSERVATION_MODIFIER", 4, 14], ["all", "OBSERVATION_MODIFIER", 18, 21], ["transitions", "OBSERVATION_MODIFIER", 42, 53], ["discrete", "OBSERVATION_MODIFIER", 94, 102], ["finite", "OBSERVATION_MODIFIER", 103, 109]]], ["(1), c) Discrete field of a contaminant at time t, d) discrete field of a contaminant at time after the discrete form of the PF operator has been applied, Eq.", [["a contaminant", "PROBLEM", 26, 39], ["a contaminant", "PROBLEM", 72, 85], ["the PF operator", "TREATMENT", 121, 136]]], ["The continuous form of the PF operator takes the form of the passive scalar transport [34] , Eq.", [["the PF operator", "TREATMENT", 23, 38], ["the passive scalar transport", "TREATMENT", 57, 85]]], ["The discrete form takes the form of a Markov matrix and is discussed in the following section.Representing a vector field as a Markov matrixThe Markov matrix has some special properties.", [["a Markov matrix", "TREATMENT", 36, 51], ["a vector field", "TREATMENT", 107, 121], ["a Markov matrixThe Markov matrix", "TREATMENT", 125, 157], ["discrete", "OBSERVATION_MODIFIER", 4, 12], ["Markov matrix", "OBSERVATION", 38, 51], ["Markov matrix", "OBSERVATION", 144, 157], ["special properties", "OBSERVATION_MODIFIER", 167, 185]]], ["All the values are non-negative, Eq.", [["All the values", "TEST", 0, 14]]], ["(1), on the states of the Markov matrix.", [["matrix", "CELLULAR_COMPONENT", 33, 39]]], ["The (volumetric) average contaminant concentration in the Markov states at a given time t, is given byRepresenting a vector field as a Markov matrixThe contaminant concentration in a specific cell u k , at time t is related to the contaminant density function and can be obtained for Markov state, m k t asRepresenting a vector field as a Markov matrixFor steady flow fields: given a Markov matrix P, a contaminant concentration in the Markov states at time t 0 , and a source, S, the evolution of the contaminant for some time t \u00bc mDt is governed by the simple nested matrix-vector products shown in Eqs.", [["cell", "ANATOMY", 192, 196], ["cell", "CELL", 192, 196], ["The (volumetric) average contaminant concentration", "TREATMENT", 0, 50], ["a Markov matrix", "TREATMENT", 133, 148], ["The contaminant concentration", "TREATMENT", 148, 177], ["a Markov matrix", "TREATMENT", 337, 352], ["a Markov matrix P", "TREATMENT", 382, 399], ["a contaminant concentration", "TREATMENT", 401, 428], ["the contaminant", "PROBLEM", 498, 513], ["the simple nested matrix-vector products", "TREATMENT", 551, 591], ["concentration", "OBSERVATION_MODIFIER", 164, 177]]], ["A graphical example of the discrete finite dimensional PF operator is shown in Fig. 2c and d.Representing a vector field as a Markov matrixFor unsteady flow fields: a set of Markov matrices governs the contaminant evolution at a set of time snapshots, Eq.", [["the discrete finite dimensional PF operator", "TREATMENT", 23, 66], ["a Markov matrix", "TREATMENT", 124, 139], ["unsteady flow fields", "PROBLEM", 143, 163], ["Markov matrices", "TREATMENT", 174, 189]]], ["(11).Representing a vector field as a Markov matrixThe Markov matrix P \u00f0i;i\u00fe1\u00de takes the contaminant density from time t i to time t i\u00fe1 .", [["a vector field", "TREATMENT", 18, 32], ["a Markov matrixThe Markov matrix P \u00f0i", "TREATMENT", 36, 73]]], ["The evolution of the contaminant on the time dependent flow field is calculated by Eqs.", [["the contaminant", "PROBLEM", 17, 32], ["contaminant", "OBSERVATION", 21, 32]]], ["12(aec).Representing a vector field as a Markov matrixFinally, the discrete counterpart of the output equation (Eq.", [["the output equation", "TEST", 91, 110]]], ["(5)) for both steady and unsteady flow fields for sensor locations at state j and l\u00f0k \u00bc fj; lg\u00de can be written as Eq.", [["both steady and unsteady flow fields", "PROBLEM", 9, 45]]], ["13a-c.", [["13a-c.", "CHEMICAL", 0, 6]]], ["We first define the sensing volume of a sensor placed at cell/state a as;Representing a vector field as a Markov matrixThis is simply the discrete form of the indicator function.", [["cell", "ANATOMY", 57, 61], ["cell", "CELL", 57, 61], ["a Markov matrix", "TREATMENT", 104, 119], ["discrete", "OBSERVATION_MODIFIER", 138, 146], ["indicator function", "OBSERVATION", 159, 177]]], ["For multiple sensor, we generalize this to a matrix of indicator functions, C \u00bc \u00c2 c \u00f0j\u00de c \u00f0l\u00de \u00c3 .", [["C", "CHEMICAL", 76, 77]]], ["Now, the value sensed by each sensor is simply the inner product of the contaminant vector with the indicator, and is written asRepresenting a vector field as a Markov matrixThus, the discrete sensor outputs at time t are given by, Y t .", [["a Markov matrix", "TREATMENT", 159, 174]]], ["A robust procedure of constructing Markov matrices from a generic flow field is shown in the authors' previous work [38] .", [["A robust procedure", "TREATMENT", 0, 18], ["constructing Markov matrices", "TREATMENT", 22, 50], ["a generic flow field", "TEST", 56, 76]]], ["The data driven process uses set theory and involves choosing a Markov state size, choosing the time step associated with the Markov matrix, the calculation of the entries of the Markov matrix, and efficient storage of the often sparse Markov matrix.Sensor placement algorithmThe sensor placement algorithm involves the construction and analysis of the discrete time observability gramian.", [["matrix", "CELLULAR_COMPONENT", 243, 249], ["Sensor placement algorithm", "TREATMENT", 250, 276], ["The sensor placement algorithm", "TREATMENT", 276, 306], ["size", "OBSERVATION_MODIFIER", 77, 81], ["Markov matrix", "OBSERVATION", 179, 192], ["Markov matrix", "OBSERVATION", 236, 249]]], ["The observability gramian is a control theoretic tool and is used to characterize the relative degree of observability of various states in the system (more specifically, the state space) [41] .", [["The observability gramian", "TEST", 0, 25]]], ["[37] and [42] , where we extended the definition of the observability gramian to nonlinear flow field and advection diffusion PDEs.", [["[42]", "SIMPLE_CHEMICAL", 9, 13], ["advection diffusion PDEs", "TEST", 106, 130]]], ["Roughly speaking, the observability gramian for advection diffusion PDE can be defined as a function from the physical space X to real valued nonnegative number.", [["advection diffusion PDE", "TEST", 48, 71]]], ["If the observability gramian on a particular region, say B3 X, is positive then the density function (contaminant distribution) on the set B, can be estimated by building an estimator.", [["B3 X", "GENE_OR_GENE_PRODUCT", 57, 61], ["observability gramian", "DNA", 7, 28], ["B3 X", "DNA", 57, 61], ["density", "OBSERVATION", 84, 91]]], ["On the other hand, if the gramian on a particular set is zero then one cannot design an estimator to estimate the density supported on the set.", [["density", "OBSERVATION", 114, 121]]], ["Furthermore, if the value of the gramian on set B 1 3X is large compared to B 2 3X, then it is relatively easier to observer the density function on set B 1 compared to set B 2 .", [["the value", "TEST", 16, 25], ["large", "OBSERVATION_MODIFIER", 58, 63], ["density", "OBSERVATION", 129, 136]]], ["In other words, the gain of the estimator to estimate the density function on B 1 is smaller compared to one required to estimate density function on set B 1 .", [["B 1", "GENE_OR_GENE_PRODUCT", 78, 81], ["B 1", "PROTEIN", 78, 81], ["density", "OBSERVATION", 58, 65], ["smaller", "OBSERVATION_MODIFIER", 85, 92], ["density", "OBSERVATION", 130, 137]]], ["Given the fundamental role that the observability gramian plays in the design of estimators, it is widely used in system and control theory as a natural cost function for the purpose of sensor placement.", [["sensor placement", "TREATMENT", 186, 202]]], ["Specifically, the observability gramian is constructed using the Markov matrix.", [["matrix", "CELLULAR_COMPONENT", 72, 78], ["observability gramian", "DNA", 18, 39], ["the observability gramian", "TEST", 14, 39]]], ["We then use the observability gramian to identify locations/cells that increase the relative degree of observability of various cells.", [["cells", "ANATOMY", 60, 65], ["cells", "ANATOMY", 128, 133], ["cells", "CELL", 60, 65], ["cells", "CELL", 128, 133], ["the observability gramian", "TEST", 12, 37], ["locations/cells", "PROBLEM", 50, 65], ["various cells", "PROBLEM", 120, 133], ["relative degree", "OBSERVATION_MODIFIER", 84, 99], ["various cells", "OBSERVATION", 120, 133]]], ["These cells will serve as the locations of the sensors.Sensor placement algorithmIn this section the calculation of the observability gramian is discussed for both steady state and transient flow fields.", [["cells", "ANATOMY", 6, 11], ["cells", "CELL", 6, 11], ["Sensor placement algorithmIn", "TREATMENT", 55, 83], ["transient", "OBSERVATION_MODIFIER", 181, 190], ["flow fields", "OBSERVATION", 191, 202]]], ["Also, the process of including sensor accuracy into the calculation of the observability gramian and placement constraints and sensing constraints on the sensors are discussed.Calculation of the contaminant tracking matrix Q \u00f0t\u00deTowards the construction of observability gramian we first construct the contaminant tracking matrix, Q \u00f0t\u00de , for the time interval t by identifying how a constant source of contaminants is transported over the time interval, t.", [["the observability gramian", "TREATMENT", 71, 96], ["placement constraints", "TREATMENT", 101, 122], ["contaminant", "OBSERVATION", 195, 206], ["contaminants", "OBSERVATION", 402, 414]]], ["For steady flows this is given asCalculation of the contaminant tracking matrix Q \u00f0t\u00deHere the exponent, m satisfies t \u00bc mDt, where Dt is the time step used to construct the Markov matrix [37] .", [["Dt", "PROTEIN", 131, 133], ["steady flows", "PROBLEM", 4, 16]]], ["Note that P propagates the contaminant from time t to time t \u00fe Dt, P 2 propagates the contaminant from t to t \u00fe 2Dt, and P k propagates the contaminant from t to time t \u00fe kDt.", [["P", "DNA", 10, 11], ["P 2", "DNA", 67, 70], ["P k", "DNA", 121, 124], ["Dt", "PROBLEM", 63, 65]]], ["The sum of I; P; P 2 ; \u2026; P m builds a history of states in which contaminants travel over the time interval t \u00bc mDt,Calculation of the contaminant tracking matrix Q \u00f0t\u00deRemark: The ith row of the Markov matrix stores the destination states of containment released in state i [37] after one time step.", [["matrix", "CELLULAR_COMPONENT", 203, 209], ["the Markov matrix stores", "TREATMENT", 192, 216]]], ["Similarly, the ith column of the Markov matrix stores originating states from which contaminant reaches state i, after one step.", [["the Markov matrix stores", "PROBLEM", 29, 53], ["column", "OBSERVATION_MODIFIER", 19, 25], ["Markov matrix", "OBSERVATION", 33, 46]]], ["Since the contaminant tracking matrix builds a sensing history as time evolves from time t 0 to t 0 \u00fe mDt, the columns of the contaminant tracking matrix store the originating states over m time steps.", [["matrix", "CELLULAR_COMPONENT", 31, 37], ["matrix", "CELLULAR_COMPONENT", 147, 153]]], ["A graphical example of contaminant tracking matrix is seen in Fig. 3 , for various values of m.", [["matrix", "CELLULAR_COMPONENT", 44, 50], ["contaminant tracking matrix", "PROBLEM", 23, 50], ["contaminant", "OBSERVATION", 23, 34]]], ["Here, the non-zero entries of the contaminant tracking matrix are displayed.", [["matrix", "CELLULAR_COMPONENT", 55, 61]]], ["The Markov matrix is from published data of contaminant transport in an aircraft cabin [40] .", [["Markov matrix", "OBSERVATION", 4, 17]]], ["The contaminant tracking matrix starts filling up for increasing m, indicating that flow is spreading across the domain.From the contaminant tracking matrix to the observability gramianSince the flow field has been formulated in terms of a dynamical system and the Markov matrix has defined a notion of states, the concept of observability can be utilized.", [["matrix", "CELLULAR_COMPONENT", 150, 156], ["The contaminant tracking matrix", "PROBLEM", 0, 31], ["increasing m", "PROBLEM", 54, 66], ["flow", "PROBLEM", 84, 88], ["contaminant", "OBSERVATION_MODIFIER", 4, 15], ["tracking matrix", "OBSERVATION", 16, 31], ["flow", "OBSERVATION", 84, 88], ["flow", "OBSERVATION", 195, 199]]], ["In a classical sense, observability is a metric that determines how well the states can be inferred by a system's output.", [["a system's output", "TEST", 103, 120]]], ["The outputs (in the context of this work) are the observations of sensors placed in discrete states of the domain.", [["The outputs", "TEST", 0, 11], ["sensors", "TREATMENT", 66, 73], ["outputs", "OBSERVATION_MODIFIER", 4, 11]]], ["The discrete time observability gramian determines whether an arbitrary state is observable within a given time horizon, t.", [["an arbitrary state", "PROBLEM", 59, 77]]], ["The indicator matrix C corresponding to a sensor placed in state i is given by C i .", [["matrix C", "GENE_OR_GENE_PRODUCT", 14, 22], ["The indicator matrix C", "PROBLEM", 0, 22]]], ["The relative degree of observability for different cells is given by (16) Note that Q \u00f0t\u00de C i for a single sensor placed in state i is a column vector with nonnegative entries.", [["cells", "ANATOMY", 51, 56], ["cells", "CELL", 51, 56], ["different cells", "PROBLEM", 41, 56], ["a single sensor", "TREATMENT", 98, 113], ["a column vector", "TREATMENT", 135, 150], ["degree", "OBSERVATION_MODIFIER", 13, 19]]], ["In particular, will be a column vector where the positive entries are states that are observable from state i and the zero entries are states that are not observable from state i.", [["a column vector", "TREATMENT", 23, 38]]], ["For placement of 2 sensors in locations k \u00bc fi; jg, Q \u00f0t\u00de C k is a 2 column matrix with nonnegative entries, Eq.", [["jg", "DNA", 48, 50], ["Q", "DNA", 52, 53], ["placement of 2 sensors", "TREATMENT", 4, 26], ["jg", "TEST", 48, 50], ["C k", "TEST", 58, 61], ["jg", "ANATOMY", 48, 50]]], ["(17) The positive entries of the 1st column of correspond to the states that are observable from state i, and the positive entries of the 2nd column correspond to the states that are observable from state j.", [["1st column", "ANATOMY_MODIFIER", 33, 43]]], ["The zero entries of in the 1st and 2nd column correspond to states that are not observable from states i and j respectively.", [["The zero entries", "TEST", 0, 16], ["zero", "OBSERVATION_MODIFIER", 4, 8]]], ["With some abuse of terminology, we will call as the observability gramian 3 for a set of sensor locations k and corresponding indicator matrix C k .Including sensor accuracy into the contaminant tracking matrixBased on the sensor's sensing accuracy the signal will be unavoidably corrupted by noise.", [["sensor accuracy", "TEST", 158, 173]]], ["The quality of the sensor can be naturally accounted for in the contaminant tracking matrix.", [["matrix", "CELLULAR_COMPONENT", 85, 91]]], ["In the contaminant tracking matrix, large values in a given column represent a very strong signal while smaller values represent weaker signals.", [["matrix", "CELLULAR_COMPONENT", 28, 34], ["large values", "PROBLEM", 36, 48], ["a very strong signal", "PROBLEM", 77, 97], ["weaker signals", "PROBLEM", 129, 143], ["contaminant", "OBSERVATION_MODIFIER", 7, 18], ["tracking matrix", "OBSERVATION", 19, 34], ["large", "OBSERVATION_MODIFIER", 36, 41], ["values", "OBSERVATION_MODIFIER", 42, 48], ["column", "ANATOMY", 60, 66], ["very", "OBSERVATION_MODIFIER", 79, 83], ["strong", "OBSERVATION_MODIFIER", 84, 90], ["smaller", "OBSERVATION_MODIFIER", 104, 111], ["weaker signals", "OBSERVATION", 129, 143]]], ["Although a theoretically perfect sensor may be able to accurately sense the contaminant in states with low values, realistically sensors have accuracy thresholds.", [["low values", "PROBLEM", 103, 113], ["accuracy thresholds", "TEST", 142, 161]]], ["This problem is remedied by thresholding the values in the contaminant tracking matrix.", [["matrix", "CELLULAR_COMPONENT", 80, 86]]], ["The threshold value is a nondimensional value that describes the ratio of source release rate, the release time, and the value detected at the sensor, Eq.", [["the value", "TEST", 117, 126]]], ["The sensors accuracy in this context is the percentage of the contaminant needing to be sensed over the sensing period.", [["The sensors accuracy", "TEST", 0, 20], ["contaminant", "OBSERVATION", 62, 73]]], ["Typically, a detection threshold and sensor accuracy is known for a given sensor.Including sensor accuracy into the contaminant tracking matrixUsing the sensor's accuracy as the threshold value, the values less than the accuracy of the sensor in the contaminant tracking matrix (example: 1%, 5%, 10%, etc.) are replaced by zero, while any value larger is kept for the placement analysis.", [["matrix", "CELLULAR_COMPONENT", 137, 143], ["a detection threshold", "TEST", 11, 32], ["sensor accuracy", "TEST", 37, 52], ["sensor accuracy", "TEST", 91, 106], ["the sensor's accuracy", "TEST", 149, 170], ["the threshold value", "TEST", 174, 193], ["the values", "TEST", 195, 205], ["the placement analysis", "TEST", 364, 386]]], ["This creates a new thresholded contaminant tracking matrix, Eq.", [["matrix", "CELLULAR_COMPONENT", 52, 58], ["a new thresholded contaminant tracking matrix", "PROBLEM", 13, 58], ["new", "OBSERVATION_MODIFIER", 15, 18], ["thresholded", "OBSERVATION_MODIFIER", 19, 30], ["contaminant", "OBSERVATION_MODIFIER", 31, 42], ["tracking matrix", "OBSERVATION", 43, 58]]], ["The effect of this thresholding can be seen in Fig. 4a and Fig. 4bIncluding constraints into the contaminant tracking matrixOther factors that affect the decisions of sensor placement in buildings are location constraints and sensing constraints.", [["matrixOther factors", "PROTEIN", 118, 137], ["this thresholding", "TREATMENT", 14, 31], ["sensor placement", "TREATMENT", 167, 183], ["contaminant", "OBSERVATION_MODIFIER", 97, 108]]], ["Some practical limitations include the following: the sensor location is not serviceable; occupants have the ability to move or bump into the sensor, damage the sensor, or be annoyed by the location of the sensor; and sensor design limits the placement to a wall or ceiling.", [["wall", "ANATOMY", 258, 262], ["wall", "TISSUE", 258, 262], ["the placement", "TREATMENT", 239, 252]]], ["Location constraints exist for IAQ, CBW, and TID applications.", [["TID", "CHEMICAL", 45, 48], ["CBW", "TEST", 36, 39], ["TID applications", "TREATMENT", 45, 61]]], ["Often expensive CBW and TID sensors would have to be placed outside the occupied zone, such that the sensors are not tampered with or easily damaged.", [["TID sensors", "TREATMENT", 24, 35]]], ["Occupants may not want CO2 and VOC sensors in the occupied space such that they have to walk around them, avoid stepping on them, or for ascetic reasons.", [["CO2", "CHEMICAL", 23, 26], ["CO2", "CHEMICAL", 23, 26], ["CO2", "SIMPLE_CHEMICAL", 23, 26], ["VOC sensors", "TEST", 31, 42]]], ["The placement of sensors at the top of a tall atrium may not be a good location, because if a sensor malfunctions the sensor may not be easily replaced or serviced.", [["tall atrium", "ANATOMY", 41, 52], ["atrium", "MULTI-TISSUE_STRUCTURE", 46, 52], ["The placement of sensors", "TREATMENT", 0, 24], ["a sensor malfunctions the sensor", "PROBLEM", 92, 124], ["tall atrium", "ANATOMY", 41, 52]]], ["Incorporating these constraints is done after the contaminant tracking matrix has been thresholded.", [["matrix", "CELLULAR_COMPONENT", 71, 77], ["the contaminant tracking matrix", "TREATMENT", 46, 77]]], ["If a certain state cannot accommodate a sensor (location constraint), then the column is removed from the matrix.", [["matrix", "CELLULAR_COMPONENT", 106, 112], ["column", "ANATOMY", 79, 85]]], ["To remove a set of states j2\u2115 n loc from the sensor selection process, the entries in column j th are replaced by zeros, Fig. 4c and Eq.Including constraints into the contaminant tracking matrixSensing constraints is more applicable for IAQ sensors as a designer, engineer, or architect is primarily concerned with the CO2 and VOC levels in the occupied space.", [["CO2", "CHEMICAL", 319, 322], ["VOC", "CHEMICAL", 327, 330], ["CO2", "CHEMICAL", 319, 322], ["CO2", "SIMPLE_CHEMICAL", 319, 322], ["VOC", "SIMPLE_CHEMICAL", 327, 330], ["the sensor selection process", "TREATMENT", 41, 69], ["column j th", "TREATMENT", 86, 97], ["the CO2", "TEST", 315, 322], ["VOC levels", "TEST", 327, 337], ["occupied space", "OBSERVATION", 345, 359]]], ["In this case, we want to remove any consideration of states that lie outside the occupied zone.", [["occupied", "OBSERVATION_MODIFIER", 81, 89], ["zone", "OBSERVATION_MODIFIER", 90, 94]]], ["To remove a set of states i2\u2115 nsen from sensor placementPlacement of sensorsAfter the construction of the contaminant tracking matrix, thresholding for accuracy requirements, and selection of placement and sensing constraints, the sensors can be placed.", [["sensor placement", "TREATMENT", 40, 56], ["accuracy requirements", "TEST", 152, 173], ["selection of placement and sensing constraints", "TREATMENT", 179, 225], ["the sensors", "TREATMENT", 227, 238]]], ["We perform the analysis for contaminant released in an arbitrary state, and then derive the generalized sensor placement algorithm from this discussion.", [["the analysis", "TEST", 11, 23], ["contaminant", "PROBLEM", 28, 39], ["the generalized sensor placement algorithm", "TREATMENT", 88, 130]]], ["(25).Placement of sensorsFinally, to include all possible release scenarios for every Markov state, the release scenario matrix, r \u00f0all\u00de , becomes the identity matrix, Eq.", [["matrix", "CELLULAR_COMPONENT", 121, 127], ["matrix", "CELLULAR_COMPONENT", 160, 166], ["Placement of sensors", "TREATMENT", 5, 25], ["the release scenario matrix", "TREATMENT", 100, 127]]], ["(26).Placement of sensorsEqs.", [["Placement of sensorsEqs", "TREATMENT", 5, 28], ["sensorsEqs", "OBSERVATION", 18, 28]]], ["(23) , (25) and (27) are design problems for C k to maximize s \u00f0a\u00de ; s \u00f0A\u00de ; and s \u00f0all\u00de respectively.", [["design problems", "PROBLEM", 25, 40], ["C k", "TEST", 45, 48], ["s \u00f0a\u00de", "TEST", 61, 66]]], ["The set cover problem is one of Karp's NP-complete problems [43] .", [["The set cover problem", "TREATMENT", 0, 21]]], ["The basic idea of the greedy algorithm is to choose the sensor locations based on the largest number of uncovered states.", [["largest", "OBSERVATION_MODIFIER", 86, 93]]], ["The positivity property of the Markov operator is used to prove that the greedy algorithm is optimal for sensor placement [36] .", [["the Markov operator", "TREATMENT", 27, 46], ["sensor placement", "TREATMENT", 105, 121]]], ["We remind the reader that the columns of the contaminant tracking matrix holds the observable states (nonzero entries) for a sensor placed in the respective column.", [["matrix", "CELLULAR_COMPONENT", 66, 72], ["column", "ANATOMY", 157, 163]]], ["The 1st sensor, k 1 , is placed where column support is maximized [35] (i.e. the column with the largest number of non-zero entries):Placement of sensorsPlacing the first sensor at k 1 results in a fraction of the states being observed.", [["k", "TEST", 16, 17], ["column support", "TREATMENT", 38, 52]]], ["For subsequent sensor placement consideration, these states are removed from the contaminant tracking matrix, which is denoted by b Q \u00c3\u00f0t\u00de .", [["matrix", "CELLULAR_COMPONENT", 102, 108], ["subsequent sensor placement", "TREATMENT", 4, 31], ["contaminant", "OBSERVATION_MODIFIER", 81, 92]]], ["With every new sensor being placed, the contaminant tracking matrix is updated to only reflect the states that are not currently observed.", [["matrix", "CELLULAR_COMPONENT", 61, 67]]], ["After a sensor has been placed in state 7, entries in the rows and columns of state 2, 6, 7, 8, 9, and 10 are no longer of interest.", [["state 2, 6, 7, 8, 9, and 10", "DNA", 78, 105], ["no longer", "UNCERTAINTY", 110, 119]]], ["A sensor in state 7 can sense these states, so column 7 and rows 2, 6, 7, 8, 9, and 10 are set to zero, (grayed in Fig. 5c and d) .", [["rows 2, 6, 7, 8, 9, and 10", "DNA", 60, 86]]], ["After the placement of the first sensor and the removal of its sensing volume, subsequent sensors can be placed to sense the remaining volume.", [["the removal of its sensing volume", "TREATMENT", 44, 77], ["subsequent sensors", "TREATMENT", 79, 97]]], ["The columns with the largest number of nonzero entries can observe/sense the largest percentage of states/volume in the building environment.", [["columns", "OBSERVATION_MODIFIER", 4, 11], ["largest", "OBSERVATION_MODIFIER", 21, 28], ["largest", "OBSERVATION_MODIFIER", 77, 84], ["percentage", "OBSERVATION_MODIFIER", 85, 95]]], ["The indices of the nonzero entries in the columns of the contaminant tracking matrix provide a coverage map of the observable states for a given Markov state, Fig. 6 .Overview of algorithmThe sensor placement problem is formulated as the well-known set cover problem, and a greedy algorithm is used to place a minimum number of sensors with maximum coverage.", [["matrix", "CELLULAR_COMPONENT", 78, 84], ["a coverage map", "TREATMENT", 93, 107], ["The sensor placement problem", "TREATMENT", 188, 216], ["a greedy algorithm", "TREATMENT", 272, 290], ["maximum coverage", "TREATMENT", 341, 357], ["nonzero", "OBSERVATION_MODIFIER", 19, 26], ["columns", "OBSERVATION_MODIFIER", 42, 49], ["contaminant", "OBSERVATION", 57, 68]]], ["This algorithm is designed to maximize the sensing volume of each subsequent sensor for the volume in the space not yet sensed by previously placed sensors.", [["the volume in the space", "TREATMENT", 88, 111]]], ["This algorithm accounts for all possible release scenarios (as the Contaminant tracking matrix includes all release scenarios) instead of selecting only a few scenarios (as is the case for other methods).", [["all release scenarios", "TREATMENT", 104, 125]]], ["That is, the algorithm includes release scenarios for every discrete volume (cells) in the CFD simulation.", [["cells", "ANATOMY", 77, 82], ["cells", "CELL", 77, 82], ["the CFD simulation", "TEST", 87, 105]]], ["Furthermore, the total amount of contaminant released (independent of release time) within the sensing time determines the sensor placement.", [["the sensor placement", "TREATMENT", 119, 139], ["total", "OBSERVATION_MODIFIER", 17, 22], ["amount", "OBSERVATION_MODIFIER", 23, 29], ["contaminant", "OBSERVATION", 33, 44]]], ["The variables in the placement algorithm are the number of sensors, the response time, and the total coverage of all the sensors.", [["the placement algorithm", "TREATMENT", 17, 40]]], ["Based on these inputs, three different placement strategies are outlined below.", [["three different placement strategies", "TREATMENT", 23, 59]]], ["The first few steps for each strategy are the same and are displayed in the flow chart in Fig. 7ResultsThis section discusses results including the airflow field used, contaminant transport using the Markov matrices, and the sensor placement algorithm.", [["the Markov matrices", "TREATMENT", 196, 215], ["the sensor placement algorithm", "TREATMENT", 221, 251]]], ["Three air flow field are generated using CFD.", [["Three air flow field", "TEST", 0, 20], ["CFD", "TEST", 41, 44], ["air flow", "OBSERVATION", 6, 14]]], ["Based on these flow fields Markov matrices are calculated and are shown to provide similar contaminant transport as the advection diffusion equation.", [["these flow fields Markov matrices", "TEST", 9, 42], ["the advection diffusion equation", "TEST", 116, 148]]], ["Using these Markov matrices sensors are placed in for applications in CBW and IAQ applications using different sensing and placement constraints.", [["these Markov matrices sensors", "TREATMENT", 6, 35], ["CBW", "TREATMENT", 70, 73], ["IAQ applications", "TREATMENT", 78, 94], ["different sensing and placement constraints", "TREATMENT", 101, 144]]], ["A literature comparison with an aircraft cabin is discussed in Appendix A, which provided the initial motivation for this work. other boundaries are insulated.", [["Appendix", "ANATOMY", 63, 71]]], ["The inlet temperature and the heat flux of the people and the wall were taken from a similar sensor placement CFD problem from Liu et al., 2009 [29] .", [["wall", "ANATOMY", 62, 66], ["people", "ORGANISM", 47, 53], ["wall", "TISSUE", 62, 66], ["people", "SPECIES", 47, 53], ["The inlet temperature", "TEST", 0, 21], ["a similar sensor placement CFD problem", "TREATMENT", 83, 121], ["inlet temperature", "OBSERVATION_MODIFIER", 4, 21], ["wall", "ANATOMY", 62, 66]]], ["The 2nd and the 3rd case have 1 person and 2 people in the space respectively, and a heated window on the right boundary above the outlet, Fig. 8c and Fig. 8d .", [["people", "ORGANISM", 45, 51], ["person", "SPECIES", 32, 38], ["people", "SPECIES", 45, 51], ["a heated window", "TREATMENT", 83, 98], ["right", "ANATOMY_MODIFIER", 106, 111], ["outlet", "ANATOMY", 131, 137]]], ["The CFD simulations used the turbulent RNG k-\u03b5 model, and all the residuals were solved to 1e-6.", [["The CFD simulations", "TEST", 0, 19], ["turbulent", "OBSERVATION_MODIFIER", 29, 38], ["residuals", "OBSERVATION", 66, 75]]], ["Buoyancy in flow field 2 and flow field 3 was introduced by the Boussinesq approximation for density.", [["flow", "OBSERVATION_MODIFIER", 12, 16], ["density", "OBSERVATION", 93, 100]]], ["Each simulation was discretized into 4480, 11140, and 10280 hexahedral elements for case 1, 2, and 3 respectively.", [["4480, 11140, and 10280 hexahedral elements", "DNA", 37, 79]]], ["These discretizations of the flow field produced sufficiently spatially converged values of the u and v components of velocity and the temperature when compared with meshes at higher resolutions.ResultsThe air flow field for the isothermal problem, Fig. 8b , has been compared with the data specified by the benchmark problem, IEA 1993, and the data that agreed well with the published literature.", [["the flow field", "TEST", 25, 39], ["the temperature", "TEST", 131, 146], ["meshes", "TREATMENT", 166, 172], ["The air flow field", "TEST", 202, 220], ["the isothermal problem", "PROBLEM", 225, 247], ["flow", "OBSERVATION", 29, 33], ["velocity", "OBSERVATION_MODIFIER", 118, 126], ["temperature", "OBSERVATION_MODIFIER", 135, 146], ["air flow", "OBSERVATION", 206, 214]]], ["For the other flow fields the same fluid flow model was used that validated the turbulent Rayleigh-Benard problem.", [["fluid", "ANATOMY", 35, 40], ["the other flow fields", "TEST", 4, 25], ["the same fluid flow model", "TEST", 26, 51], ["the turbulent Rayleigh-Benard problem", "PROBLEM", 76, 113], ["fluid flow", "OBSERVATION", 35, 45], ["turbulent", "OBSERVATION_MODIFIER", 80, 89], ["Rayleigh", "OBSERVATION_MODIFIER", 90, 98]]], ["In the validation of an aspect ratio 1 \u00c2 1 Rayleigh-Benard cell, the Nusselt number was compared with correlations in literature [46, 47] .", [["cell", "ANATOMY", 59, 63], ["Rayleigh-Benard cell", "CELL", 43, 63], ["Benard cell", "CELL_LINE", 52, 63], ["an aspect ratio", "TEST", 21, 36]]], ["The data produced by these simulations agreed well with the published correlations.Generation of the Markov matricesIn order to examine the sensor placement problem Markov matrices are required to calculate the contaminant tracking matrix.", [["matrix", "CELLULAR_COMPONENT", 232, 238], ["the Markov matrices", "TREATMENT", 97, 116], ["the sensor placement problem Markov matrices", "TREATMENT", 136, 180], ["Markov matrices", "OBSERVATION", 101, 116]]], ["The contaminant concentration at the centerline y \u00bc 1.5 [m] at two different times for both the Markov method and passive scalar transport is shown in Fig. 9 .", [["The contaminant concentration", "TREATMENT", 0, 29], ["the Markov method", "TREATMENT", 92, 109], ["passive scalar transport", "TREATMENT", 114, 138]]], ["The excellent comparison confirms the accuracy of the Markov matrices used in this analysis.Sensor placement results: CBW/TID and IAQ applicationsIn this subsection the sensor locations, coverage maps, and sensing times are investigated for the three flow fields with the addition of placement and sensing constraints.", [["this analysis", "TEST", 78, 91], ["CBW", "TEST", 118, 121], ["IAQ applications", "TREATMENT", 130, 146], ["coverage maps", "TREATMENT", 187, 200], ["placement and sensing constraints", "TREATMENT", 284, 317]]], ["The effect of the adding the constraints on sensing time and the coverage maps are analyzed.", [["the coverage maps", "TEST", 61, 78]]], ["Three different placement problems are addressed for each flow field; 1) the placement of sensors with no constraints, 2) placement of the sensors with a placement constraint outside of the occupied space, and 3) a placement constraint outside the occupied space along with a sensing constraint of sensing only the occupied space.Sensor placement results: CBW/TID and IAQ applicationsPlacement problem 1) with no constraints is analyzed as a reference point for when constraints are added.", [["Three different placement problems", "TREATMENT", 0, 34], ["the placement of sensors", "TREATMENT", 73, 97], ["the sensors", "TREATMENT", 135, 146], ["a placement constraint", "TREATMENT", 152, 174], ["a placement constraint", "TREATMENT", 213, 235], ["a sensing constraint", "TREATMENT", 274, 294], ["CBW", "TEST", 356, 359], ["IAQ applications", "TREATMENT", 368, 384], ["Placement problem", "TREATMENT", 384, 401], ["occupied space", "OBSERVATION", 315, 329]]], ["Placement problem 2) is designed for critical application like CBW and TID applications.", [["Placement problem", "TREATMENT", 0, 17], ["critical application", "TREATMENT", 37, 57], ["CBW", "TREATMENT", 63, 66], ["TID applications", "TREATMENT", 71, 87]]], ["The expensive sensors are placed outside the space where occupants may damage these sensors, and the entire volume is Fig. 13 .", [["The expensive sensors", "TREATMENT", 0, 21]]], ["Sensing volume fraction of the interested volume for the 3 flow fields for no constraints a), b), and c); a placement constraint of sensors outside the occupied space d), e) and f); and both a sensing constraint outside the occupied zone and a sensing constraint of sensing only the occupied space g), h), and i). observable by the sensor network to ensure that the source release location is observable.", [["Sensing volume fraction", "TEST", 0, 23], ["a placement constraint of sensors", "TREATMENT", 106, 139], ["a sensing constraint", "TREATMENT", 242, 262], ["zone", "OBSERVATION_MODIFIER", 233, 237]]], ["Placement problem 3) is designed for IAQ applications since the volume of interest is the occupied space where contaminants like CO 2 and VOCs levels need to be controlled.", [["CO 2", "CHEMICAL", 129, 133], ["CO 2", "SIMPLE_CHEMICAL", 129, 133], ["VOCs", "SIMPLE_CHEMICAL", 138, 142], ["Placement problem", "TREATMENT", 0, 17], ["IAQ applications", "TREATMENT", 37, 53], ["CO", "TEST", 129, 131], ["VOCs levels", "TEST", 138, 149]]], ["The placement of the sensors in problem 3) are also outside the occupied zone to limit the damage or movement of the sensors by occupants.", [["The placement of the sensors in problem", "TREATMENT", 0, 39], ["the damage", "PROBLEM", 87, 97]]], ["Each problem is analyzed individually, and an analysis of all the problems is discussed at the end.", [["an analysis", "TEST", 43, 54]]], ["To be consistent, a sensor accuracy is 1% is used for all the problems.Sensor placement: no constraintsThe problem of interest is case 3 described in Section 2.4 (overview of algorithm), and answers the question \"how quickly can the sensor network sense the entire space and respond with a known number of sensors?\"", [["sensor network", "MULTI-TISSUE_STRUCTURE", 233, 247], ["a sensor accuracy", "TEST", 18, 35], ["Sensor placement", "TREATMENT", 71, 87], ["no", "UNCERTAINTY", 89, 91]]], ["The contaminant tracking matrix was calculated initially for a response time equal to the timestep associated with the Markov matrix.", [["matrix", "CELLULAR_COMPONENT", 25, 31], ["matrix", "CELLULAR_COMPONENT", 126, 132], ["The contaminant tracking matrix", "PROBLEM", 0, 31], ["contaminant", "OBSERVATION_MODIFIER", 4, 15], ["tracking matrix", "OBSERVATION", 16, 31], ["Markov matrix", "OBSERVATION", 119, 132]]], ["The sensors were placed and the total coverage of the sensor network was evaluated.", [["sensor network", "MULTI-TISSUE_STRUCTURE", 54, 68], ["The sensors", "TREATMENT", 0, 11]]], ["If the coverage of the sensor network was less than the volume of the space, the response time was incremented by the Markov timestep.", [["sensor network", "MULTI-TISSUE_STRUCTURE", 23, 37], ["the sensor network", "TEST", 19, 37]]], ["The response times, sensor locations, placement order, and the sensor coverage maps are displayed in Fig. 10 .Sensor placement: no constraintsBased on the results presented in Fig. 10 , several observations can be made.", [["the sensor coverage maps", "TEST", 59, 83], ["Sensor placement", "TREATMENT", 110, 126], ["no", "UNCERTAINTY", 128, 130]]], ["The outlet seems to be a dominant place for a sensor for most of the cases.", [["outlet", "ANATOMY", 4, 10], ["dominant", "OBSERVATION", 25, 33]]], ["This result suggests that over long response times contaminant dispersed anywhere in the space eventually ends up in the outlet, which is why the outlet is often chosen as a sensor position.", [["outlet", "ANATOMY_MODIFIER", 121, 127], ["outlet", "OBSERVATION", 146, 152]]], ["For all the flow fields, as the number of sensors increase, the sensing time decreases.", [["flow", "OBSERVATION", 12, 16]]], ["Introducing obstructions increases the sensing duration needed to sense the entire domain.", [["obstructions", "PATHOLOGICAL_FORMATION", 12, 24], ["Introducing obstructions", "PROBLEM", 0, 24], ["obstructions", "OBSERVATION", 12, 24]]], ["The case with one obstruction/person takes the longest to sense.", [["person", "SPECIES", 30, 36], ["one obstruction", "PROBLEM", 14, 29], ["obstruction", "OBSERVATION", 18, 29]]], ["This may be due to the large buoyancy driven recirculation area on the right side of the domain.", [["the large buoyancy driven recirculation area", "PROBLEM", 19, 63], ["may be due to", "UNCERTAINTY", 5, 18], ["large", "OBSERVATION_MODIFIER", 23, 28], ["buoyancy driven", "OBSERVATION", 29, 44], ["recirculation", "OBSERVATION_MODIFIER", 45, 58], ["area", "OBSERVATION_MODIFIER", 59, 63], ["right", "ANATOMY_MODIFIER", 71, 76]]], ["The most difficult areas to sense seem to be centers of recirculation.", [["recirculation", "OBSERVATION", 56, 69]]], ["In the placement of multiple sensors, the location of the sensors seem to be clustered near regions of low air velocity.Sensor placement: CBW and TID applicationFor CBW and TID applications, the sensor network needs to be able to have the ability to sense the entire domain such that any release scenario can be sensed as quickly as possible.", [["TID", "CHEMICAL", 146, 149], ["multiple sensors", "TREATMENT", 20, 36], ["low air velocity", "PROBLEM", 103, 119], ["Sensor placement", "TREATMENT", 120, 136], ["CBW", "TREATMENT", 138, 141], ["TID application", "TREATMENT", 146, 161], ["CBW", "TREATMENT", 165, 168], ["TID applications", "TREATMENT", 173, 189], ["any release scenario", "TREATMENT", 284, 304], ["multiple", "OBSERVATION_MODIFIER", 20, 28], ["low air velocity", "OBSERVATION", 103, 119]]], ["Fig. 11 shows the sensor locations, response times, and coverage maps include a placement constraint of the sensors outside the occupied space.", [["coverage maps", "TREATMENT", 56, 69], ["a placement constraint", "TREATMENT", 78, 100], ["occupied space", "OBSERVATION", 128, 142]]], ["For the placement of a single sensor the times and locations are the same as the no constraint case.", [["the placement", "TREATMENT", 4, 17]]], ["The sensor locations, response times, and coverage maps may be the same if the sensors with no constraints are already placed outside the occupied space (for example, placement of 2 sensors for each flow field).", [["coverage maps", "TEST", 42, 55], ["placement of 2 sensors", "TREATMENT", 167, 189]]], ["Another situation where the response time is the same is when there are multiple sensor locations that can cover the state that are not yet observable (ex: placement of 3 sensors and 2 obstructions).", [["obstructions", "PATHOLOGICAL_FORMATION", 185, 197], ["placement of 3 sensors and 2 obstructions", "TREATMENT", 156, 197], ["obstructions", "OBSERVATION", 185, 197]]], ["Coverage maps are mostly similar, which is to be expected since the regions of low air speed do not change by simply adding placement or sensing constraints.", [["Coverage maps", "TEST", 0, 13], ["low air speed", "PROBLEM", 79, 92], ["placement or sensing constraints", "TREATMENT", 124, 156], ["mostly similar", "OBSERVATION_MODIFIER", 18, 32], ["low air", "OBSERVATION", 79, 86]]], ["The single obstruction flow field takes the longest to sense.", [["The single obstruction flow field", "PROBLEM", 0, 33], ["single", "OBSERVATION_MODIFIER", 4, 10], ["obstruction", "OBSERVATION", 11, 22], ["flow field", "OBSERVATION", 23, 33]]], ["The response time are either the same or longer, with some response times being substantially longer (ex: placement of 3 sensors for the 1 obstruction case).Sensor placement: IAQ applicationFor IAQ applications, contaminant concentrations inside the occupied zone are more a concern than concentrations outside the occupied zone.", [["obstruction", "DISEASE", 139, 150], ["placement of 3 sensors", "TREATMENT", 106, 128], ["Sensor placement", "TREATMENT", 157, 173], ["IAQ application", "TREATMENT", 175, 190], ["IAQ applications", "TREATMENT", 194, 210], ["obstruction", "OBSERVATION", 139, 150], ["occupied", "ANATOMY_MODIFIER", 315, 323], ["zone", "ANATOMY_MODIFIER", 324, 328]]], ["For this reason, a sensing constraint is added to the contaminant tracking matrix such that only the occupied zone is sensed.", [["matrix", "CELLULAR_COMPONENT", 75, 81], ["a sensing constraint", "TREATMENT", 17, 37], ["occupied", "OBSERVATION_MODIFIER", 101, 109], ["zone", "OBSERVATION_MODIFIER", 110, 114]]], ["Just like the CBW and TID applications, sensors also should not be placed where occupants can damage or move the sensors.", [["the CBW", "TREATMENT", 10, 17], ["TID applications", "TREATMENT", 22, 38], ["sensors", "TREATMENT", 40, 47]]], ["For this reason, a location constraint is also added in this situation to constrain the sensors to locations outside the occupied space.", [["occupied space", "OBSERVATION", 121, 135]]], ["Because the sensing volume is smaller, the response times are faster than the other two applications, Fig. 12 .", [["the sensing volume", "TEST", 8, 26], ["sensing volume", "OBSERVATION", 12, 26], ["smaller", "OBSERVATION_MODIFIER", 30, 37]]], ["For this application sensors tend to be placed near the occupied zone or at the outlet.", [["this application sensors", "TREATMENT", 4, 28], ["outlet", "ANATOMY_MODIFIER", 80, 86]]], ["In the examples of 4 sensors for both the isothermal and 2 obstruction cases, 3 sensors are required to sense the entire occupied space and a placement of a 4th sensor provides only redundant information.", [["the isothermal and 2 obstruction cases", "PROBLEM", 38, 76], ["a placement of a 4th sensor", "TREATMENT", 140, 167], ["obstruction", "OBSERVATION", 59, 70]]], ["This is due to the telescoping nature of the placement algorithm.", [["the placement algorithm", "TREATMENT", 41, 64]]], ["When considering the union of the column supports for multiple sensor locations, this situation may not occur.Effect of constraints on coverage of multiple sensorsWe next investigate the effect of placement and sensing constraints on the total coverage.", [["the column supports", "TREATMENT", 30, 49], ["multiple sensor locations", "PROBLEM", 54, 79], ["multiple sensors", "TEST", 147, 163], ["placement", "TREATMENT", 197, 206], ["sensing constraints", "TREATMENT", 211, 230], ["the total coverage", "TREATMENT", 234, 252]]], ["A set of response time (approximately 30 s intervals) and up to 20 sensors were placed in the three air flow fields.", [["air flow", "OBSERVATION", 100, 108]]], ["For each of the response times and the number of sensors, the sensor coverage of the interested region is displayed in Fig. 13 .", [["the sensor coverage", "TREATMENT", 58, 77]]], ["The interested region for the no constraint and the placement constraint situations is the entire domain, while the placement and sensing constraints is only the occupied space.Effect of constraints on coverage of multiple sensorsThe results in Fig. 10 show that the response times for the isothermal flow field are faster than the obstruction non isothermal cases.", [["obstruction", "DISEASE", 332, 343], ["the placement constraint situations", "TREATMENT", 48, 83], ["the placement and sensing constraints", "TREATMENT", 112, 149], ["multiple sensors", "TEST", 214, 230], ["the isothermal flow field", "TEST", 286, 311], ["the obstruction non isothermal cases", "PROBLEM", 328, 364], ["occupied space", "OBSERVATION", 162, 176], ["obstruction", "OBSERVATION", 332, 343]]], ["The addition of a placement constraint outside the occupied space affects the total sensing volume during shorter response times, Fig. 13 , but not as much for longer response times.", [["a placement constraint", "TREATMENT", 16, 38], ["total", "OBSERVATION_MODIFIER", 78, 83]]], ["For each of the situations the isothermal flow field has a higher coverage fraction as compared to the 1 obstruction and 2 obstruction flow fields.Effect of constraints on coverage of multiple sensorsOverall, the algorithm takes the discrete form of the PF-operator and constructs a contaminant tracking matrix.", [["obstruction", "DISEASE", 105, 116], ["matrix", "CELLULAR_COMPONENT", 304, 310], ["the isothermal flow field", "TEST", 27, 52], ["a higher coverage fraction", "TREATMENT", 57, 83], ["the 1 obstruction", "PROBLEM", 99, 116], ["2 obstruction flow fields", "PROBLEM", 121, 146], ["higher", "OBSERVATION_MODIFIER", 59, 65], ["coverage fraction", "OBSERVATION", 66, 83], ["obstruction", "OBSERVATION", 105, 116], ["obstruction", "OBSERVATION", 123, 134], ["flow", "OBSERVATION_MODIFIER", 135, 139], ["fields", "OBSERVATION_MODIFIER", 140, 146], ["multiple", "OBSERVATION_MODIFIER", 184, 192]]], ["The column support of the contaminant tracking matrix is used for determining sensor positions.", [["The column support", "TREATMENT", 0, 18], ["the contaminant tracking matrix", "TREATMENT", 22, 53], ["column", "OBSERVATION_MODIFIER", 4, 10], ["contaminant", "OBSERVATION_MODIFIER", 26, 37], ["tracking matrix", "OBSERVATION", 38, 53]]], ["Placement of successive sensors maximizes the coverage of the sensor being places based on the states that are currently not observable by the sensor network.", [["sensor network", "MULTI-TISSUE_STRUCTURE", 143, 157], ["successive sensors", "TREATMENT", 13, 31], ["successive", "OBSERVATION_MODIFIER", 13, 23]]], ["From the showcased flow fields, 4 major observations can be made from the algorithm.Effect of constraints on coverage of multiple sensors1.", [["the algorithm", "TEST", 70, 83], ["multiple sensors", "TEST", 121, 137], ["flow", "OBSERVATION", 19, 23]]], ["The algorithm places sensors near regions with low air speed.", [["low air speed", "PROBLEM", 47, 60], ["low", "OBSERVATION", 47, 50], ["air speed", "OBSERVATION", 51, 60]]], ["Regions where buoyancy dominants the air flow field are harder to sense than regions with higher Reynolds numbers and inertial driven air flow patterns.", [["the air flow field", "PROBLEM", 33, 51], ["inertial driven air flow patterns", "TEST", 118, 151], ["buoyancy", "OBSERVATION_MODIFIER", 14, 22], ["dominants", "OBSERVATION_MODIFIER", 23, 32], ["air flow", "OBSERVATION", 37, 45], ["higher", "OBSERVATION_MODIFIER", 90, 96], ["Reynolds", "OBSERVATION_MODIFIER", 97, 105], ["numbers", "OBSERVATION_MODIFIER", 106, 113], ["inertial driven", "OBSERVATION", 118, 133], ["air flow", "OBSERVATION", 134, 142]]], ["The addition of placement constraints and sensing constraints has a greater effect on the shorter response times.", [["placement constraints", "TREATMENT", 16, 37], ["sensing constraints", "TREATMENT", 42, 61], ["greater", "OBSERVATION_MODIFIER", 68, 75], ["effect", "OBSERVATION_MODIFIER", 76, 82]]], ["As more sensors are placed the response time decreases.DiscussionWe developed a simple algorithm that can rapidly identify optimal sensor location under various scenarios.", [["a simple algorithm", "PROBLEM", 78, 96]]], ["We illustrated this methodology for three different steady state flow fields under different sensor placement constraints and sensing constraints that are relevant to CBW and IAQ applications.", [["different sensor placement constraints", "TREATMENT", 83, 121], ["sensing constraints", "TREATMENT", 126, 145]]], ["In reality, flow fields experience perturbations by occupants moving around the space, changes in air flow conditions (boundary conditions), and are usually transient.", [["changes in air flow conditions", "PROBLEM", 87, 117], ["air flow", "OBSERVATION", 98, 106]]], ["The flow fields produced by these perturbations and the changes in supply air temperature, supply air flow rate, and changes in the building envelope surface temperatures or thermal loads are transient in nature.", [["surface", "ANATOMY", 150, 157], ["The flow fields", "TEST", 0, 15], ["these perturbations", "PROBLEM", 28, 47], ["the changes in supply air temperature", "PROBLEM", 52, 89], ["supply air flow rate", "TEST", 91, 111], ["thermal loads", "PROBLEM", 174, 187], ["flow", "OBSERVATION_MODIFIER", 4, 8], ["fields", "OBSERVATION_MODIFIER", 9, 15], ["perturbations", "OBSERVATION", 34, 47], ["air temperature", "OBSERVATION", 74, 89], ["air flow", "OBSERVATION", 98, 106], ["thermal loads", "OBSERVATION", 174, 187], ["transient", "OBSERVATION_MODIFIER", 192, 201]]], ["The elegance of considering the flow field (and the associated contaminant transport dynamics) from a dynamical systems perspective allows leveraging rigorous mathematical tools for sensor placement.", [["the flow field", "TEST", 28, 42], ["sensor placement", "TREATMENT", 182, 198]]], ["More importantly, this methodology can be naturally extended to transient flow fields (as formulated in Eq.", [["transient flow fields", "PROBLEM", 64, 85], ["flow fields", "OBSERVATION", 74, 85]]], ["This is the basis of two forthcoming papers that 1) investigate sensor locations for transient flow fields or multiple operating conditions, and 2) incorporate uncertainty in boundary conditions and the flow field to determine robust sensor locations.ConclusionsThis paper utilizes a dynamical systems approach for sensor placement for air flow fields.", [["transient flow fields", "PROBLEM", 85, 106], ["uncertainty in boundary conditions", "PROBLEM", 160, 194], ["the flow field", "TEST", 199, 213], ["a dynamical systems approach", "TREATMENT", 282, 310], ["sensor placement", "TREATMENT", 315, 331], ["air flow fields", "TEST", 336, 351], ["air flow", "OBSERVATION", 336, 344]]], ["The algorithm uses the discrete form of the Perron-Frobenius operator (a Markov matrix) to construct a contaminant tracking matrix in which sensors are placed based on the largest column support in the contaminant tracking matrix.", [["matrix", "CELLULAR_COMPONENT", 223, 229], ["Perron-Frobenius operator", "DNA", 44, 69], ["the Perron-Frobenius operator", "TREATMENT", 40, 69], ["a Markov matrix", "TREATMENT", 71, 86], ["a contaminant tracking matrix", "PROBLEM", 101, 130], ["the largest column support", "TREATMENT", 168, 194], ["contaminant", "OBSERVATION", 103, 114], ["largest", "OBSERVATION_MODIFIER", 172, 179], ["column", "OBSERVATION_MODIFIER", 180, 186]]], ["The addition of sensor accuracy along with placement constraints and sensing constraints are included in the algorithm.", [["sensor accuracy", "TEST", 16, 31], ["placement constraints and sensing constraints", "TREATMENT", 43, 88]]], ["The algorithm considers all release scenarios of the contaminant (i.e. release in all states of the Markov matrix).", [["matrix", "CELLULAR_COMPONENT", 107, 113]]], ["We envision this algorithm to be an efficient alternative to current optimization/inverse based approaches to sensor placement in buildings.ConclusionsThe designed algorithm is showcased with a literature example and three additional flow fields based on different configurations of a reading room.", [["this algorithm", "TREATMENT", 12, 26], ["current optimization/inverse based approaches", "TREATMENT", 61, 106], ["sensor placement in buildings", "TREATMENT", 110, 139], ["flow", "OBSERVATION", 234, 238]]], ["The effect of different placement and sensing constraints on the sensor network response time is also investigated.", [["different placement", "TREATMENT", 14, 33], ["different", "OBSERVATION_MODIFIER", 14, 23], ["placement", "OBSERVATION", 24, 33]]], ["In particular, this framework has direct utility for placing sensor nets for applications involving sensing of chemical and biological weapons, transmission of infectious diseases, and indoor air quality.", [["infectious diseases", "DISEASE", 160, 179], ["sensor nets", "TREATMENT", 61, 72], ["infectious diseases", "PROBLEM", 160, 179], ["infectious", "OBSERVATION", 160, 170]]], ["The contributions of this paper has the ability to help designers, engineers, and researches better understand the coverage maps, response times, and number of sensors needed to effectively control the mechanical systems in buildings and design response and evacuation strategies during extreme events.", [["evacuation strategies", "TREATMENT", 258, 279], ["extreme events", "PROBLEM", 287, 301]]], ["The proposed framework for sensor placement can be easily extended to account for various sources of uncertainty in the building environment.AcknowledgmentsBG and AF acknowledge support from Iowa Energy Center (IEC14011OG), and from NSF 1149365.", [["sensor placement", "TREATMENT", 27, 43], ["AF", "PROBLEM", 163, 165]]], ["UV acknowledges the financial support from NSF 1150405.AA set of Markov states that define the release scenarios BAA set of Markov states that define the release scenarios not covered by previously placed sensors C kAThe output matrix for a set of sensors described by k The support of the k sensor locations for a set of release scenarios with the release states being A i s \u00f0all\u00deAThe support of the k sensor locations for all possible release scenarios t Time UAAir velocity vector with components fu; v; wg uAThe x-component of the air velocity vector V Volume VukAVolume of the u k state vAThe y-component of the air velocity vector wAThe z-component of the air velocity vector xAThe position vector with directions fx; y; zg xAThe x-coordinate direction yAThe y-coordinate direction zAThe z-coordinate direction DtATimestep associated with the Markov matrix \u03b5 acc Accuracy threshold for the contaminant tracking matrix l B k \u00f0x\u00deAThe indicator function of the k sensor locations m detectAThe contaminant concentration detected at the sensor m sourceAThe source contaminant concentration [27] did not consider the outlet as an option to place the sensor.", [["NSF 1150405", "CHEMICAL", 43, 54], ["NSF 1150405", "CHEMICAL", 43, 54], ["matrix", "CELLULAR_COMPONENT", 228, 234], ["wg", "PROTEIN", 507, 509], ["sensors C kAThe output matrix", "TREATMENT", 205, 234], ["a set of sensors", "TREATMENT", 239, 255], ["the k sensor locations", "TREATMENT", 286, 308], ["a set of release scenarios", "TREATMENT", 313, 339], ["the k sensor locations", "TREATMENT", 397, 419], ["the air velocity vector", "TEST", 531, 554], ["vAThe", "TEST", 592, 597], ["the air velocity vector", "TREATMENT", 613, 636], ["the air velocity vector", "TREATMENT", 658, 681], ["directions fx", "PROBLEM", 709, 722], ["zg xAThe x-coordinate direction", "TREATMENT", 727, 758], ["the Markov matrix", "TREATMENT", 845, 862], ["the outlet", "TREATMENT", 1113, 1123], ["air velocity", "OBSERVATION", 535, 547], ["air velocity", "OBSERVATION", 617, 629], ["air velocity", "OBSERVATION", 662, 674]]], ["Using the sensor placement algorithm provided in this paper, a single sensor as well as 2 sensors are considered.", [["the sensor placement algorithm", "TREATMENT", 6, 36]]], ["For a single sensor to sense all the Markov states in the scenarios using the aircraft, the sensor can be placed in the aisle of row 2 and has a response time of 16 s, Fig. 14a .", [["14a", "GENE_OR_GENE_PRODUCT", 173, 176]]], ["The response time of the sensors is 8 s, which is less than the response time of a single sensor.", [["the sensors", "TEST", 21, 32]]], ["The thresholded and constrained contaminant tracking matrix was computed for a sensing time of t \u00bc f4; 8; 12; 16g seconds.", [["The thresholded and constrained contaminant tracking matrix", "TREATMENT", 0, 59]]], ["The column support in terms of the sensing volume for each Markov state and each time is shown in Fig. 15 .", [["The column support", "TREATMENT", 0, 18], ["the sensing volume", "TREATMENT", 31, 49], ["column support", "OBSERVATION", 4, 18]]], ["The results show that as time progresses contaminates will tend to gravitate towards the center of the aircraft.ABased on this analysis there are two observations which are consistent with the conclusions of Zhang et al., 2007 [49] and Mazumdar et al., 2008 [27] .", [["this analysis", "TEST", 122, 135], ["aircraft", "ANATOMY", 103, 111], ["consistent with", "UNCERTAINTY", 173, 188]]]], "87064846bd0610e03eaacd6ae6f531692ca8ca26": [["The management of gastrointestinal cancers has substantially evolved into personalized medicine in the last decade, due to a better understanding of molecular underpinnings of each and unique gastrointestinal cancer [1] .", [["gastrointestinal cancers", "ANATOMY", 18, 42], ["gastrointestinal cancer", "ANATOMY", 192, 215], ["gastrointestinal cancers", "DISEASE", 18, 42], ["gastrointestinal cancer", "DISEASE", 192, 215], ["gastrointestinal cancers", "CANCER", 18, 42], ["gastrointestinal cancer", "CANCER", 192, 215], ["gastrointestinal cancers", "PROBLEM", 18, 42], ["unique gastrointestinal cancer", "PROBLEM", 185, 215], ["gastrointestinal", "ANATOMY", 18, 34], ["cancers", "OBSERVATION", 35, 42], ["gastrointestinal", "ANATOMY", 192, 208], ["cancer", "OBSERVATION", 209, 215]]], ["While the oncology society has improved in learning how to provide the best care for an individual cancer patient, the novel coronavirus, SARS-CoV-2, has caught oncologists around to the world of the guard with an extremely challenging situation where finding the balance between the risk of infection due to chemotherapy and even due to hospital visits versus the risk due to acuity of controlling cancer progression.", [["cancer", "ANATOMY", 99, 105], ["cancer", "ANATOMY", 399, 405], ["cancer", "DISEASE", 99, 105], ["coronavirus", "DISEASE", 125, 136], ["SARS", "DISEASE", 138, 142], ["infection", "DISEASE", 292, 301], ["cancer", "DISEASE", 399, 405], ["cancer", "CANCER", 99, 105], ["patient", "ORGANISM", 106, 113], ["coronavirus", "ORGANISM", 125, 136], ["SARS-CoV-2", "ORGANISM", 138, 148], ["cancer", "CANCER", 399, 405], ["patient", "SPECIES", 106, 113], ["SARS-CoV", "SPECIES", 138, 146], ["infection", "PROBLEM", 292, 301], ["chemotherapy", "TREATMENT", 309, 321], ["acuity of controlling cancer progression", "PROBLEM", 377, 417], ["cancer", "OBSERVATION", 99, 105], ["infection", "OBSERVATION", 292, 301], ["cancer", "OBSERVATION", 399, 405]]], ["While the ASCO GI Symposium 2020 has focused mostly on outcomes of recent 'high-yield' clinical trials, perhaps one of the most important discussion points of the ASCO GI Symposium 2021 would be risk-adapted cancer management in pandemics.", [["cancer", "ANATOMY", 208, 214], ["cancer", "DISEASE", 208, 214], ["cancer", "CANCER", 208, 214], ["cancer management", "TREATMENT", 208, 225], ["pandemics", "PROBLEM", 229, 238], ["cancer", "OBSERVATION", 208, 214]]], ["The impact of ongoing COVID-19 infection on the management of cancer patients will be better characterized once the acute phase of this pandemic is over.", [["cancer", "ANATOMY", 62, 68], ["infection", "DISEASE", 31, 40], ["cancer", "DISEASE", 62, 68], ["cancer", "CANCER", 62, 68], ["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["ongoing COVID", "TREATMENT", 14, 27], ["cancer", "PROBLEM", 62, 68], ["infection", "OBSERVATION", 31, 40], ["cancer", "OBSERVATION", 62, 68], ["acute", "OBSERVATION_MODIFIER", 116, 121]]]], "c5c053e3ddc969ed42e566b8dfe47ee4b872b2a8": [["IntroductionOver the course of the past few years, IR has seen the introduction of a large number of successful deep learning approaches for solving all kinds of tasks previously tackled with hand-crafted features (within the learning to rank framework) or traditional retrieval models such BM25.IntroductionIn 2017, with the introduction of the transformer architecture [33] , a second wave of neural architectures for NLP has emerged.", [["hand", "ANATOMY", 192, 196], ["neural", "ANATOMY", 395, 401], ["BM25", "GENE_OR_GENE_PRODUCT", 291, 295], ["BM25", "PROTEIN", 291, 295], ["NLP", "PROTEIN", 420, 423], ["successful deep learning approaches", "TREATMENT", 101, 136], ["solving all kinds of tasks", "TREATMENT", 141, 167], ["traditional retrieval models", "TREATMENT", 257, 285], ["a second wave of neural architectures", "PROBLEM", 378, 415], ["large", "OBSERVATION_MODIFIER", 85, 90], ["neural architectures", "OBSERVATION", 395, 415]]], ["Approaches (and respective models) like BERT [7] , XLNet [41] and GPT-2 [24] have shown that it is indeed possible for one general architecture to achieve state-of-the-art performance across very different NLP tasks (some of which are also related to IR tasks, such as question answering, reading comprehension, etc.).IntroductionAd-hoc retrieval, the task of ranking a set of documents given a single query, has long resisted the success of neural approaches, especially when employed across standard IR test collections such as Robust04 1 , which come with hundreds of topics (and thus relatively little training data).", [["neural", "ANATOMY", 442, 448], ["XLNet", "TEST", 51, 56], ["GPT", "TEST", 66, 69], ["neural approaches", "TREATMENT", 442, 459], ["standard IR test collections", "TEST", 493, 521]]], ["Often, the proposed neural approaches require a very careful design of their architecture.", [["neural", "ANATOMY", 20, 26]]], ["Also, the training regime and the input data transformations have to be just right [17] in order to beat or come close to well-tuned traditional IR baselines such as RM3 [2, 16]IntroductionWith the introduction of BERT in late 2018, this has finally changed.", [["the training regime", "TREATMENT", 6, 25]]], ["Recently, a range of BERT-inspired approaches have been shown to clearly surpass all strong IR baselines on Robust04 [6, 40] and other IR corpora.IntroductionIt is still an open question though what exactly makes BERT and similar approaches perform so well on IR tasks.", [["BERT", "PROTEIN", 21, 25]]], ["While recent works try to understand what BERT learns most often by analysing attention values, e.g., [4, 12, 21, 32] , analysing BERT under the IR light requires a different set of tools.", [["BERT", "PROTEIN", 42, 46], ["BERT", "PROTEIN", 130, 134]]], ["While most NLP tasks optimise for precision, recall or other objective metrics, the goal of ad-hoc retrieval is to optimise for relevance, a complex multidimensional and somewhat subjective concept [3] .IntroductionIn this paper, we set out to explore BERT under the IR lens, employing the concept of diagnostic datasets, an IR model analysis approach (inspired by similar NLP and computer vision approaches) proposed last year by Rennings et al. [25] .", [["BERT", "PROTEIN", 252, 256], ["ad-hoc retrieval", "TREATMENT", 92, 108], ["an IR model analysis approach", "TREATMENT", 322, 351]]], ["While traditional retrieval models such as BM25 [26] can be analysed analytically, neural nets with their millions or even billions of learnt weights can only be analysed in such an empirical manner.IntroductionMore concretely, we attempt to analyse a version of BERT, DistilBERT (that was shown to attain 97% of \"vanilla\" BERT performance [28] ), fine-tuned on the TREC 2019 Deep Learning track dataset 4 .", [["neural nets", "ANATOMY", 83, 94], ["traditional retrieval models", "TREATMENT", 6, 34]]], ["We find that DistilBERT to outperform the traditional query likelihood (QL) model by 40%.", [["DistilBERT", "PROTEIN", 13, 23], ["DistilBERT", "TREATMENT", 13, 23]]], ["In contrast to our expectations however, we find that BERT does not adhere to any of the axioms we incorporate in our work.", [["BERT", "PROTEIN", 54, 58]]], ["This implies that the currently existing axioms are not sufficient and not applicable to capture 1 Robust04 is a test collection employed at the TREC 2004 robust retrieval task [35] , consisting of 528K newswire documents, 250 topics and 311K relevance judgements.", [["Robust04", "DNA", 99, 107], ["a test collection", "TEST", 111, 128]]], ["4 https://microsoft.github.io/TREC-2019-Deep-Learning/. the heuristics that a strong supervised model learns (at least for the corpus and model we explore); it is not yet clear to what extent those results generalise beyond our model and corpus combination but it opens up a number of questions about the axiomatic approach to IR.Related WorkAxiomatic Information Retrieval.", [["corpus", "ORGANISM_SUBDIVISION", 238, 244]]], ["It is an analytic technique to explore retrieval models and how best to improve them.", [["an analytic technique", "TREATMENT", 6, 27], ["retrieval models", "TREATMENT", 39, 55]]], ["In their seminal work, Fang et al. [9, 10] introduced a number of term-matching based heuristics that models should follow in order to be successful in retrieval tasks.", [["seminal", "ANATOMY", 9, 16]]], ["Subsequently, Fang et al. [11] proposed a set of axioms based on semantic matching and thus allowing non-exact matches to be accounted for in axiomatic retrieval.", [["a set of axioms", "TREATMENT", 40, 55], ["semantic matching", "TREATMENT", 65, 82]]], ["Other applications for axioms in IR include document re-ranking based on a Learning to Rank scenario [13] and query expansion [8] by exploring similar axioms.", [["axioms in IR", "TREATMENT", 23, 35], ["query expansion", "TEST", 110, 125]]], ["It should be noted, that-while sensible-it cannot be assumed that these axioms are a good fit for all kinds of corpora; they represent a general notion of how a good retrieval function should behave.", [["corpora", "MULTI-TISSUE_STRUCTURE", 111, 118]]], ["Recently, Rennings et al. [25] introduced diagnostic datasets extracted from actual corpora that each fulfil one axiom.", [["corpora", "MULTI-TISSUE_STRUCTURE", 84, 91], ["diagnostic datasets", "TEST", 42, 61]]], ["In contrast to the axiomatic approach, which requires an analytical evaluation of the retrieval functions under investigation, a diagnostic corpus enables us to analyse models' axiomatic performance that are too large to be analysed analytically (such as neural models with millions or even billions of parameters 5 ).", [["neural", "ANATOMY", 255, 261], ["an analytical evaluation", "TEST", 54, 78]]], ["Our work continues in that direction with a larger number of axioms (9 vs. 4) and the analysis of the current neural state-of-the-art (i.e., BERT).Related WorkNeural IR Models.", [["neural", "ANATOMY", 110, 116], ["the analysis", "TEST", 82, 94], ["larger", "OBSERVATION_MODIFIER", 44, 50]]], ["Neural IR models, i.e., deep learning based approaches that tackle IR problems, have seen a massive rise in popularity in the last few years, with considerable success [20] .", [["Neural", "ANATOMY", 0, 6], ["Neural IR models", "TREATMENT", 0, 16], ["IR problems", "PROBLEM", 67, 78], ["a massive rise", "PROBLEM", 90, 104], ["massive", "OBSERVATION_MODIFIER", 92, 99], ["rise", "OBSERVATION_MODIFIER", 100, 104]]], ["Models like DRMM [19] , ARCII [14] and aNMM [39] have been shown to be suitable for a range of IR tasks when sufficient training data is available; it remains at best unclear at smaller data scale whether the reported successes are not just an artefact of weak baselines [17] .Related WorkRecently, a new wave of approaches, based on the transformer architecture [33] has shown that, finally, neural models can significantly outperform traditional and well-tuned retrieval methods such as RM3 [2] .", [["neural", "ANATOMY", 393, 399], ["Models like DRMM", "PROBLEM", 0, 16], ["ARCII", "TEST", 24, 29], ["IR tasks", "TEST", 95, 103], ["weak baselines", "PROBLEM", 256, 270], ["a new wave of approaches", "PROBLEM", 299, 323], ["well-tuned retrieval methods", "TREATMENT", 452, 480], ["new", "OBSERVATION_MODIFIER", 301, 304], ["wave", "OBSERVATION_MODIFIER", 305, 309]]], ["Yang et al. [40] have shown that BERT, fine-tuned on the available TREC microblog datasets, and combined with a traditional retrieval approach such as query likelihood significantly outperforms well-tuned baselines, even on Robust04 which has shown to be a notoriously difficult dataset for neural models to do well on.", [["neural", "ANATOMY", 291, 297], ["BERT", "GENE_OR_GENE_PRODUCT", 33, 37], ["BERT", "PROTEIN", 33, 37], ["TREC microblog datasets", "DNA", 67, 90], ["Robust04", "CELL_LINE", 224, 232], ["a traditional retrieval approach", "TREATMENT", 110, 142]]], ["With similar success, Dai and Callan [6] have recently employed another BERT variant on Robust04 and ClueWeb09.", [["Robust04", "GENE_OR_GENE_PRODUCT", 88, 96], ["BERT variant", "PROTEIN", 72, 84], ["Robust04", "PROTEIN", 88, 96], ["ClueWeb09", "PROTEIN", 101, 110]]], ["Lastly we point out, that works are now also beginning to appear, e.g., [18] , that use the contextual word embeddings produced by BERT in combination with another strong neural model, again with strong improvements over the existing baselines.Related WorkAnalysing Neural IR Models.", [["neural", "ANATOMY", 171, 177], ["BERT", "PROTEIN", 131, 135], ["Neural IR Models", "OBSERVATION", 266, 282]]], ["As we aim to analyse BERT, we also consider how others have tackled this problem.", [["BERT", "PROTEIN", 21, 25]]], ["Analysing neural models-whether for IR, NLP or another research domain-is not a trivial task.", [["neural", "ANATOMY", 10, 16], ["NLP", "TEST", 40, 43], ["another research domain", "TEST", 47, 70]]], ["By now a great number of works have tried to light up the black box of the neural learning models [1] , with varying degrees of success.", [["neural", "ANATOMY", 75, 81]]], ["Within IR, Pang et al. [22] have aimed to paint a complete and high-level picture of the neural IR area, comparing the behaviour of different approaches, and showing that interaction and representation-based models focus on different characteristics of queries and documents.", [["neural IR area", "ANATOMY", 89, 103], ["neural IR", "ANATOMY", 89, 98]]], ["Closer to our work, Rosset et al. [27] employ axioms to generate artificial documents for the training of neural models and the regularization of the loss function.", [["neural", "ANATOMY", 106, 112], ["the loss function", "PROBLEM", 146, 163], ["neural models", "ANATOMY", 106, 119], ["loss", "OBSERVATION", 150, 154]]], ["In contrast, we employ axioms to analyze retrieval models.Related WorkAnother direction of research has been the development of interpretation tools such as DeepSHAP [12] and LIRME [34] that aim to generate local explanations for neural IR models.", [["neural", "ANATOMY", 230, 236], ["neural IR models", "TREATMENT", 230, 246]]], ["Recently, in particular BERT (due to its successes across a wide range of tasks and domains) has become the focus of analysisnot within IR though.", [["BERT", "PROTEIN", 24, 28], ["a wide range of tasks", "TREATMENT", 58, 79]]], ["Finally, Niven et al. [21] raise some critical points about BERT, arguing that it only \"exploits spurious statistical cues in the dataset\"; they showcase this by creating adversarial datasets that can significantly harm its performance.Diagnostic DatasetsThe usage of diagnostic datasets as a means to analyse neural models is common in NLP, e.g. [15, 36, 37] as there are a large number of fine-grained linguistic tasks (anaphora resolution, entailment, negation, etc.) that datasets can be created for with relative ease.", [["neural", "ANATOMY", 310, 316], ["diagnostic datasets", "TEST", 268, 287], ["large", "OBSERVATION_MODIFIER", 375, 380]]], ["In contrast, in IR the central notion is relevance and although we know that it can be decomposed into various types (topical, situational, etc.) of relevance [29] , we have no easy way of creating datasets for each of these-it remains a time-intensive and expensive task.", [["central", "ANATOMY_MODIFIER", 23, 30]]], ["This also explains why corpora such as Robust04 remain useful and in use for such a long time.", [["corpora", "MULTI-TISSUE_STRUCTURE", 23, 30]]], ["Instead, like Rennings et al. [25] we turn to the axiomatic approach to IR and create diagnostic datasets-one for each of our chosen retrieval heuristics.", [["diagnostic datasets", "TEST", 86, 105]]], ["In contrast to [25] which restricted itself to four term matching axioms, we explore a wider range of axioms, covering term frequency, document length, lower-bounding term frequency, semantic term matching and term proximity constraints.", [["semantic term matching and term proximity constraints", "PROBLEM", 183, 236], ["bounding term", "OBSERVATION_MODIFIER", 158, 171]]], ["We note that this covers most of the term-matching and semantic-matching axioms that have been proposed.", [["semantic-matching axioms", "TREATMENT", 55, 79]]], ["We have eliminated a small number from our work as we do not consider them relevant to BERT (e.g., those designed for pseudo-relevance feedback [5] ).Diagnostic DatasetsAs the axiomatic approach to IR has been designed to analytically analyse retrieval functions, in their original version they assume very specific artificial query and document setups.", [["small", "OBSERVATION_MODIFIER", 21, 26]]], ["It is defined as follows: given a single-term query Q = {q} and two single-term documentsDiagnostic Datasetsthe retrieval score of D 1 should be higher than D 2 if the semantic similarity between q and d 1 is higher than that between q and d 2 .", [["the semantic similarity", "TEST", 164, 187]]], ["We thus turn to the creation of datasets that exclusively contain instances of query/documents (for STMC1 an instance is a triple, consisting of one query and two documents) that satisfy a particular axiom.", [["STMC1", "PROTEIN", 100, 105]]], ["Importantly, this process requires no relevance judgements-we can simply scan all possible triples in the corpus (consisting of queries and documents) and add those to our diagnostic dataset that fulfil our requirements.", [["corpus", "ANATOMY", 106, 112], ["corpus", "MULTI-TISSUE_STRUCTURE", 106, 112]]], ["Due to the space limitations, we focus on a mathematical notation which is rather brief.", [["a mathematical notation", "TEST", 42, 65]]], ["For axioms TFC1, TFC2, LNC2 and M-TDC we follow the process described in [25] .", [["TFC2", "GENE_OR_GENE_PRODUCT", 17, 21], ["M-TDC", "GENE_OR_GENE_PRODUCT", 32, 37], ["TFC1", "DNA", 11, 15], ["TFC2", "DNA", 17, 21], ["LNC2", "DNA", 23, 27], ["axioms TFC1", "TEST", 4, 15], ["TFC2", "TREATMENT", 17, 21]]], ["We make use of the following notation: Q is a query and consists of terms q 1 , q 2 , ...; D i is a document of length |D i | containing terms d i1 , d i2 , ...; the count of term w in document D is c(w, D); lastly, S(Q, D) is the retrieval score the model assigns to D for a given Q. Apart from the proximity heuristic TP, the remaining heuristics are based on the bag-of-word assumption, i.e., the order of terms in the query and documents do not matter.", [["TP", "GENE_OR_GENE_PRODUCT", 320, 322], ["the bag", "TREATMENT", 362, 369]]], ["TFC1-Adapted.", [["TFC1", "GENE_OR_GENE_PRODUCT", 0, 4], ["TFC1", "PROTEIN", 0, 4], ["TFC1", "TEST", 0, 4]]], ["In order to extract query/document/document triples from actual corpora, we need to consider multi-term queries and document pairs of approximately the same length.", [["corpora", "MULTI-TISSUE_STRUCTURE", 64, 71]]], ["S(Q, D 1 ) > S(Q, D 2 ) holds, when D 1 has at least the same query term count as D 2 for all but one query term (and for this term D 1 's count is higher), i.e.,Diagnostic DatasetsTFC2-Adapted.", [["S(Q, D 1 )", "TEST", 0, 10], ["this term D 1 's count", "TEST", 122, 144]]], ["Analogous to TFC1, queries can contain multiple terms and documents only have to have approximately the same length.", [["TFC1", "GENE_OR_GENE_PRODUCT", 13, 17], ["TFC1", "DNA", 13, 17]]], ["Let Q = {q 1 , q 2 , .., q |Q| } and max Di,Dj \u2208{D1,D2,D3} (|D i | \u2212 |D j | \u2264 abs(\u03b4)).", [["D1", "PROTEIN", 49, 51], ["Di", "TEST", 41, 43], ["abs", "TEST", 78, 81]]], ["If every document contains at least one query term, and D 3 has more query terms than D 2 and D 2 has more query terms than D 1 , and the difference of query terms count between D 2 and D 1 should be the same as between D 3 and D 2 , for all query terms, i.e.Diagnostic DatasetsM-TDC-Adapted.", [["D 2 and D 1", "TREATMENT", 178, 189]]], ["Again, Let Q contain multiple terms and |D 1 | \u2212 |D 2 | \u2264 abs(\u03b4).", [["Let Q", "GENE_OR_GENE_PRODUCT", 7, 12], ["Let Q", "PROTEIN", 7, 12], ["D", "TEST", 50, 51], ["abs", "TEST", 58, 61]]], ["D 1 , D 2 also differ in at least one query term count (\u2203q i \u2208 Q, such that c(q i , D 1 ) = c(q i , D 2 )).", [["D 2", "GENE_OR_GENE_PRODUCT", 6, 9]]], ["If, for all query term pairs the conditions hold that c(q i , For the following semantic axioms, let us define the function \u03c3(t 1 , t 2 ) as the cosine distance between the embeddings of terms t 1 and t 2 .", [["t 1 and t 2", "DNA", 193, 204]]], ["We also define \u03c3 (T 1 , T 2 ), where T can be either a document D or a query Q, as an extension to \u03c3, defined by \u03c3 (T 1 , T 2 ) = cos( i\u2208T 1 ti |T1| , i\u2208T 2 ti |T2| ), the cosine distance between the average term embeddings for each document.STMC2-Adapted.We allow Q to be a multiple query term, D 1 to contain non-query terms and D 2 to contain query terms.", [["STMC2", "GENE_OR_GENE_PRODUCT", 242, 247], ["\u03c3", "PROTEIN", 15, 16], ["\u03c3", "PROTEIN", 99, 100], ["\u03c3", "PROTEIN", 113, 114], ["STMC2", "PROTEIN", 242, 247], ["cos", "TEST", 130, 133], ["T1", "TEST", 145, 147], ["i\u2208T", "TEST", 151, 154], ["STMC2", "TEST", 242, 247]]], ["IfSTMC3-Original.Let Q = {q 1 , q 2 } be a two-term query and d a non-query term such that \u03c3(d,ExperimentsWe create diagnostic datasets for each of these axioms by extracting instances of queries and documents that already exist in the dataset.", [["IfSTMC3", "PROTEIN", 0, 7], ["IfSTMC3", "TEST", 0, 7]]], ["In this section, we explain how these datasets were generated and how we employed them to evaluate BERT.TREC 2019 Deep Learning TrackIn order to extract diagnostic datasets, we used the corpus and queries for the Document Ranking Task from the TREC 2019 Deep Learning track 7 .", [["BERT", "PROTEIN", 99, 103], ["diagnostic datasets", "TEST", 153, 172]]], ["This is the only publicly available ad-hoc retrieval dataset that was built specifically for the training of deep neural models, with 3,213,835 web documents and 372,206 Table 1 .", [["neural", "ANATOMY", 114, 120], ["deep neural models", "TEST", 109, 127], ["deep", "ANATOMY_MODIFIER", 109, 113], ["neural models", "ANATOMY", 114, 127]]], ["The diagnostic datasets for heuristics marked with a blue background were first discussed in [25] .", [["heuristics", "PROBLEM", 28, 38], ["a blue background", "PROBLEM", 51, 68]]], ["TFC2 [9] The increase in retrieval score of a document gets smaller as the absolute query term frequency increases.", [["increase", "OBSERVATION_MODIFIER", 13, 21]]], ["M-TDC [9, 30] The more discriminating query terms (i.e., those with high IDF value) a document contains, the higher its retrieval score.Heuristic Informal description InstanceLength normalization constraints LNC1 [9] The retrieval score of a document decreases as terms not appearing in the query are added.", [["M-TDC", "CHEMICAL", 0, 5], ["The retrieval score", "TEST", 217, 236], ["higher", "OBSERVATION_MODIFIER", 109, 115]]], ["LNC2 [9] A document that is duplicated does not have a lower retrieval score than the original document.Heuristic Informal description InstanceSemantic term matching constraints STMC1 [11] A document's retrieval score increases as it contains terms that are more semantically related to the query terms.", [["a lower retrieval score", "TREATMENT", 53, 76], ["A document's retrieval score", "TEST", 189, 217]]], ["STMC3 [11] A document's retrieval score increases as it contains more terms that are semantically related to different query terms.Term proximity constraint TP [31]A document's retrieval score increases as the query terms appearing in it appear in closer proximity. what is a flail chest a constitution is best described as a(n) . -)what was the immediate impact of the success of the manhattan project?Term proximity constraint TP [31]The queries consist on average of 5.89(\u00b12.51) words while documents consist on average of 1084.88(\u00b12324.22) words.Term proximity constraint TP [31]Most often, one relevant document exists per query (1.04 relevant documents on average).", [["STMC3", "TEST", 0, 5], ["A document's retrieval score", "TEST", 11, 39], ["A document's retrieval score", "TEST", 164, 192], ["a flail chest", "PROBLEM", 274, 287], ["more terms", "OBSERVATION_MODIFIER", 65, 75], ["flail", "OBSERVATION", 276, 281], ["chest", "ANATOMY", 282, 287]]], ["These relevance judgements were made by human judges on a passage-level: if a passage within a document is relevant, the document is considered relevant.", [["human", "ORGANISM", 40, 45], ["human", "SPECIES", 40, 45], ["human", "SPECIES", 40, 45]]], ["Unlike other TREC datasets, like Robust04, there is no topic description or topic narrative.Term proximity constraint TP [31]At the time of this writing, the relevance judgements for the test queries were not available.", [["the test queries", "TEST", 183, 199], ["TREC datasets", "OBSERVATION", 13, 26], ["no", "UNCERTAINTY", 52, 54]]], ["Therefore, we split the development queries further, in a new dev and test dataset, in a 70%-30% fashion.", [["test dataset", "TEST", 70, 82]]], ["In the rest of this paper, when we refer to the test or dev dataset, we are referring to this split.", [["the test", "TEST", 44, 52]]], ["The train split remains the same as the original dataset.Retrieval and RankingWe begin by indexing the document collection using the Indri toolkit 8 , and retrieve the top-100 results using a traditional retrieval model with just one hyperparameter, namely, QL, with Indri's default setting (Dirichlet smoothing [42] and \u03bc = 2500).", [["Retrieval", "TREATMENT", 57, 66], ["a traditional retrieval model", "TREATMENT", 190, 219]]], ["Finally, for BERT, we employ Hugging Face's library 9 of DistilBERT [28] , a distilled version of the original BERT model, with fewer parameters (66 million instead of 340 million), and thus more efficient to train, but with very similar results.Retrieval and RankingWe fine-tuned our BERT 10 model with 10 negative samples for each positive sample from the training dataset, randomly picked from the top-100 retrieved from QL.", [["Retrieval", "TREATMENT", 246, 255], ["the training dataset", "TEST", 354, 374]]], ["For fine-tuning we used the sequence classification model.", [["the sequence classification model", "TEST", 24, 57]]], ["It is implemented by adding a fullyconnected layer on top of the [CLS] token embedding, which is the specific output token of the BERT model that our fine-tuning is based upon.Retrieval and RankingGiven the limitation of BERT regarding the maximum number of tokens, we limited the document length to its first 512 tokens, though we note that alternative approaches exist (e.g., in [40] the BERT scores across a document's passages/sentences are aggregated).", [["BERT", "PROTEIN", 221, 225], ["a fullyconnected layer", "TREATMENT", 28, 50], ["the [CLS] token embedding", "TREATMENT", 61, 86], ["Retrieval", "TREATMENT", 176, 185], ["the BERT scores", "PROBLEM", 386, 401]]], ["It is clear that BERT is vastly superior to QL with a 40% improvement in nDCG and 25% improvement in MRR.Diagnostic DatasetsGiven the adapted axioms defined in Sect.", [["nDCG", "CANCER", 73, 77], ["nDCG", "TEST", 73, 77], ["MRR", "TEST", 101, 104], ["Diagnostic Datasets", "TEST", 105, 124], ["clear", "OBSERVATION", 6, 11]]], ["3, we now proceed on describing how to extract actual datasets from our corpus.", [["corpus", "ANATOMY", 72, 78], ["corpus", "CANCER", 72, 78], ["corpus", "ANATOMY", 72, 78]]], ["STMC3 We define \u03c3 as the cosine distance between the embeddings of the terms and \u03c3 as the cosine distance between the average embeddings.", [["STMC3", "CHEMICAL", 0, 5], ["STMC3", "CHEMICAL", 0, 5], ["STMC3", "GENE_OR_GENE_PRODUCT", 0, 5], ["\u03c3", "GENE_OR_GENE_PRODUCT", 16, 17], ["STMC3", "PROTEIN", 0, 5], ["\u03c3", "DNA", 16, 17], ["\u03c3", "DNA", 81, 82], ["STMC3", "SPECIES", 0, 5]]], ["We trained the embeddings using GLoVe [23] on the entire corpus.", [["corpus", "ANATOMY", 57, 63], ["corpus", "ORGAN", 57, 63], ["entire", "ANATOMY_MODIFIER", 50, 56], ["corpus", "ANATOMY", 57, 63]]], ["For STMC3, we set \u03b4 = 0.2.ResultsIn Table 2 we list the number of diagnostic instances we created for each diagnostic dataset.", [["STMC3", "DNA", 4, 9], ["STMC3", "TEST", 4, 9]]], ["In addition, we also performed a sanity check on the extent to which the document order determined by each axiom corresponds to the relevance judgements.", [["a sanity check", "TEST", 31, 45]]], ["Although only a small set of instances from each diagnostic dataset contains a document with a relevant document (row II in Table 2) we already see a trend: apart from TFC1 and M-TDC where 91% and 82% of the diagnostic instances have an agreement between axiomatic ordering and relevance ordering, the remaining axioms are actually not in line with the relevance ordering for most of the instances.", [["TFC1", "TEST", 168, 172], ["small", "OBSERVATION_MODIFIER", 16, 21]]], ["This is a first indication that we have to consider an alternative set of axioms, better fit for such a corpus, in future work.ResultsIn Table 3 we report the fraction of instances both QL and BERT fulfil for each diagnostic dataset.", [["corpus", "ANATOMY", 104, 110], ["BERT fulfil", "TREATMENT", 193, 204]]], ["As expected, QL correctly (as per the axiom) ranks the document pairs or triples most of the time, with the only outlier being TP, where QL performs essentially random-again, not a surprise given that QL is a bag-ofwords model.", [["TP", "GENE_OR_GENE_PRODUCT", 127, 129], ["a bag", "TREATMENT", 207, 212]]], ["In contrast-with the exception of LNC2, where BERT's ranking is 11 Note that we only append the document to itself if the final size does not exceed 512.Resultsessentially the opposite of what the LNC2 axiom considers correct (with only 6% of the instances ranked correctly)-BERT has not learnt anything that is related to the axioms as the fraction of correctly ranked instances hovers around 50% (which is essentially randomly picking a document order).", [["LNC2", "DNA", 34, 38], ["BERT", "PROTEIN", 46, 50], ["LNC2 axiom", "DNA", 197, 207], ["BERT", "PROTEIN", 275, 279], ["size", "OBSERVATION_MODIFIER", 128, 132]]], ["Despite this lack of axiomatic fulfilment, BERT clearly outperforms QL, indicating that the existing axioms are not suitable to analyse BERT.", [["BERT", "DNA", 43, 47], ["BERT", "PROTEIN", 136, 140]]], ["The reverse ranking BERT proposes for nearly all of the LNC2 instances can be explained by the way the axiom is phrased.", [["BERT", "DNA", 20, 24], ["LNC2", "DNA", 56, 60]]], ["It is designed to avoid over penalising documents, and thus a duplicated document should always have a retrieval score that is not lower than the original document.", [["a retrieval score", "TEST", 101, 118]]], ["As we did not provide LNC2 instances in the training set, BERT is not able to rank according to the axiom, in line with the findings of other neural approaches as shown by Rennings et al. [25] .ResultsFinally, we observe that, counter-intuitively, BERT does not show a performance better than QL for semantic term matching constraints.", [["neural", "ANATOMY", 142, 148], ["LNC2", "DNA", 22, 26], ["BERT", "PROTEIN", 58, 62], ["BERT", "PROTEIN", 248, 252], ["BERT", "TREATMENT", 58, 62], ["semantic term matching constraints", "PROBLEM", 300, 334]]], ["For instance, one may expect that BERT would fare quite well on STMC1, given its semantic nature.", [["STMC1", "GENE_OR_GENE_PRODUCT", 64, 69], ["BERT", "PROTEIN", 34, 38], ["STMC1", "PROTEIN", 64, 69], ["STMC1", "TREATMENT", 64, 69]]], ["However, our results indicate that BERT is actually considers term matching as one of its key features.", [["BERT", "PROTEIN", 35, 39]]], ["In order to further explore this tension between semantic and syntactic term matching, we split the queries in our test set by their term overlap between the query and the relevant document (if several relevant documents exist for a query, we randomly picked one of them).", [["this tension between semantic and syntactic term matching", "PROBLEM", 28, 85], ["our test", "TEST", 111, 119], ["syntactic term", "OBSERVATION", 62, 76]]], ["We report results for all queries (Fig. 1 (left) ), as well as only those where the relevant document appears in the top-100 QL ranking ( Fig. 1 (right) ).", [["left", "ANATOMY_MODIFIER", 43, 47], ["right", "ANATOMY_MODIFIER", 146, 151]]], ["We find that BERT outperforms QL across all three splits, indicating that BERT is indeed able to pick up the importance of syntactic term matching.", [["BERT", "DNA", 13, 17], ["BERT", "PROTEIN", 74, 78], ["syntactic term matching", "TREATMENT", 123, 146]]], ["At the same time, as expected, BERT is performing significantly better than QL for queries that require a large amount of semantic matching.", [["BERT", "PROTEIN", 31, 35], ["semantic matching", "TREATMENT", 122, 139], ["large", "OBSERVATION_MODIFIER", 106, 111], ["amount", "OBSERVATION_MODIFIER", 112, 118], ["semantic matching", "OBSERVATION", 122, 139]]], ["That brings into question on why, then, the axiomatic performance across our semantic axiomatic datasets does not reflect that.", [["the axiomatic performance", "TEST", 40, 65]]], ["One hypothesis is that the semantic similarity we measure (based on context-free word embeddings) is different to the semantic similarity measured via contextual word embeddings.", [["word embeddings", "OBSERVATION", 162, 177]]], ["On the left, we plot all queries, on the right only those queries for which the relevant document appears in the top-100 ranked documents of the QL ranking.Discussion and ConclusionIn this paper, we set out to analyze BERT with the help of the recently proposed diagnostic datasets for IR based on retrieval heuristics approach [25] .", [["IR", "TREATMENT", 286, 288], ["retrieval heuristics approach", "TREATMENT", 298, 327], ["left", "ANATOMY_MODIFIER", 7, 11]]], ["We expected BERT to perform better at fulfilling some of the proposed semantic axioms.", [["BERT", "PROTEIN", 12, 16], ["semantic axioms", "OBSERVATION", 70, 85]]], ["Instead, we have shown that BERT, while significantly better than traditional models for ad-hoc retrieval, does not fulfil most retrieval heuristics, created by IR experts, that are supposed to produce better results for ad-hoc retrieval models.", [["BERT", "PROTEIN", 28, 32], ["ad-hoc retrieval", "TREATMENT", 89, 105]]], ["In fact, how to arrive at those additional axioms, based on the knowledge we have now gained about BERT is in itself an open question.", [["BERT", "CANCER", 99, 103]]]], "d2017c8be09e7d4e8a79e472234fe532eafbc9eb": [["IntroductionEnteric disease syndromes are a continual economic burden for the poultry industry throughout the world.", [["Enteric disease syndromes", "DISEASE", 12, 37], ["IntroductionEnteric disease syndromes", "PROBLEM", 0, 37], ["Enteric disease", "OBSERVATION", 12, 27]]], ["The major recognized enteric syndromes in poultry are poult enteritis complex (PEC) and poult enteritis mortality syndrome (PEMS) in turkeys and runting-stunting syndrome (RSS) in broiler chickens (Barnes and Guy, 2003; Barnes et al., 2000; Goodwin et al., 1993) .", [["PEC", "ANATOMY", 79, 82], ["enteric syndromes", "DISEASE", 21, 38], ["poult enteritis", "DISEASE", 54, 69], ["PEC", "DISEASE", 79, 82], ["poult enteritis", "DISEASE", 88, 103], ["PEMS", "DISEASE", 124, 128], ["stunting syndrome", "DISEASE", 153, 170], ["RSS", "DISEASE", 172, 175], ["turkeys", "ORGANISM", 133, 140], ["chickens", "ORGANISM", 188, 196], ["turkeys", "SPECIES", 133, 140], ["chickens", "SPECIES", 188, 196], ["turkeys", "SPECIES", 133, 140], ["chickens", "SPECIES", 188, 196], ["The major recognized enteric syndromes", "PROBLEM", 0, 38], ["poult enteritis complex", "PROBLEM", 54, 77], ["poult enteritis mortality syndrome", "PROBLEM", 88, 122], ["stunting syndrome", "PROBLEM", 153, 170], ["enteric syndromes", "OBSERVATION", 21, 38], ["enteritis", "OBSERVATION", 60, 69], ["enteritis", "OBSERVATION_MODIFIER", 94, 103], ["mortality syndrome", "OBSERVATION", 104, 122], ["stunting syndrome", "OBSERVATION", 153, 170]]], ["Poultry enteric disease is marked by diarrhea, stunting, and increased time to market; the more severe forms of enteric disease are characterized by immune dysfunction and increased mortality.IntroductionNumerous viruses have been detected in or isolated from the intestinal tract of poultry (both diseased and healthy), and have subsequently been implicated in poultry enteric disease.", [["intestinal tract", "ANATOMY", 264, 280], ["enteric disease", "DISEASE", 8, 23], ["diarrhea", "DISEASE", 37, 45], ["stunting", "DISEASE", 47, 55], ["enteric disease", "DISEASE", 112, 127], ["immune dysfunction", "DISEASE", 149, 167], ["poultry enteric disease", "DISEASE", 362, 385], ["intestinal tract", "ORGANISM_SUBDIVISION", 264, 280], ["poultry", "SPECIES", 284, 291], ["poultry", "SPECIES", 362, 369], ["Poultry enteric disease", "PROBLEM", 0, 23], ["diarrhea", "PROBLEM", 37, 45], ["stunting", "PROBLEM", 47, 55], ["enteric disease", "PROBLEM", 112, 127], ["immune dysfunction", "PROBLEM", 149, 167], ["increased mortality", "PROBLEM", 172, 191], ["Numerous viruses", "PROBLEM", 204, 220], ["poultry enteric disease", "PROBLEM", 362, 385], ["enteric", "OBSERVATION_MODIFIER", 8, 15], ["disease", "OBSERVATION", 16, 23], ["marked", "OBSERVATION_MODIFIER", 27, 33], ["diarrhea", "OBSERVATION", 37, 45], ["stunting", "OBSERVATION", 47, 55], ["increased", "OBSERVATION_MODIFIER", 61, 70], ["more severe", "OBSERVATION_MODIFIER", 91, 102], ["enteric disease", "OBSERVATION", 112, 127], ["immune dysfunction", "OBSERVATION", 149, 167], ["increased", "OBSERVATION_MODIFIER", 172, 181], ["mortality", "OBSERVATION_MODIFIER", 182, 191], ["viruses", "OBSERVATION", 213, 220], ["intestinal tract", "ANATOMY", 264, 280], ["poultry enteric disease", "OBSERVATION", 362, 385]]], ["These viruses include the avian reoviruses, rotaviruses, astroviruses and coronaviruses; despite these diagnostic efforts and viral descriptions, the role these viruses play in the enteric syndromes are still poorly understood (Guy, 1998; Pantin-Jackwood et al., 2008a; Pantin-Jackwood et al., 2007a; Pantin-Jackwood et al., 2008b; Pantin-Jackwood et al., 2007b; Reynolds et al., 1987; Spackman et al., 2005) .IntroductionWe recently reported the use of a molecular screening protocol to amplify and identify novel enteric viruses in the intestinal tract of poultry showing characteristic enteric disease signs (Zsak et al., 2008) .", [["intestinal tract", "ANATOMY", 538, 554], ["avian reoviruses", "DISEASE", 26, 42], ["astroviruses", "DISEASE", 57, 69], ["coronaviruses", "DISEASE", 74, 87], ["enteric syndromes", "DISEASE", 181, 198], ["enteric viruses", "DISEASE", 515, 530], ["enteric disease", "DISEASE", 589, 604], ["avian reoviruses", "ORGANISM", 26, 42], ["intestinal tract", "ORGANISM_SUBDIVISION", 538, 554], ["avian", "SPECIES", 26, 31], ["poultry", "SPECIES", 558, 565], ["These viruses", "PROBLEM", 0, 13], ["the avian reoviruses", "PROBLEM", 22, 42], ["rotaviruses", "PROBLEM", 44, 55], ["astroviruses", "PROBLEM", 57, 69], ["coronaviruses", "PROBLEM", 74, 87], ["the enteric syndromes", "PROBLEM", 177, 198], ["a molecular screening protocol", "TEST", 454, 484], ["novel enteric viruses", "PROBLEM", 509, 530], ["characteristic enteric disease signs", "PROBLEM", 574, 610], ["viruses", "OBSERVATION", 6, 13], ["enteric syndromes", "ANATOMY", 181, 198], ["viruses", "OBSERVATION", 523, 530], ["intestinal tract", "ANATOMY", 538, 554], ["enteric disease", "OBSERVATION", 589, 604]]], ["This random amplification of viral particle-associated nucleic acid identified numerous parvovirus DNA sequences directly from the intestinal homogenates of chickens with signs of enteric disease.", [["intestinal homogenates", "ANATOMY", 131, 153], ["nucleic acid", "CHEMICAL", 55, 67], ["enteric disease", "DISEASE", 180, 195], ["parvovirus", "ORGANISM", 88, 98], ["DNA", "CELLULAR_COMPONENT", 99, 102], ["intestinal homogenates", "ORGAN", 131, 153], ["chickens", "ORGANISM", 157, 165], ["parvovirus DNA sequences", "DNA", 88, 112], ["chickens", "SPECIES", 157, 165], ["parvovirus", "SPECIES", 88, 98], ["chickens", "SPECIES", 157, 165], ["viral particle", "PROBLEM", 29, 43], ["nucleic acid", "PROBLEM", 55, 67], ["numerous parvovirus DNA sequences", "PROBLEM", 79, 112], ["enteric disease", "PROBLEM", 180, 195], ["viral particle", "OBSERVATION", 29, 43], ["nucleic acid", "OBSERVATION", 55, 67], ["parvovirus DNA", "OBSERVATION", 88, 102], ["intestinal", "ANATOMY", 131, 141], ["enteric disease", "OBSERVATION", 180, 195]]], ["Initial analysis of this chicken-origin parvovirus (ChPV) revealed that it is a novel member of the Parvovirinae subfamily within the Parvoviridae, and led to the development of a specific molecular diagnostic test targeting the ChPV non-structural (NS) gene (Zsak et al., 2009) .IntroductionParvoviruses have been described that infect a wide range of invertebrates and vertebrates, and a thorough knowledge of the parvovirus genome and encoded proteins is essential to an understanding of the evolution of parvoviruses in various hosts, including tissue tropism during viral pathogenesis (Hueffer and Parrish, 2003) .", [["tissue", "ANATOMY", 549, 555], ["chicken-origin parvovirus", "ORGANISM", 25, 50], ["ChPV", "ORGANISM", 52, 56], ["Parvovirinae", "GENE_OR_GENE_PRODUCT", 100, 112], ["ChPV", "GENE_OR_GENE_PRODUCT", 229, 233], ["Parvoviruses", "GENE_OR_GENE_PRODUCT", 292, 304], ["parvovirus", "ORGANISM", 416, 426], ["parvoviruses", "ORGANISM", 508, 520], ["tissue", "TISSUE", 549, 555], ["Parvovirinae subfamily", "PROTEIN", 100, 122], ["ChPV non-structural (NS) gene", "DNA", 229, 258], ["parvovirus genome", "DNA", 416, 433], ["chicken", "SPECIES", 25, 32], ["chicken-origin parvovirus", "SPECIES", 25, 50], ["ChPV", "SPECIES", 52, 56], ["parvovirus", "SPECIES", 416, 426], ["Initial analysis", "TEST", 0, 16], ["parvovirus", "PROBLEM", 40, 50], ["the ChPV non-structural (NS)", "TREATMENT", 225, 253], ["IntroductionParvoviruses", "PROBLEM", 280, 304], ["the parvovirus genome", "PROBLEM", 412, 433], ["parvoviruses in various hosts", "PROBLEM", 508, 537], ["tissue tropism", "PROBLEM", 549, 563], ["viral pathogenesis", "PROBLEM", 571, 589], ["wide", "OBSERVATION_MODIFIER", 339, 343], ["parvovirus genome", "OBSERVATION", 416, 433], ["parvoviruses", "OBSERVATION", 508, 520]]], ["Parvoviruses are well known for causing enteric disease in mammals, with the canine parvoviruses recently emerging as important pathogens in the 1970s (Decaro et al., 2009; Truyen, 1999) .", [["Parvoviruses", "DISEASE", 0, 12], ["enteric disease", "DISEASE", 40, 55], ["canine parvoviruses", "ORGANISM", 77, 96], ["canine", "SPECIES", 77, 83], ["canine", "SPECIES", 77, 83], ["Parvoviruses", "PROBLEM", 0, 12], ["enteric disease in mammals", "PROBLEM", 40, 66], ["the canine parvoviruses", "PROBLEM", 73, 96], ["disease", "OBSERVATION", 48, 55]]], ["Parvoviruses have been known for years as the causative agent of Derzsy's disease in young geese, and are also found in Muscovy ducks, where they cause multiple clinical signs ranging from enteritis to hepatitis and infectious myocarditis (Gough, 2008) .", [["Parvoviruses", "DISEASE", 0, 12], ["Derzsy's disease", "DISEASE", 65, 81], ["enteritis", "DISEASE", 189, 198], ["hepatitis", "DISEASE", 202, 211], ["infectious myocarditis", "DISEASE", 216, 238], ["geese", "ORGANISM", 91, 96], ["Muscovy ducks", "ORGANISM", 120, 133], ["Muscovy ducks", "SPECIES", 120, 133], ["Muscovy ducks", "SPECIES", 120, 133], ["Parvoviruses", "PROBLEM", 0, 12], ["Derzsy's disease", "PROBLEM", 65, 81], ["multiple clinical signs", "PROBLEM", 152, 175], ["enteritis", "PROBLEM", 189, 198], ["hepatitis", "PROBLEM", 202, 211], ["infectious myocarditis", "PROBLEM", 216, 238], ["enteritis", "OBSERVATION", 189, 198], ["hepatitis", "OBSERVATION", 202, 211], ["infectious", "OBSERVATION_MODIFIER", 216, 226], ["myocarditis", "OBSERVATION", 227, 238]]], ["Parvoviruses have been previously described in chickens based upon their morphology via electron microscopy and upon their genome size Kisary et al., 1984) , and enteric disease signs have been attributed to parvovirus-like particles detected in turkey intestinal tracts (Trampel et al., 1983) .", [["intestinal tracts", "ANATOMY", 253, 270], ["enteric disease", "DISEASE", 162, 177], ["chickens", "ORGANISM", 47, 55], ["parvovirus-like particles", "ORGANISM", 208, 233], ["turkey", "ORGANISM", 246, 252], ["intestinal tracts", "MULTI-TISSUE_STRUCTURE", 253, 270], ["chickens", "SPECIES", 47, 55], ["turkey", "SPECIES", 246, 252], ["chickens", "SPECIES", 47, 55], ["turkey", "SPECIES", 246, 252], ["Parvoviruses", "PROBLEM", 0, 12], ["electron microscopy", "TEST", 88, 107], ["enteric disease signs", "PROBLEM", 162, 183], ["parvovirus", "PROBLEM", 208, 218], ["like particles", "PROBLEM", 219, 233], ["enteric", "ANATOMY", 162, 169], ["disease", "OBSERVATION", 170, 177], ["parvovirus", "OBSERVATION", 208, 218], ["intestinal tracts", "ANATOMY", 253, 270]]], ["A recent diagnostic survey of enteric samples collected from United States turkey and chicken flocks revealed widespread presence of parvovirus in U.S. poultry (Zsak et al., 2009) .", [["enteric samples", "ANATOMY", 30, 45], ["parvovirus", "DISEASE", 133, 143], ["enteric samples", "CANCER", 30, 45], ["turkey", "ORGANISM", 75, 81], ["chicken", "ORGANISM", 86, 93], ["parvovirus", "ORGANISM", 133, 143], ["turkey", "SPECIES", 75, 81], ["chicken", "SPECIES", 86, 93], ["turkey", "SPECIES", 75, 81], ["chicken", "SPECIES", 86, 93], ["enteric samples", "TEST", 30, 45], ["parvovirus", "PROBLEM", 133, 143], ["enteric", "ANATOMY", 30, 37], ["parvovirus", "OBSERVATION", 133, 143]]], ["This is the first indepth molecular characterization and analysis of the full-length genome sequence of ChPV.", [["ChPV", "GENE_OR_GENE_PRODUCT", 104, 108], ["full-length genome sequence", "DNA", 73, 100], ["ChPV", "DNA", 104, 108]]], ["The analysis includes comparisons to other members of the Parvovirinae that infect mammals and birds, including two novel turkey-origin parvoviruses (TuPV) recently sequenced using a similar molecular approach.IntroductionVirology 399 (2010) 59-64ResultsThe ChPV ABU-P1 genomeResultsThe fully assembled ChPV ABU-P1 genome is 5257 nucleotides (nt) in length and has a basic organization similar to previously described members of the Parvoviridae (Fig. 1) .", [["nucleotides", "CHEMICAL", 330, 341], ["Parvovirinae", "GENE_OR_GENE_PRODUCT", 58, 70], ["birds", "ORGANISM", 95, 100], ["turkey-origin parvoviruses", "ORGANISM", 122, 148], ["TuPV", "ORGANISM", 150, 154], ["ChPV", "GENE_OR_GENE_PRODUCT", 303, 307], ["ChPV ABU-P1 genomeResults", "DNA", 258, 283], ["ChPV ABU-P1 genome", "DNA", 303, 321], ["5257 nucleotides", "DNA", 325, 341], ["turkey", "SPECIES", 122, 128], ["turkey-origin parvoviruses", "SPECIES", 122, 148], ["TuPV", "SPECIES", 150, 154], ["The analysis", "TEST", 0, 12], ["a similar molecular approach", "TREATMENT", 181, 209], ["nucleotides (nt) in length", "PROBLEM", 330, 356], ["a basic organization", "PROBLEM", 365, 385], ["the Parvoviridae (Fig", "TREATMENT", 429, 450]]], ["The genome is flanked on the 5\u2032 and 3\u2032 ends by 206 nt direct repeat sequences, each of which contains 39 nt inverted repeats presumed to form a hairpin structure similar to the structures common in the parvoviruses (Fig. 2) (Farkas et al., 2004; Muzyczka and Berns, 2001; Sukhumsirichart et al., 2006) .", [["parvoviruses", "ORGANISM", 202, 214], ["5\u2032 and 3\u2032 ends", "DNA", 29, 43], ["206 nt direct repeat sequences", "DNA", 47, 77], ["39 nt inverted repeats", "DNA", 102, 124], ["nt direct repeat sequences", "TEST", 51, 77], ["39 nt inverted repeats", "PROBLEM", 102, 124], ["a hairpin structure", "PROBLEM", 142, 161], ["genome", "OBSERVATION", 4, 10], ["flanked", "OBSERVATION_MODIFIER", 14, 21], ["hairpin", "OBSERVATION", 144, 151], ["parvoviruses", "OBSERVATION", 202, 214]]], ["The 206 nt direct repeats are identical and are found in the same orientation 5\u2032 to 3\u2032 in the genome.", [["3", "GENE_OR_GENE_PRODUCT", 84, 85], ["206 nt direct repeats", "DNA", 4, 25], ["5\u2032 to 3\u2032", "DNA", 78, 86], ["The 206 nt direct repeats", "TEST", 0, 25], ["genome", "ANATOMY", 94, 100]]], ["The genome contains 32.36% A, 21.95% G, 24.08% T, and 21.61% C, with an A + T content of 56.44% and a C + G content of 43.56%.", [["C + G", "SIMPLE_CHEMICAL", 102, 107], ["G", "TEST", 37, 38], ["T", "TEST", 47, 48], ["a C + G content", "TEST", 100, 115]]], ["The overall genomic organization of ChPV ABU-P1 is similar to other parvoviruses, with two major predicted open reading frames (ORFs).", [["ChPV ABU-P1", "GENE_OR_GENE_PRODUCT", 36, 47], ["ChPV ABU", "DNA", 36, 44], ["P1", "DNA", 45, 47], ["open reading frames", "DNA", 107, 126], ["ORFs", "DNA", 128, 132], ["other parvoviruses", "PROBLEM", 62, 80], ["overall", "OBSERVATION_MODIFIER", 4, 11], ["genomic", "OBSERVATION_MODIFIER", 12, 19], ["organization", "OBSERVATION_MODIFIER", 20, 32], ["parvoviruses", "OBSERVATION", 68, 80]]], ["The 5\u2032 ORF is 2085 nt long, and a blastx search using the putative amino acid sequence revealed a protein similar to the Parvoviridae non-structural (NS) proteins NS1, with the greatest similarity to human bocavirus NS1.", [["amino acid", "CHEMICAL", 67, 77], ["amino acid", "CHEMICAL", 67, 77], ["amino acid", "AMINO_ACID", 67, 77], ["Parvoviridae non-structural (NS)", "GENE_OR_GENE_PRODUCT", 121, 153], ["NS1", "GENE_OR_GENE_PRODUCT", 163, 166], ["human", "ORGANISM", 200, 205], ["bocavirus NS1", "ORGANISM", 206, 219], ["5\u2032 ORF", "DNA", 4, 10], ["Parvoviridae non-structural (NS) proteins", "PROTEIN", 121, 162], ["NS1", "PROTEIN", 163, 166], ["human bocavirus NS1", "PROTEIN", 200, 219], ["human", "SPECIES", 200, 205], ["human bocavirus NS1", "SPECIES", 200, 219], ["a blastx search", "TEST", 32, 47], ["the putative amino acid sequence", "TEST", 54, 86], ["a protein", "PROBLEM", 96, 105], ["the Parvoviridae non-structural (NS) proteins NS1", "TREATMENT", 117, 166], ["human bocavirus NS1", "TREATMENT", 200, 219], ["bocavirus NS1", "OBSERVATION", 206, 219]]], ["The major 3\u2032 ORF is 2028 nt long, and encodes a protein similar to the Parvoviridae capsid protein VP1, with the greatest similarity to avian adeno-associated virus, a member of the Dependovirus genus.", [["avian adeno-associated virus", "DISEASE", 136, 164], ["VP1", "GENE_OR_GENE_PRODUCT", 99, 102], ["avian", "ORGANISM", 136, 141], ["adeno-associated virus", "ORGANISM", 142, 164], ["Dependovirus genus", "ORGANISM", 182, 200], ["major 3\u2032 ORF", "DNA", 4, 16], ["2028 nt long", "DNA", 20, 32], ["Parvoviridae capsid protein VP1", "PROTEIN", 71, 102], ["avian adeno-associated virus", "SPECIES", 136, 164], ["avian adeno-associated virus", "SPECIES", 136, 164], ["a protein", "TEST", 46, 55], ["the Parvoviridae capsid protein VP1", "TREATMENT", 67, 102], ["avian adeno-associated virus", "PROBLEM", 136, 164], ["adeno-associated virus", "OBSERVATION", 142, 164]]], ["The ChPV genome also contains a small (306 nt) ORF located between the major 5\u2032 and 3\u2032 ORFs.", [["ChPV", "GENE_OR_GENE_PRODUCT", 4, 8], ["ChPV genome", "DNA", 4, 15], ["ORF", "DNA", 47, 50], ["major 5\u2032 and 3\u2032", "DNA", 71, 86], ["ORFs", "DNA", 87, 91], ["a small (306 nt) ORF", "PROBLEM", 30, 50], ["ChPV genome", "OBSERVATION", 4, 15], ["small", "OBSERVATION_MODIFIER", 32, 37]]], ["This ORF shows no homology to known protein coding regions in the databases.NS1The ChPV NS1 ORF is preceded upstream by the 39 bp inverted repeat sequence.", [["NS1", "GENE_OR_GENE_PRODUCT", 76, 79], ["ChPV NS1", "GENE_OR_GENE_PRODUCT", 83, 91], ["ORF", "DNA", 5, 8], ["protein coding regions", "DNA", 36, 58], ["NS1", "PROTEIN", 76, 79], ["ChPV NS1 ORF", "DNA", 83, 95], ["39 bp inverted repeat sequence", "DNA", 124, 154], ["This ORF", "TEST", 0, 8], ["The ChPV NS1 ORF", "TREATMENT", 79, 95], ["bp inverted repeat sequence", "TEST", 127, 154], ["no", "UNCERTAINTY", 15, 17], ["NS1 ORF", "OBSERVATION", 88, 95]]], ["The NS1 start codon is in a strong Kozak context (AAGATGG) and is preceded directly upstream by a TATA box, an extended CAAT box, and a putative Inr-box (Hernandez, 1993; Rupp et al., 1990; Smale and Kadonaga, 2003) .", [["NS1", "GENE_OR_GENE_PRODUCT", 4, 7], ["NS1 start codon", "DNA", 4, 19], ["Kozak context", "DNA", 35, 48], ["TATA box", "DNA", 98, 106], ["CAAT box", "DNA", 120, 128], ["Inr-box", "DNA", 145, 152], ["The NS1 start codon", "PROBLEM", 0, 19], ["a TATA box", "TREATMENT", 96, 106], ["an extended CAAT box", "TREATMENT", 108, 128]]], ["NS1 also contains a wellconserved phosphate-binding loop (P-loop) motif (GXXXXGKT\u2026EE), distinguishing it as a member of the ATP and GTP-binding superfamily of proteins (Saraste et al., 1990 ).", [["phosphate", "CHEMICAL", 34, 43], ["ATP", "CHEMICAL", 124, 127], ["GTP", "CHEMICAL", 132, 135], ["phosphate", "CHEMICAL", 34, 43], ["ATP", "CHEMICAL", 124, 127], ["GTP", "CHEMICAL", 132, 135], ["NS1", "GENE_OR_GENE_PRODUCT", 0, 3], ["ATP", "SIMPLE_CHEMICAL", 124, 127], ["GTP", "SIMPLE_CHEMICAL", 132, 135], ["NS1", "PROTEIN", 0, 3], ["wellconserved phosphate-binding loop (P-loop) motif", "PROTEIN", 20, 71], ["GXXXXGKT", "PROTEIN", 73, 81], ["EE", "PROTEIN", 82, 84], ["ATP and GTP-binding superfamily", "PROTEIN", 124, 155], ["NS1", "PROBLEM", 0, 3], ["a wellconserved phosphate-binding loop (P-loop) motif", "TREATMENT", 18, 71], ["binding loop", "OBSERVATION", 44, 56]]], ["At the amino acid level, the ChPV NS1 protein exhibited from 45.2 to 53.9% amino acid similarity (17.1 to 19.0% identity) with NS1 from other parvovirus isolates.", [["amino acid", "CHEMICAL", 7, 17], ["amino acid", "CHEMICAL", 75, 85], ["amino acid", "CHEMICAL", 7, 17], ["amino acid", "CHEMICAL", 75, 85], ["amino acid", "AMINO_ACID", 7, 17], ["ChPV NS1", "GENE_OR_GENE_PRODUCT", 29, 37], ["amino acid", "AMINO_ACID", 75, 85], ["NS1", "GENE_OR_GENE_PRODUCT", 127, 130], ["parvovirus", "ORGANISM", 142, 152], ["ChPV NS1 protein", "PROTEIN", 29, 45], ["NS1", "PROTEIN", 127, 130], ["the amino acid level", "TEST", 3, 23], ["the ChPV NS1 protein", "TEST", 25, 45], ["amino acid similarity", "TEST", 75, 96], ["NS1", "PROBLEM", 127, 130], ["other parvovirus isolates", "PROBLEM", 136, 161]]], ["The NS1 similarity increased to 89.3 and 100% (99.3 to 83.7% identity) when ChPV was compared with two turkey-origin parvoviruses (TuPV), TuPV 260 and TuPV 1078 respectively.", [["NS1", "GENE_OR_GENE_PRODUCT", 4, 7], ["parvoviruses", "ORGANISM", 117, 129], ["TuPV", "ORGANISM", 131, 135], ["NS1", "PROTEIN", 4, 7], ["TuPV 1078", "DNA", 151, 160], ["turkey", "SPECIES", 103, 109], ["ChPV", "SPECIES", 76, 80], ["turkey-origin parvoviruses", "SPECIES", 103, 129], ["TuPV", "SPECIES", 131, 135], ["TuPV 1078", "SPECIES", 151, 160], ["The NS1 similarity", "TEST", 0, 18], ["TuPV", "TEST", 138, 142], ["increased", "OBSERVATION_MODIFIER", 19, 28]]], ["The lower identity noted when comparing the ChPV and TuPV 1078 NS1 coding sequences can be partially explained by the presence of a stop codon beginning at position 1882 in the TuPV 1078 NS1 coding region.VP1The predicted VP1 ORF begins at position 2998 in the ChPV genome.", [["ChPV", "GENE_OR_GENE_PRODUCT", 44, 48], ["VP1", "GENE_OR_GENE_PRODUCT", 205, 208], ["VP1", "GENE_OR_GENE_PRODUCT", 222, 225], ["ChPV and TuPV 1078 NS1 coding sequences", "DNA", 44, 83], ["stop codon", "DNA", 132, 142], ["TuPV 1078 NS1 coding region", "DNA", 177, 204], ["VP1", "DNA", 205, 208], ["VP1 ORF", "DNA", 222, 229], ["position 2998", "DNA", 240, 253], ["ChPV genome", "DNA", 261, 272], ["The lower identity", "PROBLEM", 0, 18], ["the ChPV", "TEST", 40, 48], ["a stop codon", "PROBLEM", 130, 142], ["VP1", "TEST", 205, 208], ["The predicted VP1 ORF", "TEST", 208, 229], ["lower", "OBSERVATION_MODIFIER", 4, 9], ["VP1 ORF", "OBSERVATION", 222, 229], ["ChPV genome", "OBSERVATION", 261, 272]]], ["The predicted VP1 start codon (ATG) overlaps with the stop codon (AAT) of the predicted 306 nt ORF located between the ChPV NS1 and VP1 ORFs.", [["VP1", "GENE_OR_GENE_PRODUCT", 14, 17], ["AAT", "GENE_OR_GENE_PRODUCT", 66, 69], ["ChPV NS1", "GENE_OR_GENE_PRODUCT", 119, 127], ["VP1", "GENE_OR_GENE_PRODUCT", 132, 135], ["VP1 start codon", "DNA", 14, 29], ["stop codon", "DNA", 54, 64], ["AAT", "DNA", 66, 69], ["306 nt ORF", "DNA", 88, 98], ["ChPV NS1 and VP1 ORFs", "DNA", 119, 140], ["The predicted VP1", "TREATMENT", 0, 17], ["codon (ATG", "TREATMENT", 24, 34], ["nt ORF", "PROBLEM", 92, 98], ["the ChPV NS1", "TREATMENT", 115, 127], ["VP1 ORFs", "OBSERVATION", 132, 140]]], ["VP1 is preceded upstream by a TATA box and a polyadenylation signal (AATAAA) follows the ORF; this poly-A signal immediately precedes the 39 nt inverted repeat at the 5\u2032 end of the genome.", [["VP1", "GENE_OR_GENE_PRODUCT", 0, 3], ["poly-A", "GENE_OR_GENE_PRODUCT", 99, 105], ["genome", "CELLULAR_COMPONENT", 181, 187], ["VP1", "DNA", 0, 3], ["TATA box", "DNA", 30, 38], ["polyadenylation signal", "DNA", 45, 67], ["AATAAA", "DNA", 69, 75], ["ORF", "DNA", 89, 92], ["poly-A signal", "DNA", 99, 112], ["39 nt inverted repeat", "DNA", 138, 159], ["5\u2032 end", "DNA", 167, 173], ["VP1", "PROBLEM", 0, 3], ["a TATA box", "TEST", 28, 38], ["a polyadenylation signal", "TEST", 43, 67], ["this poly", "TEST", 94, 103], ["polyadenylation signal", "OBSERVATION", 45, 67], ["genome", "OBSERVATION", 181, 187]]], ["One of two downstream ATG codons that begin 417 and 420 nt downstream to the start of the putative VP1 ORF may serve as the start codon for a VP2 capsid protein that shares a stop codon (TAA) with VP1.", [["TAA", "DISEASE", 187, 190], ["ATG", "GENE_OR_GENE_PRODUCT", 22, 25], ["VP1", "GENE_OR_GENE_PRODUCT", 99, 102], ["ATG codons", "DNA", 22, 32], ["417 and 420 nt downstream", "DNA", 44, 69], ["putative VP1 ORF", "DNA", 90, 106], ["start codon", "DNA", 124, 135], ["VP2 capsid protein", "PROTEIN", 142, 160], ["stop codon", "DNA", 175, 185], ["VP1", "PROTEIN", 197, 200], ["two downstream ATG codons", "TREATMENT", 7, 32], ["the putative VP1 ORF", "TREATMENT", 86, 106], ["a VP2 capsid protein", "TREATMENT", 140, 160], ["VP1", "PROBLEM", 197, 200], ["ATG codons", "OBSERVATION", 22, 32]]], ["The second of these ATG codons has the stronger Kozak consensus sequence (ATGATGG) compared to the translation initiation context of the first codon (GAAATGA) and remains in frame (Kozak, 1987) .", [["ATG codons", "DNA", 20, 30], ["Kozak consensus sequence", "DNA", 48, 72], ["first codon", "DNA", 137, 148], ["GAAATGA", "DNA", 150, 157], ["these ATG codons", "TREATMENT", 14, 30], ["ATG codons", "OBSERVATION", 20, 30]]], ["A third start codon with a favorable translation initiation context (GACATGG) is present at position 3067 in the ChPV genome, and may represent the beginning of a putative VP3 ORF as has been described in the goose and Muscovy duck parvoviruses (Zadori et al., 1995) .", [["GACATGG", "GENE_OR_GENE_PRODUCT", 69, 76], ["ChPV", "GENE_OR_GENE_PRODUCT", 113, 117], ["VP3", "GENE_OR_GENE_PRODUCT", 172, 175], ["goose", "ORGANISM", 209, 214], ["Muscovy duck", "ORGANISM", 219, 231], ["parvoviruses", "ORGANISM", 232, 244], ["third start codon", "DNA", 2, 19], ["position 3067", "DNA", 92, 105], ["ChPV genome", "DNA", 113, 124], ["VP3 ORF", "DNA", 172, 179], ["goose", "SPECIES", 209, 214], ["Muscovy duck", "SPECIES", 219, 231], ["Muscovy duck parvoviruses", "SPECIES", 219, 244], ["A third start codon", "TREATMENT", 0, 19], ["a putative VP3 ORF", "PROBLEM", 161, 179], ["ChPV genome", "OBSERVATION", 113, 124], ["may represent", "UNCERTAINTY", 130, 143]]], ["The ChPV VP1 protein shares from 46.6 to 59.0% amino acid similarity (10.1 to 24.5% identity) with VP1 from other parvoviruses.", [["amino acid", "CHEMICAL", 47, 57], ["amino acid", "CHEMICAL", 47, 57], ["ChPV VP1", "GENE_OR_GENE_PRODUCT", 4, 12], ["amino acid", "AMINO_ACID", 47, 57], ["VP1", "GENE_OR_GENE_PRODUCT", 99, 102], ["ChPV VP1 protein", "PROTEIN", 4, 20], ["VP1", "PROTEIN", 99, 102], ["The ChPV VP1 protein", "TEST", 0, 20], ["amino acid similarity", "TEST", 47, 68], ["VP1 from other parvoviruses", "PROBLEM", 99, 126], ["parvoviruses", "OBSERVATION", 114, 126]]], ["The VP1 similarity increases to 100 and 95.1% (99.7 and 79.2% identity) when compared to VP1 from TuPV 260 and TuPV 1078, respectively.Phylogenetic analysisClustalW was used to align the complete ChPV genome coding region with complete parvovirus sequences from mammals and birds available in the databases, and with two recently sequenced TuPV genome coding regions.", [["VP1", "GENE_OR_GENE_PRODUCT", 4, 7], ["parvovirus", "ORGANISM", 236, 246], ["VP1", "DNA", 89, 92], ["ChPV genome coding region", "DNA", 196, 221], ["parvovirus sequences", "DNA", 236, 256], ["TuPV genome coding regions", "DNA", 340, 366], ["The VP1 similarity", "TEST", 0, 18], ["VP1", "TEST", 89, 92], ["TuPV", "TEST", 98, 102], ["TuPV", "TEST", 111, 115], ["Phylogenetic analysisClustalW", "PROBLEM", 135, 164], ["complete parvovirus sequences", "TEST", 227, 256], ["increases", "OBSERVATION_MODIFIER", 19, 28], ["ChPV genome", "OBSERVATION", 196, 207], ["parvovirus", "OBSERVATION", 236, 246]]], ["The Neighbor-Joining tree was produced using MEGA4.", [["Neighbor-Joining tree", "DNA", 4, 25], ["MEGA4", "PROTEIN", 45, 50], ["MEGA4", "TREATMENT", 45, 50], ["tree", "ANATOMY_MODIFIER", 21, 25]]], ["The turkey and chicken sequences clustered together, and were clearly separate from the other members of the Parvovirinae (Fig. 3) .", [["turkey", "ORGANISM", 4, 10], ["chicken", "ORGANISM", 15, 22], ["turkey and chicken sequences", "DNA", 4, 32], ["turkey", "SPECIES", 4, 10], ["chicken", "SPECIES", 15, 22], ["turkey", "SPECIES", 4, 10], ["chicken", "SPECIES", 15, 22]]], ["A previous phylogenetic analysis using a conserved region of the ChPV and TuPV NS1 gene produced a similar tree (Zsak et al., 2008) , and a phylogenetic analysis of the ChPV and TuPV VP1 gene produced an identical tree when compared to the full-length parvovirus coding region (data not shown).DiscussionThis is the first analysis of the complete nucleotide sequence from the ChPV ABU-P1 strain.", [["nucleotide", "CHEMICAL", 347, 357], ["nucleotide", "CHEMICAL", 347, 357], ["ChPV", "GENE_OR_GENE_PRODUCT", 65, 69], ["TuPV NS1", "GENE_OR_GENE_PRODUCT", 74, 82], ["ChPV", "GENE_OR_GENE_PRODUCT", 169, 173], ["TuPV VP1", "GENE_OR_GENE_PRODUCT", 178, 186], ["parvovirus", "ORGANISM", 252, 262], ["ChPV and TuPV NS1 gene", "DNA", 65, 87], ["ChPV and TuPV VP1 gene", "DNA", 169, 191], ["full-length parvovirus coding region", "DNA", 240, 276], ["ChPV ABU-P1 strain", "DNA", 376, 394], ["A previous phylogenetic analysis", "TEST", 0, 32], ["the ChPV", "TREATMENT", 61, 69], ["a phylogenetic analysis", "TEST", 138, 161], ["the ChPV", "TREATMENT", 165, 173], ["TuPV VP1 gene", "TREATMENT", 178, 191], ["the complete nucleotide sequence", "TEST", 334, 366], ["tree", "OBSERVATION_MODIFIER", 214, 218]]], ["Small viral particles (15 to about 25 nm) resembling parvovirus have been identified for years in the intestinal tracts of poultry (Kisary et al., 1984; Trampel et al., 1983; Woolcock and Shivaprasad, 2008) .", [["intestinal tracts", "ANATOMY", 102, 119], ["parvovirus", "DISEASE", 53, 63], ["parvovirus", "ORGANISM", 53, 63], ["intestinal tracts", "MULTI-TISSUE_STRUCTURE", 102, 119], ["Small viral particles", "PROBLEM", 0, 21], ["parvovirus", "PROBLEM", 53, 63], ["viral particles", "OBSERVATION", 6, 21], ["parvovirus", "OBSERVATION", 53, 63], ["intestinal tracts", "ANATOMY", 102, 119]]], ["The use of a particle-associated nucleic acid (PAN) sequencing technique has recently allowed the partial molecular characterization of this novel ChPV (Zsak et al., 2008) , and led to the identification and sequencing of two additional avian parvoviruses from turkeys: TuPV 260, originally detected in the intestinal tract of a turkey from California, and TuPV 1078, originally detected in the pooled intestinal tracts from a North Carolina turkey farm.", [["intestinal tract", "ANATOMY", 307, 323], ["intestinal tracts", "ANATOMY", 402, 419], ["nucleic acid", "CHEMICAL", 33, 45], ["PAN", "CHEMICAL", 47, 50], ["avian parvoviruses", "DISEASE", 237, 255], ["TuPV 260", "CHEMICAL", 270, 278], ["TuPV 1078", "CHEMICAL", 357, 366], ["nucleic acid", "SIMPLE_CHEMICAL", 33, 45], ["avian parvoviruses", "ORGANISM", 237, 255], ["turkeys", "ORGANISM", 261, 268], ["TuPV 260", "ORGANISM", 270, 278], ["intestinal tract", "ORGAN", 307, 323], ["turkey", "ORGANISM", 329, 335], ["TuPV 1078", "CELL", 357, 366], ["intestinal tracts", "MULTI-TISSUE_STRUCTURE", 402, 419], ["turkeys", "SPECIES", 261, 268], ["turkey", "SPECIES", 329, 335], ["turkey", "SPECIES", 442, 448], ["turkey", "SPECIES", 329, 335], ["TuPV 1078", "SPECIES", 357, 366], ["a particle-associated nucleic acid (PAN) sequencing technique", "TREATMENT", 11, 72], ["TuPV", "TREATMENT", 270, 274], ["intestinal tract", "ANATOMY", 307, 323], ["intestinal tracts", "ANATOMY", 402, 419]]], ["All three of these poultry isolates are very similar to each other, yet each differs significantly from other members of the Parvovirinae.", [["Parvovirinae", "GENE_OR_GENE_PRODUCT", 125, 137]]], ["The high amino acid identities noted among the turkey and chicken isolates suggests that they diverged at sometime in the recent past from a common ancestor.", [["amino acid", "CHEMICAL", 9, 19], ["amino acid", "CHEMICAL", 9, 19], ["amino acid", "AMINO_ACID", 9, 19], ["turkey", "ORGANISM", 47, 53], ["chicken", "ORGANISM", 58, 65], ["turkey", "SPECIES", 47, 53], ["chicken", "SPECIES", 58, 65], ["turkey", "SPECIES", 47, 53], ["chicken", "SPECIES", 58, 65], ["The high amino acid identities", "PROBLEM", 0, 30], ["high", "OBSERVATION_MODIFIER", 4, 8], ["amino acid", "OBSERVATION", 9, 19]]], ["It is known from studies of another member of the Parvovirinae, canine parvovirus (CPV), that the parvoviruses, despite their singlestranded DNA genome, have a mutation rate that approaches that of RNA viruses, which allows rapid evolution and host adaptation (Hoelzer et al., 2008; Shackelton et al., 2005) .", [["canine parvovirus", "DISEASE", 64, 81], ["Parvovirinae", "ORGANISM", 50, 62], ["canine parvovirus", "ORGANISM", 64, 81], ["CPV", "ORGANISM", 83, 86], ["parvoviruses", "ORGANISM", 98, 110], ["DNA", "CELLULAR_COMPONENT", 141, 144], ["singlestranded DNA genome", "DNA", 126, 151], ["canine parvovirus", "SPECIES", 64, 81], ["canine parvovirus", "SPECIES", 64, 81], ["CPV", "SPECIES", 83, 86], ["the parvoviruses", "PROBLEM", 94, 110], ["their singlestranded DNA genome", "TREATMENT", 120, 151], ["a mutation rate", "PROBLEM", 158, 173], ["RNA viruses", "PROBLEM", 198, 209], ["RNA viruses", "OBSERVATION", 198, 209]]], ["Interestingly, ChPV and TuPV do not group phylogenetically with the parvoviruses that infect geese (GoPV) and Muscovy ducks (MdPV), parvoviruses that are closely related to adeno-associated virus 2 (AAV-2), a member of the Dependovirus genus (Fig. 3) (Zadori et al., 1995; Zsak et al., 2008) .", [["ChPV", "GENE_OR_GENE_PRODUCT", 15, 19], ["TuPV", "GENE_OR_GENE_PRODUCT", 24, 28], ["parvoviruses", "ORGANISM", 68, 80], ["geese", "ORGANISM", 93, 98], ["GoPV)", "ORGANISM", 100, 105], ["Muscovy ducks", "ORGANISM", 110, 123], ["MdPV", "GENE_OR_GENE_PRODUCT", 125, 129], ["parvoviruses", "ORGANISM", 132, 144], ["adeno-associated virus 2", "ORGANISM", 173, 197], ["AAV-2", "ORGANISM", 199, 204], ["ChPV", "PROTEIN", 15, 19], ["TuPV", "PROTEIN", 24, 28], ["Muscovy ducks", "SPECIES", 110, 123], ["Muscovy ducks", "SPECIES", 110, 123], ["MdPV", "SPECIES", 125, 129], ["adeno-associated virus", "SPECIES", 173, 195], ["TuPV", "TREATMENT", 24, 28], ["the parvoviruses", "PROBLEM", 64, 80], ["parvoviruses", "PROBLEM", 132, 144], ["adeno-associated virus", "PROBLEM", 173, 195], ["AAV", "TEST", 199, 202]]], ["Further, the ChPV NS protein shares only 19.1% amino acid identity with the MdPV NS protein.DiscussionThe ITR sequences located at each end of the ChPV genome (Fig. 2 ) are each 206 nt long, somewhat shorter than those found in the prototypical human parvovirus B19 (383 nt) but longer than those found in some other autonomously replicating parvoviruses, namely the murine parvoviruses that have terminal palindromes of 115 and about 200 nt long in the same genome (Astell et al., 1979; Deiss et al., 1990) .", [["amino acid", "CHEMICAL", 47, 57], ["parvovirus B19", "DISEASE", 251, 265], ["amino acid", "CHEMICAL", 47, 57], ["ChPV", "GENE_OR_GENE_PRODUCT", 13, 17], ["amino acid", "AMINO_ACID", 47, 57], ["MdPV NS protein", "GENE_OR_GENE_PRODUCT", 76, 91], ["human", "ORGANISM", 245, 250], ["parvovirus B19", "ORGANISM", 251, 265], ["parvoviruses", "ORGANISM", 342, 354], ["murine parvoviruses", "ORGANISM", 367, 386], ["ChPV NS protein", "PROTEIN", 13, 28], ["MdPV NS protein", "PROTEIN", 76, 91], ["ITR sequences", "DNA", 106, 119], ["ChPV genome", "DNA", 147, 158], ["terminal palindromes", "DNA", 397, 417], ["human", "SPECIES", 245, 250], ["parvovirus B19", "SPECIES", 251, 265], ["murine", "SPECIES", 367, 373], ["human parvovirus B19", "SPECIES", 245, 265], ["murine parvoviruses", "SPECIES", 367, 386], ["the ChPV NS protein", "TEST", 9, 28], ["amino acid", "TEST", 47, 57], ["the MdPV NS protein", "TREATMENT", 72, 91], ["The ITR sequences", "TEST", 102, 119], ["the prototypical human parvovirus B19", "TEST", 228, 265], ["the murine parvoviruses", "PROBLEM", 363, 386], ["terminal palindromes", "PROBLEM", 397, 417], ["parvoviruses", "OBSERVATION", 342, 354]]], ["The terminal palindromes found at the 5\u2032 and 3\u2032 ends of most autonomously replicating parvoviruses bear no nucleotide identity with one another.", [["nucleotide", "CHEMICAL", 107, 117], ["nucleotide", "CHEMICAL", 107, 117], ["\u2032", "GENE_OR_GENE_PRODUCT", 39, 40], ["parvoviruses", "ORGANISM", 86, 98], ["terminal palindromes", "DNA", 4, 24], ["5\u2032 and 3\u2032 ends", "DNA", 38, 52], ["The terminal palindromes", "PROBLEM", 0, 24], ["terminal palindromes", "OBSERVATION", 4, 24], ["parvoviruses", "OBSERVATION", 86, 98]]], ["Interestingly, this is not the case with ChPV, which has identical palindrome sequences at its 5\u2032 and 3\u2032 end (Fig. 2) , a trait it shares with parvovirus B19 (Deiss et al., 1990; Muzyczka and Berns, 2001) .", [["parvovirus B19", "DISEASE", 143, 157], ["ChPV", "GENE_OR_GENE_PRODUCT", 41, 45], ["parvovirus B19", "ORGANISM", 143, 157], ["ChPV", "PROTEIN", 41, 45], ["palindrome sequences", "DNA", 67, 87], ["5\u2032 and 3\u2032 end", "DNA", 95, 108], ["parvovirus B19", "SPECIES", 143, 157], ["parvovirus B19", "SPECIES", 143, 157], ["parvovirus B19", "PROBLEM", 143, 157]]], ["It would be interesting to determine if the 5\u2032 end of the ChPV genome exists in an alternative orientation, as is the case with B19, MdPV and GoPV, in which the 5\u2032 sequence can be found in one of two \"flip\" or \"flop\" orientations, with one orientation being the inverted complement of the other (Deiss et al., 1990; Zadori et al., 1995) .DiscussionThe ChPV NS1 deduced amino acid sequence contains highly conserved motifs important for the initiation of parvovirus replication (Zsak et al., 2008) , including a well-conserved phosphate-binding loop (\"P-loop\") motif specifically involved in the binding of nucleoside triphosphates by this protein (Saraste et al., 1990) .", [["amino acid", "CHEMICAL", 369, 379], ["phosphate", "CHEMICAL", 526, 535], ["nucleoside triphosphates", "CHEMICAL", 606, 630], ["amino acid", "CHEMICAL", 369, 379], ["phosphate", "CHEMICAL", 526, 535], ["nucleoside triphosphates", "CHEMICAL", 606, 630], ["ChPV", "GENE_OR_GENE_PRODUCT", 58, 62], ["B19", "ORGANISM", 128, 131], ["MdPV", "GENE_OR_GENE_PRODUCT", 133, 137], ["GoPV", "GENE_OR_GENE_PRODUCT", 142, 146], ["ChPV", "GENE_OR_GENE_PRODUCT", 352, 356], ["amino acid", "AMINO_ACID", 369, 379], ["parvovirus", "ORGANISM", 454, 464], ["phosphate", "SIMPLE_CHEMICAL", 526, 535], ["nucleoside triphosphates", "SIMPLE_CHEMICAL", 606, 630], ["5\u2032 end", "DNA", 44, 50], ["ChPV genome", "DNA", 58, 69], ["B19, MdPV and GoPV", "DNA", 128, 146], ["5\u2032 sequence", "DNA", 161, 172], ["ChPV NS1 deduced amino acid sequence", "PROTEIN", 352, 388], ["phosphate-binding loop", "PROTEIN", 526, 548], ["P-loop\") motif", "DNA", 551, 565], ["B19", "SPECIES", 128, 131], ["parvovirus", "SPECIES", 454, 464], ["the ChPV genome", "TREATMENT", 54, 69], ["The ChPV NS1 deduced amino acid sequence", "TEST", 348, 388], ["parvovirus replication", "TREATMENT", 454, 476], ["nucleoside triphosphates", "TREATMENT", 606, 630]]], ["This motif is required for pathogenesis in the human parvovirus B19 and is found in many parvovirus isolates (Momoeda et al., 1994) .", [["parvovirus B19", "DISEASE", 53, 67], ["human", "ORGANISM", 47, 52], ["parvovirus B19", "ORGANISM", 53, 67], ["parvovirus", "ORGANISM", 89, 99], ["human", "SPECIES", 47, 52], ["parvovirus B19", "SPECIES", 53, 67], ["human parvovirus B19", "SPECIES", 47, 67], ["pathogenesis", "PROBLEM", 27, 39], ["the human parvovirus B19", "TEST", 43, 67], ["many parvovirus isolates", "PROBLEM", 84, 108]]], ["The 5\u2032 major ORF of ChPV appears to encode the viral capsid proteins VP1, VP2, and VP3.", [["ChPV", "GENE_OR_GENE_PRODUCT", 20, 24], ["VP1", "GENE_OR_GENE_PRODUCT", 69, 72], ["VP2", "GENE_OR_GENE_PRODUCT", 74, 77], ["VP3", "GENE_OR_GENE_PRODUCT", 83, 86], ["5\u2032 major ORF", "DNA", 4, 16], ["ChPV", "DNA", 20, 24], ["viral capsid proteins", "PROTEIN", 47, 68], ["VP1", "PROTEIN", 69, 72], ["VP2", "PROTEIN", 74, 77], ["VP3", "PROTEIN", 83, 86], ["VP1", "TEST", 69, 72], ["VP2", "TEST", 74, 77], ["VP3", "TEST", 83, 86], ["viral", "OBSERVATION", 47, 52], ["VP3", "ANATOMY", 83, 86]]], ["These three proteins together comprise the parvovirus virion (Muzyczka and Berns, 2001) and are responsible for the production of neutralizing antibodies during an infection (Saikawa et al., 1993) .DiscussionThe present analysis does not include members of the Densovirinae subfamily, which infect insects and other invertebrates (Muzyczka and Berns, 2001) .", [["infection", "DISEASE", 164, 173], ["parvovirus virion", "ORGANISM", 43, 60], ["Densovirinae", "GENE_OR_GENE_PRODUCT", 261, 273], ["neutralizing antibodies", "PROTEIN", 130, 153], ["Densovirinae subfamily", "PROTEIN", 261, 283], ["the parvovirus virion", "PROBLEM", 39, 60], ["neutralizing antibodies", "PROBLEM", 130, 153], ["an infection", "PROBLEM", 161, 173], ["parvovirus virion", "OBSERVATION", 43, 60], ["neutralizing antibodies", "OBSERVATION", 130, 153], ["infection", "OBSERVATION", 164, 173]]], ["ChPV and the closely related TuPVs were compared across their entire coding region with representative members of the Parvovirinae subfamily, which includes the Dependovirus, Bocavirus, Erythrovirus, Amdovirus and Parvovirus genera (Fig. 3) .", [["ChPV", "GENE_OR_GENE_PRODUCT", 0, 4], ["TuPVs", "GENE_OR_GENE_PRODUCT", 29, 34], ["Parvovirinae", "GENE_OR_GENE_PRODUCT", 118, 130], ["ChPV", "PROTEIN", 0, 4], ["TuPVs", "DNA", 29, 34], ["Parvovirinae subfamily", "PROTEIN", 118, 140], ["ChPV", "TREATMENT", 0, 4], ["the closely related TuPVs", "PROBLEM", 9, 34], ["the Dependovirus", "PROBLEM", 157, 173], ["Bocavirus", "PROBLEM", 175, 184], ["Erythrovirus", "TREATMENT", 186, 198], ["Amdovirus", "TREATMENT", 200, 209], ["Parvovirus genera", "TREATMENT", 214, 231], ["Parvovirus genera", "OBSERVATION", 214, 231]]], ["It is clear from the multiple sequence alignments and phylogenetic analysis that ChPV, along with the closely related TuPVs, represents a distinct member of the Parvovirinae subfamily and should be recognized as the prototypical member of a novel genus within the Parvovirinae.Materials and methodsAssembly of the prototypical chicken parvovirus (ChPV ABU-P1) genomeMaterials and methodsThe chicken parvovirus strain chosen for this analysis was originally isolated in Hungary from the intestines of chickens showing sings of a stunting syndrome (Kisary et al., 1984) , and this original cesium chloride gradient-purified parvovirus (provided by J. Kisary) was propagated in specific pathogen free (SPF) chickens as described previously (Kisary, 1985; Zsak et al., 2009) .", [["intestines", "ANATOMY", 486, 496], ["stunting syndrome", "DISEASE", 528, 545], ["cesium chloride", "CHEMICAL", 588, 603], ["parvovirus", "DISEASE", 622, 632], ["cesium chloride", "CHEMICAL", 588, 603], ["ChPV", "GENE_OR_GENE_PRODUCT", 81, 85], ["TuPVs", "GENE_OR_GENE_PRODUCT", 118, 123], ["Parvovirinae", "GENE_OR_GENE_PRODUCT", 161, 173], ["Parvovirinae", "CANCER", 264, 276], ["chicken", "ORGANISM", 327, 334], ["parvovirus", "ORGANISM", 335, 345], ["chicken", "ORGANISM", 391, 398], ["parvovirus strain", "ORGANISM", 399, 416], ["intestines", "ORGAN", 486, 496], ["chickens", "ORGANISM", 500, 508], ["cesium chloride", "SIMPLE_CHEMICAL", 588, 603], ["parvovirus", "ORGANISM", 622, 632], ["chickens", "ORGANISM", 704, 712], ["ChPV", "PROTEIN", 81, 85], ["TuPVs", "DNA", 118, 123], ["Parvovirinae subfamily", "PROTEIN", 161, 183], ["chicken parvovirus", "SPECIES", 327, 345], ["chicken parvovirus", "SPECIES", 391, 409], ["chickens", "SPECIES", 500, 508], ["chickens", "SPECIES", 704, 712], ["chicken parvovirus", "SPECIES", 327, 345], ["ChPV", "SPECIES", 347, 351], ["chicken parvovirus", "SPECIES", 391, 409], ["chickens", "SPECIES", 500, 508], ["chickens", "SPECIES", 704, 712], ["the multiple sequence alignments", "TEST", 17, 49], ["phylogenetic analysis", "TEST", 54, 75], ["the prototypical chicken parvovirus", "PROBLEM", 310, 345], ["The chicken parvovirus strain", "PROBLEM", 387, 416], ["this analysis", "TEST", 428, 441], ["a stunting syndrome", "PROBLEM", 526, 545], ["this original cesium chloride gradient", "TREATMENT", 574, 612], ["parvovirus", "PROBLEM", 622, 632], ["clear", "OBSERVATION", 6, 11], ["distinct", "OBSERVATION_MODIFIER", 138, 146], ["parvovirus strain", "OBSERVATION", 399, 416], ["intestines", "ANATOMY", 486, 496], ["stunting syndrome", "OBSERVATION", 528, 545], ["pathogen", "OBSERVATION_MODIFIER", 684, 692], ["free", "OBSERVATION_MODIFIER", 693, 697]]], ["A sequenceindependent polymerase chain reaction (PCR) protocol was employed to amplify particle-associated nucleic acid (PAN) present in ChPV ABU-P1-positive chicken intestinal homogenates, and has been described elsewhere in detail (Zsak et al., 2008) .", [["intestinal homogenates", "ANATOMY", 166, 188], ["nucleic acid", "CHEMICAL", 107, 119], ["PAN", "CHEMICAL", 121, 124], ["nucleic acid", "SIMPLE_CHEMICAL", 107, 119], ["PAN", "SIMPLE_CHEMICAL", 121, 124], ["ABU-P1", "GENE_OR_GENE_PRODUCT", 142, 148], ["chicken", "ORGANISM", 158, 165], ["intestinal homogenates", "ORGANISM_SUBSTANCE", 166, 188], ["P1", "DNA", 146, 148], ["chicken", "SPECIES", 158, 165], ["chicken", "SPECIES", 158, 165], ["A sequenceindependent polymerase chain reaction (PCR) protocol", "TREATMENT", 0, 62], ["nucleic acid", "TEST", 107, 119], ["positive chicken", "OBSERVATION_MODIFIER", 149, 165], ["intestinal homogenates", "OBSERVATION", 166, 188]]], ["The randomly amplified PAN was ligated into the TOPO-TA cloning vector (Invitrogen) and the ligation mix was used to transform competent TOP-10 E. coli cells (Invitrogen).", [["cells", "ANATOMY", 152, 157], ["PAN", "CHEMICAL", 23, 26], ["TOPO", "CHEMICAL", 48, 52], ["TOPO", "GENE_OR_GENE_PRODUCT", 48, 52], ["TOP-10 E. coli cells", "CELL", 137, 157], ["Invitrogen", "CELL", 159, 169], ["PAN", "DNA", 23, 26], ["TOPO-TA cloning vector", "DNA", 48, 70], ["TOP-10 E. coli cells", "CELL_LINE", 137, 157], ["E. coli", "SPECIES", 144, 151], ["E. coli", "SPECIES", 144, 151], ["The randomly amplified PAN", "TREATMENT", 0, 26], ["the TOPO-TA cloning vector", "TREATMENT", 44, 70], ["the ligation mix", "TREATMENT", 88, 104], ["E. coli cells", "TEST", 144, 157], ["coli cells", "OBSERVATION", 147, 157]]], ["Using this approach, a total of 768 clones were identified and sequenced using the M13 forward and reverse primers on an AB-3730 automated DNA sequencer.", [["clones", "CELL", 36, 42], ["DNA", "CELLULAR_COMPONENT", 139, 142], ["M13 forward and reverse primers", "DNA", 83, 114], ["this approach", "TREATMENT", 6, 19]]], ["The sequenced clones were used as query sequences to search the GenBank non-redundant nucleotide (nr/nt) database using the blastn algorithm and the non-redundant (nr) protein database using the blastx algorithm.", [["clones", "ANATOMY", 14, 20], ["nucleotide", "CHEMICAL", 86, 96], ["clones", "CELL", 14, 20], ["The sequenced clones", "TREATMENT", 0, 20], ["query sequences", "TEST", 34, 49], ["the blastn algorithm", "TEST", 120, 140], ["the blastx algorithm", "TEST", 191, 211]]], ["These contigs had no significant nucleotide similarity to database sequences, but the deduced amino acid sequence from each contig Fig. 3 .", [["amino acid", "CHEMICAL", 94, 104], ["nucleotide", "CHEMICAL", 33, 43], ["amino acid", "CHEMICAL", 94, 104], ["amino acid", "AMINO_ACID", 94, 104], ["database sequences", "DNA", 58, 76], ["database sequences", "TEST", 58, 76], ["the deduced amino acid sequence", "TEST", 82, 113]]], ["A phylogenetic tree prepared using the full coding sequence of the indicated parvoviruses.", [["parvoviruses", "ORGANISM", 77, 89], ["the full coding sequence", "TEST", 35, 59], ["parvoviruses", "PROBLEM", 77, 89], ["phylogenetic tree", "OBSERVATION", 2, 19], ["parvoviruses", "OBSERVATION", 77, 89]]], ["Representative genera within the Parvovirinae are indicated.", [["Parvovirinae", "GENE_OR_GENE_PRODUCT", 33, 45], ["genera", "OBSERVATION_MODIFIER", 15, 21]]], ["Phylogenetic analyses were conducted using MEGA4.", [["MEGA4", "DNA", 43, 48], ["Phylogenetic analyses", "TEST", 0, 21], ["MEGA4", "TREATMENT", 43, 48]]], ["GenBank Accession numbers for ChPV, GU214704; TuPV 1078, GU214705; and TuPV 260, GU214706. revealed significant similarity to the members of the family Parvoviridae in the database.", [["GU214706", "CHEMICAL", 81, 89], ["TuPV 1078", "CHEMICAL", 46, 55], ["TuPV 260", "CHEMICAL", 71, 79], ["GU214706", "CHEMICAL", 81, 89], ["ChPV", "TEST", 30, 34], ["TuPV", "TEST", 46, 50], ["significant", "OBSERVATION_MODIFIER", 100, 111]]], ["PCR primers were designed using the four assembled contigs and were subsequently used to close gaps of 58, 443, and 205 nt between the contigs and assemble the complete ChPV ABU-P1 genome.", [["PCR primers", "DNA", 0, 11], ["ChPV ABU-P1 genome", "DNA", 169, 187], ["PCR primers", "TEST", 0, 11], ["P1 genome", "OBSERVATION", 178, 187]]], ["The right terminal region of contig 4 contained a portion of the right inverted terminal repeat (ITR).", [["right terminal region", "ANATOMY", 4, 25], ["right inverted terminal repeat", "ANATOMY", 65, 95], ["right terminal region", "DNA", 4, 25], ["contig 4", "DNA", 29, 37], ["right inverted terminal repeat", "DNA", 65, 95], ["ITR", "DNA", 97, 100], ["right", "ANATOMY_MODIFIER", 4, 9], ["terminal", "ANATOMY_MODIFIER", 10, 18], ["portion", "OBSERVATION_MODIFIER", 50, 57], ["right", "ANATOMY_MODIFIER", 65, 70], ["terminal", "OBSERVATION_MODIFIER", 80, 88]]], ["Primers designed using this partial ITR used in combination with forward and reverse primers within contig 1 (left terminal region of the genome) and contig 4 resulted in the cloning of the ITR regions at both the right and left genomic termini.Sequence analysisThe ChPV and TuPV genomes and ORFs were aligned with each other and with selected parvovirus sequences available in the databases using ClustalW (Thompson et al., 1994) .", [["left terminal region", "ANATOMY", 110, 130], ["right", "ANATOMY", 214, 219], ["ChPV", "GENE_OR_GENE_PRODUCT", 266, 270], ["TuPV", "GENE_OR_GENE_PRODUCT", 275, 279], ["parvovirus", "ORGANISM", 344, 354], ["ITR", "DNA", 36, 39], ["forward and reverse primers", "DNA", 65, 92], ["contig 1", "DNA", 100, 108], ["left terminal region", "DNA", 110, 130], ["contig 4", "DNA", 150, 158], ["ITR regions", "DNA", 190, 201], ["right and left genomic termini", "DNA", 214, 244], ["ChPV and TuPV genomes", "DNA", 266, 287], ["ORFs", "DNA", 292, 296], ["parvovirus sequences", "DNA", 344, 364], ["this partial ITR", "TREATMENT", 23, 39], ["forward and reverse primers", "TREATMENT", 65, 92], ["Sequence analysis", "TEST", 245, 262], ["The ChPV and TuPV genomes", "TREATMENT", 262, 287], ["selected parvovirus sequences", "TEST", 335, 364], ["left", "ANATOMY_MODIFIER", 110, 114], ["terminal", "ANATOMY_MODIFIER", 115, 123], ["region", "ANATOMY_MODIFIER", 124, 130], ["genome", "ANATOMY", 138, 144], ["both", "ANATOMY_MODIFIER", 205, 209], ["right", "ANATOMY_MODIFIER", 214, 219], ["left", "ANATOMY_MODIFIER", 224, 228], ["genomic", "ANATOMY_MODIFIER", 229, 236], ["termini", "ANATOMY_MODIFIER", 237, 244]]], ["Searches for conserved domains and transcription factor binding sites within the ChPV genome were performed with GeneQuest (DNAStar/Laser-gene8) and the Conserved Domain Database (CDD) Search Service v2.17 at the National Center for Biotechnology Information (NCBI) website (Marchler-Bauer et al., 2009) .", [["transcription factor binding sites", "DNA", 35, 69], ["ChPV genome", "DNA", 81, 92], ["DNAStar", "DNA", 124, 131], ["Laser-gene8", "DNA", 132, 143], ["transcription factor binding sites", "PROBLEM", 35, 69], ["GeneQuest (DNAStar/Laser-gene8)", "TREATMENT", 113, 144]]], ["Phylogenetic analysis and tree construction were performed with MEGA4 using the Neighbor-Joining method (Tamura et al., 2007) .", [["MEGA4", "DNA", 64, 69], ["Phylogenetic analysis", "TEST", 0, 21], ["MEGA4", "TREATMENT", 64, 69]]]], "ad680ced7553a475ea001d4f7d30d9004c72cca0": [["INTRODUCTIONThe WHO declared the 2020 COVID-19 to be a global pandemic on March 11 th , 2020INTRODUCTIONTo identify B cells specific to the SARS-CoV-2 S protein that were circulating at this 118 timepoint, fluorescently labeled S2P and RBD probes were used as baits.", [["B cells", "ANATOMY", 116, 123], ["B cells", "CELL", 116, 123], ["SARS-CoV-2", "ORGANISM", 140, 150], ["S2P", "GENE_OR_GENE_PRODUCT", 228, 231], ["B cells", "CELL_TYPE", 116, 123], ["SARS-CoV-2 S protein", "PROTEIN", 140, 160], ["fluorescently labeled S2P and RBD probes", "DNA", 206, 246], ["SARS-CoV", "SPECIES", 140, 148], ["B cells", "PROBLEM", 116, 123], ["the SARS", "TEST", 136, 144], ["CoV", "TEST", 145, 148], ["S protein", "TEST", 151, 160], ["RBD probes", "TREATMENT", 236, 246]]], ["S2P was 119 labeled with either phycoerythrin (PE) or brilliant violet 711 (BV711) and used to stain B 120 cells concurrently.", [["B 120 cells", "ANATOMY", 101, 112], ["PE", "CHEMICAL", 47, 49], ["brilliant violet 711", "CHEMICAL", 54, 74], ["BV711", "CHEMICAL", 76, 81], ["violet 711", "CHEMICAL", 64, 74], ["BV711", "CHEMICAL", 76, 81], ["S2P", "SIMPLE_CHEMICAL", 0, 3], ["phycoerythrin", "SIMPLE_CHEMICAL", 32, 45], ["PE", "SIMPLE_CHEMICAL", 47, 49], ["brilliant violet 711", "SIMPLE_CHEMICAL", 54, 74], ["BV711", "SIMPLE_CHEMICAL", 76, 81], ["B 120 cells", "CELL", 101, 112], ["B 120 cells", "CELL_TYPE", 101, 112], ["brilliant violet 711", "SPECIES", 54, 74], ["phycoerythrin (PE", "PROBLEM", 32, 49], ["brilliant violet", "TEST", 54, 70], ["PE", "OBSERVATION", 47, 49]]], ["This double labeling strategy helped to discriminate between bona 121 fide S2P-specific B cells and non-specific background staining to the fluorophores. were also positive for the RBD.", [["B cells", "ANATOMY", 88, 95], ["RBD", "DISEASE", 181, 184], ["S2P", "GENE_OR_GENE_PRODUCT", 75, 78], ["B cells", "CELL", 88, 95], ["S2P", "PROTEIN", 75, 78], ["B cells", "CELL_TYPE", 88, 95], ["RBD", "PROTEIN", 181, 184], ["This double labeling strategy", "TREATMENT", 0, 29], ["non-specific background staining to the fluorophores", "PROBLEM", 100, 152], ["the RBD", "PROBLEM", 177, 184], ["RBD", "OBSERVATION", 181, 184]]], ["131 We hypothesized that the class-switched SARS-CoV-2-specific B cells were more likely had normal distributions of CDRH3 and CDRL3 lengths (Fig. 2 F-G) .", [["B cells", "ANATOMY", 64, 71], ["SARS", "DISEASE", 44, 48], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 44, 54], ["B cells", "CELL", 64, 71], ["CDRH3", "GENE_OR_GENE_PRODUCT", 117, 122], ["CDRL3", "GENE_OR_GENE_PRODUCT", 127, 132], ["F-G", "GENE_OR_GENE_PRODUCT", 149, 152], ["SARS-CoV-2-specific B cells", "CELL_LINE", 44, 71], ["CDRH3", "PROTEIN", 117, 122], ["CDRL3", "PROTEIN", 127, 132], ["SARS", "TEST", 44, 48], ["CoV", "TEST", 49, 52], ["specific B cells", "PROBLEM", 55, 71], ["CDRH3", "TEST", 117, 122]]], ["Consistent with the relatively short time of infection the majority of BCR sequences showed low levels of 141 somatic mutation (Fig. 2H ).", [["infection", "DISEASE", 45, 54], ["BCR", "GENE_OR_GENE_PRODUCT", 71, 74], ["BCR sequences", "DNA", 71, 84], ["infection", "PROBLEM", 45, 54], ["BCR sequences", "TEST", 71, 84], ["low levels", "PROBLEM", 92, 102], ["relatively", "OBSERVATION_MODIFIER", 20, 30], ["short", "OBSERVATION_MODIFIER", 31, 36], ["infection", "OBSERVATION", 45, 54]]], ["We conclude that the early B cell response to the SARS- 142 CoV-2 S protein is polyclonal and directed at epitopes mostly outside of the RBD.143Determining the binding specificities of anti-S monoclonal antibodies.", [["B cell", "ANATOMY", 27, 33], ["SARS", "DISEASE", 50, 54], ["B cell", "CELL", 27, 33], ["SARS- 142 CoV", "ORGANISM", 50, 63], ["S protein", "PROTEIN", 66, 75], ["epitopes", "PROTEIN", 106, 114], ["RBD", "PROTEIN", 137, 140], ["anti-S monoclonal antibodies", "PROTEIN", 185, 213], ["SARS- 142 CoV", "SPECIES", 50, 63], ["the SARS", "TEST", 46, 54], ["CoV", "TEST", 60, 63], ["polyclonal", "TREATMENT", 79, 89], ["anti-S monoclonal antibodies", "PROBLEM", 185, 213], ["RBD", "OBSERVATION", 137, 140]]], ["144 Among all successfully sequenced VH and VL transcripts, we obtained paired 145 sequences from forty-five.", [["VH and VL transcripts", "RNA", 37, 58], ["paired 145 sequences", "DNA", 72, 92]]], ["These were produced as recombinant monoclonal antibodies 146 (mAbs) of the IgG1 isotype and tested for binding to recombinant S-derived proteins 147 (Fig. 3) .", [["IgG1", "GENE_OR_GENE_PRODUCT", 75, 79], ["recombinant monoclonal antibodies 146", "PROTEIN", 23, 60], ["mAbs", "PROTEIN", 62, 66], ["IgG1 isotype", "PROTEIN", 75, 87], ["recombinant S-derived proteins 147", "PROTEIN", 114, 148], ["recombinant monoclonal antibodies", "TEST", 23, 56], ["the IgG1 isotype", "TEST", 71, 87], ["recombinant S", "TEST", 114, 127], ["derived proteins", "TEST", 128, 144]]], ["148 Most of the mAbs represented unique rearrangements, however we identified at least 4 149 expanded clones.", [["clones", "ANATOMY", 102, 108], ["mAbs", "GENE_OR_GENE_PRODUCT", 16, 20], ["clones", "CELL", 102, 108], ["mAbs", "PROTEIN", 16, 20], ["expanded", "OBSERVATION_MODIFIER", 93, 101], ["clones", "OBSERVATION", 102, 108]]], ["CV4 and CV7 were identical and unmutated.", [["CV4", "GENE_OR_GENE_PRODUCT", 0, 3], ["CV7", "GENE_OR_GENE_PRODUCT", 8, 11], ["CV4", "DNA", 0, 3], ["CV7", "DNA", 8, 11], ["CV4", "TEST", 0, 3], ["CV7", "TEST", 8, 11], ["unmutated", "OBSERVATION", 31, 40]]], ["CV1 and CV35 differed 150 by one synonymous LC mutation, CV40 and CV47 differed by 5 amino acids (Table S1 ).151CV12, CV39 and CV46 were much more mutated, up to 15 heavy chain and 6 light 152 chain mutations for CV12 (Table S1 ).", [["amino acids", "CHEMICAL", 85, 96], ["amino acids", "CHEMICAL", 85, 96], ["CV1", "CELL", 0, 3], ["CV35", "GENE_OR_GENE_PRODUCT", 8, 12], ["amino acids", "AMINO_ACID", 85, 96], ["151CV12", "GENE_OR_GENE_PRODUCT", 109, 116], ["CV39", "GENE_OR_GENE_PRODUCT", 118, 122], ["CV46", "GENE_OR_GENE_PRODUCT", 127, 131], ["CV35", "DNA", 8, 12], ["CV40", "DNA", 57, 61], ["CV47", "DNA", 66, 70], ["151CV12", "PROTEIN", 109, 116], ["CV39", "DNA", 118, 122], ["CV46", "DNA", 127, 131], ["CV12", "PROTEIN", 213, 217], ["CV1", "TEST", 0, 3], ["CV35", "TEST", 8, 12], ["CV40", "TEST", 57, 61], ["CV47", "TEST", 66, 70], ["CV39", "TEST", 118, 122], ["CV46", "TEST", 127, 131]]], ["Due to the relatively short window of time 153 between SARS-CoV-2 infection and PBMC collection, these mAbs may represent an 154 expansion of a memory B cell from a previous infection with an endemic coronavirus.155All the mAbs bound to the stabilized SARS-CoV-2 ectodomain, S2P ( Fig. 3A and E).156Consistent with the B cell staining that revealed very few RBD-specific B cells (Fig. 2B) , cell surface S. The fact that a subset of the mAbs bound to a stabilized ectodomain 163 variant of the closely related SARS-CoV S protein ( Fig. 3D and E), demonstrated that 164 there are conserved epitopes among the two viruses.", [["PBMC", "ANATOMY", 80, 84], ["memory B cell", "ANATOMY", 144, 157], ["B cell", "ANATOMY", 319, 325], ["B cells", "ANATOMY", 371, 378], ["cell surface", "ANATOMY", 391, 403], ["SARS-CoV-2 infection", "DISEASE", 55, 75], ["infection", "DISEASE", 174, 183], ["coronavirus", "DISEASE", 200, 211], ["SARS-CoV-2", "ORGANISM", 55, 65], ["PBMC", "CELL", 80, 84], ["mAbs", "GENE_OR_GENE_PRODUCT", 103, 107], ["memory B cell", "CELL", 144, 157], ["coronavirus", "ORGANISM", 200, 211], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 252, 262], ["B cell", "CELL", 319, 325], ["B cells", "CELL", 371, 378], ["Fig. 2B", "CELL", 380, 387], ["cell", "CELL", 391, 395], ["mAbs", "GENE_OR_GENE_PRODUCT", 437, 441], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 510, 520], ["PBMC", "CELL_TYPE", 80, 84], ["mAbs", "PROTEIN", 103, 107], ["memory B cell", "CELL_TYPE", 144, 157], ["mAbs", "PROTEIN", 223, 227], ["SARS-CoV-2 ectodomain", "PROTEIN", 252, 273], ["S2P", "PROTEIN", 275, 278], ["Fig. 3A and E", "PROTEIN", 281, 294], ["RBD", "PROTEIN", 358, 361], ["B cells", "CELL_TYPE", 371, 378], ["Fig. 2B", "PROTEIN", 380, 387], ["mAbs", "PROTEIN", 437, 441], ["ectodomain 163 variant", "PROTEIN", 464, 486], ["SARS-CoV S protein", "PROTEIN", 510, 528], ["Fig. 3D and E", "PROTEIN", 531, 544], ["SARS-CoV", "SPECIES", 55, 63], ["SARS-CoV", "SPECIES", 510, 518], ["SARS", "PROBLEM", 55, 59], ["CoV-2 infection", "PROBLEM", 60, 75], ["PBMC collection", "PROBLEM", 80, 95], ["these mAbs", "TEST", 97, 107], ["a memory B cell", "PROBLEM", 142, 157], ["a previous infection", "PROBLEM", 163, 183], ["an endemic coronavirus", "PROBLEM", 189, 211], ["CoV", "TEST", 257, 260], ["the B cell staining", "TEST", 315, 334], ["very few RBD", "PROBLEM", 349, 361], ["specific B cells", "PROBLEM", 362, 378], ["the mAbs bound", "PROBLEM", 433, 447], ["the closely related SARS", "PROBLEM", 490, 514], ["CoV S protein", "TEST", 515, 528], ["infection", "OBSERVATION", 66, 75], ["PBMC", "ANATOMY", 80, 84], ["may represent", "UNCERTAINTY", 108, 121], ["154 expansion", "OBSERVATION_MODIFIER", 125, 138], ["memory B cell", "OBSERVATION", 144, 157], ["infection", "OBSERVATION", 174, 183], ["endemic coronavirus", "OBSERVATION", 192, 211], ["very", "OBSERVATION_MODIFIER", 349, 353], ["few", "OBSERVATION_MODIFIER", 354, 357], ["RBD", "OBSERVATION", 358, 361], ["two viruses", "OBSERVATION", 608, 619]]], ["Consistent with the lower degree 165 of conservation of the S1 subunit between SARS-CoV and SARS-CoV-2, the anti-RBD 166 mAbs CV30 and CV43 did not cross react with SARS-CoV S2P, while CV5 showed 167 weak binding.", [["S1", "GENE_OR_GENE_PRODUCT", 60, 62], ["SARS-CoV", "ORGANISM", 79, 87], ["SARS-CoV-2", "ORGANISM", 92, 102], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 165, 173], ["S1 subunit", "PROTEIN", 60, 70], ["RBD 166 mAbs", "PROTEIN", 113, 125], ["CV30", "PROTEIN", 126, 130], ["CV43", "PROTEIN", 135, 139], ["SARS-CoV S2P", "DNA", 165, 177], ["CV5", "PROTEIN", 185, 188], ["SARS-CoV", "SPECIES", 79, 87], ["SARS-CoV", "SPECIES", 92, 100], ["SARS-CoV", "SPECIES", 165, 173], ["SARS", "TEST", 79, 83], ["CoV", "TEST", 84, 87], ["SARS", "TEST", 92, 96], ["CoV", "TEST", 97, 100], ["the anti-RBD", "TEST", 104, 116], ["mAbs CV30", "TEST", 121, 130], ["CV43", "TEST", 135, 139], ["SARS", "TEST", 165, 169], ["CoV S2P", "TEST", 170, 177], ["CV5", "TEST", 185, 188], ["weak binding", "PROBLEM", 200, 212], ["lower degree", "OBSERVATION_MODIFIER", 20, 32]]], ["These results confirmed that the antibody responses to the spike protein 168 are largely outside of the RBD, and that the conformation of the stabilized ectodomain 169 variant may differ from the membrane anchored SARS-CoV-2 spike.170The early antibody response to SARS-CoV-2 infection is largely non-neutralizing.171The S2P-binding mAbs were evaluated for their ability to neutralize SARS CoV-2 172 pseudovirus infection of 293T cells stably expressing ACE2.", [["membrane", "ANATOMY", 196, 204], ["293T cells", "ANATOMY", 425, 435], ["SARS", "DISEASE", 265, 269], ["infection", "DISEASE", 276, 285], ["CoV-2 172", "CHEMICAL", 390, 399], ["RBD", "GENE_OR_GENE_PRODUCT", 104, 107], ["membrane", "CELLULAR_COMPONENT", 196, 204], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 214, 224], ["SARS-CoV-2", "ORGANISM", 265, 275], ["S2P", "GENE_OR_GENE_PRODUCT", 321, 324], ["SARS CoV-2 172 pseudovirus", "ORGANISM", 385, 411], ["293T cells", "CELL", 425, 435], ["ACE2", "GENE_OR_GENE_PRODUCT", 454, 458], ["spike protein 168", "PROTEIN", 59, 76], ["RBD", "PROTEIN", 104, 107], ["ectodomain 169 variant", "PROTEIN", 153, 175], ["S2P-binding mAbs", "PROTEIN", 321, 337], ["293T cells", "CELL_LINE", 425, 435], ["ACE2", "PROTEIN", 454, 458], ["SARS-CoV-2", "SPECIES", 265, 275], ["SARS CoV-2 172 pseudovirus", "SPECIES", 385, 411], ["the antibody responses", "TEST", 29, 51], ["the spike protein", "TEST", 55, 72], ["the membrane anchored SARS", "PROBLEM", 192, 218], ["CoV", "TEST", 219, 222], ["The early antibody response", "TEST", 234, 261], ["SARS", "TEST", 265, 269], ["CoV", "TEST", 270, 273], ["2 infection", "PROBLEM", 274, 285], ["The S2P-binding mAbs", "TREATMENT", 317, 337], ["SARS CoV", "TEST", 385, 393], ["pseudovirus infection of 293T cells", "PROBLEM", 400, 435], ["RBD", "OBSERVATION", 104, 107], ["early", "OBSERVATION_MODIFIER", 238, 243], ["antibody response", "OBSERVATION", 244, 261], ["infection", "OBSERVATION", 276, 285], ["non-neutralizing", "OBSERVATION_MODIFIER", 297, 313]]], ["All but three of the mAbs 173 were non-neutralizing ( Fig. 4A and Table S1 ).", [["mAbs 173", "PROTEIN", 21, 29], ["S1", "PROTEIN", 72, 74], ["the mAbs", "TEST", 17, 25]]], ["Although they did not achieve 100% infection by blocking the S-ACE2 interaction through an interaction that is slightly higher The S2P variants were then further purified using a Superose 6 10/300 GL column pre- mAbs that showed >50% neutralization at 50\u00b5g/ml, or sera were further analyzed to 562 determine neutralizing potency by preparing serial dilutions and conducting the 563 neutralization assay as described above.", [["sera", "ANATOMY", 264, 268], ["infection", "DISEASE", 35, 44], ["S-ACE2", "GENE_OR_GENE_PRODUCT", 61, 67], ["S2P", "GENE_OR_GENE_PRODUCT", 131, 134], ["sera", "ORGANISM_SUBSTANCE", 264, 268], ["S-ACE2", "PROTEIN", 61, 67], ["S2P variants", "DNA", 131, 143], ["Superose 6 10/300 GL column pre- mAbs", "PROTEIN", 179, 216], ["100% infection", "PROBLEM", 30, 44], ["a Superose", "TREATMENT", 177, 187], ["sera", "TEST", 264, 268], ["serial dilutions", "TEST", 342, 358], ["neutralization assay", "TEST", 382, 402], ["infection", "OBSERVATION", 35, 44], ["slightly", "OBSERVATION_MODIFIER", 111, 119], ["higher", "OBSERVATION_MODIFIER", 120, 126]]], ["The antibody concentration or plasma dilution 564 that neutralized 50% of infectivity (IC 50 or ID 50 , respectively) was interpolated from the 565 neutralization curves determined using the log(inhibitor) vs. response --Variable slope 566 (four parameters) fit using automatic outlier detection in Graphpad Prism Software.", [["plasma", "ANATOMY", 30, 36], ["plasma", "ORGANISM_SUBSTANCE", 30, 36], ["The antibody concentration", "TEST", 0, 26], ["plasma dilution", "TEST", 30, 45], ["infectivity", "PROBLEM", 74, 85], ["IC", "TEST", 87, 89], ["ID", "TEST", 96, 98], ["neutralization curves", "TEST", 148, 169], ["the log(inhibitor", "TREATMENT", 187, 204], ["Variable slope", "TEST", 221, 235], ["automatic outlier detection", "TEST", 268, 295]]], ["As a 567 control for specificity SARS CoV2-mAbs were tested for neutralizing activity against 568 HIV-1 derived virions pseudotyped with murine leukemia virus envelope (MLV).Quantification and Statistical analysisOu, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., Guo, L., Guo, R., Chen, T., Hu, J., et al.", [["virions", "ANATOMY", 112, 119], ["CoV2-mAbs", "GENE_OR_GENE_PRODUCT", 38, 47], ["HIV-1", "ORGANISM", 98, 103], ["virions", "ORGANISM", 112, 119], ["murine leukemia virus envelope", "ORGANISM", 137, 167], ["MLV", "ORGANISM", 169, 172], ["SARS CoV2", "PROTEIN", 33, 42], ["mAbs", "PROTEIN", 43, 47], ["HIV-1", "SPECIES", 98, 103], ["murine", "SPECIES", 137, 143], ["leukemia virus", "SPECIES", 144, 158], ["HIV-1", "SPECIES", 98, 103], ["murine leukemia virus", "SPECIES", 137, 158], ["MLV", "SPECIES", 169, 172], ["specificity SARS CoV2", "TEST", 21, 42], ["mAbs", "TEST", 43, 47], ["neutralizing activity", "TEST", 64, 85], ["HIV", "TEST", 98, 101], ["derived virions pseudotyped", "PROBLEM", 104, 131], ["murine leukemia virus envelope", "PROBLEM", 137, 167], ["Quantification", "TEST", 174, 188], ["Mi", "PROBLEM", 247, 249], ["murine leukemia virus", "OBSERVATION", 137, 158], ["Lei", "ANATOMY", 230, 233], ["Li", "ANATOMY", 239, 241], ["Mi", "ANATOMY", 247, 249], ["L.", "ANATOMY", 260, 262], ["R.", "ANATOMY", 278, 280]]]], "PMC7309501": [["IntroductionHausdorff\u2019s maximal chain principle asserts that every totally ordered subset of a partially ordered set S is contained in a maximal one.", [["IntroductionHausdorff\u2019s maximal chain principle", "TREATMENT", 0, 47], ["a partially ordered set S", "TREATMENT", 93, 118]]]], "401fe5e449d17b4092d5ed4ec1c26a8886b8e512": [["IntroductionThe novel coronavirus, designated SARS-CoV-2, has caused a global outbreak of respiratory illness termed coronavirus disease 2019 since December, 2019 and are still spreading quickly in more than 100 countries.", [["respiratory", "ANATOMY", 90, 101], ["SARS-CoV-2", "CHEMICAL", 46, 56], ["respiratory illness", "DISEASE", 90, 109], ["coronavirus disease", "DISEASE", 117, 136], ["coronavirus", "ORGANISM", 22, 33], ["SARS-CoV-2", "ORGANISM", 46, 56], ["coronavirus", "SPECIES", 22, 33], ["SARS-CoV-2", "SPECIES", 46, 56], ["The novel coronavirus", "PROBLEM", 12, 33], ["respiratory illness termed coronavirus disease", "PROBLEM", 90, 136], ["global", "OBSERVATION_MODIFIER", 71, 77], ["outbreak", "OBSERVATION_MODIFIER", 78, 86], ["respiratory illness", "OBSERVATION", 90, 109], ["coronavirus disease", "OBSERVATION", 117, 136], ["spreading", "OBSERVATION_MODIFIER", 177, 186]]], ["[1] [2] [3] There have been more than 600 thousand patients with confirmed Covid-19 worldwide by the end of March, 2020.", [["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["Covid", "TEST", 75, 80]]], ["[3] [4] [5] One of the key issues has been the very high volume of patients presenting to health centers or hospitals during the outbreak.", [["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75]]], ["It clearly overwhelms the human and mechanistic capacities available, especially the need for critical care support.", [["human", "ORGANISM", 26, 31], ["human", "SPECIES", 26, 31], ["human", "SPECIES", 26, 31], ["critical care support", "TREATMENT", 94, 115]]], ["Therefore, early and effective predictors of clinical outcomes are urgent needed for risk stratification of Covid-19 patients.", [["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 117, 125], ["Covid", "TEST", 108, 113]]], ["D-dimer originates from the formation and lysis of cross-linked fibrin and reflects activation of coagulation and fibrinolysis [7] .", [["D-dimer", "GENE_OR_GENE_PRODUCT", 0, 7], ["fibrin", "GENE_OR_GENE_PRODUCT", 64, 70], ["D-dimer", "PROTEIN", 0, 7], ["cross-linked fibrin", "PROTEIN", 51, 70], ["D-dimer", "PROBLEM", 0, 7], ["lysis", "TREATMENT", 42, 47], ["cross-linked fibrin", "PROBLEM", 51, 70], ["fibrinolysis", "TEST", 114, 126], ["lysis", "OBSERVATION_MODIFIER", 42, 47], ["cross-linked fibrin", "OBSERVATION", 51, 70]]], ["It has been reported that was associated with hemostatic abnormalities, and markedly elevated D-dimer levels were observed in those non-survivors [8] .", [["hemostatic abnormalities", "DISEASE", 46, 70], ["D-dimer", "GENE_OR_GENE_PRODUCT", 94, 101], ["D-dimer", "PROTEIN", 94, 101], ["hemostatic abnormalities", "PROBLEM", 46, 70], ["markedly elevated D-dimer levels", "PROBLEM", 76, 108], ["markedly", "OBSERVATION_MODIFIER", 76, 84], ["elevated", "OBSERVATION_MODIFIER", 85, 93], ["D-dimer", "OBSERVATION_MODIFIER", 94, 101]]], ["However, the prognosis value and the optimal cut-off value for D-dimer on admission to predict mortality have not been well evaluated.Study design and participantsThe study was a retrospective study conducted in Wuhan Asia General Hospital (Wuhan, China), which was a designated hospital for Covid-19 patients.", [["D-dimer", "GENE_OR_GENE_PRODUCT", 63, 70], ["participants", "ORGANISM", 151, 163], ["patients", "ORGANISM", 301, 309], ["D-dimer", "PROTEIN", 63, 70], ["participants", "SPECIES", 151, 163], ["patients", "SPECIES", 301, 309], ["the prognosis value", "TEST", 9, 28], ["D-dimer", "PROBLEM", 63, 70], ["The study", "TEST", 163, 172], ["a retrospective study", "TEST", 177, 198], ["Covid", "TEST", 292, 297]]], ["Adult (aged 18 years or elder) patients with laboratory-confirmed Covid-19 between January 12, 2020 and March 15, 2020 were retrospectively screened.", [["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["Covid", "TEST", 66, 71]]], ["The diagnosis of Covid-19 was according to World Health Organization interim guidance [9] and confirmed by RNA detection of the SARS-CoV-2 in onsite clinical laboratory.", [["SARS-CoV", "SPECIES", 128, 136], ["Covid", "TEST", 17, 22], ["the SARS", "TEST", 124, 132], ["CoV", "TEST", 133, 136]]], ["A total of 343 participants who had a D-dimer level on admission and had a definite outcome (dead or survival) were enrolled.", [["participants", "ORGANISM", 15, 27], ["D-dimer", "GENE_OR_GENE_PRODUCT", 38, 45], ["participants", "SPECIES", 15, 27], ["a D-dimer level", "TEST", 36, 51]]], ["The study was approved and the requirement for informed consent was waived by the Ethics Commission (WAGHMEC-KY-202004).Data collectionAll clinical, laboratory, and outcome data were extracted from electronic medical records using a standardized data collection form.", [["WAGHMEC-KY-202004", "CHEMICAL", 101, 118], ["The study", "TEST", 0, 9], ["Data collection", "TEST", 120, 135]]], ["All data were checked by two physicians (SY and XL) and a third researcher (ZL) adjudicated any difference in interpretation between the two primary Accepted Article reviewers.Laboratory assay and InterventionBlood samples were collected within 24 hours after admission to perform routine laboratory tests, such as blood count, coagulation profile, serum biochemical tests (including renal and liver function) et al in onsite laboratory.", [["Blood samples", "ANATOMY", 209, 222], ["blood", "ANATOMY", 315, 320], ["serum", "ANATOMY", 349, 354], ["renal", "ANATOMY", 384, 389], ["liver", "ANATOMY", 394, 399], ["Blood samples", "CANCER", 209, 222], ["blood", "ORGANISM_SUBSTANCE", 315, 320], ["serum", "ORGANISM_SUBSTANCE", 349, 354], ["renal", "ORGAN", 384, 389], ["liver", "ORGAN", 394, 399], ["All data", "TEST", 0, 8], ["Laboratory assay", "TEST", 176, 192], ["Blood samples", "TEST", 209, 222], ["routine laboratory tests", "TEST", 281, 305], ["blood count", "TEST", 315, 326], ["coagulation profile", "TEST", 328, 347], ["serum biochemical tests", "TEST", 349, 372], ["renal", "ANATOMY", 384, 389], ["liver", "ANATOMY", 394, 399]]], ["D-dimer was determined on CS5100 automatic coagulation analyzer (Sysmex, Kobe, Japan) by utilizing a latex-enhanced photometric immunoassay (Siemens, Marburg, Germany).", [["D-dimer", "GENE_OR_GENE_PRODUCT", 0, 7], ["D-dimer", "TEST", 0, 7], ["automatic coagulation analyzer", "TEST", 33, 63], ["Sysmex", "TEST", 65, 71], ["a latex", "TEST", 99, 106]]], ["Inter and intra-day variability coefficients were 3.41% and 4.22%.Laboratory assay and InterventionThe laboratory reference range was 0-0.5 \u00b5g/ml.", [["Inter and intra-day variability coefficients", "TEST", 0, 44], ["Laboratory assay", "TEST", 66, 82]]], ["The D-dimer result was expressed in \u00b5g/ml FEU (Fibrinogen Equivalent Unit).", [["D-dimer", "GENE_OR_GENE_PRODUCT", 4, 11], ["Fibrinogen", "PROTEIN", 47, 57], ["The D-dimer result", "TEST", 0, 18]]], ["All measurements were done within 2 hours after blood sampling.Statistical analysisContinuous and categorical variables were presented as mean\u00b1standard deviation or median (Inter-quartile range, IQR), as appropriate.", [["blood", "ANATOMY", 48, 53], ["blood", "ORGANISM_SUBSTANCE", 48, 53], ["All measurements", "TEST", 0, 16], ["blood sampling", "TEST", 48, 62], ["Statistical analysisContinuous and categorical variables", "PROBLEM", 63, 119]]], ["Categorical variables were presented as n (%).", [["Categorical variables", "TEST", 0, 21]]], ["Event frequencies were compared with chi-square test.", [["chi-square test", "TEST", 37, 52]]], ["The optimal D-dimer cutoff point and C-statistic of routine tests were evaluated by receiver operator characteristic (ROC) curve.", [["The optimal D-dimer cutoff point", "TEST", 0, 32], ["routine tests", "TEST", 52, 65]]], ["Hazard ratio (HR) and 95% confidential interval (95% CI) were calculated by log-rank tests.", [["Hazard ratio", "TEST", 0, 12], ["HR", "TEST", 14, 16], ["CI", "TEST", 53, 55], ["log-rank tests", "TEST", 76, 90]]], ["The prognostic values of D-dimer and clinical variables were analyzed with Cox-proportional hazard models.", [["D-dimer", "GENE_OR_GENE_PRODUCT", 25, 32], ["The prognostic values", "TEST", 0, 21], ["D-dimer", "TEST", 25, 32], ["clinical variables", "TEST", 37, 55]]], ["A value of p<0.05 was accepted as statistically significant.", [["A value", "TEST", 0, 7], ["significant", "OBSERVATION_MODIFIER", 48, 59]]], ["The statistical software package MedCalc Statistical Software (version 16.2, Ostend, Belgium) were used for analyses.Baseline characteristics and Establishing optimum cutoff value for D-DimerOf 343 eligible patients, the median age was 62 years (IQR, 48-69 years), ranging from 18 years to 92 years.", [["patients", "ORGANISM", 207, 215], ["patients", "SPECIES", 207, 215]]], ["37.6% (129/343) patients were older than 65 years.", [["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24]]], ["50.3% (174/343) patients were female.", [["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24]]], ["Listed in Table 1 are the basic clinical characteristics of the patients, including age, gender, comorbidities, and routine laboratory results on admission.", [["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["comorbidities", "PROBLEM", 97, 110]]], ["A total of 13 all-cause deaths occurred during hospitalization.", [["deaths", "DISEASE", 24, 30]]], ["The optimum cutoff value for D-dimer to predict all-cause deaths was 2.0 \u00b5g/ml using ROC curve ( Figure 1 ) with a sensitivity of 92.3% and a specificity of 83.3%.Accepted ArticleThis article is protected by copyright.", [["deaths", "DISEASE", 58, 64], ["D-dimer", "GENE_OR_GENE_PRODUCT", 29, 36], ["D-dimer", "PROTEIN", 29, 36], ["The optimum cutoff value", "TEST", 0, 24], ["D-dimer", "TREATMENT", 29, 36], ["ROC curve", "TEST", 85, 94], ["a sensitivity", "TEST", 113, 126], ["a specificity", "TEST", 140, 153]]], ["All rights reserved Area under ROC curve for all-cause deaths was 0.89.", [["deaths", "DISEASE", 55, 61], ["ROC curve", "TEST", 31, 40]]], ["Among routine laboratory tests, D-dimer has the highest C-index to predict in-hospital mortality in Covid-19 patients (Table 2) .", [["D-dimer", "SIMPLE_CHEMICAL", 32, 39], ["patients", "ORGANISM", 109, 117], ["D-dimer", "PROTEIN", 32, 39], ["patients", "SPECIES", 109, 117], ["routine laboratory tests", "TEST", 6, 30], ["D-dimer", "TEST", 32, 39], ["Covid", "TEST", 100, 105]]], ["Besides, The C-indices indicates lymphocyte, prothrombin time, and C-reaction protein are also strong predictors for these patients (Table 2) .Accepted ArticleAccording to the optimum cutoff value, 276 patients' D-dimer levels on admission were less than 2.0 \u00b5g/ml, and 67 patients had D-dimer levels over 2.0 \u00b5g/ml.", [["lymphocyte", "ANATOMY", 33, 43], ["lymphocyte", "CELL", 33, 43], ["prothrombin", "GENE_OR_GENE_PRODUCT", 45, 56], ["C-reaction protein", "GENE_OR_GENE_PRODUCT", 67, 85], ["patients", "ORGANISM", 123, 131], ["patients", "ORGANISM", 202, 210], ["D-dimer", "GENE_OR_GENE_PRODUCT", 212, 219], ["patients", "ORGANISM", 273, 281], ["D-dimer", "SIMPLE_CHEMICAL", 286, 293], ["C-reaction protein", "PROTEIN", 67, 85], ["patients", "SPECIES", 123, 131], ["patients", "SPECIES", 202, 210], ["patients", "SPECIES", 273, 281], ["The C-indices", "TEST", 9, 22], ["lymphocyte", "TEST", 33, 43], ["prothrombin time", "TEST", 45, 61], ["C-reaction protein", "TREATMENT", 67, 85], ["the optimum cutoff value", "TEST", 172, 196], ["patients' D-dimer levels", "TEST", 202, 226], ["D-dimer levels", "TEST", 286, 300], ["lymphocyte", "ANATOMY", 33, 43]]], ["Compared to those patients with D-dimer levels below 2.0 \u03bc g/ml, patients with D-dimer levels \u2265 2.0 \u00b5g/ml had a higher incidence of underlying disease, such as diabetes (p=0.007), hypertension (p<0.001), coronary heart disease (p=0.02) and stroke history (p<0.001).", [["coronary", "ANATOMY", 204, 212], ["heart", "ANATOMY", 213, 218], ["diabetes", "DISEASE", 160, 168], ["hypertension", "DISEASE", 180, 192], ["coronary heart disease", "DISEASE", 204, 226], ["stroke", "DISEASE", 240, 246], ["patients", "ORGANISM", 18, 26], ["D-dimer", "GENE_OR_GENE_PRODUCT", 32, 39], ["patients", "ORGANISM", 65, 73], ["D-dimer", "GENE_OR_GENE_PRODUCT", 79, 86], ["heart", "ORGAN", 213, 218], ["patients", "SPECIES", 18, 26], ["patients", "SPECIES", 65, 73], ["D-dimer levels", "TEST", 32, 46], ["D-dimer levels", "TEST", 79, 93], ["underlying disease", "PROBLEM", 132, 150], ["diabetes", "PROBLEM", 160, 168], ["hypertension", "PROBLEM", 180, 192], ["coronary heart disease", "PROBLEM", 204, 226], ["stroke history", "PROBLEM", 240, 254], ["disease", "OBSERVATION", 143, 150], ["hypertension", "OBSERVATION", 180, 192], ["coronary heart", "ANATOMY", 204, 218], ["disease", "OBSERVATION", 219, 226]]], ["Additionally, lower level of lymphocyte (p<0.001), hemoglobin (p=0.003) , platelet count (p=0.009) and higher level of neutrophil (p<0.001), c-reaction protein (p<0.001), and prothrombin time (p<0.001) were also observed in those with D-dimer levels \u22652.0 \u00b5g/ml.DiscussionThe main finding of this study is that D-dimer on admission greater than 2.0\u00b5g/mL was the independent predictor of in hospital death for patients with Covid-19.", [["lymphocyte", "ANATOMY", 29, 39], ["platelet", "ANATOMY", 74, 82], ["neutrophil", "ANATOMY", 119, 129], ["death", "DISEASE", 398, 403], ["lymphocyte", "CELL", 29, 39], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 51, 61], ["platelet", "CELL", 74, 82], ["neutrophil", "CELL", 119, 129], ["c-reaction protein", "GENE_OR_GENE_PRODUCT", 141, 159], ["prothrombin", "GENE_OR_GENE_PRODUCT", 175, 186], ["D-dimer", "SIMPLE_CHEMICAL", 235, 242], ["D-dimer", "GENE_OR_GENE_PRODUCT", 310, 317], ["patients", "ORGANISM", 408, 416], ["lymphocyte", "CELL_TYPE", 29, 39], ["hemoglobin", "PROTEIN", 51, 61], ["neutrophil", "CELL_TYPE", 119, 129], ["c-reaction protein", "PROTEIN", 141, 159], ["prothrombin", "PROTEIN", 175, 186], ["patients", "SPECIES", 408, 416], ["lymphocyte", "TEST", 29, 39], ["hemoglobin", "TEST", 51, 61], ["platelet count", "TEST", 74, 88], ["p", "TEST", 90, 91], ["neutrophil", "TEST", 119, 129], ["c-reaction protein", "TEST", 141, 159], ["prothrombin time", "TEST", 175, 191], ["D-dimer levels", "TEST", 235, 249], ["this study", "TEST", 291, 301], ["D-dimer", "TEST", 310, 317], ["Covid", "TEST", 422, 427], ["lower", "ANATOMY_MODIFIER", 14, 19], ["lymphocyte", "ANATOMY", 29, 39]]], ["This finding provides a well-established cutoff value to identify those patients with Covid-19 who have poor prognosis at an early stage.DiscussionD-dimer elevation has been reported to be one of the commonest laboratory findings noted inAccepted ArticleThis article is protected by copyright.", [["patients", "ORGANISM", 72, 80], ["dimer", "PROTEIN", 149, 154], ["patients", "SPECIES", 72, 80], ["dimer elevation", "PROBLEM", 149, 164]]], ["All rights reserved Covid-19 patients requiring hospitalization.", [["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37], ["hospitalization", "TREATMENT", 48, 63]]], ["Guan and colleagues analyzed 1099 patients with laboratory-confirmed Covid-19 from over 550 hospitals in China [5] , and found the non-survivors had a significantly higher D-dimer (median: 2.12 \u03bcg/ml) than that of survivors (median: 0.61 \u03bcg/ml).", [["patients", "ORGANISM", 34, 42], ["D-dimer", "GENE_OR_GENE_PRODUCT", 172, 179], ["patients", "SPECIES", 34, 42], ["Covid", "TEST", 69, 74]]], ["Similarly, Ning T et al also observed abnormal coagulation results, especially markedly elevated D-dimer in deaths with Covid-19 [8] .", [["abnormal coagulation", "DISEASE", 38, 58], ["deaths", "DISEASE", 108, 114], ["Covid-19", "CHEMICAL", 120, 128], ["D-dimer", "SIMPLE_CHEMICAL", 97, 104], ["D-dimer", "PROTEIN", 97, 104], ["abnormal coagulation results", "PROBLEM", 38, 66], ["markedly elevated D-dimer", "PROBLEM", 79, 104], ["Covid", "TEST", 120, 125]]], ["Fei Zhou et al conducted a retrospective study involved 191 patients with Covid-19 [10] \uff0c and found that d-dimer greater than 1 \u00b5g/mL on admission was associated with in-hospital death (HR:18.42, 95%CI: 2.64-128.55).", [["death", "DISEASE", 179, 184], ["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["a retrospective study", "TEST", 25, 46], ["Covid", "TEST", 74, 79], ["d-dimer", "TEST", 105, 112], ["HR", "TEST", 186, 188], ["CI", "TEST", 199, 201]]], ["Huang and colleagues showed D-dimer levels on admission were higher in patients needing critical care support than those who did not require it (median: 0.5 \u00b5g/ml [1] .", [["D-dimer", "GENE_OR_GENE_PRODUCT", 28, 35], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["D-dimer levels", "TEST", 28, 42], ["critical care support", "TREATMENT", 88, 109]]], ["However, these previous studies did not provide well evaluated cutoff for D-dimer.", [["D-dimer", "GENE_OR_GENE_PRODUCT", 74, 81], ["D-dimer", "PROTEIN", 74, 81], ["these previous studies", "TEST", 9, 31]]], ["Therefore, a recent guidance on recognition and management of coagulopathy in Covid-19 from International Society of Thrombosis and Haemostasis (ISTH) \"arbitrarily defined markedly raised D-dimers on admission as three-four folds increase\" [6] .", [["coagulopathy", "DISEASE", 62, 74], ["Thrombosis", "DISEASE", 117, 127], ["Haemostasis", "DISEASE", 132, 143], ["ISTH", "DISEASE", 145, 149], ["D-dimers", "SIMPLE_CHEMICAL", 188, 196], ["management", "TREATMENT", 48, 58], ["coagulopathy", "PROBLEM", 62, 74], ["Covid", "TEST", 78, 83], ["Thrombosis", "PROBLEM", 117, 127], ["Haemostasis (ISTH)", "PROBLEM", 132, 150], ["markedly raised D-dimers", "PROBLEM", 172, 196], ["coagulopathy", "OBSERVATION", 62, 74], ["Thrombosis", "OBSERVATION", 117, 127]]], ["In current study, a clear cutoff value (2.0 \u00b5g/ml, fourfold increase) for D-dimer was well established by ROC curve.", [["D-dimer", "SIMPLE_CHEMICAL", 74, 81], ["current study", "TEST", 3, 16], ["a clear cutoff value", "TEST", 18, 38], ["D-dimer", "TEST", 74, 81], ["ROC curve", "TEST", 106, 115]]], ["Notably, of 12 non-survivors with D-dimers \u22652.0 \u00b5g/ml, 7 of whom had no severity symptoms on admission.", [["D-dimers", "GENE_OR_GENE_PRODUCT", 34, 42], ["D-dimers", "TEST", 34, 42], ["severity symptoms", "PROBLEM", 72, 89]]], ["Thus, for patients who have markedly raised D-dimers (cut-off: 2.0 \u00b5g/ml, four-fold increase), admission to hospital and closely monitoring should be considered even in the absence of other severity symptoms.Accepted ArticleElevation of D-dimer indicated a hypercoagulable state in patient with Covid-19, which might be attributed to several reasons as follows.", [["D-dimer", "CHEMICAL", 237, 244], ["patients", "ORGANISM", 10, 18], ["D-dimers", "GENE_OR_GENE_PRODUCT", 44, 52], ["D-dimer", "SIMPLE_CHEMICAL", 237, 244], ["patient", "ORGANISM", 282, 289], ["D-dimers", "PROTEIN", 44, 52], ["D-dimer", "PROTEIN", 237, 244], ["patients", "SPECIES", 10, 18], ["patient", "SPECIES", 282, 289], ["markedly raised D-dimers", "PROBLEM", 28, 52], ["other severity symptoms", "PROBLEM", 184, 207], ["a hypercoagulable state", "PROBLEM", 255, 278], ["Covid", "TEST", 295, 300], ["hypercoagulable state", "OBSERVATION", 257, 278]]], ["First, virus infections are usually accompanied by an aggressive pro-inflammatory response and insufficient control of an anti-inflammatory response [11] .", [["infections", "DISEASE", 13, 23], ["virus infections", "PROBLEM", 7, 23], ["an aggressive pro-inflammatory response", "PROBLEM", 51, 90], ["virus infections", "OBSERVATION", 7, 23], ["aggressive", "OBSERVATION_MODIFIER", 54, 64], ["pro-inflammatory response", "OBSERVATION", 65, 90], ["anti-inflammatory response", "OBSERVATION", 122, 148]]], ["It might induce the dysfunction of endothelial cells, resulting in excess thrombin generation [12] .", [["endothelial cells", "ANATOMY", 35, 52], ["endothelial cells", "CELL", 35, 52], ["thrombin", "GENE_OR_GENE_PRODUCT", 74, 82], ["endothelial cells", "CELL_TYPE", 35, 52], ["thrombin", "PROTEIN", 74, 82], ["the dysfunction of endothelial cells", "PROBLEM", 16, 52], ["excess thrombin generation", "PROBLEM", 67, 93], ["dysfunction", "OBSERVATION", 20, 31], ["endothelial cells", "OBSERVATION", 35, 52], ["excess thrombin", "OBSERVATION", 67, 82]]], ["Second, the hypoxia found in severe Covid-19 can stimulate thrombosis through not only increasing blood viscosity, but also a hypoxia-inducible transcription factor-dependent signaling pathway [13, 14] .", [["blood", "ANATOMY", 98, 103], ["hypoxia", "DISEASE", 12, 19], ["Covid-19", "CHEMICAL", 36, 44], ["thrombosis", "DISEASE", 59, 69], ["Covid-19", "CHEMICAL", 36, 44], ["blood", "ORGANISM_SUBSTANCE", 98, 103], ["hypoxia-inducible transcription factor", "GENE_OR_GENE_PRODUCT", 126, 164], ["hypoxia-inducible transcription factor", "PROTEIN", 126, 164], ["the hypoxia", "PROBLEM", 8, 19], ["severe Covid", "PROBLEM", 29, 41], ["thrombosis", "PROBLEM", 59, 69], ["increasing blood viscosity", "PROBLEM", 87, 113], ["a hypoxia-inducible transcription factor", "PROBLEM", 124, 164], ["dependent signaling pathway", "PROBLEM", 165, 192], ["hypoxia", "OBSERVATION", 12, 19], ["severe", "OBSERVATION_MODIFIER", 29, 35], ["thrombosis", "OBSERVATION", 59, 69]]], ["Third, hospitalized patients, especially severe patients with Covid-19, were more intend to have elder ages, underlying conditions, long-term bed rest and invasive treatment et al., which were all risk factors of hypercoagulation or thrombosis [15] [16] [17] .", [["hypercoagulation", "DISEASE", 213, 229], ["thrombosis", "DISEASE", 233, 243], ["patients", "ORGANISM", 20, 28], ["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 20, 28], ["patients", "SPECIES", 48, 56], ["Covid", "TEST", 62, 67], ["underlying conditions", "PROBLEM", 109, 130], ["long-term bed rest", "TREATMENT", 132, 150], ["invasive treatment", "TREATMENT", 155, 173], ["hypercoagulation", "PROBLEM", 213, 229], ["thrombosis", "PROBLEM", 233, 243], ["thrombosis", "OBSERVATION", 233, 243]]], ["As evidence, the lung organ dissection of critical patient with Covid-19 have reported occlusion and micro-thrombosis formation in pulmonary small vessels [18] .", [["lung organ", "ANATOMY", 17, 27], ["pulmonary small vessels", "ANATOMY", 131, 154], ["micro-thrombosis", "DISEASE", 101, 117], ["lung organ", "MULTI-TISSUE_STRUCTURE", 17, 27], ["patient", "ORGANISM", 51, 58], ["pulmonary", "ORGAN", 131, 140], ["small vessels", "MULTI-TISSUE_STRUCTURE", 141, 154], ["patient", "SPECIES", 51, 58], ["the lung organ dissection", "PROBLEM", 13, 38], ["Covid", "TEST", 64, 69], ["occlusion", "PROBLEM", 87, 96], ["micro-thrombosis formation in pulmonary small vessels", "PROBLEM", 101, 154], ["lung organ", "ANATOMY", 17, 27], ["dissection", "OBSERVATION", 28, 38], ["occlusion", "OBSERVATION", 87, 96], ["micro-thrombosis", "OBSERVATION", 101, 117], ["pulmonary", "ANATOMY", 131, 140], ["small vessels", "ANATOMY", 141, 154]]], ["Forth, some patients might developAccepted ArticleThis article is protected by copyright.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20]]], ["All rights reserved to sepsis-induced coagulopathy or even disseminated intravascular coagulation [8, 19] .", [["intravascular", "ANATOMY", 72, 85], ["sepsis", "DISEASE", 23, 29], ["coagulopathy", "DISEASE", 38, 50], ["intravascular coagulation", "DISEASE", 72, 97], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 72, 85], ["sepsis", "PROBLEM", 23, 29], ["coagulopathy", "PROBLEM", 38, 50], ["even disseminated intravascular coagulation", "PROBLEM", 54, 97], ["sepsis", "OBSERVATION", 23, 29], ["coagulopathy", "OBSERVATION", 38, 50], ["disseminated", "OBSERVATION_MODIFIER", 59, 71]]], ["At all events, elevated D-dimer was always associated with unfavorable events [20, 21] .", [["D-dimer", "GENE_OR_GENE_PRODUCT", 24, 31], ["D-dimer", "PROTEIN", 24, 31], ["elevated D-dimer", "PROBLEM", 15, 31], ["unfavorable events", "PROBLEM", 59, 77]]], ["Previously, the lack of specificity has been regarded as a disadvantage of D-dimer [7] .", [["D-dimer", "CHEMICAL", 75, 82], ["D-dimer", "SIMPLE_CHEMICAL", 75, 82]]], ["However, low specificity has presently been transformed into one of its advantage in the evaluation of prognosis.Accepted ArticleThis study has several limitations.", [["the evaluation", "TEST", 85, 99], ["ArticleThis study", "TEST", 122, 139], ["low specificity", "OBSERVATION_MODIFIER", 9, 24]]], ["First, our study might have selection bias because it was a single-center, retrospective study, even if it had sufficient power to detect the significant differences between groups in mortality.", [["our study", "TEST", 7, 16], ["retrospective study", "TEST", 75, 94], ["significant", "OBSERVATION_MODIFIER", 142, 153]]], ["Despite our efforts to include all qualified patients, some patients still excluded in enrollment due to absence of D-dimer level on admission.", [["patients", "ORGANISM", 45, 53], ["patients", "ORGANISM", 60, 68], ["D-dimer", "GENE_OR_GENE_PRODUCT", 116, 123], ["D-dimer", "PROTEIN", 116, 123], ["patients", "SPECIES", 45, 53], ["patients", "SPECIES", 60, 68], ["D-dimer level", "PROBLEM", 116, 129]]], ["Second, due to difference of patient's size and medical resources, the lengths from illness onset to admission of the included patients might not be representative, which might influence D-dimer levels on admission.", [["illness", "DISEASE", 84, 91], ["patient", "ORGANISM", 29, 36], ["patients", "ORGANISM", 127, 135], ["D-dimer", "GENE_OR_GENE_PRODUCT", 187, 194], ["patient", "SPECIES", 29, 36], ["patients", "SPECIES", 127, 135], ["D-dimer levels", "TEST", 187, 201]]], ["In addition, the half-life of d-dimer was approximately 8 hours [22] .", [["d-dimer", "TEST", 30, 37]]], ["Therefore, dynamic measurement of D-dimer will reveal more information.", [["D-dimer", "CHEMICAL", 34, 41], ["D-dimer", "GENE_OR_GENE_PRODUCT", 34, 41], ["D-dimer", "PROTEIN", 34, 41], ["dynamic measurement of D-dimer", "TEST", 11, 41]]], ["Third, the fully adjusted model analysis for HR was not performed, given the low number of events.", [["HR", "TEST", 45, 47]]], ["Forth, a multiple-parameter prediction model including D-dimer and other variables might provide better predictive ability for Covid-19 patients.ConclusionD-dimer on admission greater than 2.0\u00b5g/mL (fourfold increase) could effectively predict in-hospital mortality in patients with Covid-19, which indicated D-dimer could be an early and helpful marker to improve management of Covid-19 patients.Accepted ArticleThis article is protected by copyright.", [["D-dimer", "GENE_OR_GENE_PRODUCT", 55, 62], ["patients", "ORGANISM", 136, 144], ["ConclusionD-dimer", "GENE_OR_GENE_PRODUCT", 145, 162], ["patients", "ORGANISM", 269, 277], ["D-dimer", "SIMPLE_CHEMICAL", 309, 316], ["patients", "ORGANISM", 388, 396], ["D-dimer", "PROTEIN", 55, 62], ["ConclusionD-dimer", "PROTEIN", 145, 162], ["patients", "SPECIES", 136, 144], ["patients", "SPECIES", 269, 277], ["patients", "SPECIES", 388, 396], ["D-dimer", "TEST", 55, 62], ["Covid", "TEST", 127, 132], ["ConclusionD", "TEST", 145, 156], ["Covid", "TEST", 283, 288], ["D-dimer", "PROBLEM", 309, 316], ["Covid", "TEST", 379, 384]]], ["Receiver operator characteristic curve for D-dimer to predict deathsThe optimum cutoff point, identified as the point closest to upper left corner, was 2.0 \u03bcg/ml with 92.3% for sensitivity and 83.3% for specificity.", [["left corner", "ANATOMY", 135, 146], ["deaths", "DISEASE", 62, 68], ["D-dimer", "GENE_OR_GENE_PRODUCT", 43, 50], ["D-dimer", "PROTEIN", 43, 50], ["sensitivity", "TEST", 177, 188], ["specificity", "TEST", 203, 214], ["optimum", "OBSERVATION_MODIFIER", 72, 79], ["cutoff", "OBSERVATION", 80, 86], ["upper", "ANATOMY_MODIFIER", 129, 134], ["left", "ANATOMY_MODIFIER", 135, 139], ["corner", "ANATOMY_MODIFIER", 140, 146]]], ["Area under receiver operator characteristic curve for mortality was 0.89.Figure 2.", [["mortality", "TEST", 54, 63]]], ["Kaplan-Meier survival curves for D-dimer levels on admissionStatistical significance of separation between two groups was achieved at seven days after admission.", [["D-dimer", "GENE_OR_GENE_PRODUCT", 33, 40], ["Meier survival curves", "TEST", 7, 28], ["D-dimer levels", "TEST", 33, 47]]], ["HR: Hazard ratio;Figure 2.", [["Hazard ratio", "TEST", 4, 16]]], ["Kaplan-Meier survival curves for D-dimer levels on admissionAccepted Article", [["D-dimer", "SIMPLE_CHEMICAL", 33, 40], ["Meier survival curves", "TEST", 7, 28], ["D-dimer levels", "TEST", 33, 47]]]], "0d7490388d328e0f14a7c1067d95bb0ee616f6a2": [["However, the desire to be first to publish and achieve high click-through rates has led to an increase in clickbait, both pre-and post-publication editorialization of titles and headlines that may misrepresent the actual content of the articles [1] .", [["high click", "PROBLEM", 55, 65], ["an increase in clickbait", "PROBLEM", 91, 115], ["increase", "OBSERVATION_MODIFIER", 94, 102]]], ["These trends may have contributed to the increased media mistrust that is discussed today under the controversial term fake news, described as \"a poorly-defined and misleading term that conflates a variety of false information, from genuine error through to foreign interference in democratic processes\" [2] .IntroductionIn some instances, undisclosed post-publication changes have swung the overall message and tone of news articles and, when revealed, have angered readers [4] .", [["the increased media mistrust", "PROBLEM", 37, 65], ["genuine error", "PROBLEM", 233, 246], ["undisclosed post-publication changes", "PROBLEM", 340, 376], ["increased", "OBSERVATION_MODIFIER", 41, 50], ["media mistrust", "OBSERVATION", 51, 65]]], ["Can we trust publishers to guarantee that a link you share with a friend will contain the same content you have read?IntroductionRevisionista.PT 1 allows readers to see all kinds of post-publication changes, and allows scholars to research this phenomenon and reason about how these changes affect the readers perception of news in the age of social media.Proposed SolutionIn this demo paper, we propose a meta-journalistic tool that reveals postpublication changes in articles published by Portuguese online news media.", [["post-publication changes", "PROBLEM", 182, 206], ["a meta-journalistic tool", "TEST", 404, 428], ["postpublication changes", "PROBLEM", 442, 465], ["postpublication", "OBSERVATION", 442, 457]]], ["The goal of Revisionista.PT is to discover significant post-publication changes in news articles and to present them in a transparent auditable timeline.", [["Revisionista", "TREATMENT", 12, 24], ["significant post-publication changes", "PROBLEM", 43, 79], ["significant", "OBSERVATION_MODIFIER", 43, 54], ["post-publication", "OBSERVATION", 55, 71]]], ["The most important raw materials to achieve this objective are historical collections of web page snapshots from news outlets that are preserved by the Portuguese Web Archive, Arquivo.PT 2 .Proposed SolutionTo create this project, we had to build solutions to solve a number of technical challenges: Given a web page, how to extract the textual content of the article?, What are the significant differences between article revisions?, and, most importantly, What dimensions can be used to classify the changes found?.Proposed SolutionIn Fig. 1 we presents a simplified overview of the pipeline that we use to process a collection of news article URLs and generate the summaries of the changes that will be shown in the user interface.", [["article revisions", "TREATMENT", 415, 432], ["Proposed SolutionIn Fig", "TREATMENT", 517, 540], ["significant", "OBSERVATION_MODIFIER", 383, 394], ["differences", "OBSERVATION_MODIFIER", 395, 406], ["revisions", "OBSERVATION", 423, 432]]], ["The pipeline can be described in three main steps: (1) fetching of HTML snapshots, (2) text extraction from HTML, and (3) changes extraction from text.News Article URLs.To build a list of news article URLs our strategy was to develop URL slug templates that are matched when fetching news articles of a given news source (e. g., https://observador.pt///", [["text extraction", "TREATMENT", 87, 102], ["changes extraction", "TREATMENT", 122, 140], ["URL slug templates", "PROBLEM", 234, 252], ["slug templates", "OBSERVATION", 238, 252]]]]}